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Next Generation Sequencing-Based Genotyping of Human Blood Groups: FY, JK 
and ABO Genes.  
Malik Abdullah Altayar 
Serological discrepancies in matching blood group antigens between donors and 
patients for blood transfusion may lead to alloimmunisation, especially in multiply 
transfused patients. Blood group genotyping (BGG) has contributed in reducing this 
issue. ABO, Fy and Jk antigens are among those to be causative for alloimmunisation 
through transfusion or pregnancy. The number of alleles of these clinically significant 
blood groups is ever increasing. Currently, all commercially available high-throughput 
BGG platforms are only based on pre-defined polymorphisms. Consequently, novel or 
rare alleles that might have clinical significance are not identified. Next generation 
sequencing (NGS) circumvents this issue by providing high-throughput comprehensive 
genotyping of blood group genes in discovery mode to find all existing and novel 
mutations. Accordingly, a large number of individuals can be genotyped in a single run. 
Here, we describe an NGS-based method coupled with long-range polymerase chain 
reaction (LR-PCR) for high-throughput, rapid and extensive genotyping of FY, JK and 
ABO blood group genes. The Ion Torrent Personal Genome Machine (PGM
TM
) was 
used for sequencing the entire FY, JK and ABO blood group genes including flanking 
regions. Accordingly, high resolution genotyping was obtained. 53 genomic DNA 
samples were sequenced and genotyped for FY, 67 for JK and 47 for ABO. Sequencing 
data were aligned to the gene reference sequence derived from the human genome 
(hg19) to analyse variants. Analysis was accomplished by software packages, such as 
Ion Torrent Suite
TM 
plugins. Sanger sequencing of cDNA and cDNA clones was used to 
confirm findings in the JK gene. The sequencing data had a coverage depth of more 
than 5000x for FY, 700x for JK and 600x for ABO. NGS data matched with the 
serological phenotypes of FY alleles FY*A, FY*B and FY*02 Null main polymorphisms, 
such as FY*A/FY*B (125G>A) in exon 2 and (-67 T>C) in the promotor region. JK 
variant analysis revealed that the JK*01W.01 allele (130G>A) is common (10/67 
samples) with normal antigenicity. The previously described silencing polymorphism 
(810G>A), leading to a purported JK*B null allele, restores a splice site and does not 
correlate with loss of Jk
b
 antigenicity (10/67 samples). JK intron analysis revealed 
several new JK alleles described in this thesis. All 7 exons, introns and the flanking 
regions of the ABO gene were covered by only four amplicons. Several rare O alleles 
were found, such as O73 and O75, while one suggested novel O allele was characterised 
by a missense SNP 482G>A (Arg161His) in exon 7. The ABO reference sequence from 
hg19 appeared to resemble (O01 and O02) alleles. The intronic SNPs might be used to 
distinguish between alleles more accurately as a correlation of the intronic SNPs with 
the alleles was noted for the homozygous O alleles. It is predicted that NGS-based 
genotyping will replace not only microarray-based genotyping but also serology in the 
blood group typing of individuals, with great advancements in technology and 
molecular knowledge being expected in the near future. 
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1.1 Introduction to blood groups  
Blood groups were first discovered by Karl Landsteiner in early 20
th
 century 
(particularly 1901). He found that plasma samples of a number of individuals showed 
agglutination when exposed to red blood cells (RBCs) of others but not with their own 
RBCs. Subsequent investigations led to the identification of the three ABO blood 
groups (A, B and O) for the first blood group system, ABO. Subsequently, in the 
following year, a fourth group (AB) for the ABO system was described by Decastello 
and Sturli (Landsteiner, 1961, Levine, 1961, Owen, 2000, Watkins, 2001, Schwarz and 
Dorner, 2003, Giangrande, 2000).  
Each blood group is characterised by specific antigens, which can be defined as 
inherited polymorphic markers present on the external membrane of RBCs and are 
detected by specific antibodies. The blood group antigens can elicit an immune response, 
which is marked by the synthesis of corresponding antibodies that occur naturally, as a 
result of exposure to antigens in the environment or alloimmunisation of those who lack 
the antigens that are acquired through blood transfusion or pregnancy. These specific 
alloantibodies are utilised to serologically detect blood group antigens (Reid et al., 2012, 
Daniels, 2013). These antigens are either protein or carbohydrate molecules attached to 
protein or lipid of the RBC membrane forming protein, glycoprotein, or glycolipid 
structures (Reid and Mohandas, 2004, Daniels, 2005). The various blood group antigens 
are encoded or controlled by either a single gene, such as the JK blood group system, or 
two or three genetically discrete genes that exist as a cluster of closely linked 
homologous genes, as in the case of the RH and MNS blood group systems, 
respectively (Daniels, 2013). The blood group genes either encode for the enzyme that 
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transfers the carbohydrate determinants to the membrane glycoprotein or glycolipid, as 
is the case with the ABO antigen formation, or directly encode for the amino acid (aa) 
sequence in the protein determinates blood group antigens, such as those of JK (Reid 
and Mohandas, 2004). These genes have been mapped to diverse chromosomes in the 
human genome (Storry and Olsson, 2004). The International Society of Blood 
Transfusion (ISBT) has recognised more than 300 blood group antigens that are 
categorised into 36 blood group systems (Table 1.1) (ISBT, 2016). 
1.2 Blood group terminology 
In 1980, the ISBT set up a working party on Red Cell Immunogenetics and Blood 
Group Terminology, which later became a committee, in order to establish a uniform 
nomenclature that is based on the genetic bases of the antigens and is easily readable by 
machine, software and eye.  Blood group antigens (authenticated) are classified into 
four categories: systems, collections, low incidence antigens (700) and high incidence 
antigens (901) (Daniels et al., 2004). A blood group system consists of one or more 
antigens that are controlled by a single gene or by two or three closely linked 
homologous genes. Collections represent sets of antigens that are serologically, 
biochemically or genetically related but do not fulfil the requirements for inclusion into 
a blood group system, which is suggested because lack of information regarding the 
gene identity. Nevertheless, upon identification of the gene, a collection might 
subsequently become recognised as a system and become an obsolete collection. 
Examples are the Cromer collection (202) that became a blood group system (021) 
(Daniels, 2013, Reid et al., 2012) Table 1.1) and the 212 Vel (212) collection, which 
was declared obsolete and categorised as the VEL (034) blood group system after 
identification of the relevant gene (Storry et al., 2013, Ballif et al., 2013, Cvejic et al., 
2013). The antigens that have an incidence of less than 1% in most populations and are 
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not included in the system or collection criteria, fit into the 700 series. The 901 series, 
previously known as 900, consists of high-frequency antigens, with incidence greater 
than 90% in populations, but do not belong to system or collections. Similarly, those 
antigens might be included in a blood group system if the pertinent criteria are fulfilled, 
as seen in the case of Lan (901 high-incidence antigen) that was declared as the Lan 
blood group system after the identification of the corresponding gene (ABCB6) in 2012 
(Helias et al., 2012, Storry et al., 2014). 
With regard to the ISBT terminology of the blood group antigens, each antigen 
belonging to a system is denoted and identified by six digits, the first three of which 
represent the blood group system, for instance 008 for the FY system, whereas the last 
three identify the antigen. For example, 008001 denotes the first antigen of the FY 
system (Fy
a
). Alternatively, the system alphabetical symbol can be used instead of the 
numerical ones, followed by the antigen number with (FY001) or without the 
sinistral zeros (FY1) to represent the antigen (Fy
a
). Phenotypes are represented by the 
system symbol followed by a colon then by a list of the antigens present and separated 
by a comma, while absent antigens marked by a minus (for example FY: -1, 2 for Fy (a-
b+)). Alleles are denoted by the system symbol followed by an asterisk then the antigen 
number or letter, all in italics; for example, FY*01 or FY*A encodes for Fy
a
. Genotypes 
are denoted by the system symbol followed an asterisk then the alleles or haplotypes are 
separated by a slash, all in italics; for example, FY*01/02 or FY*A/B. Null or amorph 
alleles are represented by zero; for example, KEL*0 or letter N as for example 
FY*01N.01 is responsible for the Fy null phenotype. The gene is denoted by the 
italicised symbol of the ISBT blood group system, which is mostly used instead of that 
defined by the HUGO Gene Nomenclature Committee (HGNC), in which the names 
reflect the function of the gene product. The nomenclature for the antigens in collections, 
700 and 901 is similar to that in the system where the system digits are replaced by the 
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collection number or 700 and 901, respectively.   
The establishment of the numerical terminology was mainly for the purpose of 
computer storage of information on the blood group antigens and genetic classification. 
However, the routine use of such terminology might not be suitable, which has led to 
emergent of alternative approved terminology for blood group antigens and phenotype 
that are popular and more user-friendly. Examples are Fy
a
 instead of FY001 and Fy 
(a+b-) instead of FY:1,-2 for the antigen and phenotype, respectively, see (see the ISBT 
website for more examples) (ISBT, 2016, Daniels et al., 2004, Daniels et al., 2007, 
Storry et al., 2011, Daniels, 2013). The 36 blood group systems are listed in Table 1.1, 
with the system name, the ISBT symbol, ISBT number, number of antigens per system, 





ISBT Number System name ISBT Symbol*  
No. of 
Antigens 
Gene name (**) Chromosome 
001 ABO ABO 4 ABO 9 
002 MNS MNS 48 GYPA,GYPB,GYPE (3) 4 
003 P1PK P1PK 3 A4GALT 22 
004 Rh RH 54 RHD,RHC (2) 1 
005 Lutheran LU 22 BCAM 19 
006 Kell KEL 35 KEL 7 
007 Lewis LE 6 FUT3 19 
008 Duffy FY 5 ACKR1 1 
009 Kidd JK 3 SLC14A1 18 
010 Diego DI 22 SLC4A1 17 
011 Yt YT 2 ACHE 7 
012 Xg XG 2 XG,  CD99 (2) 22 
013 Scianna SC 7 ERMAP 1 
014 Dombrock DO 10 ART4 12 
015 Colton CO 4 AQP1 7 
016 Landsteiner-Wiener LW 3 ICAM4 19 
017 Chido/Rodgers CH/RG 9 C4A, C4B (2) 6 
018 H H 1 FUT1 19 
019 Kx XK 1 XK 21 
020 Gerbich GE 11 GYPC 2 
021 Cromer CROM 18 CD55 1 
022 Knops KN 9 CR1 1 
023 Indian IN 4 CD44 11 
024 OK OK 3 BSG 19 
025 Raph RAPH 1 CD151 11 
026 John Milton Hagen JMH 6 SEMA7A 15 
027 I I 1 GCNT2 6 
028 Globoside GLOB 2 B3GALT3 3 
029 Gill GIL 1 AQP3 9 
030 RHAG RHAG 4 RHAG 6 
031 Forsman FORS 1 GBGT1 9 
Table 1.1 Blood Group Systems.  * When in italic, ISBT gene name. ** Gene name according to 







1.3 The molecular basis of blood group polymorphisms 
The cloning of the blood group genes allows the study of the genetic bases of blood 
groups, revealing polymorphisms and variations. This has paved the way for better 
understanding and investigation of the molecular background of blood group antigens. 
The cloning of blood group genes was first performed in 1986, when the blood group 
gene GYPA encoding the MN blood group antigens (of the MNS system) was cloned 
(Siebert and Fukuda, 1986). Subsequently, more genes were cloned to extend the 
investigation at the molecular level, such as ABO and RH in between 1990 and 1992 
(Yamamoto et al., 1990b, Avent et al., 1990, Le van Kim et al., 1992). Consequently, 
with the advances made in DNA analysis technology, such as sequencing techniques, 
more data regarding the molecular basis of most of the clinical blood group genes, such 
as polymorphisms, were acquired and suggested to be known (Daniels, 2013). The 
polymorphism can be defined as a character that is present in two or more different 
forms in a single population (Daniels, 2005). The expression of the diverse blood group 
antigens involves various polymorphisms in the genes at the molecular level. In fact, a 
number of genetic mechanisms account for polymorphisms, for instance single 
nucleotide polymorphisms (SNPs) and gene deletion. SNPs, which can be defined as a 
substitution of nucleotides in the gene, are the most common cause of the genetic 
diversity among blood group systems, if not the entire human genome. In fact, around 
1.42 million SNPs have been recorded in the human genome map (Sachidanandam et al., 
032 Junior JR 1 ABCG2 4 
033 Lan LAN 1 ABCB6 2 
034 VEL Vel 1 SMIM1 1 
035 CD59 CD59 1 CD59 11 
036 Augustine AUG 2 SLC29A1 6 
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2001), and this number increased significantly to almost 15 million SNPs as reported by 
the 1000 genome project in 2010 (Genomes Project et al., 2010) and the NCBI database 
(www.ncbi.nlm.nih.gov/snp). 
Polymorphisms can exist at various points in the gene, such as exons, introns, in splice 
regions (between exons and introns) and even in regulatory regions. With regard to 
SNPs occurring in exons (the coding region of the genes), they could be silent, whereby 
no apparent change may occur in the aa sequence or changes may be noted in the 
encoded product, i.e. the protein or the enzyme (glycosyltransferase), manifesting as 
missense or non-sense mutations. The missense SNPs in exons that lead to aa 
substitutions in the gene product account for the majority of blood group 
polymorphisms and antigen diversity (Storry and Olsson, 2004, Daniels, 2005). 
Nonsense SNPs are reported to cause substitution of the aa to a premature stop codon, 
resulting in a truncated gene product that might affect antigen expression. Such SNPs 
were reported in a previous study (Rios et al., 2000) which indicated the presence of 
various nonsense mutations in the exon 2 of the FY gene in three unrelated individuals 
belonging to different ethnicities with phenotype Fy (a-b-). The mutation changes the 
tryptophan to a premature stop codon, which prevents the expression of the Fy antigen 
on the red cell membrane and as suggested from all tissues. The mutations occurred at 
different points in each individual that is, G>A mutation at nucleotides 287, 408 in 
FY*A background and 407 in FY*B background (Rios et al., 2000). In addition to 
abolishing antigen expression, SNPs may weaken the antigenicity, reduce the number of 
antigen copies expressed, as seen in the Fy
x
 phenotype, reducing the expression levels 
of Fy antigens, particularly Fy
b
, on the RBC surface due to missense SNPs encoding aa 
change mainly, Arg89Cys along with the Ala100Thr (Tournamille et al., 1998, Olsson 
et al., 1998, Gassner et al., 2000). The emergence of polymorphisms is believed to 
occur as the result of exposure to pathogens, and therefore, the individuals’ blood group 
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antigens evolve to tolerate such pathogens. This can be seen in the case of individuals 
with the null Fy phenotype with no expression of the antigen which is suggested to be a 
receptor for the malaria parasite (Miller et al., 1975, Miller et al., 1976); such 
individuals are most likely resistant to the malarial parasite (to be discussed in FY 
section 1.6.1). Polymorphisms in introns, especially, at splice sites, might disrupt 
antigen expression. Splice site sequences are important for exon fusion after the 
removal of the introns in the mechanism of splicing during the formation of messenger 
RNA (mRNA) in the transcription process. Mutations that affect these splice sequences, 
particularly the conserved GT in the intron of the 5ʹ-donor splice site or the AG at -1 
and -2 of the 3ʹ-acceptor splice site (Berget, 1995, Zhang et al., 2003) might affect this 
process, leading to exon skipping and altered antigen expression. Examples of this 
effect can be seen in two studies investigating the null phenotypes JK and KEL. With 
regard to the JKnull phenotype, the analysis of Polynesian individuals with the phenotype 
Jk(a-b-) showed a SNP in the invariant G in the 3ʹ-acceptor splice site of intron 5 to A 
that resulted in exon 6 skipping, thereby affecting antigen expression (Irshaid et al., 
2000). Similarly, the K0 phenotype, in which K antigen is absent from the RBC 
membrane, was attributed to a SNP in the invariant GT>AT sequence at the end of the 
5ʹ-donor splice sequence in intron 3 (Lee et al., 2001). Mutations have been reported to 
occur in regulatory regions that might alter antigen expression. A common example 
would be as in African individuals with the Fy(a-b-) phenotype, in which  the Fy 
antigen expression is abolished from the RBCs as a result of a SNP in the binding site of 
the erythroid transcription factor GATA-1 in the promoter region of the FY*B 
background (Tournamille et al., 1995). This is, as mentioned before, a manifestation of 
the suggested evolution to avoid the pathogens since the FY antigen is a receptor for the 
malarial parasite and, especially Plasmodium vivax, which implies that those with such 
mutation are protected against infestation of P. vivax (Miller et al., 1976). Those with 
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null phenotypes, particularly rare ones, are vulnerable to immunisation through blood 
transfusion, and consequently, if immunised, the availability of matched blood would be 
difficult due to its rarity (Storry and Olsson, 2004). An example of which is the rare 
Rhnull phenotype, characterised by the lack of expressions of all Rh antigens, that may 
produce anti-Rh29 (which reacts with RBCs of all Rh phenotypes except Rhnull), if 
immunised (Daniels, 2013).  
In addition to SNPs, there are other genetic mutation mechanisms that account for 
polymorphisms of the blood groups. Deletion or insertion of nucleotides or the entire 
gene deletion can also affect the blood group antigen expression. The deletion of the 
entire RHD gene is a common reason for the absence of the expression of the D antigen 
leading to D-negative phenotype in Caucasians (Wagner and Flegel, 2000).  
Deletion of nucleotides has been reported to cause shift in the open reading frame of the 
sequence, thereby affecting the encoded amino acid (aa) after the deletion and altering 
antigen expression (Daniels, 2005).  This is illustrated in two diverse single nucleotide 
deletions in exons 6 and 7 of the A101 allele, accounting for the O01 and A201 alleles, 
respectively (Yamamoto et al., 1990a, Yamamoto et al., 1992). Furthermore, sequence 
duplication can also account for inactivation and loss of expression of antigens, as seen 
in Africans carrying an inactive RHD gene (RHDψ), pseudogene, with 37-bp 
duplication split between intron 3 and exon 4; this results in a reading-frame shift and 
premature stop codon, along with a nonsense mutation (Tyr269stop) in exon 6 
disturbing the RhD antigen expression on RBCs (Singleton et al., 2000). Intergenic 
recombination between homologous genes might alter or eliminate the expression of 
antigens and lead to various phenotypes. The Rh blood group system has been reported 
in cases of hybrid gene or crossover between RHD and RHCE in sharing sequences; this 
can result in a hybrid gene, RH (D-CE-D) that might abolish the expression of the D 
antigen in Africans (Daniels, 2005). Another example of the hybrid gene is the one 
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possibly responsible for the partial D phenotype (D
VI
 type I); this phenotype is encoded 
by a hybrid RH (D-CE-D) gene, in which exons 4 and 5 of the RHD gene are replaced 
by those of the RHcE allele (Avent et al., 1997). 
 
1.4 The immunogenicity of blood groups 
A number of blood group antibodies are considered clinically significant, leading to 
adverse reactions by damaging cells, especially RBCs, which carry the corresponding 
antigens. These antibodies may be naturally existing; for example, antibodies, mostly 
IgM, against the absent antigens of the ABO system are naturally present in blood. On 
the other hand, alloimmunisation with immunoglobulin G (IgG) antibodies occurs as a 
consequence of the exposure to blood group antigens absent in an individual, which 
generally occurs via transfusion or foeto-maternal haemorrhage during pregnancy. 
These antibodies result in various adverse effects, mainly haemolytic transfusion 
reaction (HTR) and haemolytic disease of fetus and newborn (HDFN) (Daniels, 2013), 
which are briefly described in the next subsections. 
 
1.4.1 Haemolytic transfusion reaction (HTR) 
The transfusion of mismatched blood units, particularly red cell units, may lead to the 
destruction of the transfused red cells (i.e. an HTR); this reaction can be mild or fatal. 
Intravascular HTR is characterised by rapid haemolysis, in which the circulatory RBCs 
are damaged within 10 minutes. This antibody-mediated haemolysis is caused by IgM 
antibodies that can activate the complement classical pathway, forming the membrane 
attack complex and puncturing the RBC membrane. As a result, free haemoglobin is 
released into the plasma, followed by clinical signs, such as haemoglobinemia, 
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haemoglobinuria, hypotension, chills, shock, and more serious complications of 
disseminated intravascular coagulation and renal failure. ABO antibodies, which are 
mainly IgM, are commonly the cause for intravascular HTR (Poole and Daniels, 2007, 
Dean, 2005).  
HTR can be extravascular, where the IgG antibodies are involved. This mostly occurs in 
the case of mismatch with clinically significant antibodies other than those of the ABO 
system. IgG antibodies rarely activate the complement to initiate the haemolytic process, 
but rather coat the RBCs which then bind the Fc receptors on macrophages in the spleen 
or liver and destroy them by phagocytosis. The clinical manifestations are similar to 
those of intravascular HTR but less severe. The extravascular HTR can be immediate 
(few hours) or delayed (few days, typically 5–7 days); the immediate reaction occurs 
when the antibody level is serologically detectable, whereas the latter occurs in cases 
with low levels of antibodies (often too low to be detected by serology). Examples of 
antibodies causing extravascular HTR are those of the Rh and JK systems (Poole and 
Daniels, 2007). 
1.4.2 Haemolytic disease of fetus and newborn (HDFN) 
HDFN occurs as a consequence of immunisation of an antigen-negative mother exposed 
to antigen-positive foetal RBCs (inherited from father), usually after foeto-maternal 
haemorrhage (FHM). As a result, the immune system of the mother is sensitised and 
forms antibodies, which are initially IgM that do not to cross the placenta. In subsequent 
pregnancies, the maternal antibodies are IgG (mostly IgG1 and IgG3), which are 
capable of crossing the placenta to enter the foetal circulation, acting against the foetal 
antigen on RBCs and coating the RBCs, leading to their destruction by macrophages in 
the spleen (Urbaniak and Greiss, 2000, Dean, 2005). This might lead to complications, 
such as jaundice, or pose risk to the foetus’ life. The antibodies of various blood group 
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systems, such as anti-D,-c, -K, Fy and Jk, are able to cause HDFN at different levels of 
severity although anti-D is known to be the most common cause (Basu et al., 2011, 
Poole and Daniels, 2007). Those of ABO, FY and JK will be discussed later (sections 
1.5.5, 1.6.3 and 1.7.3).  
A preventative management of HDFN, particularly that of anti-D, has been applied by 
the administration of IgG anti-D prophylaxis to unsensitised D-negative mothers. This 
likely reduces the risk of immunisation by coating the foetal RBCs leaked to the 
mothers’ circulation and thus rapidly destroying and removing these cells by 
macrophages in the spleen before triggering the mother’s immune response of 
alloimmunisation with anti-D (Kumpel, 2008). 
 
 
1.5 ABO blood group system  
In 1900-1901, the ABO system (001) was the first blood group system discovered by 
Karl Landsteiner (Landsteiner, 1961; Levine, 1961; Owen, 2000). In transfusion 
medicine, it is considered to be one of the most important blood group systems. This is 
because in contrast to other blood groups systems, such as the Rh system, the antibodies 
against A or B antigens are naturally present in the blood circulation of those with the 
absent antigens (Yamamoto, 2004, Storry and Olsson, 2009), thereby definitively 
causing a critical transfusion reaction in the case of mismatched blood units.  The ABO 
system consists of A, B, AB and A1 antigens, which are expressed on the red cells and 
on the surface of other types of cells and secretions. Accordingly, it can be also referred 
to as a histo-blood group system rather than a blood group system alone (Yamamoto, 
2004). As a result, matching for the ABO group is critical for both safe blood 
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transfusion and safe transplantation of cells, tissue and organs. Moreover, it can be used 
in forensic investigation for the detection of saliva, blood and hair traces found in crime 
scenes and used in suspect exclusion. Although the main ABO groups are A, B, AB and 
O, numerous subgroups encoded by a considerable number of alleles (381 alleles) with 
various polymorphisms (dbRBC, 2016) have also been reported. A number of these 
polymorphisms alter enzyme activity, resulting in various degrees of agglutination and 
patterns (Chester and Olsson, 2001). Pathogens and diseases may affect the expression 
of A and B antigens; for example, in cancerous tumours, glycosylation of the cell 
surface proteins is altered, which could be due to the down-regulation of the 
glycosyltransferase and thus affect the expression of A and B antigens (Dabelsteen and 
Gao, 2005, Yamamoto, 2004). 
 
1.5.1 Discovery  
The ABO blood group system was the first blood group system discovered, and 
therefore, it is marked with the number 001 as per the official ISBT terminology system 
(Daniels et al., 2004). In 1901, Landsteiner observed and described agglutination of 
individuals’ RBCs with liquid components (sera) of some of his colleagues but not with 
those of others. This phenomenon was later postulated to be due to the existence of 
naturally occurring antibodies (anti-A and anti-B) against the absent antigens in 
individuals; these antibodies probably occur as a result of natural immunisation by 
stimulation of substances, such as bacteria, food and pollen. In other words, anti-A and 
anti-B antibodies are absent in the serum of individuals who show expression of the 
respective antigens in their own red cells, whereas both antibodies are present in those 
with group O, who do not express any of the ABO antigens on their red cell surfaces 
(Watkins, 2001) (Table 1.2).  Subsequently, according to the agglutination pattern, the 
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ABO system was categorised by Landsteiner into three main groups, A, B, and O 
(originally called C), with O being derived from the German word “ohne”, which means 
“without” (Landsteiner, 1961, Levine, 1961, Owen, 2000, Watkins, 2001). 
Subsequently, one more group (AB) characterised by expression of both antigens and 
absence of both antibodies was described in the following year by Decastello and Sturli 
reviewd by (Watkins, 2001), thus making four blood groups in the ABO system and 
four basic phenotypes (A, B, AB and O) (Yamamoto, 2004)  (Table 1.2).  
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Table 1.2 Basic concept of ABO system with the relation between antigens and antibodies. 
 
1.5.2 Biosynthesis of ABO blood group antigens  
The A and B antigens along with the H antigens are carbohydrate determinants on 
glycoproteins (mainly) or glycolipids on red cells and other tissues (Yamamoto, 2004). 
The synthesis process can be described as a sequential addition of monosaccharides into 
oligosaccharide chains with polypeptides forming glycoproteins or with ceramide to 
form glycolipids (Clausen et al., 1994). The process is initiated by the action of the 
glycosyltransferase enzymes, the product of the ABO system genes, in transferring the 
specific immunodominant sugar of A or B antigens from the nucleotide substrate (donor) 
to the acceptor substrate (the H antigens), which is the main carbohydrate foundation for 
the formation of the A and B antigens (Storry and Olsson, 2009). 
The synthesis of the ABO antigens is dependent on the H antigens, which is the main 
foundation upon which the structure of A and B antigens are built (Morgan and Watkins, 
1948). H antigen is inherited by two genes, FUT1 and FUT2, located on chromosome 
19. FUT1 encodes for 2-α-L-fucosyltransferase (α2FUCT1), which is responsible for 
the production of H antigen on precursor type 2 that lies on mesodermal cells, including 
RBCs, whereas FUT2 is responsible for H antigen synthesis in secretions mainly on 
precursor type 1 with 2-α-L-fucosyltransferase (α2FUCT2) enzyme. Briefly, these 
enzymes catalyse the transfer of the Fucose (FUC) from guanosine diphosphofucose 
ABO Blood Group Red Cell Antigen Antibodies in Serum 
A A Anti-B 
B B Anti-A 
O None Anti-A,B 
AB A and B None 
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(GDP-L-fucose) donor to the terminal galactose of one of the precursor types. These 
structures act as an acceptor substrate for the carbohydrate determinants transferred by 
the A and B glycotransferase, GTA and GTB, respectively, which are the products of 
the ABO gene to form A and B antigens (Daniels, 2013).    
The ABO blood group is occasionally called the ABO histo-blood group due to its 
widespread distribution among the tissues, depending on  the H antigen and the 
precursor type (Storry and Olsson, 2009). The antigens found on the type 2 precursor 
and encoded by FUT1 account for the main ABO antigens present on red cells, whereas 
type 1 precursor along with FUT2 are mainly the holders for the ABO antigens in 
secretions, for example plasma (Mollicone et al., 1995). Consequently, the A and B 
antigens are absent from red cells and secretions in individuals who lack H antigen 
(silenced FUT1 and 2); this phenotype is referred to as the Bombay phenotype (Oh) 
(Storry and Olsson, 2009, Moores et al., 1975, Yunis et al., 1969). 
Blood group A is formed as a result of the act of the A allele that encodes for an enzyme 
3-α-N-acetylgalactosaminyltransferase (GTA), which catalyses the transfer of N-acetyl-
D-galactosamine (GalNAc), the immune dominant sugar of A antigen from the donor 
substrate uridinediphosphate (UDP)-N-acetylgalactosamine to the fucosylated 
galactosyl (Gal) residue of the H antigen (H precursor) Fuc α (1-2)Galβ-GlcNAcβ-R. 
On the other hand, individuals with blood group B possess the B allele that encodes for 
the 3-α-galactosyltransferase (GTB), which catalyses the transfer of galactose from 
UDP-galactose to the H precursor via a process similar to the one described for the A 
group (Daniels, 2005, Hosoi, 2008) see (Figure 1.1).  With respect to group O, however, 
its alleles lack the production of active enzyme, leaving the H antigens unaltered, 
thereby suggesting that those with blood group O illustrate the highest amount of H 
antigens (Daniels, 2005, Yamamoto et al., 1993). AB individuals inherit both A and B 





Figure 1.1 A brief diagram of A, B and H antigen (also O group) oligosaccharides 
structure biosynthesis.  
The process of the synthesis of the group A and B antigens from H antigen is shown, by 
A-transferase and B-transferase enzymes, the products of A and B alleles. R, remainder of 
molecule; GlcNAc, N-acetylglucosamine; Gal, galactose; Fuc, fucose; GalNAc, N-


















1.5.3 Inheritance and molecular genetics  
The ABO antigens, carbohydrate antigens, are encoded indirectly by the ABO gene as 
the gene encodes for the glycosyltransferase enzymes, which are involved in the 
synthesis of the antigens (Green, 1989, Watkins, 2001). The ABO blood group system 
are recognised as inherited, with the A and B antigens being inherited codominantly and 
O being inherited recessively (Storry and Olsson, 2009, Yamamoto, 2004).  
The ABO glycosyltransferases are transmembrane proteins of the Golgi apparatus that 
consist of short N-terminal domain (cytoplasmic) and large C-terminal catalytic domain 
(Figure 1.2) (Paulson and Colley, 1989). They also show to contain two domains that 
recognise the acceptor substrate (H antigen) and the donor substrate (UDP-Gal or UDP-
GalNAc) (Patenaude et al., 2002). Therefore, the effect of the genetic variations and 
polymorphisms would further increase the complexity of the expression due to the 
sequential actions of different gene (ABO and H) products that are enzymes involved in 
the synthesis of the ABO antigens.   
The ABO cDNA encodes for GTA was cloned by Yamamoto (Yamamoto et al., 1990b). 
The ABO gene is located on the long arm of chromosome 9 (9q34) (Bennett et al., 1995), 
consisting of 7 exons spanning about 20 kilobase pairs (kbp) that encode for 
glycotransferase of 354 aa. Exons 6 and 7 hold the majority of the coding sequence, 
accounting for 77% of the enzyme, particularly the catalytic domain (Yamamoto et al., 







Figure 1.2 Diagramatic illustration of the products (glycotransferases), of four ABO alleles, located in Golgi membrane. 
The ABO glycotransferases are transmembrane proteins of Golgi apparatus that consist of short N-terminal domains (cytoplasmic) and large C-
terminal catalytic domains. The amino acids (aa) and their locations that differ from those of the A1 transferase are shown. A and B transferase 
differ by four amino acids at positions 176, 235, 266 and 268 in the C-terminal. A2 transferase differs from A1 by aa change at location 156 
(underlined) with a C deletion at 1061 in A201 allele, leading  to 21 aa longer C-terminal. A deletion in exon 6 in O01 allele leads to a truncated 
glycotransferase (catalytic domain affected) (adapted from Avent ND 2016 Transfusion and transplantation science in preparation. Oxford 
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106G>T   
Val36Phe  
Figure 1.3 The  ABO gene (seven exons and six introns). 
ABO gene is approximately 20039 bp (According to NCBI GenBank) with 7 exons shown as boxes while the 6 introns are illustrated as a fine line. 
Crucial polymorphisms, most of which encode for amino acid changes, are illustrated: those that differ between the A
1
 (A101) and the B (B101) allele are 
(Gly268Ala, Leu266Met, Gly235Ser, and Arg176Gly), (1061delC and Pro156Leu) are associated with A
2
 (A102) allele, the 261delG are with O
1 
(O01), 
which is also associated with (O02) allele along with Pro74Ser, Arg63His and Val36Phe. The order of the exons is in reverse direction (right to left) due 





1.5.4 ABO polymorphisms (ABO alleles) 
The ABO gene is known to be significantly polymorphic, especially in exon 7, giving 
rise to a considerable number of alleles. Some polymorphisms affect the specificity of 
the product (glycotransferase) that accounts for the blood groups A, B or O, whereas 
other mutations might affect the enzyme activity, giving rise to weakened expression of 
ABO blood group phenotypes (antigens) that are referred to as subgroups. These 
polymorphisms can occur in various parts of the ABO gene with different mechanisms, 
such as exons, introns and regulatory regions (Chester and Olsson, 2001). There has 
been a significant growth in the number of the ABO alleles due to the continuous 
emergence of the polymorphisms in the ABO alleles. Seventy-two different ABO alleles 
were mentioned in 2001 by Chester and Olsson; this number grew to 215 alleles in 2009 
(Storry and Olsson, 2009), and most recently, in August 2016, the Blood Group Antigen 
Gene Mutation Database, ‘dbRBC’ reports 381 ABO alleles (dbRBC, 2016), some of 
which might result in different patterns and levels of agglutination in serology, if 
antigenicity is affected (Yamamoto, 2004). 
The common allele of A (A101) (often considered the consensus allele) varies from the 
B (B101) allele by seven nucleotides in exon 6 (297 A/G) and in exon 7 (526 C/G), 
657C/T, 703 G/A, 796 C/A, 803G/C and 930G/A), four of which encode for aa changes 
Arg176Gly, Gly235Ser, Leu266Met and Gly268Ala in the produced enzymes 
(Yamamoto et al., 1990a, Daniels, 2005). On the other hand, the most common O allele 
(O01) shows an identical sequence to that of A101 apart from a G deletion in exon 6, 
which causes a shift in the reading frame altering the aa sequence after aa 88. As a result, 
a premature stop codon signal is present after aa 117, which encodes for an inactive 




The A antigen is divided into two common subgroups—A1 and A2 subgroups—which 
can be serologically distinguished by the anti-A and anti-A1 antibodies.  A1 reacts with 
anti-A and A1, whereas A2 reacts with anti-A but not with anti-A1 (Daniels, 2005).  The 
A2 phenotype is commonly encoded by the A201 allele, which differs from A101 by a 
missense SNP in exon 7 (467C>T, Pro156Leu) and a deletion in the codon before the 
translation stop codon in exon 7. Consequently, a disruption in the stop codon occurs, 
resulting in the production of an enzyme with an extra 21 aa at the C-terminus which are 
likely responsible for reducing its activity. This leads to possibly lower A antigen 
expression and a weaker phenotype on the red cells comparing to case with the 
production of the GTA enzyme in the A1 phenotype (Yamamoto et al., 1992). 
There are considerable ABO alleles, some of which result in weak expression of the 
antigens (subgroups) with various genetic polymorphisms and hybrid genes. The 
detailed discussion of these alleles, which occur at various frequencies among 
populations, is not within the scope of this thesis (Reid et al., 2012, dbRBC, 2016, 
Chester and Olsson, 2001). Another example of the A1 allele is A102, which differs 
from A101 by SNP 467C>T, Pro156Leu, and is common among Asians (Reid et al., 
2012). With regard to O alleles, another common allele is O02, which shows a G 
deletion in exon 6 but differes from O01 by nine SNPs spread across exons 3-7 (Olsson 
and Chester, 1996, Reid et al., 2012). Several other weak expression subgroups have 
been attributed to hybrid alleles (crossover between two different alleles) (Chester and 
Olsson, 2001). An example of subgroups with weak expression is the Ax phenotype. 
One possible molecular mechanism for this phenotypes is hybrid alleles of O02 and B 
or A, with exon 7 from the former and the rest from the latter; the contradiction between 
exon 7 of the O allele (normally encoding for silencing enzyme) without the deleteion 
in exon 6 leads to an unexpexted phenotype with weak antigen expression (Olsson and 




Polymorphisms in introns have been reported to be specific for alleles; for example, 
introns 6 of A101 and O101 have been described to be identical, whereas that of B101 
and O02 differ by 12 and 13 positions, respectively, (Chester and Olsson, 2001). In 
addition, intron polymorphisms might have an affect on the antigen exprssion. Bm 
phenotype, which is charaterised by the reduced expression of B antigens on the RBCs, 
is associated with a deletion in an erythroid-specific regulatory element containing 
binding sites for the GATA-1 haemopoietic transcription factor. This deletion is located 
in intron 1 (5.6–6.1 kb from the beginnging of the ABO gene) (Sano et al., 2012), which 
is speculated to cause downregulation of allele (B
m 
allele) transcription. With regard to 
the upstream area of the ABO gene, it has been pointed out that a minisatellite (sequence 
repeats) of 43 bp might play a role in transcription reglution since it contains a CBF/NF-
Y transcription factor binding site (Kominato et al., 1997). Further, it has been reported 
that various ABO alleles carry different number of repeats as four copies were carried in 
A201, B101, O101 and O02, whereas A101 and O03 (O
2
) have one repeat (Irshaid et al., 
1999). Vartiations in these sequences might disrupt the ABO antigens, which has been 
implicated in the weak expression of the B antigen in two samples that might be as the 
result of reduced number of the 43-bp repeats (Seltsam et al., 2007).  
These various polymorphisms and alleles, along with their distribution, are suggested to 
be the result of evolution, possibly to tolerate pathogens (Storry and Olsson, 2009, 
Yamamoto, 2004). The common G deletion in exon 6 is suggested to appear once in 
human evolution of the more ancient O02 allele and the O01 allele arised from 





1.5.5 ABO antibodies (clinical significance) 
The antibodies of the ABO system (anti-A and anti-B) are naturally occurring 
antibodies in the sera of those lacking the antigens (as explained earlier) from the age of 
six months. They are thought to be the result of exposure to environmental materials, 
such as bacterial carbohydrates (A- and B-antigen-like), found in bacterial cell walls, 
that evoke the immune response (Watkins, 2001). This can be seen in the study where 
children of blood group A were fed parenterally in an attempt to avoid introduction of 
bacteria, leading to the absence of the expected B antibodies (Storry and Olsson, 2009). 
In addition, the anti-B activity increased in infants (groups A and O) fed by bacteria 
(Escherichia coli O86), which mainly resembles antigen B activity in vitro (Springer and 
Horton, 1969). Anti-A and anti-B antibodies are mainly IgM, but also may exist as IgG. 
As a consequence of their characteristics, i.e. natural occurrence and immediate 
reactivity, A and B antibodies are considered to be the most clinically significant in 
transfusion. A major mismatch in red cells, for example from donor A to recipient B, 
could lead to rapid haemolytic transfusion reaction (HTR) (section 1.4.1), which can be 
fatal (Janatpour et al., 2008). On the other hand, the effect of those antibodies seems to 
be rare and mild in the case of haemolytic disease of the newborn. Mainly, this occurs 
in group O mothers of foetuses with other blood groups (A or B) in that the mothers 
may have low levels of IgG antibodies capable of crossing the placenta and the density 
of A and B antigens on the foetal RBCs are stated to be low (Daniels, 2013). In addition, 
since the ABO antigens are expressed in various bodily tissues, the corresponding 
antibodies may impact the success of solid organ transplantation. Although anti-A and 
anti-B antibodies might cause hyperacute rejection of solid organs, such as the heart and 
liver, ABO-mismatched renal transplantation has become common practice. It is 
accomplished with the treatment of the recipient by reducing the antibody level in the 
recipient plasma (Daniels, 2013, Storry and Olsson, 2009). 
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1.6 Duffy blood group system (FY) 
The FY blood group system is considered to be a clinically significant blood group 
since it is reported to be involved in HTR and HDFN cases. The Fy glycoprotein is 
located on RBCs and other tissues and has been suggested to act as a chemokine and 





 antigen was recognised during an investigation of a case of 
haemolytic transfusion reaction. The patient (surname was Duffy) suffered from rigors 





 were discovered one year later, reviewd by (Meny, 2010, 
Westhoff and Reid, 2004). The FY gene locus is the first human gene to be assigned to 




are inherited in a 
codominant fashion of FY*A and FY*B alleles. Other alleles encode weakened antigen 
expression or abolish the antigen expression (Meny, 2010, Reid et al., 2012). 
1.6.1 Duffy glycoprotein and FY gene. 
Duffy glycoprotein has been suggested to act biologically as a receptor for chemokines, 
which are signals involved in the interaction between cells required for various 
processes, such as activation and movement of leucocytes (chemotactic cytokines) 
(Davenport, 2009). As a result, the Fy glycoprotein was named Duffy Antigen Receptor 
for Chemokines (DARC). However, the Fy glycoprotein structure has been shown to 
differ from the conventional (typical) chemokine receptors in terms of lacking the motif 
Asp-Arg-Tyr/DRY in the second cytoplasmic loop that is required for binding G-protein, 
leading to lack of signalling ability. Accordingly, the Duffy glycoprotein has been 
assigned to a new chemokine class namely (Atypical Chemokine Receptor) and named 
ACKR1, which is also the name of the FY gene according to HGNC (ACKR1) 
(Bachelerie et al., 2014, Bachelerie et al., 2015). The function of the Fy glycoprotein is 
not entirely known, although some suggest that it acts as a sink or scavenger present on 
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RBCs for binding the excess plasma proinflammatory chemokines to prevent activation 
of neutrophils and inflammation (Pruenster and Rot, 2006). This was seen in a study 
that compared the chemokine levels in the RBCs of Duffy-positive and Duffy-negative 
volunteers intravenously infused with endotoxin; as compared to the Duffy-negative 
cohorts, the level of the chemokine was higher in those with positive Duffy expression 
(2-3 times in plasma) and 20-50 times associated with RBCs (Mayr et al., 2008). 
Another role of the Duffy glycoprotein is a receptor for the malarial parasites, P. vivax 
and Plasmodium knowlesi (Miller et al., 1975). In an experiment, in which 11 patients 
exposed to P. vivax mosquitos were tested, only those with Fy(a-b-) phenotype were 
found to be resistant (Miller et al., 1976). This has been suggested to occur due to an 
interaction of the P. vivax Duffy-binding protein (PvDbp) with the Duffy antigen on 
RBC to allow infection (King et al., 2008). As a result, those with the phenotype Fy (a-
b-), which are mainly of black African ethnicity (Reid et al., 2012), are most likely 
resistant to malaria (Miller et al., 1976). Consequently, the P. vivax malaria strain is 
absent in West Africa, where the majority of the population is Fy(a-b-) (Meny, 2010). 
Fy antigens are reported to be also expressed on the epithelial cells of other organs, 
including the kidney (Hadley et al., 1994, Chaudhuri et al., 1997).  
The Fy glycoprotein (antigen), which is encoded directly by the FY gene, is a 336-aa 
(N-glycosylated) protein, spanning the RBC membrane seven times, with extracellular 
N-terminus (glycosylated) and cytoplasmic C-terminus, as shown in Figure 1.4 
(Westhoff and Reid, 2004). It is the product of the major and more abundant mRNA 
form from the FY gene.  
The FY or ACKR1 gene is  located on the long arm of chromosome 1 (1q21-22) (NCBI, 
2016b). Two forms of mRNA transcripts have been described, with a single exon in one 
and two exons in the other (Daniels, 2013) encoding for minor and major forms of the 
Fy glycoprotein, respectively. Firstly, the FY cDNA was cloned and described to be 
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encoded by one exon gene that produces a 338-aa glycoprotein (Chaudhuri et al., 1995, 
Iwamoto et al., 1995). Subsequently, it was described that a predominant and more 
abundant transcript consists of two exons, with the first containing the translation-
initiating codon (Met), and separated by a 479-bp intron. This transcript encodes for the 
major form of the glycoprotein with 336 aa (Iwamoto et al., 1996a). The major and 
predominant form of the glycoprotein and the mRNA has been preferably used for the 
numbering of the nucleotides and aa and will be used for this project (Reid et al., 2012, 
Daniels, 2013, dbRBC, 2016). 





 antigens are inherited co-dominantly by FY*A and FY*B alleles, manifested 
by three phenotypes, namely Fy (a+b-), Fy (a-b+) and Fy (a+b+). The two alleles differ 
by a missense SNP at location 125 in exon 2 (G in FY*A and A in FY*B) that encodes 




 (Figure 1.4) 
(Tournamille et al., 1995b, Reid et al., 2012). Other Fy high-frequency antigens are Fy3, 
Fy5 and Fy6, which are detected by reactions with specific antibodies. Fy3 is found on 
RBCs of all Duffy phenotypes apart from those with Fy (a-b-) and located on the third 
extracellular loop of the glycoprotein (Wasniowska et al., 2004) (Figure 1.4). This 
antigen is defined by anti-Fy3, which is synthesised by immunised individuals with the 
Fy (a-b-) phenotype; therefore, those with anti-Fy3 antibody should be transfused with 
Fy (a-b-) red cells (Daniels, 2013). Unlike, Fy
a/b
, Fy3 antigenic determinant is resistant 





 phenotypes but not those of Fy (a-b-) (Meny, 2010). Fy5 is similar to Fy3 as 
it is resistant to enzyme treatment but differs by its absence in individuals with Rhnull 






 and thus Fy3 antigens (Meny, 2010, Daniels, 2013). 
Anti-Fy6 antibody, which is a murine antibody, recognises a linear epitope located on 
the N-terminal extracellular domain of the Fy glycoprotein between aa 19 and 26 
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(Waśniowska et al., 1996, Wasniowska et al., 2004, Daniels, 2013). Fy6 is found in all 
Duffy-positive phenotypes, and unlike Fy3, it is sensitive to enzyme treatment, such as 
papin (Daniels, 2013). 
The expression of Fy antigens has been reported to be weakened or abolished by 
different polymorphisms and thus alleles (Reid et al., 2012). An example of the 
weakened Fy antigen expression phenotype is the Fy
x
 phenotype, Fy (b+
w
), which is 
characterised by a reduced expression of Fy
b
 along with decreased expression of Fy3, 
Fy5 and Fy6 antigens encoded by the allele on the FY*B background (FY*02M.01). 
This allele resembles the backbone of FY*B allele but carries a missense SNP 265C>T 
in exon 2 that leads to an aa change Arg89Cys located in the first cytoplasmic loop of 
the Fy antigen (Figure 1.4). This might lead to the instability of the glycoprotein, 
compromising its insertion in the RBC membrane (Tournamille et al., 1998, 
Yazdanbakhsh et al., 2000). In addition, another aa change, Ala100Thr (due to 298G>A 
in exon 2), exists in those with Fy
x 
encoded by FY*02M.01, but it is stated that there is 
no effect on reducing the antigen expression if this change is present alone (Olsson et al., 
1998, Gassner et al., 2000). This weakened phenotype might be mistyped by serology as 
Fy
b
 negative that might lead to delayed HTR in an immunised recipient (Olsson et al., 
1998, Daniels, 2013) Serologically, it has been shown to be  impossible to distinguish 
between the heterozygous FY*B/X and FY*B/B) (Daniels, 2013). Moreover, the null 
phenotype Fy (a-b-), which is common among black individuals of African descent 
(about 70%)  has been reported to arise from various polymorphisms (Meny, 2010, 
Daniels, 2013). One example is the common allele (FY*02N.01) among blacks of 
African origin, which is carried on the FY*B background (identical to FY*B) but with 
SNP T>C 67bp upstream (-67) of the major translation start codon, which is in the 
GATA  promoter region, disrupting the binding site of the erythroid transcription factor 
(GATA-1) (Tournamille et al., 1995). Consequently, since this erythroid promotor 
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controls the antigen expression on RBCs, those with this allele lack the Fy antigen 
expression on RBCs but not other cells, such as endothelial cells in the spleen (Peiper et 
al., 1995, Iwamoto et al., 1996b). Accordingly, those with this phenotype are believed 
to possess only anti-Fy
a
 antibodies but not anti-Fy
b
 antibodies (Westhoff and Reid, 
2004).  Although it has been associated with FY*B, this GATA mutation has 
subsequently been seen on the FY*A background (FY*01N.01) in Papua New Guinea 
(Zimmerman et al., 1999). The null phenotype is reported to be rare in ethnic groups 
other than those of black origins (Daniels, 2013, Reid et al., 2012). Those arising from 
various polymorphism mechanisms such as nonsense SNP, leading to stop codon or 
nucleotide deletion. For example, the allele FY*01N.02 carries a 14-bp deletion in exon 
2 in FY*A, resulting in a reading frame shift and stop codon in Caucasians (Mallinson et 
al., 1995). In addition, a nonsense SNP leading to premature stop codon has been 
reported to occur in both FY*A and FY*B backgrounds of Caucasians in exon 2. For 
FY*A: 408G>A and 287G>A, to account for the silencing alleles FY*01N.03 and 
FY*01N.04, respectively, while 407G>A accounts for FY*02N.02 (FY*B background). 
These alleles encode for truncated protein, that unlike that of black Africans, leads to 
loss of expression in all cells, including RBCs (Rios et al., 2000). According to 
BGMUT database, there are 16 variant FY alleles with various polymorphisms that 
might affect the expression, and the number is expected to continually increase due to 
the discovery of novel SNPs and alleles not yet included; for example, two novel 
silencing FY*B alleles were described in 2014 to result from 2 nucleotides deletion and 
a missense SNP 895G>A leading to Ala299Thr, respectively (Westoff et al., 2014, 













RBC membrane  
Extracellular 
Figure 1.4. The structure of the Duffy protein (7-transmembrane domain). 
The Fy glycoprotein spans the RBC membrane seven times, with extracellular 







 are shown. In addition, Fy 3 location, which is detected by 
antibody, is displayed (adapted from Avent ND 2016, Transfusion and 






















1.6.3 FY antibodies (clinical significance) 
FY antibodies exist as a consequence of immunisation via exposure to the 
corresponding antigens acquired through blood transfusion or, rarely, pregnancy (Meny, 
2010, Daniels, 2013). They are mostly IgG, IgG1 and, rarely, IgM (Westhoff and Reid, 
2004), and they could lead to immediate and delayed HTRs (Poole and Daniels, 2007) 




antibodies (Daniels, 2013). 
Therefore, it is suggested that red cells with the negative Fy antigen should be given to 
those with pre-existent antibodies.  




 antibodies usually lead to mild reactions, 
although it can be severe, as seen in the case of three incidences out of 68 cases 
possessing anti-Fy
a
 requiring intrauterine transfusion due to anaemia in the foetus 
(Goodrick et al., 1997). 
1.7 Kidd blood group system (JK)  
The JK blood group system is considered to be among one of the most clinically 
significant groups after ABO and Rh systems; the antibody pertinent to this system 
might lead to transfusion reactions or HDFN. The discovery of the Kidd blood group 
system was made in 1951 when HDFN was investigated in a patient (Mrs Kidd) leading 




 antibody was described two 
years later in an individual with a transfusion reaction (Plaut et al., 1953, Westhoff and 
Reid, 2004). Subsequently, the anti-Jk3 antibody was detected in individuals with 





(Irshaid et al., 2000). Accordingly, three Jk antigens are recognised by ISBT for the JK 









1.7.1 JK glycoprotein and the JK gene 
The JK glycoprotein is suggested to act as a urea transporter, as shown in a urea lysis 
test. It has been reported that RBCs with the phenotype Jk (a-b-) are resistant to lysis, 
while those with the common Jk phenotype are rapidly lysed in 2 M urea (Heaton and 
McLoughlin, 1982, Daniels, 2013). Kidd glycoproteins are distributed on red cells and 
other tissues, such as kidney, brain and heart tissues (Olivès et al., 1996). The 
glycoprotein is an integral protein spanning the membrane ten times with both the N- 
and C-terminal being intracellular and N-glycosylation being present at Asn211, which 
is on the third extracellular loop (Lucien et al., 2002b) (Figure 1.5).  
The JK gene (SLC14A1) is located on chromosome 18 at 18q12.3 (NCBI, 2016b) and 
consists of 11 exons distributed over about 30 kb. The translation start codon is located 
in exon 4; therefore, exons 411 account for the production of the mature protein, which 
consists of 389 aa (Cartron et al., 1998, Lucien et al., 1998). In addition, -837 to -336 
upstream contains the erythroid-specific GATA-1 transcription factor binding site 





















Figure 1.5 The Kidd glycoprotein, showing 10 membrane spanning domains.  




, is located on the fourth loop. Glu44Lys, is associated with 
weak Jk
a
 expression, which is also shown. The N-glycan on the extracellular loop is also 
displayed. (Adapted from Avent ND 2016, Transfusion and Transplantation Science, Oxford 
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 are inherited via a co-dominant mechanism by the JK*A and JK*B 
alleles, respectively  (Daniels, 2013). JK*A and JK*B alleles differ by a missense SNP 
(838G>A) in exon 9 that encodes for the aa change Aps280Asn that is located on the 
fourth extracellular loop of the Jk glycoprotein. It has also been pointed out to differ by 
a silenct SNP in exon 7 (588A in JK*A and 588G in JK*B) (Olivès et al., 1997, Irshaid 




 RBCs, although the responsible 
specific aa is unknown (Westhoff and Reid, 2004) (Figure 1.5).  
The inheritance for the Jk null phenotype has been suggested to be due to homozygous 
or heterozygous inheritance of recessive silencing alleles with inactivating mutations 
and is rare in some ethnic populations but abundant in Polynesians (Reid et al., 2012). 
Those with this phenotype produce anti-Jk3 antibodies upon immunisation (Daniels, 
2013) and might require Jk3-negative units (Irshaid et al., 2000). Several polymorphism 
mechanisms have been reported to account for silencing alleles which could be on the 
background of JK*A or JK*B, such as SNPs (missense and nonsense) in exons, splice 
sites and exon deletion (Reid et al., 2012, Daniels, 2013). Two different SNPs among 
two populations were described in a study by Irashid et al (2000): one occurs in the 
invariant acceptor splice site on intron 5 (G>A) that led to skipping to exon 6 in 
Polynesians, and the other was a missense SNP (871T>C, Ser291Pro) observed in Finns; 
both were expected to abolish the expression by affecting glycosylation (Irshaid et al., 
2000). The abolished antigen expression has been shown to be also caused by exon 
deletion, for instance, the deletion of exons 4 and 5 has been reported to account for the 
null Jk phenotype as the translation initiation codon in exon 4 is absent, affecting the 
production of the Jk glycoprotein (Irshaid et al., 2002, Lucien et al., 2002a). On the 
other hand, it has been suggested that an inheritance of a dominant gene In(JK), which 
appears to be unrelated to the JK gene might account for a silent phenotype although the 
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molecular basis is yet unknown (Daniels, 2013).  




) has been reported and might be due to 
polymorphisms, particularly SNPs, in various parts of the coding areas (exons) within 
diverse alleles (Reid et al., 2012). One example is the allele JK*01W.1 described by 
Wester et al (2011), which occurs on a JK*A background and results in reduced 
expression of mainly the Jk
a 
antigen. This allele holds a missense SNP (130G>A) that 
leads to aa change Glu44Lys that is suggested to locate in the cytoplasmic N-terminal 
domain (Figure 1.5) along with JK*B-like silent SNPs 588G and -46G in intron 9. 
Homozygous or heterozygous inheritance of that allele has been shown to react weakly 
with anti-Jk
a
 antibodies, that might lead to false-negative interpretations of Jk
a 
 and 
possible HTR (Wester et al., 2011). Different other polymorphisms have also emerged, 
leading to 36 JK alleles reported so far in the BGMUT database (dbRBC, 2016). 





, which are mainly IgG or mixed with IgM, have been 
reported to cause HTRs that can be severe (Hussain et al., 2007, Daniels, 2013). They 
are more commonly associated with delayed HTRs due to their tendency to drop to 
undetectable levels in the plasma (Schonewille et al., 2006). It is estimated that around 
one-third of delayed HTRs (DHTRs) were due to anti-Jk
a
 (Pineda et al., 1999). In 
addition, anti-Jk3 antibody has been reported to cause severe immediate and delayed 
HTR (Marshall et al., 1999, Daniels, 2013).  As a result, matching blood units (antigen-
negative) for those with Kidd antibodies is preferable. On the other hand, with respect 
to HDFN, Kidd antibodies are rarely associated with severe cases, although a few 





1.8 Blood group genotyping  
1.8.1 Serology and genotyping 
The determination of the individual blood group type is of great clinical importance for 
the safety of blood transfusions and organ transplantations. Identifying the blood group 
type has been routinely accomplished through simple serology utilising the 
agglutination process. The RBC agglutination is inhibited due to the negative charge on 
their surface owing to the sialic acid residues. Specific antibodies react with antigens on 
the RBCs to bridge the gap between adjacent RBCs causing agglutination (Pamphilon 
and Scott, 2007). The direct antiglobulin test (DAT) is used to investigate whether 
RBCs are sensitised by antibodies, for example in autoimmune haemolytic anaemia, in 
which antihuman globulin is added to patient’s sensitised RBCs causing agglutination. 
On the other hand, indirect antiglobulin test (IAT) can be used for matching blood units, 
for instance; the antibodies in the recipient plasma are tested against the donor’s RBCs, 
when they are added together, followed by the addition of antihuman globulin to check 
for agglutination (Coombs and Roberts, 1959).  
Despite the fact that the serological approach has been found to be reliable, cheap, 
simple and sensitive in defining the blood group status in individuals and been the gold 
standard approach for the transfusion practices, serological typing holds limitations that 
can be overcome by DNA-based analysis. Examples of such circumstances include 
determination of the blood group of multi-transfused patients, which can possibly carry 
mixed blood antigenicity from donor’s RBCs, leading to inaccurate serological typing 
(Reid et al., 2000). In addition, serological typing is difficult in the case of limited 
availability of manufactured antisera for a number of infrequent blood groups (like the 
case of Dombrock system) (Baumgarten et al., 2006). Other drawbacks are difficulty in 
addressing discrepancies and in interpretation of unexpected weak antigen expression 
(phenotype) due to allelic variation, especially rare, at the molecular level (McBean et 
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al., 2014). Moreover, on a large scale, serological typing can be labour intensive and 
expensive in terms of the need of a large number of reagents to include a wide range of 
antigens. As a result, the high-throughput typing for donors using serology is unfeasible, 
which results in a low number of inventories for antigen-negative blood (matched blood 
especially for multi-transfused individuals) (Reid, 2009). Therefore, genotyping, 
particularly high throughput, has been considered for typing the blood group antigens of 
patients and donors in order to provide extensively matched blood units. Accordingly, 
this might lead to a fully typed donor database, preventing further transfusion reactions 
(Avent, 2009, Veldhuisen et al., 2009); thus, genotyping would be superior to serology 
if performed in high throughput and with high accuracy. In addition, the phenotype of 
individuals with IgG-coated RBCs is difficult to be assigned by serology (Reid, 2009). 
The limitations of serology have been suggested to be solved by blood group 
genotyping (BGG), which is being used for such circumstances, but generally to support 
serology (Avent, 2009). 
The molecular background, the gene sequence and polymorphisms affecting antigen 
expression of the majority of the human blood groups, particularly the clinically 
significant ones, has been defined. This knowledge regarding these topics has 
accelerated since the cloning of the major blood group genes RH (Avent et al., 1990) 
and ABO (Yamamoto et al., 1990a). A large amount of molecular information, 
including various genetic mechanisms, such as SNPs (see section 1.3) account for a 
great number of emerging alleles, some of which affect the expression of the antigens. 
The number of these polymorphisms and alleles is increasing; the number of alleles 
identified previously was 1568, which has increased to 1779 at present and is expected 
to grow further (McBean et al., 2014, dbRBC, 2016). As a result, these vast variations 
in antigen expression pose challenges to comprehensive analysis of blood groups via 
serology. For example, a significant number (over 50) of monoclonal anti-D is 
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necessary to cover the D epitopes in order to differentiate among partial D variants 
phenotypes (Avent, 2009). As in the case of RhD and other blood groups, those variants, 
such as those epitope missing in the DVI variant, could elicit the immune response if 
missed in the testing of red cells (Avent, 2009).  Therefore, the use of DNA-based 
analysis (genotyping) has become more feasible to predict the individual blood group 
phenotype and secure more comprehensive information about individual blood groups 
than serology alone (Reid and Denomme, 2011, Avent, 2007). Consequently, 
considerable efforts have been placed to develop new systems and platforms to enhance 
the ability of utilising the DNA from donors and patients in performing large-scale, 
high-throughput BGG, which would provide more comprehensive and extended 
information of the phenotype than that provided by serology (Avent, 2009). 
1.8.2 Applications of BGG 
Many advantages can be achieved by using BGG over conventional serology upon the 
knowledge of the molecular information of the blood group systems. It has been 
suggested that BGG can be utilised instead of serology if the RBCs are not available to 
assess the phenotype and if molecular data would provide better knowledge than 
serology in a more cost- and labour-effective  and efficient manner (Daniels, 2013).  
A few clinical applications of the BGG have been defined, one of which is to reduce 
and manage the cases of HDFN. The foetal blood group is determined via genotyping 
the cell-free DNA (cffDNA) found in the maternal plasma. This procedure prevents the 
invasive procedure of obtaining the sample, eliminates the unnecessary prophylactic 
administration of anti-D antibodies antenatally to those carrying a foetus negative for 
Rh or other clinical blood groups and, most importantly, reduces the risk of HDFN 




A number of patients, such as those with sickle cell disease, require regular blood 
transfusion in order to survive. Nevertheless, receiving multiple blood donations is 
problematic since it may cause alloimmunisation against various blood antigens or high-
frequency antigens, resulting in difficulties in providing matched blood units. Extended 
blood group typing would be difficult by serology, especially due the possibility of the 
presence of the transfused RBCs in the circulation. Therefore, genotyping, especially 
high-throughput, is suggested to allow extended blood group typing of a large number 
of donors that will increase the inventory for compatible blood for such patients and 
prevent further immunisations (Reid et al., 2000, Avent, 2009, Wilkinson et al., 2012). 
Otherwise, multi-transfused patients may develop DHTRs because the antibodies 
corresponding to blood groups are difficult to detect by cross-matching serologically. 
Some examples of such antibodies are those of the JK and FY system (Avent, 2009).  
The extended genotyping and matching might also be beneficial in organ transplantation, 
particularly in the case of antibodies against antigens known to be expressed in other 
cells (histo-blood groups); for example, it has been reported that a mismatched FY renal 
transplant resulted in increased signs of chronic lesions (Lerut et al., 2007).  Other 
applications of BGG are determining the frequency of blood group polymorphisms in a 
population, screening blood donors for rare phenotypes, determining the blood group in 
autoimmune haemolytic anaemia and addressing difficult serological cases, particularly 
in blood group reference laboratories, by providing more accurate prediction of the 
phenotype (Anstee, 2009). 
1.8.3 High throughput 
Considering the many applications in which genotyping is superior to serology, it may 
be inferred that a genotyping approach with high-throughput capacity is necessary in 
order to address the growing demand for routine BGG (Stabentheiner et al., 2011). The 
routine extended typing (to include more blood groups other than ABO and RHD) for a 
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large number of donors in order to establish a database of matching blood units, 
especially for immunised individuals, is believed to be difficult (large number of anti-
sera required, non-availability of anti-sera or weakly expressed antigens that might not 
be detected) and costly by serology and suggested to be replaced by high-throughput 
genotyping approach in the future due to it importance in such cases (Perreault et al., 
2009, Jungbauer et al., 2012). The high-throughput approach for extended genotyping at 
a large scale has been shown to be feasible due to its rapid, reliable, cost-efficient and 
accurate results, unlike the case with serology (Jungbauer et al., 2012). The high-
throughput methods continue to be developed and improved in terms of accuracy, cost 
effectiveness, and ease of processing and analysis and might provide more informative 
prediction of the phenotype from the genotype (Avent, 2009). 
 
1.8.4 Genotyping technology and methodology  
With the knowledge of the molecular basis of blood group systems gained since the 
cloning of blood group genes, BGG has become feasible. Several methods have been 
developed for BGG, mainly including PCR-based assays. Examples of these approaches 
are polymerase chain reaction (PCR) coupled with restriction fragment length 
polymorphism (RFLP-PCR), to analyse amplified relevant sequences of blood group 
genes and SNPs of interest (Fukumori et al., 1995); sequence specific primer-PCR 
(SSP-PCR) and real time PCR (RT-PCR) (Polin et al., 2008). Although these methods 
have been reported to be accurate and reliable for genotyping, they are not considered 
high-throughput platforms due to their limited capacity and output that hinders large-
scale genotyping (McBean et al., 2014, Veldhuisen et al., 2009). Moreover, some of 
these methods require post-PCR gel based analysis that might lead to contamination in 
addition to the difficulties in automation (Veldhuisen et al., 2009).  An example for 
commercially available blood group genotyping platform is RBC-FluoGene (from Inno-
41 
 
train). This platform is based on the approach of SSP-PCR with the TaqMan
® 
probes for 
the fluorescence detection of various blood group antigens in automation manners and 
without the need for post run analysis with agarose gel. Different kits (plates) that cover 
predefined blood group antigens, such as some of ABO antigens in one kit whereas 












 are provided (Inno-train, 2017). 
Although this platform is fast (90 minutes) and automated, the fact of the reliant on 
predefined mutations and the low throughput pose limitations to meet the demand for 
routine BGG. 
It has been suggested that a DNA micro-array-based approach might overcome these 
limitations with the advances in high-throughput genotyping of blood group antigens 
(Bugert et al., 2005, Beiboer et al., 2005). The DNA microarray technology is 
characterised by a high multiplexing capability using solid surface that can be glass, 
chip or bead arrays. These DNA arrays carry numerous probes that are specific to 
various blood group alleles. During the microarray process, an allele-specific 
hybridisation occurs between the labelled, amplified PCR products and the 
corresponding probes, which is measured in order to predict the phenotype (McBean et 
al., 2014). 
There are several commercially available platforms that utilise the microarray 
technology such as BloodChip reference and human erythrocyte antigen (HEA) 
BeadChip. 
The BloodChip (from Progenika) was developed between 2003 and 2006  by the 
Bloodgen project, funded from a European Framework V grant, in order to establish an 
array-based platform that covers a great number of blood group polymorphisms (Avent 
et al., 2007). The PCR-amplified DNA products are fluorescently labelled and then 
hybridised to probes that are specific to known blood-group SNPs and alleles attached 
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on a glass array. Hybridisation to the allelic probes is then detected by a laser scanner, 
with software that then analyses the genotype and predicts the phenotype. It is 
suggested that the BloodChip reference version v4.1 can detect up to 33 clinically 
significant antigens from ten different blood group systems (Avent et al., 2009).  
The HEA BeadChip, developed by BioArray Solutions, principle is similar to that of the 
abovementioned platform but has probes attached to a colour-coded bead assembled 
into arrays on chips, then fluorescent signals from hybridisation are detected to predict 
phenotypes. It is suggested that the BeadChip platform can genotype SNPs within 18 
alleles associated with 24 blood-group antigens from 10 blood group systems, such as 
FY and JK. In addition, this platform is suggested to be capable of genotyping up to 96 
samples in four hours (Hashmi et al., 2005, Hashmi et al., 2007). Another platform, 
MassARRAY
® 
System, was introduced by (Agena Bioscience) that can provide high- 
throughput BGG. Two panels, namely, Hemo ID
TM
 Blood Group Genotyping and 
Donor Quick Screen (DQS) panels can be used with this system to enable genotyping  
of up to 101 antigens of 16 blood group systems for up to 3000 samples. These panles 
cover predefined polymorphisms. Briefly, the process involves multiplex PCR followed 
by loading the samples to a SpectroCHIP
®
 Array before detection by the mass 
spectrometry (Agena Bioscience, 2017a, Agena Bioscience, 2017b).  
Although these platforms have revolutionised the genotyping approach with their high-
throughput ability, they are only capable of detecting known SNPs and alleles included 
in the system array. With the emergence of novel or rare SNPs and combinations of 
other mechanisms of polymorphisms in alleles of clinical significance, which can alter 
antigen expression of blood group systems, current microarray platforms fail to detect 
those not included in the system array. For example, microarray platforms might 
provide false prediction of normal expression phenotype for null or weak phenotypes 
due to presence of silencing SNPs not included in the system. Consequently, the 
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predicted phenotype from an apparent normal allele might contradict with the 
serological expression. As a result, constant update to the array-based platforms for new 
alleles, especially if they are clinically significant, is required; this would be costly and 
labour intensive (McBean et al., 2014, Tilley and Grimsley, 2014, Avent et al., 2015). 
Consequently, sequencing-based typing (SBT) has been applied to overcome these 
constraints since it analyses the entire gene, nucleotide by nucleotide, to provide the 
order of the four nucleotides: adenine (A), thymine (T), cytosine (C) and guanine (G). 
As a result, with the molecular knowledge of blood groups, novel alleles are likely to be 
identified. In fact, Sanger sequencing has increasingly been used to solve discrepant 
results of serological phenotype and those predicted by genotype approaches 
(mentioned above) resulting from rare or null polymorphisms or complex genetic 
variations (an example is shown in JK chapter, section 4.4.4). Although Sanger 
sequencing might be able to detect novel alleles, it is not considered to be high 
throughput; this could be a significant limitation in light of the massive demand for 
genotyping of donors and emerging alleles. As a consequence, sequencing-based typing 
with the ability of high-throughput sequencing is suggested to be the great candidate to 
address the importance of genotyping donors and patients (Avent et al., 2015). 
DNA sequencing has been based on Sanger’s chain-terminating dideoxynucleotide 
sequencing with capillary electrophoresis, reviwed by (Shendure and Ji, 2008). The 
original Sanger sequencing principle was based on chain-terminating dideoxynucleotide 
triphosphates (ddNTPs) which lack the 3ʹ hydroxyl group required for the 
phosphodiester bond between two nucleotides. In four separate reactions, single-strand 
DNA template, polymerase and normal dNTPs initiate growth (sequence by synthesis) 
of the DNA chain until the incorporation of the terminating ddNTPs that stop the 
extension. These are loaded onto four adjacent lanes on a polyacrylamide 
electrophoresis gel, and the sequence is visualised and analysed according to size 
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separation and nucleotide type, with the shortest sequence fragments appearing on the 
bottom and longest ones on the top (Sanger et al., 1977, Mardis, 2013). Then, 
fluorescent dye-labelled ddNTPs (distinct for each ddNTP, to allow simultaneous 
addition of all ddNTPs in one reaction) were introduced (Prober et al., 1987) along with 
the capillary electrophoresis that enabled automation (Wong, 2013). Each ddNTP has a 
unique fluorescent dye that stops the reaction of the primer extension when integrated to 
the PCR amplicon strand. This results in products of different sizes, depending on the 
order of the corresponding nucleotides that subsequently flow, and the products are 
separated, according to size, in capillary electrophoresis. They are detected, based on 
their wavelength, by laser technology which produces a visible electropherogram that 
represents the PCR sequence (Wong, 2013). The number of capillaries has increased to 
96 or 384, allowing simultaneous sequencing to increase the throughput. It has been 
suggested that Sanger sequencing can sequence up to 1000 bp per run per capillary at a 
high level of accuracy (99.999%) with  a cost of $0.50 per kilobase (Shendure and Ji, 
2008). Therefore, one run of 96 capillaries would generate 96 kb, which would have to 
be repeated 31,250 times to sequence 1X coverage of the human genome. This is labour 
intensive, expensive and time consuming. This can be seen in the Human Genome 
Project (HGP) that started in 1990, in which automated Sanger-based technology was 
used with capillary electrophoresis (Liu et al., 2012). A draft of the human genome 
(90%) was published with a cost of about $300 million and was produced over a 15-
month period. A full human genome (about 3 billion bases) was then completed in 2003 
and is estimated to have cost ~$150 million (Consortium, 2004). Therefore, it is 
estimated that since the beginning, the HGP cost about $3 billion and required 13 years 
to complete (NHGRI, 2016). Thus, although Sanger sequencing is accurate (99.999%), 
the limited capacity is insufficient, expensive and time consuming to address the 
demand of large-scale genotyping. Consequently, it would be wise to develop a new 
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sequencing technology that can overcome these limitations (Metzker, 2010). The high-
throughput ability has been suggested to provide time- and cost-effective output.  Next-
generation sequencing technology (NGS) can overcome the limitations of Sanger 
technology, thereby reducing the costs of human genome sequencing and to eventually 
as little as 1000 dollars, as per a long-term goal of National Human Genome Research 
Institute (NHGRI), by utilising the technology’s massive ability of producing a 
significant amount of data per run rapidly. These benefits are mainly attributed to the 
mechanism of massively parallel sequencing per run (Wong, 2013, Voelkerding et al., 
2009). In fact, it has been reported that the human genome sequencing cost decreased 
significantly since sequencing centres have switched to NGS technology from 
automated Sanger (Wetterstrand, 2016). In 2008, a human genome was sequenced by 
massively parallel sequencing (NGS platform) Genome sequencer FLX instrument 454 
at a cost of less than $1 million within 2 months (Wheeler et al., 2008). This shows the 
great advancement of NGS capabilities, which is still improving, compared to that 
Sanger used in 2003 (mentioned earlier). Owing to its comprehensive and large-scale 
capability, the technique will be cost effective, not only in terms of a single run but also 
in terms of eliminating the costs of transfusion complications and other further analysis 
(Avent, 2009). 
1.8.5 Next-generation sequencing  
Following the human genome project (HGP), the high-throughput sequencing approach 
was considered to produce large-scale data rapidly at low costs. Accordingly, various 
companies have participated in the race to develop NGS platforms due to the 
importance of the technology and potential for application in many medical fields. 
Examples of the resultant platforms are 454 by Roche, which was the first commercially 
available NGS platform (Margulies et al., 2005), SOLiD (Sequencing by Oligo Ligation 





 (Life Technologies), all of which are based on the massively parallel 
sequencing principle (which is also used to describe NGS). NGS platforms are diverse 
in their chemistry of sequencing and detection (Liu et al., 2012). The Roche product, 
454 for example, relies on sequencing-by-synthesis, particularly pyrosequencing, which 
is the detection of pyrophosphate released during nucleotide incorporation. On the other 
hand, Ion PGM
TM
 detects the pH that changes as a result of the production of hydrogen 
ions when nucleotides are incorporated (Rothberg et al., 2011). In addition, platforms 
differ by their capacity, speed and costs, upon which platforms are selected in 
laboratories with the application size needed, such as whole genome or targeted genes. 
For instance, the output of SOLiD is suggested to be 120 Gb, whereas that from llumina 
HiSeq 2000 is 600 Gb (Quail et al., 2012, Liu et al., 2012). Examples of different NGS 
platforms with their sequencing chemistry are shown in Table 1.3.  
Although NGS platforms may differ in their sequencing chemistry, the majority of these 
innovations share a similar workflow. Following the extraction of the genomic material 
(here was DNA), the sequencing library is constructed. The targeted region of the DNA, 
defined by PCR (amplicon), is fragmented by enzymatic shearing or physical sonication. 
Then, the fragmented DNA is ligated to adapters (both ends), which are unique 
sequences for each platform such that they are complementary to the sequence on the 
surface they attach to for clonal amplification. The subsequent step is template 
preparation, which involves clonal amplification. The sequencing library (ligated) is 
immobilised on beads or solid surface, depending on the platform for commencing the 
clonal amplification. Depending on the platform, the clonal amplification can be 
accomplished by emulsion PCR or solid phase amplification (bridge amplification PCR). 
As a result, each DNA fragment is amplified to increase the intensity of the signal 
generated from the sequencing for sufficient and sensitive detection (Metzker, 2010, 
Shendure and Ji, 2008, Mardis, 2013). 
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The development in sequencing technology has led to the emergence of the single-
molecule long-read sequencing approach, which is referred to as third-generation 
sequencing. PacBio and Oxford Nanopore Technology (ONT) have been introduced. 
This technology has several advantages; for example, no clonal PCR amplification is 
needed, which might reduce the duration for preparation. In addition, single-molecule 
DNA is sequenced, which is useful in assigning the location of the mutation cis/trans 
effect of polymorphisms to individual blood group alleles because PacBio and ONT 
allow sequencing of up to 50 kb and 200 kb, respectively, which is greater than the size 
of most human blood group genes (Avent et al., 2015, Goodwin et al., 2016).  The Ion 
Torrent (PGM
TM
) was the platform of choice in the current project since it was available 
in the research lab in Plymouth University.  Since the NGS approach has been used in 
various applications and fields, it has been utilised specifically for BGG, which is the 













NGS Platform Clonal amplification Sequencing chemistry 
Highest average read 
length 
454 Emulsion PCR Pyrosequencing (sequencing by synthesis) 700 bp 
SOLiD Emulsion PCR Oligonucleotide 8-mer chained ligation (sequencing by ligation) 75 bp 
Ion Torrent Emulsion PCR Proton detection (sequencing by synthesis) 400 bp 
Illumina Bridge amplification Reverse dye terminator (sequencing by synthesis) 300 bp 
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 was developed by Ion Torrent and then purchased by Life Technologies
TM 
and is currently owned by Thermo Fisher Scientific. It was introduced in the market in 
2010 by Ion Torrent as a feasible, affordable, reliable and fast (running time 
approximately from 2 to 7 hours depending on the capacity needed) sequencing 
platform that can be used for smaller laboratories (Hodkinson and Grice, 2015, 
ThermoFisher, 2015). It is based on semiconductor technology and pH detection 
chemistry of sequencing by synthesis, unlike other NGS platforms that utilise light or 
camera detection. During the sequencing, each nucleotide is incorporated into the 
nascent strand of DNA by a polymerase leading to hydrogen ion (H
+
) release. As a 
result, the pH of the solution surrounding the bead changes (0.02 pH unit per base 
incorporation), which is detected by a sensor (works as a solid-state pH meter) 
underneath converting the change into a voltage signal that is digitalised as base calling 
information by off-chip electronics within only 4 seconds. The four nucleotides are 
flooded in a stepwise fashion into wells containing the templated beads. In each 
nucleotide flow, if a nucleotide is incorporated, a signal is reordered; however, if more 
than one, for instance two nucleotides are incorporated, the voltage is doubled. A wash 
step between each nucleotide flow is conducted to remove the remaining nucleotides 
from the well (Rothberg et al., 2011, Mardis, 2013, ThermoFisher, 2016). Figure 1.6 
illustrates the sequencing reaction and detection principle of Ion PGM
TM
.  
The workflow consists of library preparation, template preparation and sequencing. The 
DNA library is produced by targeting the genomic region by PCR (in this case, long-
range PCR), followed by fragmentation by enzymes, which can also be alternatively be 
achieved physically (by sonication). Then, these fragments are ligated with adapters that 
can be recognised by complementary sequences on the beads. During their preparation, 
templates on the beads undergo clonal amplification by emulsion PCR—a process in 
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which each bead is confined in a droplet surrounded by oil, resulting in millions of 
uniform DNA fragments in order to increase the signal produced. Then, the oil is 
separated from the beads (emulsion breaking), disassociating the complement strand 
and leaving single-strand DNA. Finally, with the DNA polymerase and sequencing 
primer, the enriched beads (beads with insufficient DNA are removed) are loaded into 
the chip wells and sequenced as explained earlier (Mardis, 2013, Goodwin et al., 2016) 
(Figure 1.7). This sequencing process occurs in each well of the chip, which is designed 
to use the complementary metal oxide semiconductor (CMOS) process and contains 
millions of 3.5-mm-diameter wells (depending on the chip size, 314, 316 and 318), with 
a pH sensor underneath each well. Thus, simultaneous detection of massively parallel 
independent sequencing reactions (massively parallel sequencing principle) is allowed, 
resulting in high-speed and throughput and low-cost sequencing (Rothberg et al., 2011). 
The sequencing capacity and output depends on the chip used and therefore, on the well 
- the number of wells as well as the read length (the longer the read length, the greater is 






 for the Ion 
PGM
 TM
 consist of 1.2, 6.3, and 11.3 million wells that would allow an output of 20 Mb, 
200 Mb and up to 1 GB for read length of 200 bp, respectively (Merriman et al., 2012). 
The capacity has been increased by improving the chip’s capacity with a second version 
of Ion Chips that allows read length of up to 400 bp with an output of up to 2 Gb 
(ThermoFisher, 2015) (Table 1.4). Based on the output, the Ion PGM
 TM
 is considered 
beneficial for small laboratories with smaller projects such as targeted DNA and RNA 
sequencing, gene sequencing and genotyping (ThermoFisher, 2015). On the other hand, 
a new platform (Ion Proton
TM
) by Life Technologies has much higher capability than 
Ion PGM
 TM
 and is suitable for large projects. A whole human genome and up to two 
human exomes (exons of the human genome) can be sequenced within two to four 
hours. The Ion Proton
TM
 II chip consists of 660 million wells, allowing a significantly 
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higher output of up to 10 Gb and 60 to 80 million reads (Liferechnologies, 2012, 
Merriman et al., 2012, ThermoFisher, 2014), which is a great advancement in high-
throughput and results in significant time and cost reduction.   
With regard to calculating the scalability that affects the number of samples and the 
choice of the chip used, a calculation by Ion community was suggested  to guide the 
determination of the number of samples that can be used for the chip. It involves the 
length of the target to be sequenced, read length and coverage depth. For example, if the 
sample target size is 20 kb and the coverage needed is 20x, (20 x 20) = 400 kb total 
reads would be obtained from each sample. Therefore, for this example, Ion 314
TM
 chip, 
which has the lowest capacity (20 Mb) for a 200-base read, can sequence 50 samples 









Figure 1.6 Ion PGM
TM
 sequencing technology and chemistry. 
A) The structure of the well in the chip is shown with the templated bead. A flow of nucleotides allows incorporation to correspondent 
sequence that leads to a hydrogen ion H
+ 
per nucleotide. This changes the pH in the solution that is detected by the sensor underneath the 
well, converting the information into voltage that becomes digitalised to be readable base calling.  (B) the sequencing by syntheses is 
illustrated, in which nucleotide addition leads to H
+ 












Figure 1.7 Summary of the Ion PGM
TM 
workflow.  
A) An overview for the steps of Ion PGM
TM
 workflow from library preparation to 
sequencing results. (B) DNA library fragmentation and ligation before, (C) clonal 
amplification of the single fragment attached to a bead, by emulsion PCR. (D) Beads are 
then loaded into wells in the chip, in which the sequencing process and the base calling 
commence. The incorporation of one nucleotide gives one signal, while incorporation of 2 







Table 1.4 Updated chips v2 of Ion PGM
TM
 in terms of capacity and run time according to 
















600 Mb–1 Gb 














1.8.7 NGS and BGG 
Several groups have found the benefits and feasibility of utilising NGS platforms in the 
genotyping of blood groups. Stabentheiner and colleagues (2011) used GS FLX (NGS 
platform) to sequence samples with serologically weak Rh phenotypes and found that 
the majority of polymorphisms for RHD were comparable (95%) to results of Sanger 
sequencing (Stabentheiner et al., 2011).  Rieneck at al. (2013) used Illumina GAIIx to 
successfully predict the phenotype of foetal Kell blood group status from cell-free foetal 
DNA in maternal plasma (Rieneck et al., 2013). Another group illustrated that NGS is 
suitable for genotyping blood group genes; 18 genes involved in 15 blood group 





technology (Fichou et al., 2014). The latter involves a custom designed 
panel, in which multiplex primers are provided, resulting in amplicons that target areas 
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of interest that are mainly the coding and untranslated regions (Merriman et al., 2012). 
Prediction of the blood group phenotype from the database containing the data produced 
by the NGS platforms was described in 2015 (Giollo et al., 2015). Subsequently, 
another group illustrated the prediction of the phenotype for RBCs antigens and 
platelets from whole genome sequencing completed by Illumina HiSeq NGS platform 
(Lane et al., 2016). Furthermore, another group show the feasibility of high throughput 
genotyping of ABO blood group by NGS platform (Illumina) that enabled the studies of 
the allele frequency and discovery of novel alleles (Lang et al., 2016). Additionally, 
NGS coupled with LR-PCR approach has been used recently to genotype blood group 





1.9 Thesis aims  
BGG provides more comprehensive blood group typing than the conventional serology. 
BGG with the high-throughput capability allows large-scale genotyping for extended 
blood groups in individuals (donors and recipients). This would have a significant 
impact in reducing the risk of alloimmunisation, especially in those in need of multiple 
transfusions, such as those with sickle cell disease (SCD). NGS allows a sequencing-
based genotyping with high-throughput that provides large scale genotyping in a 
discovery mode, allowing the definition of all polymorphisms including novel and rare 
ones.  
In this project, the powerful NGS-based genotyping platform was used to provide 
comprehensive genotyping of the blood group genes FY, JK and ABO. The Ion PGM
TM
 
NGS platform with Long range PCR (LR-PCR) was used to sequence the entire gene 
plus flanking regions in each case. Accordingly, all polymorphic mechanisms can be 
explored. In general, the feasibility of using NGS for genotyping these genes will be 
determined. The sequence-based mode of the NGS would allow the discovery of all 
polymorphisms, including rare and novel ones, which would provide comprehensive 
analysis of the molecular basis of the blood group systems alleles, thus more accurate 
reflection and prediction of the phenotype from alleles. 
The objectives for this project were: 
FY blood group system  
 To develop and optimise a reliable NGS protocol for extensive FY gene 
genotyping. 
 To explore all the polymorphisms in the coding regions (exons). 
 Also, to explore the polymorphisms in other regions, such as introns, splice sites 
and regulatory regions. This would provide more informative reflection on the 
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phenotype (predicted phenotype). 
 To analyse the association of intronic polymorphisms with FY alleles. 
 To use FY BGG by NGS as a test platform for BGG of other blood group genes 
using NGS  
JK blood group system  
 To develop and optimise a reliable NGS protocol for high resolution JK gene 
genotyping. 
 To utilise the discovery mode of the NGS to detect all existing polymorphisms 
in the exons. 
 To assess the polymorphisms in introns, splice sites and flanking regions. 
 To analyse the correlation of detected polymorphisms with the key JK SNPs to 
evaluate their allele specificity, allowing discovery of allele specific sequences. 
 ABO blood group system  
 To develop and optimise a reliable NGS protocol for comprehensive ABO gene 
genotyping. 
 To analyse all polymorphisms in all 7 exons, in addition to those in introns, 
splice sites and outer regions. 






 Materials and Methods 
2.1 Genomic DNA (gDNA) and RNA from whole blood samples 
RNA and genomic DNA (gDNA) were extracted and purified from whole blood 
samples collected (with consent and full ethical approval) from randomly selected 
anonymous donors obtained from National Health Service Blood and Transplant 
(NHSBT; Filton, Bristol UK)). Ethylenediamine tetraacetic acid (EDTA) tubes 
containing whole blood samples were centrifuged at 3500xg for 5 minutes in order to 
separate the whole blood component and obtain the buffy coats (containing white blood 
cells), which were then processed to extract DNA. RNA was extracted from the first 
layer of red blood cells (RBCs) of the supernatant, in which most of the reticulocytes 
(nucleated red cells) are believed to be found (refer to Chapter 4 of JK).  
 
2.2 Sequencing of blood group genes by next-generation sequencing  
The current study uses targeted region sequencing using the Ion PGM
TM
 sequencer 
(Thermo Fischer Scientific Inc., Leicestershire, UK), by which the entire gene, 
including up- and downstream flanking regions (in order to discover all polymorphisms 
within and outside of the gene exon-intron, such as those in promoter regions) are 
sequenced. The first step of the process is preparation of a genomic library (containing 
gDNA); this involves targeting the region by long-range polymerase chain reaction 
(PCR), in which long PCR overlapping products (about 4-14kb amplicons) are 
generated from gDNA, utilising specific primers that cover the entire target gene plus 
flanking regions, without missing parts of the gene sequence. Following this, the long 
amplicons are chemically fragmented by enzymes (or physically by sonication), 
resulting in fragments of approximately 200bp in size. These fragments will be then 
ligated with barcoded adapters that are used to distinguish between samples. The next 
59 
 
step involves template preparation, in which the ligated fragments (including individual 
fragments) are immobilised on beads via complementary base pairing with the adapter 
sequence, and undergo clonal amplification by use of emulsion PCR (emPCR). Each 
step in the described procedure is followed by purification and quality control (QC) 
steps using magnetic bead purification and Bioanalyzer®, respectively. Next, the 
enriched beads are loaded onto an ion chip, within which the sequencing commences 
when inserted into the Ion PGM
TM 
(Thermo Fischer Scientific Inc., Leicestershire, UK). 
Finally, the data will be analysed and aligned with the sequence of a reference gene of 
interest, using various bioinformatics software packages which interpret polymorphisms 

























Figure 2.1. Overview of the process for sequencing blood group genes by 
Next-Generation Sequencing. The main steps involve gDNA library 




2.2.1 gDNA extraction and purification 
Sample gDNA was extracted using a QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, 
Germany), which is based on a spin column procedure extracting and purifying DNA 
from the buffy coat. The kit contains the following: buffers (lysis buffer AL and 
washing buffers AW1 and AW2 with 96-100% ethanol added) and lyophilised 
QIAGEN Protease, dissolved in 1.2ml protease solvent (preservative).   
Whole blood samples were transferred into 15 ml Falcon tubes and centrifuged at 
2500xg for 10 minutes at room temperature (20
o
C) to obtain three distinctive layers: 
plasma; buffy coat (containing concentrated nucleated leukocytes) and the RBC-
concentrated layer. The buffy coat was collected in 1.5ml tubes and spun at 10000 rpm 
to obtain a distinctly separated buffy coat from the extra serum and red cells, following 
which 200µl of the buffy coat was transferred into a new 1.5ml tube and placed on ice 
to be used in the procedure. The DNA extraction procedure followed: 20µl QIAGEN 
Protease was thoroughly mixed with 200µl buffy coat and an equal volume (200µl) of 
AL buffer by pulse-vortexing for 15 seconds, until a homogenous solution was observed. 
Subsequently, tubes were briefly centrifuged and then incubated at 56
o
C for 10 minutes 
(suggested to give the best DNA yield), followed by a pulse spin to collect residual 
sample form the inside of the tube lids. 200 µl ethanol (96-100%) was added to the 
samples and mixed by pulse-vortex for 15 seconds, then spun briefly. This mixture was 
then carefully applied to the QIAamp mini spin column in the provided 2ml collection 
tube and centrifuged at 16300xg (to avoid clogging of buffy coat) for 1 minute, before 
transferring the column to new 2ml tubes and discarding the collection tube that 
contains the filtrate.  
Subsequently, 500µl Buffer AW1 was added to the mixture and spun for 1 minute at 
16300xg and the above column centrifugation process was repeated. Following this, 
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500µl Buffer AW2 was added to the QIAamp mini spin column and centrifuged at 
20,000xg for 3 minutes. Afterwards, the collection tubes were replaced with new 2ml 
Eppendorf 
® 
tubes to perform further centrifugation at 20,000xg for 1 minute, as 
recommended by the company, in order to remove any residual Buffer AW2. The 
QIAamp mini spin column was then placed into new sterile 1.5ml Eppendorf 
® 
tubes 
and the filtrate discarded. Following this, 200µl Buffer AE were added (for the purpose 
of DNA elution) to the column and incubated for 5 minutes (to increase DNA yield) at 
room temperature. Samples were then centrifuged at 16300xg for 1 minute. DNA was 
divided in two separate sterile aliquots and stored at - 20
o
C. DNA was quantified using 
several approaches and platforms, including NanoDrop
TM
 (Thermo Fischer Scientific 
Inc., Leicestershire, UK), NanoVue
TM 
Plus (GE Healthcare Life Sciences, 
Buckinghamshire, UK) and Qubit® 2.0 Fluorometer with Qubit® dsDNA Broad range 
(BR) assay Kit (Invitrogen
TM
, Paisley, UK). 
2.2.2 RNA extraction and purification  
Samples designated for RNA extraction were processed immediately by centrifugation 
at 2500xg for 10 minutes at room temperature in order to separate the whole blood 
components, plasma, buffy coat, and red cells (Figure 2.2). Subsequently, the buffy coat 
was carefully transferred into sterile 1.5 ml Eppendorf 
® 
tubes and placed on ice for 
gDNA extraction; however, RNA extraction was conducted first due to its higher 
vulnerability.  
RNA extraction and purification were accomplished using QIAamp RNA Blood Mini 
Kit (QIAGEN, Hilden, Germany), with addition of RNase-Free DNase Set (QIAGEN, 
Hilden, Germany). The top 1 ml of RBC layer (thought to be the location of the 
reticulocytes) was transferred into sterile 1.5 ml
 
tubes and mixed with 5x the sample 
volume (5 ml) EL buffer, incubated for 15 minutes on ice and briefly vortexed twice to 
obtain a transparent solution (indicating lysis of erythrocytes). Next, samples were spun 
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at 400xg for 10 minutes at 4
o
C before removing the supernatant carefully, leaving a 
trace of the supernatant (100µl) - advised for RNA extraction from reticulocytes 
(instead of leucocytes, for which the kit was intended by the manufacturers). 2 ml 
Buffer EL was added to the samples, and cells were re-suspended by vortexing briefly, 
followed by centrifugation at 400xg for 10 minutes at 4
o
C. Afterwards, the supernatant 
was discarded carefully, leaving a small trace (50µl) which was mixed with 600µl RLT 
buffer containing 143 mM β-mercaptoethanol (β-ME) (Sigma-Aldrich Company Ltd, 
UK), then vortexed and transferred directly onto  a QIAshredder spin column, placed in 
2 ml collection tubes.  Samples were then spun for 2 minutes at maximum speed to 
obtain homogenised lysates, while columns were discarded. 600 µl 70% ethanol was 
added to the homogenised lysates and mixed by pipetting, then carefully transferred into 
new QIAamp spin column tubes. The columns were then centrifuged at ≥8000xg for 15 
seconds, following which the flow-through and collection tubes were discarded and 
replaced with new collection tubes. Subsequently, an on-column DNase digestion was 
conducted by washing the spin column membrane, via the addition of 350µl of Buffer 
RW1 to the column, and spun at ≥8000xg for 15 seconds. Again, the flow-through and 
collection tubes were discarded and replaced with new collection tubes. Next, 80µl 
incubation mix was prepared by adding 10µl DNase I stock solution to 70µl Buffer 
RDD and mixed gently (due to the sensitivity of DNase to physical denaturation) by 
inverting the tube. This was followed by brief spinning of the solution and its direct 
addition to the QIAamp spin column membrane (to ensure a full DNase digestion) for 
incubation at room temperature for 15 minutes. Next, 350µl Buffer RW1 was added to 
the column; the samples were centrifuged for 15 seconds at ≥8000xg and the flow-
through discarded. The columns were then transferred into provided 2ml collection 
tubes, followed by the addition of 500µl working solution of Buffer RPE mixed with 4 
volumes of 96-100%) ethanol, and then spun again for 15 seconds at ≥8000xg 
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(discarding the collection tubes containing the flow-through. This step was repeated; 
however, samples were then centrifuged at 20,000xg for 3 minutes. In order to prevent 
Buffer RPE carryover, columns were then transferred into new 2 ml Eppendorf 
® 
tubes 
and re-spun at 20,000xg for 1 minute. For RNA elution, the QIAamp spin columns were 
transferred into provided 1.5 ml micro centrifuge tubes and 40µl RNase-free water was 
directly added into the column membrane, followed by centrifugation at ≥8000xg for 2 
minutes. 2µl RNA was used for quantification by NanoDrop 2000
TM
 (Thermo Scientific, 
USA). 
 
2.2.2.1 RNA quantification 
Quantification by Nano Drop 2000
TM
 (Thermo Scientific, USA) involved blanking the 
spectrophotometer with 1µl nuclease free water and loading 1µl RNA, resulting in a 
concentration of ng/ µl and the purity of the RNA from contaminants (given by the 
absorbance ratio of A260/A280) at the recommended range of 1.9-2. 
In turn, gDNA was extracted from samples as explained in Section 2.2.1 and quantified 
by Qubit® 2.0 Fluorometer with Qubit® dsDNA Broad range (BR) assay Kit 
(Invitrogen
TM

























2.2.3 DNA quantitation 
The PCR amplicon quantitation is very critical for the downstream processing; therefore, 
it is crucial to quantify the gDNA and PCR amplicons as accurately as possible.  In the 
very first gDNA quantification attempt of this project, NanoDrop
TM
 (Thermo Scientific, 
USA), NanoVue
TM
 (GE Healthcare Life Sciences, Buckinghamshire, UK) and 
NanoDrop 2000
TM
 (Thermo Scientific, USA)  were used due to availability. However, 
comparison of data with that obtained using a Qubit® 2.0 Fluorometer and Qubit® 
dsDNA Broad range (BR) assay Kit (Invitrogen
TM
, Paisley, UK) showed that the former 
approach (apart from NanoDrop 2000
TM
) resulted in clear overestimation of the 
concentration of extracted gDNA. Data obtained from NanoDrop 2000
TM 
were 
comparable, although slightly elevated, to that of Qubit® 2.0 Fluorometer (data not 
shown). Therefore, the Qubit® 2.0 Fluorometer, which is more accurate due to its high 
selectivity for double-stranded DNA over RNA, was subsequently used. There are two 
kits for DNA quantification: Qubit® dsDNA Broad range (BR) and High sensitivity 
Figure 2.2. Separation of blood components in a tube.   
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(HS) assay Kit, both of which are used with the Qubit® 2.0 Fluorometer to measure 
DNA concentration. The former is capable of measuring concentrations within the range 
of 100pg/µl to 1000ng/µl, whereas the latter measures within a range of 10 pg/µl to 
100 ng/µl. Therefore, gDNA quantification was conducted using the Broad range (BR) 
assay Kit, which consists of Qubit® dsDNA Broad Range Reagent, buffer, standard 1 
and standard 2. First, all reagents were brought up to room temperature (22-28 
o
C) for 
30 minutes (or until complete thawing of Qubit® (BR) reagent), according to 
manufacturer instructions. Then, Qubit® working solution was prepared as follows: a 
1:200 dilution of Qubit® reagent in Qubit® BR buffer was achieved by adding 1 x n µl 
reagent to 199 x n µl buffer (where n = the number of samples plus the 2 standards), in a 
sterile 50 ml tube although a volume for 5 extra samples were added to avoid pipetting 
errors. Subsequently, 2µl from of extracted gDNA and 10µl of each standard were 
added to 0.5ml Qubit® assay tubes (Invitrogen
TM
, Paisley, UK), and a final volume of 
200µl per tube was achieved by adding 198µl of working solution to the samples tubes 
and 190 µl to the standard tubes. Next, the tubes were vortexed for 3 seconds, followed 
by incubation at room temperature for 2 minutes in order to reach the optimal 
fluorescence of the Qubit® assay. Before measuring the sample tubes, the Qubit® 2.0 
Fluorometer was calibrated by measuring the standards, following which data was 
obtained as a Qubit® 2.0 Fluorometer (QF) value.  Concentrations of samples (gDNA) 
were calculated as follows: {Sample concentration = QF value x (200/2)} in ng/ µl. 
2.2.4 Amplicon library preparation for next-generation sequencing 
2.2.4.1 Primers 
Several software packages were utilised to design the oligonucleotide primers for FY, 
JK and ABO. Primer 3 software (http://frodo.wi.mit.edu/primer3/) was initially used to 
design the primers; the NCBI BLAST database (http://blast.ncbi.nlm.nih.gov/) was used 
to confirm the specificity of primers; the UCSC Genome Browser database 
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(http://genome.ucsc.edu) was also used to analyse the specificity of the primers; in 
addition, visualisation of the location of the amplicons within the genome was done 
using the in-silico PCR (virtual PCR) service in UCSC.  
Primers were designed to target the entire FY, JK and ABO genes, including the 
flanking (upstream and downstream) regions, by generating long amplicons. For the FY 
gene, the entire gene and flanking regions were targeted by single Long-range PCR 
amplicon, due to the small size of the FY gene (3194bp according to the Genecards 
database (www.genecard.org; Table 2.1). For JK and ABO genes, several amplicons had 
to be designed to cover the larger JK (28765bp) and ABO (20039bp) genes (3 and 4 
amplicons for JK and ABO, respectively). The amplicons on the latter two genes (JK 
and ABO) overlapped and were of various sizes (Tables 2.2 and 2.3). With regard to 
amplifying ABO, two amplicons (named 1A, adapted from (Huh et al., 2011), and 1B), 
covering the upstream region, exon 1 and part of intron 1, were used since not all of 
ABO alleles were amplified with the same primer pair. Nevertheless, the other 3 
amplicons were utilised for all samples (Table 2.3). The primers were received 
lyophilised from Eurofins Genomics (Ebersberg, Germany) in HPLC (High 
Performance Liquid Chromatography) purity, and were re-suspended by adding 
nuclease-free water (Ambion®, Applied Biosystems, Thermo Fisher Scientific, USA) as 







Table 2.1. LR-PCR forward (F) and reverse (R) primers for FY amplification. Each 
primer is 23 bp in size.  
 Primers (5’- 3’) 
Amplicon 
size 
Position within the 











Table 2.2. LR-PCR forward (F) and reverse (R) primers for JK amplifications. Each 
primer is 25 bp in size (the combined size of amplicons is 36730bp). 















R TGAGGGCAAATGGGAGGTGATACAA  





































Table 2.3. LR-PCR of forward (F) and reverse (R) primers for ABO amplifications (the 
combined size of amplicons, with 1A or 1B, is 35430bp or 36187bp, respectively).  The 
length of the primers is given in brackets after the primer sequence.  
 































and part of 
intron 1 R 
CACTCATTTGCCAGGTTTCTCAAAGA 
(26) 
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part of intron 4, 






2.2.4.2 LR-PCR amplicon amplification 
In a UV-sterilised hood, 50l (PCR) master mix for LR-PCR reactions was prepared in  
0.2 ml sterilised nuclease free tube strips (BIOplastics, Landgraaf, the Netherlands). The 
master mix contained: 1x LongAmp® Hot Start Taq Master Mix (New England 
BioLabs Inc., Herts, UK); 500nM forward and reverse primers; and gDNA template 
(100ng for FY, as shorter than the other genes, 200ng for JK amplicons 1 and 2, 400ng 
for amplicon 3 and 200ng for ABO). Sterile filter tips (Fisher Scientific, Loughborough, 
UK) and sterile forceps were used to handle tubes and minimise contamination. First, 
gDNA was added first to the 0.2 ml tubes; PCR mix, prepared separately in 1.5 ml 
Eppendorf 
® 
tubes, was then added and samples were mixed gently by pipetting up and 
down, followed by brief spinning prior to thermocycling. Thermocycling was carried 
out on a Veriti Thermal Cycler (Life Technologies, Paisley, UK) and included the 
following optimisation attempts (data not shown): temperature gradients for annealing 
and the other stages; and time alteration. The optimised thermocycling conditions for 
FY, JK and ABO (amplicons 2, 3 and 4) are described in Tables 2.4, 2.5 and 2.6. 
Following gDNA amplification, amplicons were visualised by agarose gel 
electrophoresis. 
The ABO amplicons 1A and 1B master mix contained: 200ng gDNA; 1x Phusion Flash 
High-Fidelity PCR Master Mix (Thermo Scientific, Leicestershire, UK); and 1000nM 
forward and reverse primers. The master mix for ABO amplicons 2, 3 and 4 contained: 
200ng gDNA, 1x LongAmp® Hot Start Taq Master Mix (New England BioLabs Inc, 
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Herts, UK); and 400nM forward and reverse primers. The thermocycling conditions can 




               Table 2.4. Optimised thermocycling conditions for FY  
Step Temperature Time Cycles 
Initial denaturation 95
o
C 30 seconds 1 
Denaturation 95
o
C 30 seconds 
30 Annealing 62
o
C 30 seconds 
Extension 72
o
C 3 minutes 
Final extension 72
o
C 5 minutes 1 
Holding 4
o




          Table 2.5. Optimised thermocycling conditions for JK 
Step Temperature Time Cycles 
Initial denaturation 94
o
C 5 minutes 1 
Denaturation 94
o
C 30 seconds 
30 Annealing 60
o
C 30 seconds 
Extension 65
o
C 10 minutes 
Final extension 65
o
C 10minutes 1 
Holding 4
o





         Table 2.6. Optimised thermocycling conditions for ABO amplicons 2, 3 and 4. 
Step Temperature Time Cycles 
Initial denaturation 94
o
C 5 minutes 1 
Denaturation 94
o
C 30 seconds 
30 Annealing 62
o
C 30 seconds 
Extension 65
o
C 10 minutes 
Final extension 65
o
C 10minutes 1 
Holding 4
o




Table 2.7. Optimised thermocycling conditions for ABO amplicons 1A and 1B. *Two-
step PCR (annealing and extension combined) was used as the Tm value was 
approximately 72
o
C when calculated by Thermo Scientific’s Tm calculator. 
Step Temperature Time Cycles 
Initial denaturation 98
o
C 3 minutes 1 
Denaturation 98
o
C 10 seconds 35 
Extension*  72
o
C 2 minutes 35 
Final extension 72
o
C 3 minutes 1 
Holding 4
o
C ∞ - 
 
 
2.2.4.3 Agarose gel electrophoresis  
Agarose gel electrophoresis was used to separate gDNA fragments by size and visualise 
the presence of the amplicon amplified by the PCR reaction. For FY and ABO samples, 
1% Hi-Res Standard Agarose (Geneflow Limited, Staffordshire, UK) was prepared by 
melting 1.4g of the agarose powder in 140ml of 1xTAE (40mM Tris-acetate-1mM 
EDTA) and staining with 14µl GelRed (10,000X, BT41003, Cambridge Bioscience). 
3µl Generuler 1kb Plus DNA ladder (Thermo Scientific, Leicestershire, UK) was used 
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to assess the average size of the amplicons (Figure 2.3). For each sample, 8µl PCR 
reaction mix was mixed with 2µl DNA gel loading buffer (containing 100mM Tris–HCl, 
pH 8.3, 10% (v/v) glycerol and 0.05% (w/v) Orange G dye), 10µl of which was then 
loaded into individual wells. DNA was electrophoretically separated at 85 V for 1 hour 
for FY and at 80 Volts for 1 hour and 40 minutes for ABO. The same process was 
carried out for JK analysis; however, the first two amplicons were separated by 1% 
agarose gel, whereas the third amplicon was separated by a 0.8% (w/v) agarose gel, 
according to its size (approximately 15kb), and run for 1 hour and 20 minutes at 70 V. 





















1Kb Plus DNA ladder (Thermo Fisher Scientific) used 




After checking for the presence of the amplicons, the remaining PCR mix (40 µl) for 
each sample was purified using magnetic beads purification, which ensures removal of 
primer dimers and free nucleotides that may interfere with downstream processing. At 
the start of the project, particularly for the first two sequencing experiments of FY and 
JK, Agencourt® AMPure® XP beads Reagent (Beckman Coulter, High Wycombe, UK) 
was used for the purification of the PCR product, as well as  for all purification steps in 
the gDNA library preparation process (Figure 2.4). However, SPRIselect
® 
reagent kit 
(Beckman Coulter, High Wycombe, UK), which utilises the same principle, was used 
for subsequent experiments. SPRIselect
® 
reagent kit (Beckman Coulter, UK) has an 
advantage over the AMPure® XP beads Reagent, in that the former can be used for a 
size selection approach (Section 2.2.4.10), in addition to as a means of purification for 
the library. Other advantages of using SPRIselect
® 
reagent kit for purification and size 
selection include reduced time, errors, costs and increased throughput of libraries, when 
compared to using Pippin Prep
TM
 instrument (Sage Science, Inc., Beverly, USA) for 
size selection (Section 2.2.4.10). According to manufacturer’s instructions, beads were 
re-suspended at room temperature for 30 minutes before commencing the purification 
(this step is only required for AMPure® XP beads in contrast to those of SPRIselect
® 
reagent kit ). 70% molecular grade-ethanol (Fisher Scientific, UK) diluted in nuclease-
free water (Ambion
®
, Applied Biosystems, Thermo Fisher Scientific, USA) was used 
for washing steps.  
In a nuclease-free 1.2ml well plate (Thermo Scientific Abgene, USA), 40µl PCR 
product was mixed with 72µl (1.8x the sample volume) bead solution by pipetting and 
incubated at room temperature for 7 minutes. This particular bead-sample ratio is 
suggested to attract a PCR product of >100bp and eliminate contaminants, such as free 
nucleotides and primer dimer which are of smaller sizes (Figure 2.5). The plates 
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containing PCR product were then placed on a magnetic plate (Agencourt
®
 SPRIPlate 
96R - Ring Super Magnet Plate, Beckman Coulter, UK) for 3 minutes, which promoted 
attachment of amplicon-carrying beads to the side of the wells, leaving a clear 
supernatant on top, which was then carefully discarded. Following this, without 
removing the plate from the magnet, two washing steps were carried out: 30µl freshly 
prepared 70% ethanol was added to wells and incubated for 30 seconds at room 
temperature, before the supernatant was carefully discarded without disturbing the pellet. 
Afterwards, without removing the plate from the magnet, residual ethanol was removed 
by pipetting with smaller size pipette tips (20µl; to avoid disturbing the pellet) and the 
beads air dried for 3 minutes at room temperature.  
Next, purified amplicons were eluted by removing the plate from the magnet plate and 
re-suspending the pellet by adding 15µl of nuclease-free water (Ambion
®
, Applied 
Biosystems, Thermo Fisher Scientific, USA). This was followed by a thorough 
trituration of the solution (10x; to release the DNA into the water), after which plates 
were placed back onto magnetic plates until the solution became clear. The solution, 
containing purified DNA (amplicons), was then transferred to new 0.2 ml sterilised 
nuclease free tube strips (BIOplastics, Landgraaf, the Netherlands), with 2µl used for 
amplicon quantification. The PCR amplicons were first quantified using the Qubit® 2.0 
Fluorometer with High sensitivity (HS) assay kit; however, as the DNA concentration 
of some samples was higher than 100 ng/µl, the Qubit® dsDNA Broad range (BR) 
assay Kit (Invitrogen
TM
, Paisley, UK) was subsequently used, as it measures higher 
concentration samples more accurately. In addition, it is more cost-effective since it is 
recommended that extracted gDNA to be quantified by a BR kit. Amplicon 
quantification is critical for downstream stages of the library construction process, such 
as amplicon pooling, fragmentation and ligation, in order to result in full coverage of 
the target.  
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Figure 2.4. The principle of the purification mechanism using magnetic beads 
(applies to both AMPure® XP and SPRIselect
® 
beads reagent kits). 1) Beads are 
added to the PCR reaction, 2) magnetic beads bind PCR amplicons (the desired 
size range determines the bead-amplicon ratio), 3) separation of PCR amplicons 
from contaminants using magnetic beads, 4) ethanol wash, 5) elution of PCR 
amplicons from the magnetic particles and 6) transfer of amplicons from beads 






























2.2.4.5 Sample aliquots 
In order to prepare for the next step of the process (amplicon library fragmentation), 
100ng DNA was required, according to manufacturer’s instructions. Accordingly, based 
on the concentrations obtained from the Qubit® 2.0 Fluorometer, equal concentrations 
from each amplicon (which ensures equal representation of each amplicon) were 
calculated to provide 100ng, when pooled. First, aliquots of equal concentrations were 
prepared to simplify the pooling process, by adding equal volumes from each sample of 
amplicon and avoiding pipetting errors. With regard to FY samples, aliquots containing 
20 ng/µl DNA in 30µl nuclease-free water (Ambion
®
, Applied Biosystems, Thermo 
Fisher Scientific, USA) were prepared from each sample for the purpose of DNA 
fragmentation. A few samples containing low DNA concentrations were diluted in 15µl 
PCR material: free nucleotides 
and primer dimers (around 100 
bp) are removed. 
Un-purified    
10,380 bp 
Purified   
35 bp 
Figure 2.5. Example Bioanalyzer® readout of purified and un-purified 





nuclease-free water. This was done using the following equation: C1 (from Qubit®) x 
V1 (volume taken from the stock) = C2 (20ng/µl) x V2 (30µl or 15 µl). As a result, 5 µl 
(= 100ng) from each aliquot was added to the fragmentation mix.   
Unlike FY, which has only one amplicon, the complete JK gene target is represented by 
3 amplicons, plus flanking regions, which therefore needed to be pooled in order to be 
fragmented together. As 100ng was required from 3 combined amplicons, 33.3ng 
(100/3 = 33.3ng) of each amplicon was added to the fragmentation reaction. First, 
aliquots were prepared to achieve a concentration of 16.6ng/µl (33.3/2) in a total 
volume of 10µl (using a similar equation to that used for FY); therefore, 2µl of each 
amplicon aliquot provided, in total, the 100ng needed for the fragmentation reaction. 
Similarly, 25ng (100ng/4) of each of the 4 amplicons of ABO required pooling to 
provide 100ng for the fragmentation reaction mix. Aliquots of DNA at a concentration 
of 12.5ng/µl were prepared in a total volume of 10µl, applying a similar equation to that 
used for FY and JK; therefore, 2µl of each amplicon was added to the fragmentation 
reaction to provide 100ng. Regarding aliquot preparation, a number of samples with low 
DNA concentrations, that did not require dilution with nuclease-free water (Ambion
®
, 
Applied Biosystems, Thermo Fisher Scientific, USA), were instead directly added to the 
fragmentation reaction mix (volumes chosen resulted by dividing 33.3 by the JK 
amplicon concentration and 25 by the ABO amplicon concentration. 
2.2.4.6 Amplicon library fragmentation (purified fragmented library) 
For this step, Ion Xpress
TM 
Plus Fragment Library Kit was used, which includes two kits: 
Ion Shear
TM
 Plus Fragment library Kit (for fragmentation) and Ion Plus Fragment 
Library Kit (Life Technologies, Paisley, UK). The samples were enzymatically 
fragmented (sheared) using Ion Shear
TM
 enzyme and Ion Shear
TM
 Plus Fragmentation 
Kit, which contains: Ion Shear
Tm
 Plus 10x reaction buffer, Ion Shear
Tm
 Plus Enzyme 
Mix II and Shear
Tm





 Plus 10x reaction buffer and Ion Shear
Tm
 Plus Enzyme Mix II were 
thoroughly mixed by vortexing and brief centrifugation, followed by placing on ice 
(according to manufacturer’s instructions).  In sterile 1.5ml Eppendorf LoBind
®
 tubes, 
the following contents were added in the order recommended by the manufacturer: 
100ng pooled amplicons (for FY amplicons, 5µl were added and 2 µl of JK and ABO 
amplicons were added, with the exception of low concentration samples); 5µl Ion 
Shear
Tm
 Plus 10x reaction buffer (pre-mixed prior to addition) plus nuclease-free water 
(Ambion
®
, Applied Biosystems, Thermo Fisher Scientific, USA) to make up the total 
reaction volume to 40µl. The fragmentation mix was then briefly vortexed (for 5 
seconds) and pulse-spun. Subsequently, 10 µl Ion Shear
Tm
 Plus Enzyme Mix II (pre-
mixed prior to addition) was added to the mix to reach a total volume of 50µl, which 
was then rapidly triturated (10x), avoiding bubbles. The mixing step, using a 40µl 
pipette tip, ensures homogenous mixing of enzyme with amplicons and buffer. 
Afterwards, the tubes were incubated at 37
o
C for the manufacturer-recommended 
amount of time that yields a median fragment size of 200-300bp (acquiring a target read 
length of 200 bases, which is suitable for downstream preparation steps, such as ligation 
and template preparation). After several optimisation attempts (see below), the 
incubation length for the reaction time was set for 5 minutes for FY samples and 8 
minutes for JK and ABO (the variation in time is due to the difference in PCR product 
sizes).  Next, 5µl Shear
Tm
 Plus stop buffer was immediately added and mixed 
vigorously by vortexing for 10 seconds, following which the tubes were placed on ice. 
The reaction tubes were purified by Agencourt® AMPure® XP beads Reagent in the 
first two experiments with FY and JK but in subsequent experiments were purified using 
the SPRIselect
® 
reagent kit (Beckman Coulter, UK). For the purification, the 50µl 
reaction mix was transferred to nuclease-free 1.2 ml well plates (Thermo Scientific, 
USA), then thoroughly mixed with 90µl (1.8 x sample volume) magnetic bead solution 
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by trituration (8-10x) to homogenise the solution, followed by incubation at room 
temperature for 7 minutes. Subsequently, the steps of the bead purification were the 
same as explained in Section 2.2.4.4, with the exception of the volume of 70% ethanol 
used for washes, which here was 500 µl (2 washes). Following air drying of beads, the 
plate was removed from the magnetic plate (Agencourt
®
 SPRIPlate 96R - Ring Super 
Magnet Plate, Beckman Coulter, UK) and the fragmented library was eluted in 25µl 
Low (10mM Tris pH 8.0, 0.1mM EDTA) (TE), which is provided in the Ion Plus 
Fragment Kit (Life Technologies, Paisley, UK), by the same method of elution 
explained in Section 2.2.4.4 To check for shearing integrity, 2µl of purified supernatant 





Agilent High Sensitivity DNA Kit (Agilent Technologies Ltd, UK) (Section 2.2.4.7), 
while the rest of purified fragmented library (PF) was transferred to new 0.2 ml 
sterilised nuclease free tube strips (BIOplastics, Landgraaf, the Netherlands) in 







(Agilent Technologies, California, USA) is an on-chip 
electrophoresis system that provides digital data and information regarding the size 
distribution, quantitation and quality control of DNA, RNA, proteins and cells, which 
are displayed as gel-like images (bands) and electropherograms (peaks; Figure 2.6). For 
this project, Agilent High Sensitivity DNA Kit (Agilent Technologies UK Limited) was 




instrument, which is capable of accurately 
analysing a size range of 50-7000bp. The Agilent High Sensitivity DNA Kit contains: 
10 high-sensitivity DNA chips (11 samples per chip can be analysed), a syringe kit, 
electrode cleaner and spin filters. The reagent box contains: high-sensitivity DNA 
ladder, high-sensitivity DNA marker (lower 35bp and higher 10380bp marker); high-
sensitivity DNA dye concentrate; and gel matrix. Prior to chip preparation and 
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experimentation, a few adjustments were made to the chip priming station, which is 
where the chip is placed while the samples are loaded. With each new kit, the syringe 
was replaced in priming solution to prevent an air leak and maintain optimum pressure. 
Then, the base plate of the priming station was adjusted to the C marker, while the 
syringe clip was adjusted to the lowest position. Subsequently, Gel-Dye mix was 
prepared by, first, allowing the DNA dye concentrate and the gel matrix to equilibrate to 
room temperature for 30 minutes in the dark, to completely thaw the DMSO and protect 
the gel-Dye from light. Then, the high sensitivity DNA dye was vortexed for 10 seconds 
and briefly centrifuged, following which 15 µl was added to the high-sensitivity DNA 
gel matrix. The gel-dye mix was then vortexed for 10 seconds and carefully transferred 
to the spin filter (provided within a collection tube), followed by a spin for 10 minutes 
at room temperature at a speed of 2240xg ± 20%, (equal to ~2680xg). The filter was 
discarded and the mix was kept for future use, protected from light, for 6 weeks as per 
manufacturer’s instructions. Next, the gel-dye mix (equilibrated to room temperature) 
was loaded onto the high-sensitivity DNA chip and placed on the priming station. 9 µl 
gel-dye mix was dispensed carefully to the bottom of the well (indicated in Figure 2.7), 
taking special care to avoid pipetting error. The syringe plunger was then positioned to 
1ml before carefully closing the priming station, the station properly closed (as 
indicated by a click). Next, the plunger was pressed down for 60 seconds and released 
by the clip release mechanism (to reach the 0.3 ml), following which the plunger was 
briefly left for 5 seconds and then slowly pulled back to the 1ml mark. Subsequently, 
the chip priming station was opened and 9µl of the gel-dye mix was added to the 
remaining 3 wells (Figure 2.7), followed by the addition of 5µl of high-sensitivity DNA 
marker to all 11 sample wells plus the ladder well. Afterwards, 1µl DNA ladder was 
loaded into the indicated well, and 1µl of each of the 11 samples was added to the 
relevant sample wells. 1µl DNA marker was also added to any unused sample wells 
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(Figure 2.7). Then, the chip was placed horizontally onto the adapter of the IKA vortex 
mixer (Model MS3, supplied together with the Bioanalyzer
® 
instrument) and vortexed at 
2400 rpm for 60 seconds. Within the next 5 minutes, the chip was placed on the 2100 
Bioanalyzer
® 
instrument and the readout was carried out, which took 45 minutes. 
During this, the electrodes were cleaned with the electrode cleaner chip. The name of 
























Figure 2.6. The Bioanalyzer
®
 instrument and the chip, into which samples are 
loaded, B) an example of data showing peaks and sizes of samples (X axis shows 




















2.2.4.8 Optimisations of the fragmentation reaction time (to confirm the desired 
fragment size range) 
Although it is recommended in the protocol that a 15 minute incubation may be 
required for the reaction to yield a 200-300bp median fragment, with a fragment size 
range of 100-700 bp, the optimum reaction (fragmentation) was obtained following 
several optimisations that included testing of different time periods. In addition, 
fragmentation size distribution is not only affected by the incubation time, but also is 





instrument and Agilent High Sensitivity DNA Kit 
(Agilent Technologies, California, USA) were chosen to test the various incubation 
times as well as the shearing integrity. The examination of several incubation times for 
FY were: 20, 15, 10 and 5 minutes, the last of which was chosen for better size 




Figure 2.7. The wells of the High sensitivity DNA chip, into which samples are 
loaded before running on the Bioanalyzer
®
 instrument. 
The indicated wells (white) of the high-sensitivity DNA chip. 1) the well that is 
to be pressurized. 2) 9 gel-dye mix was added to the indicated wells. 3) 5 µl 
DNA marker was added to all 12 wells, including the one containing the DNA 
ladder. 4) 1 µl DNA ladder was carefully added. 5) Samples were added to the 
indicated wells, while 1 µl DNA marker was added where sample was not 
needed. 6) The chip was then vortexed for 60 seconds at 2400 rpm, prior to its 
placement into the  Bioanalyzer
® 
instrument for the readout (adapted from 
Agilent Technologies, California, USA).   
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distribution (Figure 2.8), as there is a difference in size distribution and median 
fragment size between samples processed for 20 minutes and 5 minutes. 
For JK, incubation on the heating block was tested at 10, 15 and 20 minutes. As 10 and 
15 minutes were acceptable, since the size of pooled amplicons (~36kb) that was larger 
than FY, when checked by Bioanalyzer
 ®
instrument, an incubation time of 12 minutes 
was chosen for the first JK sequencing experiment. Then, samples from the fragmented 





instrument and Agilent High Sensitivity DNA Kit (Agilent Technologies, 
California, USA). Although samples fragmented for 12 minutes were eventually 
sequenced successfully, they did not achieve the recommended parameter for optimum 
output; therefore, in subsequent experiments for JK, samples were fragmented for 8 
minutes, which gave a better size range (Figure 2.9). As the total size for the pooled 
amplicons of ABO were similar to that of JK (~36kb), fewer optimisations were carried 
out and included test incubation periods of 6 and 7 minutes (Figure 2.10). Following 







































20 minutes  
FY fragmentation time 
5 minutes  
Figure 2.8. Variations in the peak of 200-300bp between FY samples fragmented 
for 20 or 5 minutes. Samples processed for 20 minute show that the majority of 
fragments are approximate 150 bp in size, which is lower than the required median 
concentration of the library. Samples fragmented for 5 minutes yielded better 
concentrations of the library, at around 200-300 bp, which is the required range. 




































12 minutes  
8 minutes  
JK fragmentation time 
Figure 2.9. Variations in the peak of 200-300bp between JK samples fragmented 
for 12 or 8 minutes. Samples processed for 12 minutes showed peaks 
approximating 150 bp in size, which is lower than the required median 
concentration of the library. Samples fragmented for 8 minutes yielded better 
concentrations of the library, at around 200-300 bp, which is the required the 




6 minutes  
ABO fragmentation time 
Figure 2.10. The size distribution of an ABO sample fragmented at 6 minutes. There 
is a good distribution of 100-700 bp and a good peak at 200-300bp. However, 8 
minutes was the incubation period used for subsequent ABO samples in the 
experiments due to the size similarity with JK, which would yield more concentrated 





2.2.4.9 Ligation of barcoded adapters (purified-ligated library) 
Following fragmentation, and ensuring a size range of 100-700bp with optimum target 
median fragment size of around 200-300bp, the samples were ligated to barcoded 
adapters (P1 and Ion Xpress
TM 
Barcode X adapter) from the Ion Xpress
TM 
Barcode 
adapters Kit (Life Technologies, Paisley, UK). P1 is the universal adapter that is 
compatible and recognised by the Ion PGM
TM
, and the X adapter (X referring to the 
desired barcode number) contains a distinct barcode (about 13bp) to distinguish the 
samples when pooled, prior to sequencing. The combined size of the adapters is ~80bp.  
For general ligation, the kit used was the Ion Plus Fragment Library Kit (Life 
Technologies, Paisley, UK) that contains: 5x End repair buffer, End repair enzyme 
(which is only used if the samples are fragmented physically), 10x Ligase buffer, DNA 
Ligase, Nick repair polymerase, dNTP mix, adapters (which are used if non-barcoded 
adapters are required), Platinum
® 
PCR SuperMix High Fidelity, Library Amplification 
Primer Mix (which is used with Platinum
® 
PCR SuperMix High Fidelity, in case the 
sample library needs amplification afterwards), and Low TE. The ligation of barcoded 
adapters involved  transferring the fragmented purified library (PF; 20µl) to 0.2ml 
sterilised nuclease-free tube strips (BIOplastics, Landgraaf, the Netherlands) from the 
previous step of fragmentation. Then, each of the following reagents were triturated 
before their addition to the 0.2ml tube in the indicated order: 10 µl 10x Ligase buffer; 
2µl universal adapter (P1); 2µl distinctive Ion Xpress
TM 
Barcode X adapters (taking care 
to avoid cross-contamination or mixing adapters); 2 µl dNTP mix; 54µl nuclease-free 
water (Ambion
®
, Applied Biosystems, Thermo Fisher Scientific, USA); 2µl DNA ligase; 
and 8µl Nick repair polymerase, which led to a total reaction mix volume of 100µl. The 
reaction mix was then triturated using 80µl pipette tips (taking care to avoid bubbles) 
and briefly spun. Afterwards, the reaction was placed on a Veriti Thermal Cycler (PCR 
thermocycler; Life Technologies, Paisley, UK) to start the nick repair reaction, by 
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which the linkage between the adapters and the DNA fragments is completed. The 
thermocycling conditions were: 25
o
C for 15 minutes; 72
o
C for 5 minutes; and 4
o
C for 
up to 1 hour, as this was not stopping point. Next, within 1 hour, the reaction mix 
(100µl) was transferred to fresh nuclease-free 1.2ml well plates (Thermo Scientific 
Abgene, USA) to prepare them for the next step of bead purification. 120µl (1.2x 
sample volume) of SPRIselect
® 
reagent was mixed thoroughly by trituration until a 
homogenous solution was visible, followed by incubation at room temperature for 7 
minutes. The plate was then placed on a magnetic plate (Agencourt
®
 SPRIPlate 96R - 
Ring Super Magnet Plate, Beckman Coulter, UK) for 3 minutes, or until the solution 
became clear, following which the supernatant was carefully removed without 
disturbing the pellet. The purification process then continued, as in Section 2.2.4.4, 
including two wash with 500µl 70% ethanol (freshly prepared) up to the elution step 
where 20µl low TE was added, after which the plate was removed from the magnet. 
Next, the samples with low TE were vigorously mixed by trituration (at least 10 times), 
before being placed back on the magnet and incubated for 1 minute or until a clear 
solution was observed as the magnet beads migrated to the bottom of the plate. 
Subsequently, 2µl of reaction mix was used to check the size difference, which was 





instrument and Agilent High Sensitivity DNA Kit (Agilent Technologies 
UK Limited), while the rest of the PL samples (18µl) were transferred to new 0.2ml 
sterilised nuclease-free tube strips (BIOplastics, Landgraaf, the Netherlands) and stored 
at - 20
 o
C for subsequent use. A few sequencing batch samples proceeded directly to the 





Figure 2.11.B A sample of FY fragmented library (top graph) and 
the same library with adapter ligated (bottom graph), resulting in a 
~80bp increase in size. The X axis is seconds, as the ladder required 




Purified Fragmented Library peaked at around 200bp 
200bp 































Purified Fragmented Library  
Purified Fragmented-ligated Library 
Figure 2.11.A A sample of the JK fragmented library (top graph) and the same 
library with adapter ligated (bottom graph) resulting in shifting of the size 







2.2.4.10 Size selection of the library 
In order to achieve the optimum DNA target read length, the adapter-ligated library was 
size selected for optimum length, which was conducted for the first two experiments of 
FY and JK, using the Pippin Prep
TM 
instrument (Sage Science, Inc., Beverly, USA) and 
Pippin Prep™ Kit 2010 with Ethidium Bromide cassettes (Figure 2.12). Although the 
Pippin Prep
TM 
instrument was used for size selection of the first two experiments of FY 
and JK, SPRIselect
® 
reagent kit (Beckman Coulter, UK) was subsequently used for 
several reasons. First, SPRIselect
® 
reagent kit (Beckman Coulter, UK) has an advantage 
in terms of multi-functionality and cost effectiveness, as in the library construction 
protocol it can be used for both purification and size selection (negating the need for the 
former after size selection), in contrast to the Pippin Prep
TM
, which needs a purification 
step using AMPure® XP beads Reagent. Second, although the Pippin Prep
TM 
provides a 
narrow and more consistent size range, which can be altered as required (tight or broad; 
Figure 2.13), it is time consuming, expensive and labour-intensive. This is because each 
of the Pippin Prep™ Kit 2010 with Ethidium Bromide cassettes (10 cassettes per kit) is 
only capable of processing 4 samples (Figure 2.12) per run, which takes about 1 hour 
and 10 minutes (for a peak at ~330bp). In contrast, significantly more samples can be 
processed by a 60ml SPRIselect
® 
reagent kit (Beckman Coulter, UK), with less time 
required to accomplish the size selection procedure. Since the Pippin Prep™ was only 
used for the first experiments, the protocol is listed here briefly. Pippin prep is 
automated electrophoresis with fluorescence-based DNA detection that can be 




































Figure 2.13. Two JK samples from the first experiment. (Top) experiment 
programmed to be size selected for broad range (peak around 200-250bp), 
which elevates the yield of the size selected DNA according to the 
protocol. (Bottom) the sample was size selected for a narrow range (peak 
at 318bp). All samples were processed by the Pippin Prep
TM 
instrument. 
Broad range size selection  
Narrow range size selection  
Figure 2.12. The Pippin Prep™ Kit 2010 with Ethidium Bromide cassette. A) a 
zoom in one of the 4 samples lanes in the gel-filled cassette, through which the 
DNA travels toward the elution wells at the positive electrode. B) The Pippin 
Prep™ cassette which has only 4 lanes for samples. NOTE: 4 lanes are used for 










In terms of using the Pippin prep
TM 
instrument, first the machine optics were calibrated 
using the provided plate, as instructed, by entering 0.8 in the LED target setting I ph, 
mA. Then, the cassette to be used was inspected visually for any leakage and bubbles 
behind the elution wells, which can be removed by tapping and removing the adhesive 
strips to place in the optical nest. Next, all the original buffer from the elution wells was 
replaced by fresh 40µl electrophoresis buffer, after which the wells were sealed using 
adhesive strips. The level of buffer in the sample wells was filled to the top before 
running the continuity test, which measures the current in each cassette channel (the 
separation-elution). For a successful run, this test requires a PASS result before running 
the samples. Before loading the samples, the PL samples were prepared for the Pippin 
prep
TM
; to achieve this, the volume was made up to 30µl by adding 12µl low TE and 
then mixing with 10µl of provided loading solution, pre-equilibrated to room 
temperature. Then, the mix was vortexed and spun briefly, before commencing the 
loading procedure. This entailed removing 40µl of buffer from the first sample well 
(which was assigned as the marker well) and immediately replacing it with 40µl of 
provided marker B. This loading process was repeated for the remaining 4 samples. The 
loading was carried out carefully to avoid damaging the gel by piercing the bottom or 
the sides of the wells. Although the recommended protocol for library preparation 
involved a certain programme (BP target setting at 315bp for library size of 200bp), the 
size selection range programme selected was mainly broad to give a higher yield 
(Tables 2.8.A 2.8.B). This programme was optimised and selected according to size 
distribution of the fragmented-purified samples. After the run stopped (90 minutes), 
samples (~40-60 µl; some made up to 60µl by adding nuclease-free water (Ambion
®
, 
Applied Biosystems, Thermo Fisher Scientific, USA) to unify the beads ratio) which 
were in Tris-TAPS buffer (50 mM Tris, 30 mM TAPS, 0.1 mM EDTA) were collected 
in 1.5 ml Eppendorf 
® 
tubes, followed by purification (Section 2.2.4.4) with 1.8x the 
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volume beads (Agencourt® AMPure® XP), washes with 70% ethanol, and elution with 
25 µl low TE. Subsequently, the samples were checked by the 2100 Bioanalyzer
® 
instrument for sample distribution and concentration. However, the first 12 size-selected 
samples for FY showed very low distribution (around 200-300bp), which accounted for 
the low concentrations of the size selected library. Therefore, an extra step of 
amplification of the library was carried out to increase the size selected library and the 
accuracy of the 2100 Bioanalyzer® instrument, as well as to determine the dilution 
factor for the purpose of template preparation.  
For the amplification, 20µl of adapter-ligated and size selected library was mixed with 
100µl Platinum® PCR SuperMix High Fidelity and Library Amplification Primer Mix 
(provided in the Ion Plus Fragment Library Kit), then run on the thermal cycler with the 
following PCR programme: initial denaturation at 95
o
C for 5 minutes; then (for 5 cycles 
instead of 8 in order to avoid PCR errors) denaturation at 95
 o
C for 15 seconds; 
annealing at 58
 o
C for 15 seconds; extension at 70
 o
C for 1 minute; and hold at 4
o
C. 
Then, the amplified library was purified by the bead-sample ratio of 1.5X the volume of 
the sample and eluted in 20µl Low TE, before being stored at -20
o
C ready to be checked 








Table 2.8.A. The size selection range programme for FY samples. The column titles are 
exactly as shown on the instrument screen. BP target is the expected peak size; BP start 
is where the fragment with this size is collected; BP ends is where the collection is 
stopped. *It is considered that the broader the range the higher amount of DNA 
collected, while smaller amounts of DNA are collected in tight ranges. The inconsistent 
ranges were selected during optimisations, where it was noticed that those ranges were 
slightly comparable. Each cassette can take up to 4 samples and a control. Run time was 
~1-2 hours. 
Sample BP Target BP start BP ends 
Description of 
range* 
1b 322 290 355 Broad 
2 315 290 340 Tight 
3 322 290 355 Broad 
4 320 290 350 Broad 
5 318 290 350 Broad 
 
 
Table 2.8.B. The size selection range programme for JK samples. The column titles are 
exactly as displayed on the instrument screen. BP target is the expected peak size; BP 
start is where the fragment with this size is collected; and BP ends is where the sample 
collection stops. *It is suggested that the broader the range the higher amount of DNA 
collected, while in tight ranges smaller amounts of DNA are collected. The inconsistent 
ranges resulted during optimisations, where it was noticed that those ranges were 
slightly comparable. Each cassette can take up to 4 samples and a control. Run time was 
~1-2 hours. Samples 1, 2, 4 and 5 had a very broad range to result in higher yield, as 
those samples where fragmented for longer time. 
Sample BP Target BP start BP ends 
Description of 
range* 
1 240 170 310 Broad 
2 240 170 310 Broad 
3 320 290 350 Broad 
4 240 170 310 Broad 




Size selection with the SPRIselect
® 
reagent kit (Beckman Coulter, UK) was started by 
transferring 18µl PL samples into nuclease-free 1.2 ml well plates (Thermo Scientific 
Abgene, USA). Then, 32µl nuclease-free water (Ambion
®
, Applied Biosystems, 
Thermo Fisher Scientific, USA) was added to result in a total volume of 50µl. This 
volume was chosen in consideration of the volume of the beads. Subsequently, 40µl 
(0.8x sample volume) SPRIselect
® 
reagent magnetic bead solution was added to the 
samples, which were then mixed by trituration (10x) to create a homogenous solution, 
followed by an incubation for 5 minutes at room temperature. Next, the plate was placed 
on a magnetic plate (Agencourt
®
 SPRIPlate 96R - Ring Super Magnet Plate, Beckman 
Coulter, UK) for 3 minutes or until the solution became clear. Keeping the plate on the 
magnet, supernatant (~85µl) from each sample was transferred to a new nuclease-free 
1.2 ml well plate (Thermo Scientific Abgene, USA). Afterwards, 35µl (0.7x starting 
volume) SPRIselect
® 
reagent was added to and mixed with the samples by trituration 
(10x), then incubated for 5 minutes at room temperature. The plate was then placed on 
the magnet and incubated for 3 minutes to attract the beads to the bottom of the wells, 
leaving a clear supernatant on top. Next, keeping the plate on the magnet, the 
supernatant was discarded carefully, without disturbing the beads. This was followed by 
a washing step, with the plate on the magnet, with 200µl 80% ethanol (freshly prepared), 
which was made up by mixing calculated volumes of absolute molecular biology grade 
ethanol (Fisher Scientific, UK) with nuclease-free water (Ambion
®
, Applied Biosystems, 
Thermo Fisher Scientific, USA). Plates were incubated for 30 seconds, with the ethanol 
then discarded. The washing step was repeated, without disturbing the bead pellet, then 
the wells were left to air dry for 3 minutes at room temperature to remove any residual 
ethanol. The plate was removed from the magnet plate, then 25µl nuclease-free water 
(Ambion
®
, Applied Biosystems, Thermo Fisher Scientific, USA) was added directly 
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onto and triturated with the bead pellet to re-suspend it, before placing the plate on the 
magnet plate. Next, the supernatant, which contains the purified size selected library 
(PSS), was transferred to fresh 0.2 ml sterilised nuclease free tube strips (BIOplastics, 




2.2.4.11. Library quantitation using 2100 Bioanalyzer® instrument for Ion 
Template preparation. 
In order to proceed with template preparation, using the Ion OneTouch™ System (Life 
Technologies, Paisley, UK) to prepare enriched template-positive Ion OneTouch™ 200 
Ion Sphere™ Particles (ISPs; Life Technologies, Paisley, UK), the library had to be 
quantified and subsequently diluted. Dilution of the library ensures that the optimal 
input concentration of the library required for template preparation is acquired, and thus, 
the recommended ideal percentage (10-30%) of template-positive Ion OneTouch™ 200 
Ion Sphere™ Particles (ISPs), which subsequently affects the quality of the sequencing, 
is achieved. Less than 10% indicates an insufficient number of template ISPs, which 
would prevent optimal loading density, leading to less data. On the other hand, a 
percentage above 30% would lead to polyclonal fragments (multi-template ISPs) on 
beads instead of a single population on each bead (monoclonal). 
Next, barcoded and size selected libraries were pooled in equimolar amounts, to ensure 
equal representation of each barcoded library in the sequencing run. The dilution factor 
for the libraries was calculated from the molar concentration (pmol/l) of sample 
obtained from running the PSS on the 2100 Bioanalyzer
® 
instrument (Figure 2.14). The 
recommended dilution factor led to a concentration of 26pM, which is suitable for 
downstream template preparation. While this concentration was recommended by the 
manufacturer in the 2013 version of the protocol, it has since been amended to 100pM 
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to optimize results. The manufacturer also suggested that the 2100 Bioanalyzer
® 
instrument may produce less accurate quantitation data than, for instance, qPCR. 
Therefore, it was suggested that 3 serial dilutions be conducted: 1x library dilution 
(26pM); 0.5x dilution (13pM); and 2x dilution (52pM). Proportional dilutions were also 
applied to the updated concentration of 100pM. The actual recommended concentration 
was performed and, according to the percentage of template-positive Ion PGM™ 
Template OT2 200 Ion Sphere™ Particles (ISPs), the concentration was re-calculated as 
follows: 
Dilution factor = (library concentration pM/26 or pM/ 100). 
The library was diluted according the above dilution factor. For example, with a dilution 
factor 50, 1µl of library was added to 49µl nuclease-free water (Ambion
®
, Applied 
Biosystems, Thermo Fisher Scientific, USA). Then, to ensure equal representation of 
each barcoded library, equal volumes (5 µl) of each diluted library were pooled into a 
1.5ml Eppendorf LoBind
®
 tube and stored at 4
o
C (to use within 48 hours), while the rest 




2.2.5 Template preparation 
The process of template preparation was performed by Dr Michele Kiernan in the 
Systems Biology Centre at Plymouth University. For template preparation, the Ion 
OneTouch™ 2 System (Life Technologies, Paisley, UK) was used to prepare enriched, 
template-positive Ion PGM™ Template OT2 200 Ion Sphere™ Particles with clonally 
amplified DNA (200bp average insert libraries), by the Ion PGM Template OT2 200 Kit 
and used on the Ion Personal Genome Machine
®
 (Ion PGM™) System. The Ion 
OneTouch™ 2 System includes: the Ion OneTouch™ 2 Instrument, and the Ion 




















Template-positive ISPs, containing clonally amplified DNA, were prepared using the 
Ion PGM Template OT2 200 Kit (Life technologies, Paisley, UK), for 200 base-read 
libraries, with the Ion OneTouch™ 2 Instrument (which is based on emulsion PCR 
(emPCR)). First, the Ion OneTouch™ 2 Instrument was initialised by installing the 2 
Ion OneTouch™ Recovery Tubes, the Ion OneTouch™ Recovery Router, amplification 
plate, disposable injector and the Ion OneTouch™ Oil and the Ion PGM™ OT2 
Recovery Solution (reagents tubes). Then, the following reagents were processed for the 
amplification solution, by equilibrating to room temperature and vortexing: Ion PGM
TM 
Template OT2 200 reagent Mix, Ion PGM
TM 
Template OT2 200 PCR reagent B, 
Enzyme Mix and Ion PGM
TM 
Template OT2 200 Ion Sphere
TM
 particles (the latter two 
were not vortexed). Subsequently, the pooled library was diluted by mixing 6.5µl 
Figure 2.14. A purified size selected (PSS) JK sample assessed using the 2100 
Bioanalyzer
® 
instrument. The molarity of the two peaks were added to result in a 
total molarity of 6617.5 pmol/l or 6617.5 pM. 
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library with 18.5µl nuclease-free water (Ambion®, Applied Biosystems, Thermo Fisher 
Scientific, USA) to reach a total volume of 25µl, which was then vortexed for 5 seconds 
and spun for 2 seconds, before being placed on ice to use within 48 hours. Next, in a 
1.5-mL Eppendorf LoBind® Tube, the amplification solution was prepared by adding, 
in a designated order, the following: 25µl nuclease-free water; 500µl Ion PGM™ 
Template OT2 200 Reagent Mix; 300µl Ion PGM™ Template OT2 200 PCR Reagent B; 
50 µl of Ion PGM™ Template OT2 200 Enzyme Mix; and 25 μl diluted library. The 
amplification solution was then vortexed vigorously for 5 seconds, followed by brief 
centrifugation for 2 seconds. Subsequently, 100μl Ion PGM™ Template OT2 200 Ion 
Sphere™ Particles (ISPs), (pre-mixed) was added to the amplification solution, which 
was then vortexed thoroughly for 5 seconds and dispensed into the Ion OneTouch™ 2 
instrument, within 15 minutes. The entire solution (1ml) was then added to the Ion 
OneTouch™ 2 instrument, to which 1.5ml Ion OneTouch™ Reaction Oil was also 
added, before commencing the amplification reaction (which also involves 
centrifugation). The template-positive ISPs were recovered, within 16 hours, by 
carefully removing almost all of the solution from two recovery tubes, leaving 50μl 
recovery solution (containing the ISPs pellets). These pellets were re-suspended by 
trituration and together transferred into the first well of the 8-well strip provided Ion 
OneTouch™ ES Supplies Kit, for enrichment. However, this solution can also be stored 
for 3 days at 2-8 °C combined with 1 ml Ion OneTouch™ Wash Solution.  
2μl amplification solution was used to assess the quality of the unenriched, template-
positive ISPs, using the Ion Sphere™ Quality Control assay on the Qubit® 2.0 
Fluorometer to check the percentage of template-positive ISPs. The optimum data 
output for template-positive ISPs is 10-30%; although, a percentage outside this range 
may still provide good data, as suggested by the manufacturer. The enrichment of 
Template-positive ISPs with Ion OneTouch™ ES involved adding reagents into the 8-
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well strip well (containing 100μl unenriched template-positive ISPs in well 1) in the 
following order: 130µl Dynabeads® MyOne™ prepared solution; 300µl of Ion 
OneTouch™ Wash Solution (W); 300µl Ion OneTouch™ Wash Solution (W); 300µl 
Ion OneTouch™ Wash Solution (W) and 300µl Ion OneTouch™ Wash Solution (W). 
300 µl freshly-prepared Melt-Off Solution was added to well 7, and wells 6 and 8 were 
left empty. After completing the enrichment step, ~230 µl solution containing the 
enriched ISPs were next used for sequencing, using the Ion PGM™ Sequencing 200 Kit 
v2. 
2.2.6 Sequencing  
The chip loading and sequencing steps were conducted by Dr Michele Kiernan who 
runs the Genomics Facility of the Systems Biology Centre. Templates were loaded onto 
the 316
TM
 chip after processing with the Ion PGM™ 200 Sequencing Kit v2 (Life 
technologies, Paisley, UK). Although a 314
 TM
 chip would have sufficed for this 
protocol, loading onto that model of chip was unsuccessful due to the size of its wells 
(section 3.4.1). Samples were then sequenced using Ion Torrent PGM
TM 
(Life 
technologies, Paisley, UK). The sequencing protocol started by preparing the enriched, 
template-positive ISPs as follows: 5µl Control Ion Sphere™ Particles was added to a 
0.2-ml non-polystyrene PCR tube and triturated thoroughly, followed by centrifugation 
for 2 minutes at 15,500×g, which is the first step of annealing the enriched, template-
positive ISPs with the sequencing primers. Then, the supernatant was carefully removed 
without disturbing the pellet, leaving 15μl in the tube (confirmed by visually comparing 
to 15 μl of water in a separate tube). Next, 12μl Sequencing Primer was added, 
following which the solution was triturated and placed in a thermal cycler set up as 
follows: 95°C for 2 minutes;  37°C for 2 minutes, after which the reaction was kept at 
room temperature and the chip integrity was checked. The chip check involved carefully 
placing the chip onto the Ion PGM™ Sequencer grounding plate, or in the Ion 
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centrifuge adapter/rotor bucket and following the testing protocol, as instructed by the 
manufacturer. It was crucial to ensure the chip was not damaged, faulty or leaky and 
was functioning properly prior to loading the samples. Subsequently, the reaction (the 
enriched template-positive ISPs with annealed Sequencing Primer) was processed, via a 
binding reaction, by adding 3μl Ion PGM™ Sequencing 200 v2 Polymerase to the 
solution, which was then triturated and incubated for 5 minutes. Next, this solution 
(30μl) was carefully loaded into a 316
 TM
 chip (Life Technologies, Paisley, UK) after 
discarding all the liquid in the chip. The chip was then placed into the Ion PGM 
machine. The instrument was programmed with the necessary details for the run and 
with the required plugins.  
2.2.7 Data analysis and bioinformatics 
The raw sequence data generated from each Ion PGM
TM
 run was transferred to the Ion 
Torrent server, then the Ion Torrent Suite
TM
 converted data into different file formats, 
such as VCF (Variant Calling Files), FASTQ files and BAM files. In addition, a report 
illustrating a summary of the sequencing status, including the percentage loading onto 
the chip was provided by Ion Torrent Suite
TM
. These were analysed using 
bioinformatics software, by aligning the resulting reads with the reference FY gene 
(NM_002036) and JK (NM_001146036.2), which has 11 exons and ABO 
(NM_020469.2) sequence and human genome 19 (hg19). 
Alleles and variants were analysed and visualised using the following software 
packages and plugins: Ion Torrent Suite
TM
 plugins (such as coverage analysis 
v3.6.63324, VariantCaller v3.6.59049 and FastQC v3.4.1.1), Integrative Genomics 
Viewer (IGV) and Ion Reporter
TM
. In addition, the SeattleSeq annotation 137 online 
tool was used for data analysis (available at 
http://snp.gs.washington.edu/SeattleSeqAnnotation137/index.jsp). These software 
packages were connected to a database, such as 1000 genome 
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(http://www.1000genomes.org) and dbSNP (http://www.ncbi.nlm.nih.gov/SNP), in 
order to identify variants and SNPs. 
The sequence data obtained by the Ion Torrent server had average coverage depths of 
5600x for FY; 750x for JK; and 650x for ABO. The above software, linked to database 
such as the 1000 genome database (http://www.1000genomes.org), was used to align 
and analyse these reads with the reference sequences for the JK gene 
(NM_001146036.2), FY gene (NM_002036) and the ABO gene (NM_020469.2) from 
the human genome database (hg19).   
2.3 JK: cDNA analysis of G810A (exon 8 near splice region) and 
A588G (exon 7 with JK*01W). 
 
2.3.1 (JK) cDNA analysis of G810A  
This analysis required the blood samples to be as fresh as possible, due to the 
vulnerability of RNA; therefore, the most fresh fully typed (Kidd included) blood units 
used here were 4 days old. The extraction of gDNA and RNA was conducted in parallel, 
so as not to affect RNA extraction by any possible delays. Since the first step of the 
experiment involved RNA, gDNA, once extracted, was stored. Sample RNA was 
quantified prior to synthesising cDNA, followed by amplification using specific PCR 
primers. These primers were designed to start (attach) within exons 8 and 9, due to an 
absence of introns in the messenger RNA. Finally, the cDNA was sequenced by Sanger 
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Figure 2.16. Overview of the A588G analysis 
 
2.3.2 (JK) cDNA analysis of A588G 
The workflow for this protocol was the same as that in section 2.3.1, until the point of 
amplification of the cDNA, for which different specific PCR primers were used. These 
primers were designed to cover JK exons 4-9 to include the following SNPs: G130A, 
A588G, G810A and G838A. These SNPs were used to analyse the association of 
A588G in exon 7 with JK*01W. Molecular cloning was then carried out in order to be 
able to sequence individual alleles of interest and possibly confirm the association of 

























2.3.3 Primers  
Several primers were designed in order to evaluate the best pair to amplify the cDNA 
from the required areas of the gene (exon 8 and 9; Table 2.9) and (exon 4 to 9; Table 
2.10). Due to the fact that, naturally, the introns are spliced out from the RNA in the 
transcription process, the primers need to be designed to anneal within the exons (See 
chapter JK; figure 4.13).  
Therefore, several databases were used to design and confirm the specificity of the 
primers, namely: Primer 3 software (http://frodo.wi.mit.edu/primer3); the NCBI Blast 
database (http://blast.ncbi.nlm.nih.gov/), and the UCSC Genome Bioinformatics 
database (https://genome.ucsc.edu). In particular, in-silico PCR (virtual PCR; 
https://genome.ucsc.edu) was used to confirm the specificity of primers and 












Table 2.9. The primers designed to cover the gene region within exons 8 and 9 of JK 
for the analysis of G810A (exon 8 near splice region). Tm: melting temperature, as 
indicated by the NCBI BLAST database. More than 3 pairs of primers were analysed; 
the primers indicated here were selected as they displayed similar Tm and specificity. 
From these primers, FR5 (highlighted in grey) was the pair selected for the current 












































Table 2.10. The primers designed to cover the gene region within exons 4 to 9 of JK for 

























2.3.4 cDNA synthesis and specific amplification  
Briefly, cDNA generation is catalysed by reverse transcriptase (RT), which synthesises 
cDNA from messenger RNA (mRNA) via complementary base pairing of free 
nucleotides to single-stranded mRNA.  
 
Using RT-PCR, synthesis of the first cDNA strand was conducted using the Superscript 
® III First Synthesis System (Invitrogen
TM
, Paisley, UK), which contains the  
SuperScript® III Reverse Transcriptase enzyme. To start this process, 40ng extracted 
RNA (~4μl, depending on the concentration of the extracted RNA) was added together 
with the reagents included in the kit, namely 1μl 50μM oligo(dT) and 1μl 10 mM dNTP, 
in 0.2ml sterile strips. DEPC-treated water was added to reach a total volume of 10μl 
(i.e. if 4 μl RNA was used, 4 μl DEPC-treated water was added). The solution was then 
briefly mixed and centrifuged, followed by incubation at 65°C for 5 minutes in a 
thermocycler machine and subsequent cooling on ice for at least 1 minute. Next, the 
cDNA synthesis mix was prepared by adding the following components (provided in 
the kit), in the following order: 2μl 10X RT buffer; 4μl 25mM MgCl2; 2 μl 0.1 M DTT; 
1μl RNaseOUT
TM
 (40 U/μl) and 1μl SuperScript® III RT (200 U/μl). To avoid pipetting 
errors, the master mix was made up with 10% extra volume. Of this cDNA mix, 10μl 
was added to the RNA-containing mix and gently triturated, followed by brief 
centrifugation. The cDNA-RNA mix was then incubated in the thermocycler machine at 
50°C for 50 minutes and the reaction was terminated at 85°C for 5 minutes, before the 
tubes were placed on ice. Afterwards, the tubes were spun and 1μl of RNase H, which 
removes the remaining RNA, was added to the tubes, following which they were 
incubated at 37°C for 20 minutes in the thermocycler. A working aliquot of 6μl first-




2.3.5 Amplification of target cDNA 
The synthesised first-strand cDNA was next amplified by PCR, where JK exon 8-9- and 
JK exon 4-9-specific primers were utilised to enable amplification of that region of the 
gene and amplicon quantification, thereby facilitating downstream analysis. In this case, 
successful amplification would indicate successful synthesis of cDNA from RNA. 50μl 
amplification reaction mix (containing primers flanking JK exons 8-9 for the analysis of 
the G810A on exon 8, near splice region) contained the following: 4-7μl cDNA; Q5® 
Hot Start High-Fidelity 1X Master Mix (New England BioLabs inc, UK); 500nM 
primers; and a volume of nuclease-free water required to bring the total volume to 50μl 
(depending on the volume of cDNA added). Prior to amplification, several optimisation 
tests were carried out (data not shown), which included changes in temperature, times 
and other thermocycling conditions. Thermocycling was carried out using a Veriti 
Thermal Cycler (Life Technologies, Paisley, UK), under conditions indicated in Table 
2.11. Subsequently, amplicons were visualised by agarose gel electrophoresis, using 1.5% 
Hi-Res Standard agarose gel (Geneflow Limited, Staffordshire, UK). 10µl amplicons 
was mixed with 2µl DNA gel loading buffer and loaded into gels, following which 
electrophoresis was carried out at 90V for 1 hour and bands were visualized and 
compared against TriDye
TM
 100 bp (New England BioLabs® inc., UK). Amplicons 







Table 2.11. Thermocycling conditions for cDNA amplification, specific for the analysis 
of the JK (G810A on exon 8 near splice region) 
Step Temperature Time Cycles 
Initial denaturation 98
o
C 30 seconds 1 
Denaturation 98
o
C 5 seconds 
35 Annealing 64
o
C 20 seconds 
Extension 72
o
C 30 seconds 
Final extension 72
o
C 2 minutes 1 
Holding 4
o
C ∞ - 
 
Amplification of target cDNA that covers JK exon 4-9, including SNPs G130A, A588G, 
G810A and G838A (for the analysis of the association of A588G in exon 7 with 
JK*01W) was different for this particular amplicon, as molecular cloning was required. 
The 50μl amplification reaction mix included 80ng cDNA and BioMix
TM 
2x reaction 
mix (BioLine, UK), with a primer concentration of 500nM (Table 2.10), mixed in 0.2 
ml tube strips. The BioMix
TM
 2x reaction mix contains a stable Taq DNA that leaves the 
nucleotide A overhang on the PCR product, which is critical for the cloning process. 
Thermocycling was carried out using a Veriti Thermal Cycler (Life Technologies, 
Paisley, UK), with the optimised conditions indicated in Table 2.12. The final extension 
was prolonged to 20 minutes to ensure that all cDNA amplicons were of full length, 
with nucleotide A overhang at the 3’ end. The amplicons were then visualised by 
agarose gel electrophoresis, using 1% Hi-Res Standard agarose gel (Geneflow Limited, 
Staffordshire, UK), with electrophoresis carried out at 90V for 1 hour. Amplicons 





Table 2.12. Optimised thermocycling conditions for cDNA amplification, specific for 
analysis of JK A588G in exon 7. The final extension was prolonged by 20 minutes to 
ensure full length cDNA with nucleotide A overhang at the 3’ end. 
Step Temperature Time Cycles 
Initial denaturation 94
o
C 30 seconds 1 
Denaturation 94
o
C 5 seconds 
35 Annealing 60
o
C 20 seconds 
Extension 72
o
C 30 seconds 
Final extension 72
o
C 20 minutes 1 
Holding 4
o
C ∞ - 
 
 
2.3.6 cDNA Sequencing (Sanger) of amplicon covering G810A 
The cDNA amplicons for the analysis of the G810A were purified and diluted according 
to the manufacturer’s instructions for the SmartSeq Kit (Eurofins Genomics), whose 
name subsequently changed to Mix2Seq kit. http://www.eurofinsgenomics.eu. This kit 
contains pre-labelled, barcoded tubes with secure lid sealing, which are recognised by 
Eurofins company, in which the purified template (here was cDNA amplicon) and 
specific primer were premixed and loaded before sending them for sequencing.  The 
amplicons were purified by SPRIselect
® 
reagent kit with 80% of freshly prepared 
molecular biology grade ethanol (Fisher Scientific, UK).  In a plate, the remaining 
volume of cDNA (40 µl) were mixed thoroughly with 1.8X SPRIselect
® 
magnetic beads 
(72 µl) by pipetting 10 times and incubated at room temperature for 10 minutes. Next, 
the plate was placed on the magnetic plate (Agencourt
®
 SPRIPlate 96R - Ring Super 
Magnet Plate, Beckman Coulter, UK) for 3 minutes with which the Amplicon-carrying 
beads attached to the wall of the wells leaving a clear solution supernatant on top, which 
was then carefully discarded; however the supernatant of the very first experiment of 
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the cDNA purification was kept as due to small size (237bp), there was a concern that 
there may be a failure in the beads attracting the small amplicons. The supernatant of 
the first cDNA amplicon purification experiment was tested and revealed that the 
amplicons were successfully attracted by beads as showing negative in the gel of the 
supernatant (data not shown). Subsequently, without removing the plate from the 
magnet, a 2 times wash was conducted by the addition of 30µl of the 80% ethanol, then 
incubated for 30 seconds and discarded. After that, an air-dry for 3 minutes was 
performed before removing the plate from the magnet and purified amplicons were 
eluted by 30µl of nuclease-free water (Ambion
®
, Applied Biosystems, Thermo Fisher 
Scientific, USA) as explained in several sections. Afterwards, those purified cDNA 
samples were quantified by Qubit® dsDNA Broad range (BR) assay Kit (Invitrogen
TM
, 
Paisley, UK), in order to calculate the dilutions to meet the requirements of the 
SmartSeq Kit or Mix2Seq kit (Eurofins Genomics). For optimum Sanger sequencing 
results using SmartSeq Kit or Mix2Seq kit (Eurofins Genomics), 15 µl with 
concentration of (1ng/ µl) of purified  PCR product (cDNA amplicons in this case) was 
required to mix with 2 µl of 10pmol/µl  each forward and reverse primer. Therefore, 2 
diluted aliquots, as two sequencing reactions are needed so each sample would be 
sequenced on both strands with forward and reverse primer. Each aliquot was prepared 
with volume of 20 µl (with 1ng/ µl), to avoid pipetting error, by the following equation: 
volume to be taken from the purified cDNA amplicon = 1(ng)x 20(µl)/concentration of 
the cDNA amplicon (from the Qubit®) and make up to 20 µl with nuclease free water. 
On the other hand, 10pmol/ µl aliquot with volume made up to 50 µl with nuclease free 
water of each forward and reverse primer (specific primers for G810A analysis). In two 
1.5 ml Eppendorf tubes for each sample, 15 µl of the (1ng/ µl) purified cDNA 
amplicons were mixed with 2 µl of (10pmol/ µl) of forward or reverse primers in 
indicated tubes ensuring the volume of this mix to at least 17µl. Then, these premixed 
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solutions were transferred and loaded into the barcoded tubes provided in the Mix2Seq 
kit (Eurofins Genomics) and sealed before sending them to the designated company 
(Eurofins Genomics) address to be Sanger sequenced. 
2.3.7 Molecular cloning 
The molecular cloning process utilised TOPO
®
 TA Cloning® Kit for sequencing 
(Invitrogen
TM
, Paisley, UK) with pCR
TM 
4-TOPO® vector (TOPO®vector)- and Top10 
One Shot® Chemically-competent cells, and was conducted near a Bunsen Burner. First, 
the TOPO
®
 Cloning reaction (6µl) was performed by adding the following reactants 
into 0.2 ml nuclease-free tube strips, in the indicated order: 4µl freshly prepared PCR 
product (Taq-amplified cDNA); 1µl Salt solution (provided in the kit); and 1µl 
TOPO®vector, which enables ligation of the PCR product (insert) to plasmid 
(recombinant) DNA. This reaction was then gently mixed, followed by incubation for 
15 minutes at room temperature and placement on ice for the chemical transformation 
process.  
The mixed cloning reactants were transformed into Top10 One Shot® Chemically 
competent cells as follows: 2µl TOPO
®
 Cloning reaction was carefully added into a vial 
of One Shot® chemically competent E. coli and then mixed by gently rotating, followed 
by incubation on ice for 20 minutes. Subsequently, the vial was subjected to a heat-
shock at 42°C for 30 seconds (without shaking) and immediately replaced on ice.  Next, 
250µl S.O.C. medium (provided in the kit and equilibrated to room temperature) was 
carefully added to the vial, which was then placed horizontally into a shaking (200 rpm) 
incubator at 37°C for 1 hour. Then, in 5 separate 1.5ml sterile Eppendorf tubes, 50µl of 
this transformation solution was mixed with 20µl S.O.C. medium to homogenously 
spread the transformation solution over 5 pre-warmed selective plates (LB plates 
containing 50µg/ml Kanamycin). Plates were incubated overnight at 37°C. The reason 
for using 5 separate plates was to use up all the transformation solution (250µl) and 
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thereby culturing all possible colonies, so as not to miss a colony containing the needed 
insert (JK*01W allele). Subsequently, 30 colonies were randomly selected from the 5 
plates and sub-cultured, by inoculating a minute amount (using the tip of a sterile loop) 
into a graded selective plate, followed by overnight incubation (growth) at 37°C and 
subsequent storage at 2-8°C.  
Meanwhile, the majority of the 30 colonies were cultured overnight in individual tubes 
containing 5ml medium (LB medium contacting 50µg/ml Kanamycin) at 37°C in a 
shaking (80rpm) incubator. Then, the cultured colonies with recombinant DNA 
(Plasmid DNA with the insert) were isolated and purified using the PureLink®Quick 
Plasmid Miniprep Kit (Invitrogen
TM
, Paisley, UK).  
2.3.7.1 Isolation and purification of plasmid DNA 
Purification of plasmid DNA allowed analysis for positive insertion of the cDNA and 
was required prior to sequencing. During this procedure, 4.5ml LB-culture inoculated 
(overnight) broth, was centrifuged at 4500 rpm for 10 minutes at room temperature. 
500µl of LB-culture broth was stored together with 15% (v/v) sterile glycerol at -80°C 
for future use. Following centrifugation, the supernatant was removed gently, without 
disturbing the pellet, and discarded. The pellet was re-suspended by adding 250µl 
Resuspension Buffer with RNase A (R3; provided in the kit) and solution was 
homogenised by trituration. Cells were then lysed by adding 250µl Lysis Buffer L7 
(provided in the kit) to the tube, which was then gently mixed by inversion until 
homogenous and incubated at room temperature for 5 minutes. Next, the solution was 
precipitated by adding 350µl Precipitation Buffer N4 (provided in the kit) and 
immediately mixed by inversion, until a turbid white homogenous solution formed, 
which was then centrifuged at >12000xg for 10 minutes. The supernatant was loaded 
onto a (provided) spin column (placed in 2ml wash tubes) for the binding process and 
spun for 1 minute at 12000xg, after which the flow-through was discarded and the 
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column replaced into the washing tube. The column was then washed using 500µl Wash 
buffer (W10; with ethanol), incubated for 1 minute at room temperature, then spun 
again for 1 minute at 12000xg, before discarding the flow-through. Another wash was 
performed as above, this time 700µl Wash buffer (W9; with ethanol), following which 
the column was centrifuged again, without the addition of any buffers, at 12000xg for 1 
minute and flow-through discarded. Columns were then placed in fresh 1.5 ml recovery 
tubes (provided in kit). Subsequently, 75µl TE buffer (preheated to 65-70°C) was added 
to the centre of each column for elution, and then incubated for 1 minute at room 
temperature. Columns were then centrifuged at 12000xg for 2 minutes and discarded, 
while the recovery tubes (containing purified plasmid DNA) were equally aliquoted and 
stored at - 20°C. Purified plasmid DNA was quantified using the Qubit® 2.0 
Fluorometer and the Qubit® dsDNA Broad range (BR) assay Kit (Life Technologies, 
Paisley, UK), prior to screening for plasmid DNA with positive insertions, which was 
conducted via restriction enzyme (RE) analysis using EcoRI (Promega, UK).  
2.3.7.2 Restriction enzyme analysis to screen plasmid DNA for insert 
The restriction digest solution contained the following reagents, added to 0.2 ml PCR 
tube strips in the indicated order: 15.3µl nuclease-free water; 2µl RE 10X buffer; 0.2µl 
Acetylated BSA (10µg/µl); 2µl purified plasmid DNA (mixed by trituration); and 0.5µl 
EcoRI (10U/µl) to result in a 20 µl reaction mix, which was subsequently triturated and 
incubated 37°C for 1 hour in a thermocycler. To visualise the plasmid DNA with the 
insert, the total restriction digest mix was loaded into a 1.5% Hi-Res Standard Agarose 
gel (Geneflow Limited, Staffordshire, UK), mixed with 4µl DNA gel loading buffer. In 
addition, 2µl uncut purified plasmid DNA was mixed with 3µl DNA gel loading buffer, 
which was used as control. Gel electrophoresis was carried out 90V for 1 hour, 
following which bands of the desired size (indicating plasmid DNA samples with 
positive insertions) were sequenced using the Sanger method. Plasmid DNA with 
115 
 
positive insertions was diluted as to be used for the SmartSeq Kit (Eurofins Genomics, 
Ebersberg, Germany), according to the manufacturer’s instructions. For Sanger 
sequencing of plasmid DNA, aliquots containing DNA concentrations of 80ng/µl were 
prepared as previously described in 2.3.6; 15µl was loaded into 2 separate barcoded 
tubes with 2µl (10pmol/µl) primers (T3; 5´-ATTAACCCTCACTAAAGGGA-3´) and 
(T7; 5´-TAATACGACTCACTATAGGG-3´) provided in the TOPO
®
 TA Cloning® Kit 
for Sequencing (Invitrogen
TM
, Paisley, UK), prior to sequencing.  
2.4 Sanger sequencing for ABO gene  
In the first NGS ABO run, various SNPs from exons 3, 4 and 6 were investigated and by 
Sanger sequencing to confirm the NGS data validity. Primers were designed to amplify 
around SNPs in exon 3 ( 103G/A, 106G/A), exon 4 (188G/A, 189C/T) and exon 6 
(297A/G).  The primers used for amplification of these SNPs are listed in Table 2.13; 
these primers were used together with the Q5® Hot Start High-Fidelity 2X Master Mix 
(New England BioLabs inc, UK), with thermocycling conditions described in Table 2.14.  













F1 CAGCTTCACCGGGAACTCTT 20 59.4 
210 3 
R1 ATGGATGCTCCACCTGCTCT 20 59.4 
F2 CACAGTGATGGTTGTTCTGTGA 22 58.4 
368 4 
R2 GGCCAAGTCAGGGTAGAGACT 21 61.8 
F3 AGAAGCTGAGTGGAGTTTCCAG 22 60.3 
318 6 










2.5 Sanger sequence analysis 
Sequences of forward and reverse reactions were visualised and analysed using the 
software packages: Sequence Scanner software 2 (Seq scanner 2, Applied Biosystems, 
Paisley, UK), and Integrative Genomics Viewer (https://www.broadinstitute.org). These 
software packages were used for aligning and matching forward and reverse sequences 
with the reference sequences, providing an overview of the sequence variations, 









Step Temperature Time Cycles 
Initial denaturation 98
o
C 30 seconds 1 
Denaturation 98
o
C 5 seconds 
35 Annealing 62
o
C 20 seconds 
Extension 72
o
C 30 seconds 
Final extension 72
o
C 2 minutes 1 
Holding 4
o
C ∞ - 
Table 2.14 Thermocycling conditions for amplification of the primers in Table 




Chapter 3  




3.1 Introduction    
The Duffy blood group system (FY/ISBT 006) is represented by a single gene (FY or 
ACKR1) (see section 1.6.1). Initially, this gene was described to have one exon 
(encoding 338 amino acids)(Chaudhuri et al., 1993); however, subsequently, the gene 
was shown to have two exons, encoding for 336 amino acids – assigned as the major 
(predominant) transcript (section 1.6.1) (Iwamoto et al., 1996a).  The major transcript 
has been used here as the reference sequence, including the numbering of nucleotides 
and amino acids. The FY blood group system is considered to be clinically significant, 
as the corresponding alloantibodies have been reported to be involved in haemolytic 
transfusion reactions and haemolytic disease of the foetus or newborn (HDFN), in cases 
of incompatible blood transfusion or pregnancy (Daniels, 2013). The main Fy 
polymorphic antigens (Fy
a/b
) are thought to be directly encoded by two main co-
dominant alleles (FY*A and FY*B) which differ by a single nucleotide polymorphism 
(SNP) (125G>A) leading to the amino acid change, Gly42Asp. However, there are, in 
fact, numerous FY alleles; according to the NCBI Blood Group Antigen Gene Mutation 
Database (dbSNP; www.ncbi.nlm.nih.com), there are 16 FY alleles, a number of which 
impair or demolish (null phenotype) the expression of Fy antigens. Examples of these 
are FY*X (FY*02M.01), associated with the SNPs 265C>T and 298G>A,  which 
weakens the expression of Fy
b
 antigen (Olsson et al., 1998), and the FY*Null associated 
with SNP (-67T>C) in the GATA promoter region, found commonly among African 
Americans (Reid et al., 2012, Tournamille et al., 1995). The number of FY alleles 
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continues to  increase, many of which may have not been included in the NCBI 
database yet – especially low frequency alleles (Westoff et al., 2014). These new alleles 
arise from different mutation mechanisms, such as SNPs and deletions, which may alter 
the amino acid sequence or lead to a premature stop codon, thereby affecting 
antigenicity. Accordingly, it is suggested that providing extended genotyping of 
clinically significant blood group systems is suggested to improve the safety of blood 
transfusions  and minimise alloimmunisation, especially for transfusion-dependant 
individuals, such as those with sickle cell disease (SCD) (Avent, 2009). Blood group 
genotyping (BGG) has impacted greatly on the management of alloimmunisation, by 
which better interpretation of the phenotype is provided (Castilho, 2007). High 
throughput genotyping is suggested to be vital in addressing the demand to screen for a 
large number of alleles (Anstee, 2009), especially those that may be rare. However, 
despite their high throughput capabilities, all current commercially available platforms, 
such as microarray-based platforms, are dependent on previous knowledge of the 
molecular basis of the alleles and, consequently, novel or rare mutations and alleles, 
which may affect the antigenicity, might be missed due to the absence of corresponding 
probes in the array. As a result, the genotyping system requires constant updating. On 
the other hand, Next Generation Sequencing (NGS) technology, which is sequence-
based genotyping, circumvents the requirement of previous knowledge of, for example, 
SNPs, thereby allowing a discovery mode. This provides a key opportunity to 
thoroughly explore all existing and novel alleles, so as to provide comprehensive 
interpretation of the phenotype from the genotype (McBean et al., 2014, Tilley and 








3.2 Aim of the study 
The aim of this project was to use the powerful NGS-based genotyping platform to 
establish an optimised and reliable protocol for comprehensive genotyping of the entire 
gene of the blood group FY plus the flanking regions. Here, the Ion Torrent PGM
TM
 (the 
available platform at Plymouth University, was used with long-range polymerase chain 
reaction (LR-PCR) (single amplicon). Considering the NGS capability of discovering 
novel polymorphisms, in addition to known ones across the gene, extensive genotyping 
of all existing polymorphisms in exons, introns and regulatory regions will be provided, 
enabling comprehensive interpretation of associated phenotypes. In addition, intronic 
SNPs will be analysed and catalogued in order to investigate their association with 
alleles, such as weak or null alleles. Accordingly, a refined illustration of the molecular 
basis of the FY alleles reference sequences will be provided, in addition to the discovery 
of new alleles. Moreover, this NGS genotyping and analysis approach will be evaluated, 









3.3 Results   
3.3.1 Long-range PCR of the FY gene 
For complete FY genotyping by NGS, gDNA of 53 blood samples was sequenced. The 




 phenotype was provided for 43 donor samples 
(Table 3.1). Using primer 3 software and the NCBI database (see section 2.2.4.1), a 
primer pair was designed to produce a single long amplicon (4784bp) to target the entire 
FY gene plus flanking regions (up- and downstream; Figure 3.1). For the LR-PCR 
amplification reaction, the forward 5’-3’ GTGTGAGTGAGTGAGAGGCAGAG and 
reverse 5’-3’ GCCAGAGAGGAGACAGAAGACAG primers (see Table 2.1) were 
mixed with the gDNA and 2x LongAmp® Hot Start Taq Master Mix (New England 
BioLabs Inc., Herts, UK), which consists of a blend of Hot Start Taq and Deep VentR® 
DNA Polymerases (see section 2.2.4.2). As a result, the fidelity of this master mix is 
two-fold greater than that of Taq DNA polymerase alone, according to the 
manufacturer’s instructions.  FY  PCR amplicons were loaded onto a 1% agarose gel 
and electrophoresed at 85 V for 1 hour (section 2.2.4.3); amplicons were detected  as a 
single ~5kbp band (Figure 3.2). Then, the amplicons were purified by a magnetic bead 
technique (see section 2.2.4.4) to ensure the removal of primer dimers and free 
nucleotides that may interfere with downstream processing. Subsequently, purified 
amplicons were quantified using the Qubit® 2.0 Fluorometer with Broad range (BR) 
assay Kit (Invitrogen
TM
, Paisley, UK; section 2.2.4.4), which is crucial in order to 
prepare the 100 ng concentration of amplicons (Section 2.2.4.5) required for the 
fragmentation process. As a single amplicon was utilised to cover the FY gene, aliquots 













Exon 1 Exon 2 
5’ 3’ 






(- 67 T>C ) 
Figure 3.1. Single long amplicon (generated by LR-PCR) covers the entire FY 
gene plus flanking regions (including the promoter region).  
 
FY gene is (2488bp according to NCBI GenBank and found as over 1.5kb in (Reid et 
al., 2012) with 2 exons shown as boxes while the intron is represented by a line. The 
main SNP that differs FY*A/FY*B is shown in exon 2, while the SNP suggested to be 





Table 3.1.  The serology information of the 53 blood samples provided from National Health Service Blood and Transplant (NHSBT; 
Filton, Bristol UK). * represents the sample ID provided. Note, the serology of a number of samples displays only the status of the Fy
a
 
antigen, with the status of the Fy
b
 antigen being represented by ?**. ND, serology not defined. The FY008 number, which is the ISBT 
number assigned for the FY blood group system (Daniels, 2013, Reid et al., 2012), is used here to name the samples accordingly to the FY 













FY008.01 470D ND FY008.21 4648 ND FY008.41 4576 Fy (a+b?**) 
FY008.02 9 Fy (a+b-) FY008.22 12 Fy (a-b+) FY008.42 4208 Fy (a+b+) 
FY008.03 25 Fy (a+b-) FY008.23 15 Fy (a-b+) FY008.43 581Z ND 
FY008.04 35 Fy (a+b-) FY008.24 17 Fy (a-b+) FY008.44 469B ND 
FY008.05 36 Fy (a+b-) FY008.25 19 Fy (a-b+) FY008.45 5800 ND 
FY008.06 45 Fy (a+b-) FY008.26 76 Fy (a-b+) FY008.46 470P Fy (a+b?**) 
FY008.07 51 Fy (a+b-) FY008.27 74 Fy (a-b+) FY008.47 580X ND 
FY008.08 11 Fy (a+b-) FY008.28 97 Fy (a-b+) FY008.48 3 Fy (a+b+) 
FY008.09 40 Fy (a+b-) FY008.29 99 Fy (a-b+) FY008.49 4 Fy (a+b+) 
FY008.10 50 Fy (a+b-) FY008.30 101 Fy (a-b+) FY008.50 5 Fy (a+b+) 
FY008.11 54 Fy (a+b-) FY008.31 104 Fy (a-b+) FY008.51 6 Fy (a+b+) 
FY008.12 55 Fy (a+b-) FY008.32 111 Fy (a-b+) FY008.52 14 Fy (a+b+) 
FY008.13 59 Fy (a+b-) FY008.33 73 Fy (a-b+) FY008.53 22 Fy (a+b+) 
FY008.14 60 Fy (a+b-) FY008.34 1 Fy (a-b-)    
FY008.15 71 Fy (a+b-) FY008.35 2 Fy (a-b-)    
FY008.16 69 Fy (a+b-) FY008.36 10 Fy (a-b-)    
FY008.17 75 Fy (a-b+) FY008.37 26 Fy (a-b-)    
FY008.18 437R Fy (a-b+) FY008.38 28 Fy (a-b-)    
FY008.19 459F ND FY008.39 29 Fy (a-b-)    
FY008.20 453R ND FY008.40 31 Fy (a-b-)    
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Figure 3.2.  The FY amplicons produced by LR-PCR.  
The whole FY gene was covered by a single amplicon of ~5kbp size 
(4784bp). In this example, the amplicons of 8 samples are shown. The last 
column (-ve) represents a negative control, which is a master mix without 
gDNA added. Samples were loaded on a 1% (w/v) agarose gel and 
electrophoresed at 85 V for 1 hour. The GeneRuler
TM 
1Kb Plus DNA 
ladder (Thermo Fisher Scientific) was used as a marker of DNA size. The 









1% (w/v) agarose gel  





3.3.2 Next Generation Sequencing of the FY gene 
 
3.3.2.1 FY amplicon library fragmentation (purified fragmented library) 
Following amplicon purification and quantitation, NGS libraries were fragmented using 
the Ion Xpress
TM 
Plus Fragment Library Kit (section 2.2.4.6). The incubation length of 
the enzymatic fragmentation reaction was 5 minutes, which was selected as this allows a 
wide fragment size distribution with sufficient yield (peak) around 200-300bp – the 
recommended target median fragment size by the manufacturer (Figure 3.3: an example 
of a FY fragmented-purified amplicon). Subsequently, samples were purified by 
magnetic beads (Agencourt® AMPure® XP beads Reagent or SPRIselect
® 
reagent kit 
(Beckman Coulter, UK). Fragment size distribution of samples was assessed by the 
Agilent® 2100 Bioanalyzer and Agilent High Sensitivity DNA Kit (Agilent 





















3.3.2.2 Ligation of barcoded adapters (FY purified-ligated library) 
The ligation of barcoded adapters to the fragmented samples is critical to allow the 
identification and distinguishing of samples after pooling. The samples were ligated to 
barcoded adapters (P1 and Ion Xpress
TM
Barcode X adapter), from the Ion Xpress
TM 
Barcode adapters Kit (Life Technologies, Paisley, UK), using DNA ligase. 
Subsequently, ligated libraries were purified and assessed by Agilent® 2100 
Bioanalyzer and Agilent High Sensitivity DNA Kit (Agilent Technologies UK Limited). 
This analysis was optional and estimates the success of the adapter ligation in a form of 
an increase shift of size distribution by 80bp (see section 2.2.4.9). Figure 3.4 illustrates 
the shift in the size distribution between one FY fragmented library and then a FY 
fragmented-ligated library.  
Figure 3.3. An electropherogram of a fragmented-purified FY DNA library. 
This is an example of a FY amplicon fragmented using the Ion Xpress
TM 
Plus 
Fragment Library Kit for 5 minutes. The arrow displays the peak around 200-
300 bp. The green line (35bp) is the lower marker and the purple (10380bp) is 
the upper marker. Results shown were obtained using the Bioanalyzer
® 




3.3.2.3 Size selection  
The size selection process is applied to the purified ligated library to produce the length 
size that provides the best reads possible when processed by the Ion PGM™ Template 
OT2 200 kit and run on the Ion PGM™ 200 Sequencing Kit.  In the process of 
sequencing 53 samples, three experiments were conducted. 12 samples were sequenced 
in the first experiment, 17 in the second and 24 samples in the third sequencing 
experiment. The first 12 samples underwent the majority of the library construction 
optimisations: fragmentation for 9 minutes; size selection by the Pippin Prep
TM 
instrument (Sage Science, Inc., Beverly, USA) and Pippin Prep™ Kit 2010 with 
Ethidium Bromide cassettes; and purification by magnetic beads. This was set to target 
the optimum target peak (330bp), which provides the highest number of reads. However, 
as the fragmentation length (9 minutes) leads to a lower concentration around 200-
300bp, this size selection attempt resulted in a low concentration, around 330bp (Figure 






Figure 3.4. Two electropherograms of the same FY amplicon library. 
A) Fragmented-purified library with the peak around 200-300bp 
B) Fragmented-ligated purified library with the peak shifted to the right (due to adapter ligation, evident as an increase in size by ~ 80bp. 




A) Fragmented-purified library 























Figure 3.5. Two electropherograms of the same FY amplicon library, 
fragmented for 9 minutes and size selected by Pippin Prep
TM
. (Both purified) 
A) FY library was fragmented for 9 minutes, which clearly provides median 
fragment size 100-200bp. 
B) Same library was size selected (by Pippin Prep
TM 
instrument) with the 
required target of 330bp, which clearly provides low concentration due to low 
DNA distribution around this area. Note the total library concentration here is 
(991 pmol/l) as the actual concentration 99.1 was multiplied by 10 due to 
diluted library.   
  The green (35bp) represents the lower marker while (purple 10380) is the upper 






 size selected library 330bp target 
size  
A) 9 minutes fragmentation reaction library 
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Accordingly, the next set of 17 samples were fragmented for 5 minutes, in order to 
attain a sufficient concentration around 200-300bp, and size-selected by Pippin Prep
TM 
instrument after ligation of the adapters. Figure 3.6 illustrates 3 electropherograms of 
the fragmentation, ligation and size-selection of one of the 17 FY libraries. The 
remaining 24 FY libraries were size-selected using SPRIselect
® 
reagent magnetic beads 
(see section 2.2.4.10) to provide a peak around 200 bp, which is compatible with the Ion 
PGM™ Template OT2 200 kit.  Figure 3.7 shows a purified-ligated FY library that has 
been size-selected by SPRIselect
® 
reagent magnetic beads.  
The size selection step of the amplicon library preparation, the concentrations of which 
were determined by the Bioanalyzer
® 
instrument (see section 2.2.4.11) that were critical 
for template preparation (section 2.2.5), was followed by sequencing using Ion torrent 
PGM
TM 






Figure 3.6. three electropherograms of the same FY DNA library. 
A) 5 minute-fragmented library with the peak at around size 200-300bp. 
B) Same library was ligated with clear shift to the right. 
C) Size election was done by Pippin Prep
TM 
instrument targeting the size 
around 300bp. 
D) The red circle represents the concentration calculated to determine the 
Dilution factor for next step (template preparation) here the total is 1662.3 
pmol/l. The green line (35bp) is the lower marker and the purple line 




D) Library concentration   
A) 5 minutes fragmented FY 
library  
B) Fragmented-Ligated  FY library  
 





           
 
Figure 3.7 an electropherograms of size selected FY DNA library (by SPRIselect
® 
reagent magnetic bead). 
It can be seen that peak is around 200bp (212-223bp).  The red circle represents the concentration calculated to determine the Dilution 
factor for next step (template preparation) here the total is 9442 pmol/l. The green line (35bp) is the lower marker and the purple line 






3.3.3 Next Generation Sequencing data quality control  
 
3.3.3.1 Sequencing Data summary report 
Following sequencing, the sequencing data were transferred to the Ion Torrent Server 
software and was processed, for example, by trimming adapters’ sequence. A 
sequencing summary of the data generated is by default produced by Torrent Suite™ 
Software Version 4.4. The average of the total reads generated from the 53 FY samples 
was ~ 3.130 million, with a mean coverage depth of about 5600x. Table 3.2 summarises 
the sequencing report of the total reads of the FY samples from the 3 separate runs). 
Figure 3.8 illustrates a part of a sequencing report of single FY sequencing run on the 
Ion PGM
TM
, which is representative of other runs. Here, the loading percentage of the 
316
TM 
chip wells was 75%, which indicates the potential addressable wells containing 
ISPs. The total number of usable reads for downstream analysis was ~3.5 million, which 
made up 74% of the total reads containing library ISPs. These reads were processed in 
two steps using software to ensure their quality and accuracy: well classification and 
read filtering (and trimming). The former step mainly distinguishes the empty wells 
from the loaded wells, with the ISP-addressable wells providing the bead loading 
density (ISP loading percentage). In addition, this step distinguishes between control 
fragments and the library ISPs. The second step is applied to trim the reads from 
polyclonal ISPs (22%), while maintain those clonal ISPs (78%).  Clonal ISPs represent 
a population of single unique template fragments that have been amplified by Ion 
OneTouch™, whereas the polyclonal reads represent fragments containing more than 
just one amplified sequence. Moreover, reads of low quality, short reads (less than 4 
base pairs) and primer dimers (less than 8 bp) are filtered out. The percentage of the 




Following this, different aspects of the sequencing data were analysed by various 
plugins of the Torrent Suite
TM
, generating Variant Call format (VCF) files and Binary 
Alignment/Map (BAM) files. The quality of the sequencing reads was checked by 
FastQC. Variants were analysed by the variantCaller plugin, which was linked to IGV 




Table 3.2. A summary of the Ion PGM
TM
 sequence run output of the 53 FY 
samples, collectively processed in 3 runs. 
 
No. of samples 










































Figure 3.8 A summary report for a single sequencing run of FY library. (NOTE: the figure is on the next page). 
A) 501 million bp were aligned to the reference. The percentage (75%) represents chip wells containing the ISPs (both 
templated and non-templated). The colour represents the loading percentage of ISP across the physical 316
TM 
chip 
plate surface. 99% of filtered bases of all reads were aligned to the reference. 
B) The total number of reads is 3,501,099, which are provided after trimming and filtration from empty wells, non-
templated and polyclonal reads. The percentage of usable sequence (74%) is calculated by dividing the percentage of 
filtered library reads (3,501,099)/ number of the reads containing ISPs (4,735,364) multiplied by 100. The 
live/enrichment percentage is 100%, which indicates that ISPs contain a strong sequence signal from test fragment and 
library.  
C) A histogram shows a mean reading length of 143bp. The read count is displayed in the y-axis, while the read length, in 





A) B) C) 
Results of Well classification 
Results of filtering and trimming 
136 
 
3.3.3.2 NGS data quality control   
The quality of the NGS data is crucial for further analysis, which includes genotyping. 
The mean coverage depth (5600X) (obtained by using coverage analysis: an Ion Torrent 
Suite
TM
 plugin), which is the number of times the reads and bases were sequenced and 
aligned to the reference sequence (which increases the confidence for variant calling) 
and various quality aspects were analysed. FastQC, a plugin on the Torrent Suite, was 
used to check the quality of the generated sequence data as ‘per base sequence quality’ 
and ‘per sequence quality’ scores, with reference to the Phred score, which gives an 
initial impression of the quality and status of the data. The FastQC quality evaluation of 
the data is explained in the following two sections. 
3.3.3.2.1 Per base sequence quality 
Figure 3.9 illustrates an overview of the quality of sequenced base pairs at their position 
on the reads, according to Phred score (Table 3.3). In this run, the mean quality score of 
sequenced bases was around 30-31 (Phred score represented in the y axis). As a result, 
according to the Phred score, the base call accuracy is 99.9% – a probability of 1 in 
1000 of the base being incorrectly called. To explain the graph briefly, the background 
of the graph splits the y axis into three coloured parts, describing the quality scores: the 
best quality call (top/green), reasonable (middle/orange) and poor quality (bottom/red). 
A BoxWhisker-type plot is drawn for each base pair position, which itself consists of 
number of parts. Yellow boxes represent the inter-quartile range (25-75%), within 
which the median value is illustrated as a central red line. The mean quality value is 
represented by a blue line that, here, mainly indicates a value of (30-31) but reduces 
when approaching the longer read length. The reason for this is that the quality of calls 
of this platform, and most platforms, drops as the run approaches the end of the reads, 
which is due to the degradation of sequencing chemistry (Andrews, 2016). The 10% and 
90% points are represented by the upper and lower whiskers. The quality of all three 
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runs was comparable (above 99% base call accuracy, according to the Phred score; 
Table 3.4). 
3.3.3.2.2 Per sequence quality scores 
An output report from the FastQC plugin demonstrates the quality score, according to 
the Phred score, of the sequences and assesses whether a subset of these were generated 
with low quality values. The sequences reads shown in Figure 3.10 mainly received a 
30 Phred score, which matches the quality indication previously discussed. Accordingly, 
these parameters and the coverage depth provide confidence in the high throughput data 
for further analysis. The quality of all three runs was comparable (above 99% base call 
accuracy, according to the Phred score; Table 3.4). 
 
Table 3.3 Phred quality score and the base call accuracy. (Ion Torrent community) 
The various Phred scores with their quality representation for base call accuracy are listed. 
 
Phred Quality Score 
Probability of incorrect 
base call 
Base call accuracy 
10 1 in 10 90% 
20 1 in 100 99% 
30 1 in 1000 99.9% 
40 1 in 10000 99.99% 


































Figure 3.9 Mean Phred quality scores across all bases of FY samples in a 
single run. 
The Phred score is displayed on the y-axis, whereas the x-axis represents the position 
of bases in the reads. Three colours of background represent levels of quality, 
according to the Phred score: very good (green), reasonable (orange) and poor quality 
base calling (red). A BoxWhisker-type plot is drawn for each position with the 25-75% 
interquartile range represented by yellow boxes. Upper and lower whiskers represent 
the 10% and 90% points. The blue line represents the mean value of the base call 
quality (30-31), which indicates a 99.9% base call accuracy. The red line denotes the 


































Figure 3.10 The mean quality score of the FY sequences generated from 
a single run. 
The mean quality score (Phred score, x-axis) of the sequences across the number 
of reads (y-axis) is shown. The majority of sequences have a mean quality of more 
than 30, which indicates high quality of generated reads with an accuracy of 99.9% 


















Table 3.4 Summary of the sequencing quality of the 3 FY NGS runs. 
All runs showed base call accuracy above 99%, especially the third run, which has a quality of 
99.9%. 
Run Per base sequence quality 




 27-28 26-27 
2
nd
 28-30 28 
3
rd
 30-31 30-31 


















3.3.3.3 NGS sequence visualisation  
Different aspects of the 53 samples of FY complete gene sequencing were analysed. The 
sequencing data was visualised by the IGV software (2.3) using the BAM files. Using 
this software, the sequencing reads were aligned against the reference FY gene sequence 
of human genome (hg19), allowing assessment of various crucial aspects of the data. 
The nucleotide and amino acid locations were based on the major FY transcript that 
consists of 2 exons with associated mRNA (NM_002036). The integrity of the sequence, 
in terms of the full coverage of the FY gene as well as the flanking regions, coverage 
depth and genomic variations are visible. Examples of genomic information obtained 
from IGV are: gene mutations, such as SNPs, insertions and deletions; zygosity; and the 
chromosomal location of the nucleotides. All these data was assessed by IGV and at 
least one other software package or database in order to ensure validity and accuracy of 
the variants detected (Robinson et al., 2011). The reference sequence of the FY gene is 
also shown as nucleotides and the amino acids sequence it encodes. Figure 3.11 
illustrates an analysis, using IGV, to visualise and assess a FY sample with serologically 
defined phenotype Fy (a+b+). The distribution of the sequence across the whole gene 
plus up- and downstream flanking regions is shown, reflecting the integrity of the 
library preparation step and the specificity of the designed primers. In addition, in this 
figure the FY*A/FY*B critical missense mutation (SNP) (125G>A, in exon 2) at 
chromosomal location ch1: 159175354 was shown to be heterozygous (50% of each G 
and A were represented), with a coverage depth at this base of 6116X. As a result, the 
amino acid substitution Gly42Asp occurred. Two intronic SNPs were found in intron 1: 
G>C 159174824 and C>T 159174920; homozygous and heterozygous, respectively. 
Accordingly, genotyping of this SNP in exon 2 matched the serological phenotype 
























Exon 1  Exon 2  
Figure 3.11 An IGV image illustrating the visualisation analysis of the sequencing data 
of a Fy (a+b+) sample with FY*A/FY*B genotype. 
A) The reference FY (DARC) gene (blue) is fully covered and aligned by the 
sequencing reads. The coverage depth is shown above. The coloured bars above 
denote SNPs: 1 SNP in exon 2 and 2 in intron 1(C>T 159174920 and G>C 
159174824). The first intronic SNP is homozygous (solid bar) while the latter is 
heterozygous (split bar). 
B) The missense mutation (SNP 125G>A, in exon 2), at chromosomal position 
159175354 encodes an amino acid substitution of Gly42Asp (GGT>GAT). This 
SNP is heterozygous, displayed by the spilt box (orange/green) for 50% G and 50% 
A, respectively. This shows a match between the genotype and serology 






Gly42Asp (GGT>GAT) 159175354 
The reference FY (DARC) gene 
1 SNP in exon 2 and 2 SNPs in the intron  
Intron 1  
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3.3.3.4. Variant analysis and Genotyping  
The sequencing data generated from the Ion PGM
TM
 and projected from Ion Suite were 
analysed for various mutations, such as SNPs (in exons, intron and flanking regions), 
insertions and deletions, in addition to zygosity. Firstly, the Variant Caller software, 
which is a plugin of the Ion Suite
TM
 software, was used, which analyses the aligned 
reads generated in BAM format generated from the Ion Suite
TM
. This programme has an 
advantage over other annotation software packages as it can be set to automatically 
analyse the sequencing data in terms of mutations annotations and zygosity against the 
reference gene. In addition, this software is linked to the IGV software, enabling direct 
visualisation of the mutations and the ability to conduct further analysis (see section 
3.3.3.3). Moreover, the Data generated from the Variant Caller are in VCF format files 
which were used with different party software for confirmation. The VCF files were 
utilised and uploaded in an annotation online tool SeattleSeq Annotation 137, which 
provides a wide range of information, such as the chromosomal location mutations, type 
of mutation, the transcript number, amino acid change and nucleotides the cDNA based 
on database in the NCBI. Figure 3.12 illustrates an example of the SeattleSeq 
Annotation 137 output. 














        
        
        
        
        
        
        
        
        
        
        
        
        





3.3.4 FY genotyping results from Next Generation Sequencing  
NGS provided an extensive genotyping of the entire FY gene and flanking regions to 
reveal all existing mutations (known and novel). Sequencing and analysis of 53 
individual samples revealed various mutations, including SNPs. The genotype was then 




Figure 3.12 An example of a variant annotation report provided from 
the SeattleSeq Annotation 137 online tool of a Fy (a+b+) sample with 
FY*A/FY*B genotype. 
As an example, the highlighted mutation (FY*A/FY*B critical missense mutation) 
gives information on SNPs, chromosomal location (ch1:159175354), the reference 
base (G), heterozygosity (A/G located at cDNA 125), reference transcript number 
(NM_002036.3) and a missense mutation encoding Gly42Asp. The SNP is known 
as has been reported in the dbSNP and has an rsID number. Two intronic SNPs are 
also shown.  
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3.3.4.1 Mutations in exons and the promoter region  
43 out of 53 samples were of a known FY serological phenotype. The NGS genotyping 
data matched and confirmed these phenotypes with FY alleles FY*A, FY*B and 
FY*02(Null) main polymorphisms. The SNPs found in exons and the promoter region 
are listed in Table 3.5. The crucial SNP FY*A/FY*B (125G>A) in exon 2, encoding for 
Gly42Asp, was in concordance with FY phenotype and zygosity. The silencing SNP (- 
67 T>C) in the promoter region was found to be homozygous in 7 out of 53 Fy (a-b-) 
samples carrying a FY*B background with homozygous 125G>A encoding for the 
FY*02N.01 allele. 16 out of 53 samples were found to carry the SNP 298G>A (15 were 
heterozygous and 1 homozygous) encoding for the amino acid change Ala100Thr. This 
SNP appears to be associated with the FY*B allele as it was found to be homozygous in 
a FY*B/FY*B sample, 15 heterozygous situations across (9 FY*B/FY*B, 5 FY*A/FY*B 
and 1 FY*02M.01) and was homozygous G in FY*A/ FY*A. All phenotyped samples 
carrying this SNP show positive expression of Fy
b
, suggesting that this mutation has no 
effect on Fy
b
 antigenicity. In addition, 1 sample of FY*B background carried 2 SNPs: 
298G>A (Ala100Thr), along with a 265C>T point mutation that encodes the amino acid 
change Arg89Cys. The sample phenotype was Fy (a-b+), suggesting normal expression 
of Fy
b
, although the 2 SNPs combined relate to the phenotype Fy
x
 and 
FY*02M.01allele. Only 1 out of 53 samples, of phenotype Fy (a+b+), was shown to 
carry a SNP (714G>A) in exon 2 encoding a synonymous substitution Gly238Gly. 
Accordingly, the NGS genotype was FY*A/ FY*B. Table 3.7 provides more detailed 
information regarding the chromosomal location of all the discussed SNPs. The 
confirmed determination of those SNPs, for example 265C>T and 298G>A whether 
carried on the same allele (cis) or not (trans) might be challenging by the NGS 
platform. This is because of the chemistry of the sequencing that needs small fragments 
200-400bp (see section 6.4). 
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These SNPs observed from NGS genotyping required no further confirmation or 
validation because as well as the fact that the coverage depth for all the FY samples was 
significantly high (5600X), all these SNPs are reported in the NCBI database (dbSNP) 
and have been previously validated. 
 
3.3.4.2 Mutations in the intron and downstream region. 
As the NGS protocol here was optimised to cover the entire FY gene and flanking 
region, this allowed extensive exploration of all existing gene mutations, including 
those in introns and outer regions.  Four SNPs and 1 deletion were found in intron 1 
(Table 3.6). From Table 3.7, it can be seen that there is no complete correlation between 
FY*A, FY*B and FY*02 Null alleles and intronic SNPs; although, SNP 159174885 T>C 
was shown to be heterozygous and homozygous in FY*B alleles and absent in FY*A 
alleles. One SNP (G>C 159174824) was found to be homozygous in all 53 samples (all 
FY alleles), while the deletion (T>Del 159175005) was homozygous in all FY*B and 
FY*Null alleles.  However, this deletion was also found in 14 FY*A haplotypes (8 
heterozygous and 1 homozygous in FY*A, FY*A, and 4 homozygous in FY*A, FY*B). 
Several SNPs were found in up- and downstream regions, at various distances, and, 
although these were found on the NCBI database, their effect on the FY gene remains 
unknown. Despite the fact there is no complete correlation of intronic SNPs with FY*A, 
FY*B and Null alleles, the analysis of the distribution of these SNPs illustrated unique 
patterns that may define new FY alleles (Table 3.7), as various sets of these intronic 












Variation Serology (n) 
  
(Exon 2) 













(- 67 T>C) 
 
 
FY*A/FY*A 16 G/G  (16) C/C (16) G/G (16) G/G (16) T/T (16) Fy (a+b-) (15) 






G/G (16) T/T (16) Fy (a-b+) (13) 





T/T (13) Fy (a+b+) (7) 
FY*B/FY*02M.01 1 A/A (1) C/T (1) G/A (1) G/G (1) T/T (1) Fy (a-b+) (1) 
FY ⃰ 02N.01/ FY ⃰ 02N.01 7 A/A (7) C/C (7) G/G (7) G/G (7) C/C (7) Fy (a-b-) (7) 
Table 3.5 NGS genotyping of 53 samples of differing Fy phenotypes 
53 different DNA samples (43 of which were phenotyped) were sequenced by FY-specific LR-PCR. All phenotyped samples showed a complete concordance with NGS 
genotyping data, particularly 125G>A and T-67C mutations.  16 out of 53 samples were shown to carry the 298G>A mutation (15 heterozygous and 1 homozygous) with a 
positive phenotype of Fy
b
 – suggesting normal Fy
b
 antigenicity. 1 Fy (a-b+) sample was shown to be heterozygous for both 298G>A and 265C>T (Arg89Cys), associated 
with the Fy
x





















rsID Chromosomal position Position in the Gene Nucleotide change  IVS1* 
rs3027009 159173887 -863 upstream A>G - 
rs41264467 159174077 -673 upstream G>A - 
rs3027012 159174123 -627 upstream C>T - 
rs3027013 159174209 -541 upstream C>T - 
rs2814778 159174683 Promoter - 67 T>C - 
rs863001 159174824 Intron 1 G>C +54 
rs7550207 159174885 Intron 1 T>C +115 
rs863002 159174920 Intron 1 C>T +150 
rs17838198 159175005 Intron 1 T>DEL -246 
rs3027016 159175193 Intron 1 A>G -58 
rs12042349 159176490 250 Downstream C>T - 
rs863003 159176508 268 Downstream A>G - 
Table 3.6 The list of SNPs in the intron of the FY gene and flanking regions. 
The table shows information on the chromosomal position, the base change, and the position in and from the gene. *Distance 
from the last nucleotide of exon 1 (+) whereas (-) from the first nucleotide of exon 2 (only those in introns is provided). These 
mutations are reported in the NCBI (dbSNP) database and have a rsID (rs number). Grey highlighted polymorphisms have been 

















Table 3.7 NGS genotyping of 53 FY samples, 43 of which are of known phenotype (NOTE: the table is on the next page). 
The table graphically illustrates the various FY alleles found in this study. The SNPs in FY*A (the reference sequence, according to the 
125G>A change found in the NCBI database) are shown in red, blue in FY*B and green in FY*0(Null). Homozygous mutations are 
represented by solid colour, whilst crossed colour represents heterozygous mutations. The chromosomal position (chromosome 1/hg19), 
SNP location in the FY gene and amino acid changes are shown at the top of the table. The FY*A/FY*B SNP is highlighted in orange, 
SNPs in exons and the promoter region are yellow, high frequency SNPs (such as the homozygous 159174824) are grey.  Sample number 
and phenotype are shown on the left side of the table. Analysis of the exonic and intronic SNPs revealed different patterns of FY alleles: 4 
FY*A alleles, more than 4 FY*B and 2 FY ⃰ 02N.01. Samples with no phenotype were denoted as ND (not defined). 2 samples were of Fy 
(a+) but not (b) status, so the phenotype for these samples is denoted as Fy(a+b ?*). SNPs in up- and downstream flanking regions are 
also listed. The number 008 was used in accordance with the number of the FY blood group system (ISBT number). The rsID for 








rsID 3027009 41264467 3027012 3027013 2814778 863001 7550207 863002 17838198 3027016 12075 34599082 13962 36007769 12042349 863003
A>G G>A C>T C>T (- 67 T>C G>C T>C C>T T>DEL A>G 125G>A 265 C>T 298 G>A 714G>A C>T A>G 
159173887 159174077 159174123 159174209 159174683 159174824 159174885 159174920 159175005 159175193 159175354 159175494 159175527 159175943 159176490 159176508
Upstream Upstream Upstream Upstream Promoter intron 1 intron 1 intron 1 intron 1 intron 1 Exon 2 Exon2 Exon2 Exon2 Downstream Downstream 
HIGH FREQUENCY FY*A/FY*B  GLY42ASP Arg89Cys Ala100Thr Gly238Gly
Genotype Synonymous variant
16 FY*A/FY*A SAMPLE NUMBER Phenotype
FY*A/FY*A FY008.01 ND A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.02 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.03 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.04 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.05 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.06 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.07 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.08 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.09 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.10 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.11 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/T DEL/DEL A/A G/G C/C G/G G/G C/T A/A
FY*A/FY*A FY008.12 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.13 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.14 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.15 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
FY*A/FY*A FY008.16 Fy (a+b-) A/A G/G C/C C/C T/T C/C T/T C/C T/T A/A G/G C/C G/G G/G C/C A/A
16 FY*B/FY*B
FY*B/FY*B FY008.17 Fy (a-b+) A/G G/G C/T C/T T/T C/C C/T C/T DEL/DEL A/A A/A C/C G/G G/G C/C A/G
FY*B/FY*B FY008.18 Fy (a-b+) A/A G/G C/C C/C T/T C/C C/T C/T DEL/DEL A/G A/A C/C G/A G/G C/C A/G
FY*B/FY*B FY008.19 ND A/A G/G C/C C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C A/A G/G C/C G/G
FY*B/FY*B FY008.20 ND A/A G/G C/C C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C G/A G/G C/C G/G
FY*B/FY*B FY008.21 ND A/A G/G T/T C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY*B/FY*B FY008.22 Fy (a-b+) A/A G/G C/T C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C G/A G/G C/C A/G
FY*B/FY*B FY008.23 Fy (a-b+) G/G G/G T/T T/T T/T C/C C/C C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY*B/FY*B FY008.24 Fy (a-b+) A/G G/G C/T C/T T/T C/C C/C C/C DEL/DEL A/G A/A C/C G/G G/G C/C A/A
FY*B/FY*B FY008.25 Fy (a-b+) A/A G/G C/C C/C T/T C/C C/T C/T DEL/DEL A/G A/A C/C G/A G/G C/C A/G
FY*B/FY*B FY008.26 Fy (a-b+) A/A G/G C/C C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C G/A G/G C/C G/G
FY*B/FY*B FY008.27 Fy (a-b+) A/G G/G C/T C/T T/T C/C C/T C/T DEL/DEL A/A A/A C/C G/A G/G C/C A/G
FY*B/FY*B FY008.28 Fy (a-b+) A/G G/G T/T C/T T/T C/C C/T C/T DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY*B/FY*B FY008.29 Fy (a-b+) A/A G/G C/C C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C G/A G/G C/C G/G
FY*B/FY*B FY008.30 Fy (a-b+) A/G G/A C/T C/T T/T C/C C/C C/C DEL/DEL A/G A/A C/C G/G G/G C/C A/A
FY*B/FY*B FY008.31 Fy (a-b+) A/G G/G C/T C/T T/T C/C C/T C/T DEL/DEL A/A A/A C/C G/A G/G C/C A/G
FY*B/FY*B FY008.32 Fy (a-b+) A/A G/G C/T C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/C G/A G/G C/C A/G
1 FY*B/FY*02M.01
FY ⃰ B/FY*02M.01 FY008.33 Fy (a-b+) A/A G/G C/T C/C T/T C/C T/T T/T DEL/DEL A/A A/A C/T G/A G/G C/C A/G
7 FY ⃰ 02N.01/FY ⃰ 02N.01
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.34 Fy (a-b-) A/A G/G C/C C/C C/C C/C T/T C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.35 Fy (a-b-) A/A G/G C/C C/C C/C C/C T/T C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.36 Fy (a-b-) A/A G/G C/C C/C C/C C/C T/T C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.37 Fy (a-b-) A/A G/G C/C C/C C/C C/C C/C C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.38 Fy (a-b-) A/A G/G C/C C/C C/C C/C T/T C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.39 Fy (a-b-) A/A G/G C/C C/C C/C C/C T/T C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
FY ⃰ 02N.01/FY ⃰ 02N.01 FY008.40 Fy (a-b-) A/A G/G C/C C/C C/C C/C T/T C/C DEL/DEL A/A A/A C/C G/G G/G C/C A/A
13 FY*A/FY*B
FY*A/FY*B FY008.41 Fy (a+b?*) A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/A C/C G/G G/G C/C A/G
FY*A/FY*B FY008.42 Fy (a+b+) A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/A C/C G/A G/G C/C A/G
FY*A/FY*B FY008.43 ND A/G G/G C/T C/T T/T C/C C/T C/C T/DEL A/A G/A C/C G/G G/G C/C A/A
FY*A/FY*B FY008.44 ND A/A G/G C/C C/C T/T C/C T/T T/T DEL/DEL A/A G/A C/C G/G G/G C/C A/G
FY*A/FY*B FY008.45 ND A/A G/G C/C C/C T/T C/C C/T C/C T/DEL A/G G/A C/C G/G G/G C/C A/A
FY*A/FY*B FY008.46 Fy (a+b?*) A/A G/G C/T C/C T/T C/C T/T C/T DEL/DEL A/A G/A C/C G/G G/G C/T A/A
FY*A/FY*B FY008.47 ND A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/A C/C G/A G/G C/C A/G
FY*A/FY*B FY008.48 Fy (a+b+) A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/A C/C G/A G/G C/C A/G
FY*A/FY*B FY008.49 Fy (a+b+) A/A G/G C/C C/C T/T C/C C/T C/C T/DEL A/G G/A C/C G/G G/G C/C A/A
FY*A/FY*B FY008.50 Fy (a+b+) A/A G/G C/C C/C T/T C/C T/T C/T DEL/DEL A/A G/A C/C G/A G/A C/T A/G
FY*A/FY*B FY008.51 Fy (a+b+) A/A G/G C/C C/C T/T C/C T/T T/T DEL/DEL A/A G/A C/C G/A G/G C/C A/G
FY*A/FY*B FY008.52 Fy (a+b+) A/A G/G C/C C/C T/T C/C T/T C/T T/DEL A/A G/A C/C G/G G/G C/C A/G








3.4.1 Next Generation Sequencing of the FY library   
For the construction of FY libraries for our NGS genotyping protocol, several 
optimisation steps were applied to primers, purification and size-selection so as to 
achieve an effective protocol. SPRIselect
® 
reagent kit (Beckman Coulter, UK) was 
preferred for purification and size selection over the Pippin Prep
TM 
instrument due to its 
advantages of being less time consuming and more cost-effective. In addition, the 
Pippin Prep
TM 
instrument was limited in the number of samples per cassette and 
required an extra step after size selection (purification), thereby increasing workload 
and the error rate (section 2.2.4.10). FY templates were loaded onto a 316
TM
 chip, 
despite the fact that a 314
 TM
 chip would have been sufficient for our FY samples and is 
cheaper. The reason for using the 316
TM
 chip here was due to an initial unsuccessful 
loading of samples onto a 314
 TM
 chip, which resulted in a poor loading density (data 
not shown). This issue was mentioned in the manufacturer technical support (Ion 
Technical Support, 2013) and was explained by its smaller flow cell, which hindered the 
movement of loading liquid across the chip surface. 
 
3.4.2 Quality control of Next Generation Sequencing data 
The quality check of the high-throughput NGS data gives an initial impression of the 
validity of the data for downstream analysis. FastQC, which can be either used as a 
plugin for Torrent Suite software or independently, provides a quality report of both the 
sequencer instrument (here this was the Ion PGM
TM
) and the library (Andrews, 2016). 
According to the Phred score, the quality of the NGS data was above 99% base call 
accuracy, with a 1 in 1000 probability of an incorrect base call. This high accuracy, 
along with a good mean coverage depth of 5600X, increases the confidence of the data 
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for further analysis, such as variant analysis. With regard to the accepted coverage depth 
in genotyping, there is as yet no fixed guideline for the number of times the target gene 
should be sequenced. There are various views on this issue; for example, in a study 
carried out by the Bentley group in 2008, in which the human genome was sequenced 
by massively parallel sequencing technology (using an Illumina platform), an average of 
40X read depth was determined to cover the whole human genome accurately, with all 
homozygous and heterozygous polymorphisms detected at 15X and 33X, respectively 
(Bentley et al., 2008). Using a similar approach, Wang’s group set a standard of 36X for 
their study, in which whole genome sequencing of an Asian individual was first 
described and provided high accuracy sequencing reads (Wang et al., 2008), while 
another group used 30X of depth to sequence the first Korean genome (Ahn et al., 2009). 
In 2011, in a study by Ajay and colleagues, whole genome sequencing (WGS) was 
conducted using high throughput sequencing technology and aimed to establish a 
sequencing guide, in terms of coverage, that reflects accurate and reliable 
polymorphism calling. The group found that not only was 50X adequate coverage for 
accurate base calling for WGS, but 35X coverage depth actually yielded comparable 
accuracy with updated software and improved newer sequencing chemistry (with 
reduced GC bias) (Ajay et al., 2011). Both Stabentheiner (2011) and Fichou (2014) 
agreed on the coverage depth of 50X for identification of heterozygous polymorphisms 
when genotyping the RHD gene in the former study, and sufficient to genotype 18 genes 
involved in 15 blood group systems using the Ion AmpliSeq
TM
 Library on the Ion 
PGM
TM
 in the latter study (Stabentheiner et al., 2011, Fichou et al., 2014). Furthermore, 
it is speculated that a coverage of at least 30X may be sufficient (Tilley and Grimsley, 
2014) as was used in a study by Lane’s group (2016), in which WGS data of at least 
30X was used for studies to predict red blood cell and platelet antigens (Lane et al., 
2016). Despite all these views, the coverage depth for sequencing FY – which can be 
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defined as the number of times that the reads and bases are sequenced and aligned to the 
reference sequence, thereby conveying the confidence level of the variant (Sims et al., 
2014) – was significantly higher than that in other reports of NGS-based genotyping of 
human blood groups, such as that of Stabentheiner’s group (2011). The reason for this 
considerable number is suggested to be that only a fraction of the 316
TM
 chip capacity 
was used in each run. With regard to the scalability and the number of samples that can 
be sequenced for FY genotyping in a single run, different aspects are considered, such as 
the coverage depth, the read length and the target size. Applying the calculation 
(mentioned in Chapter 1), using the 200 base reads, up to 83 samples can be 
simultaneously sequenced for the entire FY gene and flanking regions when using the 
314
TM
 chip (version 1), if the desired coverage depth was 50X, as was suggested by 
Stabentheiner et al. (2011) and Fichou et al. (2014). This chip (314
TM
) has the lowest 
capacity among other sequencing chips. Similarly, more than 800 and 4000 samples can 




 chips, respectively. These chips, 
however, were first versions of chips produced by Life Technologies, who have since 
developed newer chips (v2) and those for the Ion Proton platform, with a much higher 
capacity (Chapter 1). These chips allow parallel sequencing of a very large number of 
samples, thereby reducing the cost of sequencing each sample for all mutations, 
including SNPs, deletions and insertions. The approximate estimation for the cost per 
sample library preparation, including the PCR reaction, fragmentation, purification and 
the quality check by Bioanalyzer was calculated to be about £50. On the other hand, the 
cost of the sequencing run, using the 316
TM
 chip, was approximately £454 – which 
includes template preparation and sequencing by the Ion PGM
TM
 machine. By applying 
these metrics, the cost of sequencing the entire FY gene per sample was estimated to be 
only £0.6, which would be further lower with increased chip capacity. The cost of a 
sequence run on this platform (Ion PGM
TM
) is suggested to be cheaper than others, such 
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as Illumina GAIIX. In 2013, Rieneck and colleagues conducted a study, using the latter 
platform, to analyse the Kell blood group K/k SNP with the purpose of predicting the 
antenatal phenotype of the foetal Kell blood group (Rieneck et al., 2013). The cost of 
reagents for a single sequence was approximately $1500 (£1039.61), which is more than 
double the cost of the platform used here. Thus, it appears to be more cost-effective to 




3.4.3 Validity of FY Next Generation Sequencing genotyping  
Consequently, having evaluated the sequencing data from FY samples, no further 
validation approaches, such as Sanger sequencing, were required for several reasons. As 
the linear relation of coverage depth and base calling accuracy was previously agreed, in 
several studies (Ajay et al., 2011, Lane et al., 2016), the coverage here was considerably 
high, in addition to a base call accuracy of nearly 99.99% – a Phred score of 30, which 
was higher here than in Ajay’s 2011 study (Phred score of 20+). The critical 
FY*A/FY*B SNP was in complete concordance with the Fy
a/b
 serology. Moreover, all 
the mutations found during FY sequencing did not raise any further investigations as 
they are common and had already been reported in the dbSNP NCBI database (and 
those polymorphisms were marked as validated by previous groups). 
 
3.4.4 FY Next Generation Sequencing genotyping  
FY genotyping is suggested to be highly beneficial by enabling more comprehensive 
understanding of the molecular mechanisms underlying the alleles, as well as their 
correlation with the phenotypes provided by serology. Castilho (2007) suggested that 
genotyping can provide a higher inventory of blood units for transfusion-dependent 
(SCD) individuals with the Fy (a-b-) phenotype, which manifests from a SNP in the 
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GATA promoter. In the study, 28 individuals (with a Fy (a-b-) phenotype) received Fy 
b+ blood without any signs of anti-Fy
b 
production, which could be due to the expression 
of the antigen on non-erythroid cells (Castilho, 2007).  From these individuals, 3 were 
heterozygous for the FY*B GATA SNP, while 25 were homozygous. High throughput 
genotyping platforms, based on microarray technology, have illustrated better 
interpretation and understanding of the molecular mechanisms of the FY phenotype; for 
example,  Hashmi and colleagues (2005) have shown that, by using HEA BeadChip, 1 
out of 52 patients phenotyped as Fy b- lack the FY*B allele, while the rest carry that 
allele, but  contains the GATA SNP (Hashmi et al., 2005). As a result, according to the 
assumption of Castilho, they (51) could receive Fy b+ blood components. Despite the 
advantages of microarray-based platforms, such technologies have the disadvantage of 
not being able to identify novel mutations that could affect antigenicity; therefore, NGS 
is suggested to address this issue. 
To our knowledge, this is the first NGS-based genotyping study of the FY gene using 
LR-PCR, in which comprehensive genotyping and analysis of polymorphisms of the 
entire FY gene (intron, exons and outer regions) was carried out. Some crucial aspects 
were taken into consideration, such the ability to couple NGS with LR-PCR rather than 
another approach, such as exome sequencing, where mostly coding regions (exons) are 
targeted. Sequencing of the whole gene enables the analysis of polymorphisms in, exons, 
introns and outer regions; for example, identification of the silencing SNP (- 67 T>C) in 
the promoter region resulted in higher resolution, complete genotyping and, thus, better 






3.4.4.1 Mutations in exons and the promoter region 





antigens. The NGS genotyping data matched and confirmed the phenotypes of FY 
alleles  FY*A, FY*B and FY*02(Null) in terms of the crucial SNPs previously described 
(Reid et al., 2012), while the SNP and amino acid locations were based on the major FY 
form (Daniels, 2013). The crucial SNP FY*A/FY*B (125G>A) in exon 2, encoding for 




 phenotype, as was the zygosity. The 
allele FY*02N.01 was found in 7 out of 53 samples and results from the aforementioned 
silencing SNP (- 67 T>C) in the promoter region, causing the binding of the erythroid 
transcription factor (GATA1) to be disrupted. This allele was found to be homozygous 
in all 7 samples and impaired Fy
a/b
 antigenicity of the erythrocytes, which manifested 
with the phenotype Fy (a-b-) samples carrying a FY*B background with homozygous 
125G>A. The missense SNP 298G>A in exon 2 is common and was found in 16 out the 
53 samples, all of which expressed the FY*B allele (17 FY*B haplotype); none of the 
samples genotyped as FY*A, FY*A (16/53) showed the SNP 298A. This SNP leads to 
the amino acid change Ala100Thr, which has been found to be expressed along with 
another polymorphism – SNP 265 C>T in exon 2 (amino acid change Arg89Cys) of the 
FY*X (FY*02M.01) allele (Olsson et al., 1998, Yazdanbakhsh et al., 2000). This allele 
encodes  reduced expression of Fy
b
 antigens; however, the existence of 298G>A 
(Ala100Thr) alone may not affect the expression of Fy
b
 antigens, but rather may play a 
cumulative role with SNP 265 C>T, as suggested by (Gassner et al., 2000) and Olsson 
et al. (1998). The latter author found this SNP in 22% of samples with the normal Fy (a-
b+) phenotype (Olsson et al., 1998) and the frequency of this SNP alone is near to that 
found in Caucasians with FY*B (around 15%) (Reid et al., 2012) . The FY*X 
(FY*02M.01) allele encodes for weakened expression of Fy
b 
antigens, as shown by the 
weak reaction of these samples with anti-Fy
b 
(Olsson et al., 1998, Gassner et al., 2000), 
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and was found here in 1 sample; however, despite the presence of that allele, the sample 
showed normal Fy
b
 antigenicity with a Fy (a-b+) phenotype. Nevertheless, it might be 
argued that this sample was Fy
b
+ due to both SNPs (265 C>T and 298G>A) being 
heterozygous; however, weak reactivity was found in 2 patients, one of whom carried 
FY*B, FY*X and the other was homozygous for both SNPs (265 C>T and 298G>A) 
(Olsson et al., 1998, Daniels, 2013). The NGS approach was able to show that this 
weakening allele (FY*X), in contrast to serology, may not be detected in samples 
initially typed as Fy (a+b-) but with FY*A and FY*B (with weak anti-Fy
b 
serological 
reaction), which is suggested to be due to the FY*X allele (Murphy et al., 1997). 
 
Another mutation in exon 2 was a 714G>A SNP that has no apparent effect on the 
amino acid (Gly283Gly). As a result, the Fy
a/b
 antigenicity was not affected due to 
normal expression and a phenotype of Fy (a+b+); thus, according to the FY*A, FY*B 
SNP (125G>A), the genotype was FY*A/FY*B.  The observed low frequency of this 
SNP here (1 sample in 53), was in agreement with the data provided by the 1000 
genomes project (above 2% in the UK, 1% in Europe and 0.3% worldwide).  
 
3.4.4.2 Mutations in introns  
Due to the extensive data that can be obtained from NGS genotyping, analysis of 
mutations, such SNPs and deletions, in introns (which be allele specific) of the FY 
alleles could enable refining of the reference sequence for those.  However, despite 
finding mutations in intronic regions of this gene, there was no complete correlation 
observed with the FY*A, FY*B mutations. A high frequency deletion (77% in Europe, 
1000 genomes; T>Del 159175005) was found in samples and, although it was shown to 
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be associated with a FY*B allele background, it was also found in 14 FY*A haplotypes. 
All 53 samples (106 haplotypes) were homozygous for the G>C 159174824 SNP, which 
implies that all our sequenced samples deferred from the reference sequence derived 
from the Human Genome Project (hg19). One explanation for this could be that this 
sequence variation is rare but found when the human genome was assembled.  
The SNP catalogue approach, collated here (Table 3.7), using a colouring scheme, lists 
the mutations provided by NGS across the predicted genotype and phenotype, allowing 
simplified analysis of different allele patterns. In 2000, Gassner and colleagues 
suggested that the FY*X allele may arise from 3 point mutations: 265 C>T (Arg89Cys) 
and 298G>A (Ala100Thr) in exon 2 and an intronic SNP (190 C>T, where the first T in 
the intron is number 1). The latter SNPs may exert a cumulative effect with the former 
in reducing Fy
b
 expression (Gassner et al., 2000). Although the chromosomal location 
was not mentioned, it could be SNP 159174920 (C>T) (as all intronic SNPs of FY in 
our samples were analysed, see Table 3.7). From Table 3.7, it can be seen that in 
samples of FY*B background, 298G>A (Ala100Thr) persistently coexists with 
159174920 T. Although there was no clear reference intronic SNPs (allele-specific 
SNPs), different FY alleles could be pointed out by looking at the various patterns in 
Table 3.7; for example, 4 FY*A alleles, at least 4 FY*B and 2 FY ⃰ 02N.01. These 
intronic SNPs are catalogued, although their effect on the antigenicity is not yet known; 
nevertheless, they may be useful to consider when designing primers to avoid primer 
binding site issues. The new alleles with different patterns of intronic SNPs may be 
further studied in a wider population to assign the frequency of alleles to different ethnic 
backgrounds. This was in fact accomplished by a study by Schmid et al (2012), in 
which the frequency of  FY alleles among 54 African American was investigated by 
high resulution genotyping that included polymorphism analysis in the exons, intron 
and untranslated regions. According to the intronic polymorphisms (those highlited in 
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Table 3.6), along with those in exons and the GATA box, 11 diiferent FY alleles were 
described, including 3 FY*A, 4 FY*B, 2 FY ⃰ 02N.01, 1 FY*B with 298G>A and 1 FY*02 
M.01. In addition, the author suggested terminology to reflect the high resolution 
genotyping, for example for the 3 different FY*A alleles (FY*01:1, FY*01:2 and 
FY*01:3). Moreover, it was suggested that the extensive genotyping, especially the 
polymorphisms in introns, may help in the studies of evolution (Schmid et al., 2012).  
3.4.5 The advantage of Next Generation Sequencing genotyping of FY  
Here, the NGS shows superiority over other high throughput genotyping approaches 
(for example, microarray platforms) in that all existing mutations within the FY gene in 
all 53 samples were revealed, including introns and flanking regions. This 
comprehensive method of genotyping could provide a better picture of the phenotype 
from the genotype. In addition, NGS is capable of discovering novel SNPs (due to 
genotyping be sequencing) that may account for new antigenicity-affecting alleles, in 
contrast to SNP probe-reliant platforms that fail to detect novel SNPs and may falsely 
predict a positive phenotype encoded by rare silencing or weak alleles. To prevent this, 
the probe list needs to be updated frequently to prevent negative consequences, such as 
allelic dropout of low frequency alleles (McBean et al., 2014, Avent et al., 2015, Tilley 
and Grimsley, 2014).  
Examples of new FY*B alleles that silence Fy
b
 expression (Fy b-), were described in 
2014 by Westoff’s group, in 2 samples (Westoff et al., 2014). The phenotype of the first 
sample was Fy (a-b-) but was predicted as Fy (a-b+) by HEA BeadChip.  A sequencing 
approach then revealed a 2 nucleotide deletion, which was suggested to lead to a 
frameshift and formation of a premature stop codon, 179_180delCT (Ser60CysfsTer16) 
in exon 2 (Westoff et al., 2014). Similarly, the second sample was in concordance with 
the Fy
b 
phenotype, as suggested by DNA testing; however, sequencing revealed a 
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missense mutation in exon 2 895G>A (Ala299Thr) that was thought to be a silencing 
SNP. The frequency of these alleles were predicted to be low, thus, corresponding 
probes were not added to the HEA BeadChip assay, although they will presumably need 
to be added subsequently (Westoff et al., 2014).  
Furthermore, it was pointed out that the commercially available microarray high 
throughput platforms, such as BloodChip and BeadChip, were designed to respectively 
cover SNPs of specific populations, namely European and American (including 
African-American). This is advised to be considered when using such platforms in a 
multi-ethnic population, such as Australia (McBean et al., 2014). NGS, on the other 
hand, circumvents this issue due to its sequencing-based approach which provides 
discovery capability (Avent et al., 2015). 
In conclusion, NGS with LR-PCR proved to be capable of genotyping the FY gene 
extensively. Using only one single PCR product, all existing mutations (in introns, 
exons and regulatory regions) were identified. Moreover, due to its high throughput 
sequencing capability, NGS features a discovery mode that can reveal novel SNPs and 
alleles in a large number of samples, allowing more accurate prediction of antigen 
phenotypes. This surpasses the microarray-based method, in which predefined 
knowledge of SNPs is required, with rare or novel SNPs frequently missing from the 
probe list and thus needing further investigations.  
The high throughput productivity of NGS allows a significant number of samples to be 
sequenced at a high resolution for all mutations in a single run, thereby reducing costs. 
In addition, it allows a comprehensive scan of intronic SNPs, which can be further 
studied for association with FY alleles and considered for primer design. Importantly, 
NGS allows for more comprehensive association analysis between the genotype and the 
phenotype.  In addition, if applied to a large cohort, reference sequences for FY alleles 
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could be provided and the prevalence of different polymorphisms among different 
populations can be assessed. Furthermore, applying this approach of extensive NGS 
genotyping, analysis and cataloguing of SNPs, cases with unusual discrepancies 
between genotype and phenotype can be investigated, which ultimately enables the 
direction of the interpretation from genotype to phenotype.  
Finally, this chapter has illustrated that this NGS protocol can be applied to genotyping 
FY and, probably, for other more complex blood groups, such as JK and ABO 
(discussed in the following chapters) – and thus is potentially important towards 
obtaining a more comprehensive profile of blood group mutations and, thus, facilitating 

















Genotyping of the JK Blood Group by Next Generation 
Sequencing 
 
4.1 Introduction   
The Kidd blood group system (JK/ISBT 009) is represented by a single gene (JK or 
SLC14A1) (see section 1.7.1) comprising 11 exons, with the translation start codon 
located in exon 4, encoding for 389 amino acids (Lucien et al., 1998, Horn et al., 2012). 
The main polymorphic Jk antigens, Jk
a/b
, are thought to arise from a single SNP 
(838G>A in exon 9) within the co-dominant JK*A/JK*B alleles, encoding amino acid 
change Asp280Asn (Olivès et al., 1997). According to The NCBI Blood Group Antigen 
Gene Mutation Database (BGMUT), additional JK alleles (36 in total) have been 
uncovered due to many additional polymorphisms (dbRBC, 2016), some of which 
might reduce or remove expression of the Jk antigens (Reid et al., 2012), with the 
number of JK alleles continually rising due to novel polymorphisms (Keller et al., 2014). 
These polymorphisms may cause discrepancy and false interpretation of the Jk 
phenotype and antigenicity, which carries the risk of adverse reactions during clinical 
blood transfusions. There is evidence of both Jk
a/b
 antibodies causing delayed 
haemolytic transfusion reactions (DHTRs) (Hussain et al., 2007, Pineda et al., 1999) 
and haemolytic disease of the foetus and newborn (HDFN), although the latter was less 
common (Ferrando M, 2008, Daniels, 2013). There is, therefore importance in 
expanding genotyping of the clinically-significant blood group systems (including genes 
such as JK) as a means of ensuring the safety of blood transfusions and reducing 
alloimmunisation – especially in patients requiring multiple blood transfusion (for 
example, those with sickle cell disease) (Avent et al., 2015). A high-throughput 
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genotyping approach has been suggested to tackle the large demand for screening the 
high number of alleles (Anstee, 2009). However, all commercially available platforms 
for high-throughput genotyping, particularly microarray technology, currently rely on 
known polymorphisms and alleles; thus, they are unable to detect new or rare 
polymorphisms not already included in the array and need constant updating as a result. 
Next Generation Sequencing (NGS) is a recently introduced high-throughput sequence-
based genotyping technology that is capable of detecting new polymorphisms, thereby 
enabling extensive genotyping of blood group genes and accurate interpretation of the 
associated phenotypes. 
4.2 Aim of the study 
Similarly to the FY chapter (section 3.2), the aim of this study was to combine the 
powerful capability of NGS, together with long-range polymerase chain reaction (LR-
PCR) to establish a protocol to comprehensively genotype and analyse the entire JK 
gene. The discovery mode of NGS will allow detection of all existing, rare or new 
polymorphisms of both intronic and exonic origin. The correlation of all detected 
polymorphisms was assessed with key JK SNPs in order to evaluate their allele 
specificity and uncover any allele-specific sequences (‘fingerprints’) that may also be 
associated with weakening or silencing JK alleles. This would also allow more accurate 
analysis of the molecular basis of JK alleles, thus, better prediction of the resulting 
phenotype. The feasibility of using NGS for genotyping of JK and other blood groups, 










4.3.1 LR-PCR of the JK gene  
The gDNA of 67 samples was used for extensive genotyping of JK by NGS. Serology 
information on the Jk (a/ b) phenotype was provided for most of the samples (59/67) 
and was used for sample selection (Table 4.1). Using Primer 3 software and the NCBI 
database (see section 2.2.4.1), a total of 3 primer pairs were designed to produce 3 
overlapping amplicons of various sizes (11012, 11053 and 14665bp, see Table 2.2). The 
entire JK gene plus flanking regions was amplified, as illustrated in Figure 4.1. For the 
LR-PCR amplification reaction, LongAmp® Hot Start Taq Master Mix was used under 
thermocycling conditions (Table 2.5; section 2.2.4.2). The first two amplicons (11012bp 
and 11053bp) were loaded onto 1% (w/v) agarose gel and appeared as single bands 
above 10kb (Figure 4.2). The third amplicon (14665bp) was loaded onto an 0.8% (w/v) 
agarose gel and appeared as a single band below 20kb (Figure 4.2; section 2.2.4.3). The 
amplicons were then purified using a magnetic bead technique (section 2.2.4.4) and 
quantified using the Qubit® 2.0 Fluorometer with the broad range (BR) assay kit. This 
enabled preparation of the required (100 ng) of amplicons required for the 
fragmentation process. To ensure equal representation of the 3 JK amplicons, 
approximately 33.3ng (100/3= 33.3) of each amplicon was pooled for the fragmentation 




                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
                   
Figure 4.1 The JK gene is illustrated with the three overlapping long amplicons generated by LR-PCR: 1 (11012bp), 2 
(11053bp) and 3 (14665bp). These amplicons cover the entire JK gene and flanking regions.  
The JK gene is 28765 bp in length (according to NCBI GenBank), comprising 11 exons (shown as boxes) and 10 introns 
(represented by a fine line). The crucial SNP that generates JK*A and JK*B is located in exon 9, while the suggested SNP 
responsible for generation of the JK*01W allele (JK*01W.01) is located in exon 4. Refer to Table 2.2 for more details on 
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Table 4.1 Serology information on the 67 blood samples provided by the National Health Service Blood and Transplant (NHSBT; Filton, Bristol UK). 
Asterisks (*) denotes samples for which sample ID were provided. ND, serology not defined. JK009 is the ISBT number assigned for the JK blood 
group system (Daniels, 2013, Reid et al., 2012) and is used here to name samples in accordance with the JK NGS genotyping experiment.  
Sample 
number 









JK009.01 RJ Jk(a+b-) JK009.26 39 Jk(a+b-) JK009.51 54 Jk(a-b+) 
JK009.02 4 Jk(a+b-) JK009.27 R2 Jk(a+b+) JK009.52 55 Jk(a-b+) 
JK009.03 33 Jk(a+b-) JK009.28 4715 ND JK009.53 56 Jk(a-b+) 
JK009.04 580X ND JK009.29 RG Jk(a-b+) JK009.54** 470P (Jka-b+) 
JK009.05 RD Jk(a+b-) JK009.30 RN Jk(a-b+) JK009.55* RH Jk(a+b+) 
JK009.06 6 Jk(a+b-) JK009.31 RX Jk(a-b+) JK009.56 R9 Jk(a+b+) 
JK009.07 16 Jk(a+b-) JK009.32 RK Jk(a-b+) JK009.57 RB Jk(a+b+) 
JK009.08 13 Jk(a+b-) JK009.33 R7 Jk(a-b+) JK009.58* RL Jk(a+b+) 
JK009.09 32 Jk(a+b-) JK009.34 R8 Jk(a-b+) JK009.59* R97 Jk(a+b+) 
JK009.10 35 Jk(a+b-) JK009.35 48 Jk(a-b+) JK009.60* 2 Jk(a+b+) 
JK009.11 36 Jk(a+b-) JK009.36 49 Jk(a-b+) JK009.61 17 Jk(a+b+) 
JK009.12 37 Jk(a+b-) JK009.37 5800 ND JK009.62 453R ND 
JK009.13 28 Jk(a+b-) JK009.38 437R Jk(a-b+) JK009.63 469B ND 
JK009.14 40 Jk(a+b-) JK009.39* 3 Jk(a-b+) JK009.64 4208 Jk(a+b+) 
JK009.15 438P Jk(a+b-) JK009.40 7 Jk(a-b+) JK009.65 4576 Jk(a+b+) 
JK009.16 79 Jk(a+b-) JK009.41 8 Jk(a-b+) JK009.66 469Z ND 
JK009.17 82 Jk(a+b-) JK009.42 22 Jk(a-b+) JK009.67 476D ND 
JK009.18 86 Jk(a+b-) JK009.43 42 Jk(a-b+)    
JK009.19 RP Jk(a+b-) JK009.44 43 Jk(a-b+)    
JK009.20 4680 ND JK009.45 44 Jk(a-b+)    
JK009.21 5 Jk(a+b-) JK009.46 45 Jk(a-b+)    
JK009.22 41  Jk(a+b-) JK009.47 46 Jk(a-b+)    
JK009.23 26 Jk(a+b-) JK009.48 47 Jk(a-b+)    
JK009.24 579J Jk(a+b-) JK009.49 50 Jk(a-b+)    



















1% agarose gel  1% agarose gel  
0.8 % agarose gel  
Figure 4.2 Amplification of the entire JK gene using 3 amplicons produced by LR-PCR.  
For each sample, the entire JK gene and flanking regions were covered by 3 amplicons of different sizes: 1 (11012bp), 2 (11053bp) and 3 
(14665bp). The above images are examples of amplicons from three samples, A (JK009.04), B (JK009.62) and C (JK009.67). Amplicons 1 
and 2 were loaded onto 1% agarose gel, while amplicon 3 was loaded onto 0.8% agarose gel due to large size (~15kb) to allow easier 
migration of the band. All amplicons were electrophoresed at 70 V for 1 hour and 20 minutes. The GeneRuler
TM
1Kb Plus DNA ladder 








1 3 2 









4.3.2 NGS the JK gene  
4.3.2.1 JK amplicon library fragmentation (purified-fragmented library) 
Fragmentation of NGS libraries was conducted following amplicon purification and 
quantification. For each sample, the 3 amplicon-pool (100ng) was fragmented using Ion 
Xpress
TM
 Plus Fragment Library Kit (section 2.2.4.6). The enzymatic fragmentation 
reaction was incubated for 8 minutes, after which samples were purified using magnetic 
beads (section 2.2.4.6). The Agilent® 2100 Bioanalyzer and Agilent High Sensitivity 
DNA Kit (section 2.2.4.7) were used to assess fragment size distribution. Figure 4.3 
















Figure 4.3 An electropherogram of a fragmented-purified JK DNA library (consists of a pool of 3 amplicons).  
An example of a JK sample fragmented using the Ion Xpress
TM
 Plus Fragment Library Kit for 8 minutes. A wide fragment size 
distribution can be seen with a peak around 200-300bp (marked by a blue arrow), which is recommended for the 200bp read length on 
the Ion PGM
TM
. The green line (35bp) is the lower marker and the purple line (10380bp) is the upper marker. Results shown were 
obtained using the Bioanalyzer® 2100 instrument. 
8 minute-fragmentation reaction  
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4.3.2.2 Ligation of barcoded adapters (JK purified-ligated library) 
The fragmented-purified samples were ligated to barcoded adapters, in which P1 and 
the Ion Xpress
TM 
Barcode X adapter (provided by the Ion Xpress
TM
 Barcode adapters 
Kit) were used along with DNA ligase. The ligated libraries were then purified and 
analysed using Agilent® 2100 Bioanalyzer with Agilent High Sensitivity DNA Kit 
(section 2.2.4.9). Figure 4.4 shows the size distribution of one of the JK sequencing 
libraries after ligation.  
4.3.2.3 Size selection 
The ligated libraries were then size-selected to provide a suitable size range (around 
200bp) for the Ion PGM
TM
 Template OT2 200 Kit. Sequencing of the 67 samples was 
conducted in four separate experiments. In the first two experiments, 12 and 20 samples 
were sequenced and size-selected using the Pippin Prep
TM 
instrument respectively. In 
the remaining experiments (17 and 18 samples respectively), samples were size-selected 
using SPRIselect
®
 reagent magnetic beads. The SPRIselect
®
 was selected over Pippin 
Prep
TM 
instrument for the last two experiments due to its technical advantages (see 
section 2.2.4.10). Figure 4.5 depicts two size-selected JK samples by the two 
approaches. The concentrations of these libraries were obtained and calculated using the 
Bioanalyzer
®
 2100 instrument (section 2.2.4.11) for the purpose of template preparation 
(section 2.2.5) prior to sequencing using the Ion Torrent PGM
TM
 (section 2.2.6).  
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Figure 4.4 Two electropherograms of the same JK amplicon library.  
A) A fragmented-purified library with a peak of around 200-300bp.  
B) A fragmented-ligated purified library showing a peak shift to the right (caused by adapter ligation (size about 80bp), evident as an 
increase in size).  
The green line (35bp) is the lower marker and the purple line (10380bp) is the upper marker. Results shown were obtained using the 
Bioanalyzer® instrument. 
A) Fragmented-purified library 
B) Fragmented-ligated purified library 
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The peaks obtained from the two different approaches were comparable. 
A) JK library size-selected by Pippin Prep
TM
, in which a broad range was selected (around 200-250bp). 
 B) JK library size-selected by SPRIselect
®
 reagent to obtain a peak around 200bp (220-230bp).  
The green line (35bp) is the lower marker and the purple line (10380bp) is the upper marker. Results shown were obtained using the Bioanalyzer® 2100 
instrument. 
A) Size selected by Pippin Prep
TM 
instrument 









4.3.3 NGS data quality control 
4.3.3.1 Sequencing data summary report  
The 67 JK samples were sequenced using Ion PGM
TM 
in four separate runs. The data 
was then processed and a summary was produced by the Torrent Suite
TM
 Software 
Version 4.4 (section 3.3.3.1). The average of the total reads generated from the 67 JK 
samples was 3,548,400, with a mean coverage depth of around 750x. A summary of the 
JK sequencing report from the 4 separate runs is shown in Table 4.2. A brief sequencing 
report of a single representative JK sequencing run is displayed in Figure 4.6. In this 
report, the ISP loading density was 88%, while 12% of the 316
TM
 chip wells were 
empty. There were around 4 million usable reads in total, which is 72% of the total 
reads containing the library ISPs usable for downstream analysis. These reads were 
thoroughly processed by well classification and read filtering to ensure their quality 
(section 3.3.3.1). Clonal ISPs (in which single template fragments were amplified) was 
made up 78 % of reads, while 22 % were polyclonal ISPs. After filtering out 1 % of test 
fragments and 8 % of low quality reads, the final percentage of the final library was 91% 
with a mean read length of 147 bp (Figure 4.6).  
Table 4.2 A summary of the Ion PGM
TM
 sequence report of the 67 JK samples, processed 
in 4 runs.* 18 samples were sequenced in 3
rd
 run and 26 in 4
th
 run but those repeat 
samples were excluded from the actual genotyping analysis 
 
No. of samples 










 run report 12 72 2,770,072 64 131 bp 
2
nd 
run report 20 79 3,274,431 66 134 bp 
3
rd 
run report 17+1 repeat* 82 4,147,776 80 133bp 
4
th














Figure 4.6 A report of a representative single sequencing run of the JK library  
A) The percentage of ISP loading density of the ISP addressed by the 316
TM 
chip wells was 88 %. Colouring represents the loading percentage of ISP across the 
physical 316
TM
 chip plate surface (red is highest; blue is lowest).  
B) The total number of usable reads is 4,001,319, after trimming and filtration from empty wells, non-templated and polyclonal reads. The percentage 72% is 
obtained by dividing these reads by the number of reads containing the library ISPs (5, 564, 617). The live/enrichment percentage is 100%, which indicates 
that ISPs contain a strong sequence signal from test fragment and library (templated). 
C) Histogram shows a mean reading length of 147bp. The read count is displayed in the y-axis, while the read length, in bp, is shown on the x-axis. 
 
A) B) C) 
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4.3.3.2 NGS data quality control 
Good quality NGS data is important for accuracy of further analysis, including 
genotyping. The mean coverage depth (750X) and the quality of the generated sequence 
data were assessed, in accordance with the Phred score, using the FastQC plugin on the 
Torrent Suite. Assessment of per base and per sequence quality was projected, by the 
FastQC, which provides an initial impression of the overall quality of the data. 
4.3.3.2.1 Per base sequence quality 
Figure 4.7 illustrates an overview of the quality of sequenced base pairs at their position 
on the reads from a single run, according to the Phred score. The mean quality score of 
sequenced bases in this run was 29-30, which gradually decreased with longer read 
length; this was suggested to be due to degradation of the sequencing chemistry near the 
end of the run (Andrews, 2016). According to the Phred score, the per base sequence 
quality of this run (30) indicated a base call accuracy of 99.9%, with a probability of 1 
in 1000 of incorrect base call. The quality of all four JK sequencing runs was 
comparable (above 99% base call accuracy, according to the Phred score; Table 4.3). 
4.3.3.2.2 Per sequence quality scores 
FastQC also provides per sequence quality scores, which assess the quality of sequences 
and whether a subset of the generated sequences had poor quality. Figure 4.8 shows the 
mean sequence quality (30; according to the Phred score) of a single run, which matches 
the quality indication previously discussed. Thus, the base call accuracy of the run is 
high (99.9%). The high quality of the analysed parameters, including coverage depth, 
provide confidence in the high throughput data for further analysis. The quality of all 








Table 4.3 Summary of the sequencing quality of the four JK NGS runs. 
 All runs achieved base call accuracy above 99%. The accuracy of the fourth run was 
mainly 99.9%. *The quality scoring was based on Phred score. 
Run Per base sequence quality* 




 28-29 28-29 
2
nd
 28-30 29 
3
rd
 29-30 29-30 
4
th
 29-30 30 















Figure 4.7 Mean Phred quality scores across all bases of JK samples in a single run. 
The x-axis represents the position of bases in the read, while the Phred score is displayed on the y-axis. A tri-coloured 
background divides the y-axis into three regions of different quality levels, according to the Phred score: very good 
(green); reasonable (orange); and poor quality base calling (red). A Box-Whisker-type plot is drawn for each position 
along with a 25-75% interquartile range. Upper and lower whiskers represent the 10% and 90% points. The blue line 
represents the mean value of the base call quality (29-30), which mainly indicates a 99.9% base call accuracy. The 














Figure 4.8 The mean quality score of the JK sequences generated from a single run.  
The mean quality score (Phred score, x-axis) of the sequences across the number of reads (y-axis) is shown. The 
mean quality of most of the sequences was ~30 (Phred score), which indicates high quality of generated reads, with 




4.3.3.3 NGS sequence visualisation  
Visualisation of the generated sequencing data of the JK samples was conducted using 
IGV software (2.3) and the BAM file format. The sequencing reads were aligned 
against the JK reference sequence of the human genome (hg19), associated with the 
accession number NM_001146036.2. The following factors were analysed using this 
visualisation tool: the integrity of the sequence, in terms of full coverage across the JK 
gene and flanking regions; coverage depth; and genomic information. Examples of 
genomic information obtained from IGV are: gene mutations, such as SNPs, insertions 
and deletions; zygosity; and the chromosomal location of the nucleotides. IGV was used 
alongside other analytical software packages, such as the Torrent Suite
TM
 plugin, 
Variant Caller, to aid significantly in the analysis, as previously described  (Robinson et 
al., 2011). Figure 4.9 shows an example of this analysis, to visualise and assess a JK 
sample with serology Jk (a+b+). The integrity of the library preparation step and the 
specificity of the designed primers can be assessed using the full distribution of the 
sequence across the entire JK gene plus up- and downstream flanking regions. 
Moreover, the JK*A/JK*B critical missense mutation (SNP 838G>A, in exon 9) at 
chromosomal location ch18:43319519 was found to be heterozygous (50% of each G 
and A were represented) at a coverage depth of 838X at this location. This SNP encodes 
for the amino acid substitution Asp280Asn. The genotyping of this SNP in exon 9 





   
Figure 4.9 An IGV output image showing visualisation analysis of the 
sequencing data of a Jk (a+b+) sample of JK*A/JK*B genotype.  
A) The reference JK gene (SLC14A1) (blue) is aligned with the sequencing reads, 
while the coverage depth is shown above. The coloured bars above represent SNPs 
across the gene (in exons and introns). Solid bars denote homozygous SNPs, while 
heterozygous SNPs are denoted by split bars.  
B) Red arrows show the critical JK*A/JK*B missense mutation (SNP 838G>A, in 
exon 9) at chromosomal location ch18:43319519, which encodes for the amino acid 
substitution Asp280Asn (GAC>AAC). This SNP is heterozygous, denoted by the 
split bar (orange/green) for 50 % G/A. Thus, there is a match between the genotype 







4.3.3.4 Variant analysis and genotyping 
The Variant caller plugin of the Ion Suite
TM
 software was used here to analyse the 
aligned sequence data generated from Ion Suite
TM
 against the reference gene in terms of 
mutations and zygosity, and was linked to the IGV software (for direct visualising of the 
mutations). In addition, VCF files obtained from the Variant Caller plugin were used 
together with other software, such as IGV and SeattleSeq Annotation 137, for 
confirmation. The VCF files were utilised and uploaded online at SeattleSeq Annotation 
137 (SeattleSeqAnnotation137, 2016), which provides a wide range of information, 
based on the NCBI database, such as the chromosomal location, type of mutation, the 
transcript number, amino acid change and nucleotide location on the cDNA. Figure 4.10 











Figure 4.10 An example of variant annotation report on a Jk (a+b+) sample 
(JK*A/JK*B genotype) obtained from the SeattleSeq Annotation 137 online 
tool. 
In this example, the JK*A/JK*B mutation is shown at chromosomal location ch18: 
43319519; the reference base is G; the SNP is heterozygous (A/G at 838). The reference 
transcript number is NM_001146036.2 and the missense mutation encodes Asp280Asn. 




4.3.4 JK genotyping by NGS 
Extensive genotyping of the JK gene was carried out using to NGS, which enabled 
detection of existing mutations (known and novel). A variety of mutations, including 
exonic and intronic SNPs, were analysed in 67 JK samples. The genotypes were then 
correlated with the phenotypes. 
4.3.4.1 NGS analysis and Genotyping of the JK gene  
The JK gene was fully sequenced in 67 different samples, most of which (59/67) were 
of known JK serological phenotype. The NGS genotyping data matched with the main 
predicted phenotypes of JK alleles JK*A, JK*B and JK*01W. The exonic SNPs are 
listed in Table 4.4; a concordance between the crucial JK*A/JK*B allele-defining SNP 




 phenotype (and zygosity) can be seen in all samples 
with known phenotypes (59 samples). In addition, 10/67 samples were found to carry 
the SNP 130G>A (encoding for the amino acid substitution Glu44Lys). This mutation 
has been assigned to JK*01W allele (JK*01W.01) and is known to weaken Jk
a
 
expression (Wester et al., 2011), although these samples showed normal expression of 




). Out of the 67 samples, 9 were heterozygous for the 
130G>A SNP and displayed normal expression of the Jk
a
 antigen: 6/7 had known 
phenotype Jk (a+b-) and 1/2 had known phenotype Jk( a+b+). One sample with the Jk 
(a+b-) phenotype was homozygous for this SNP.  
The synonymous amino acid substitution Pro196Pro, encoded by the SNP 588A>G in 
exon 7, was also found in the samples. Genotyping was carried out in four separate runs: 
in the first two runs, this SNP (588G) was only found in JK*B and JK*01W 
(JK*01W.01) alleles, while the rest of the JK*A samples carried the nucleotide (588A), 
which suggested a cumulative effect of both 588G and 130A on weakening Jk
a
 
expression. To ensure the cis existence of the 588G SNP in both JK*B and JK*01W 
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alleles, further investigation was conducted involving sequencing of cDNA clones 
(section 4.3.5.2). Following further NGS runs, the 588A>G SNP was also found in the 
JK*A allele: 1/18 heterozygous in JK*A/JK*A; 1/13 homozygous in JK*A/JK*B; and 
1/7 homozygous in JK*A/JK*01W (Table 4.4). This may suggest that the 588A>G SNP 
is not involved in the weakening of the Jk
a
 antigen.  
Of the sequenced cohort, 10/67 samples were heterozygous for the 810G>A SNP, 
which encodes the synonymous amino acid substitution Ala270Ala. This SNP appears 
to be only carried by the JK*B allele, as found in 7/29 JK*B/JK*B and 3/13 JK*A/JK*B 
samples. The SNP is located at the exon 8/intron 8 boundary (near the splice region), 
which may suggest an effect on Jk
b 
expression. In fact, it was previously suggested that 
this SNP may abolish the expression of Jk
b
 antigens and thus represent a novel JK*B 
Null allele (Henny et al., 2014). This SNP is currently not included in the BGMUT 
database, although it has been reported in the NCBI dbSNP database (dbRBC, 2016, 
NCBI, 2016a). After cDNA sequence analysis here, no effect of this SNP on Jk
b
 
expression was observed (section 4.3.5.1). A G>A SNP in exon 1, at chromosomal 
location ch18: 43304182, was noted in all samples carrying the JK*01W allele; however, 
exon 1 is not translated and the SNP results in a synonymous substitution (AGG>AGA), 
where both nucleotides encode Arg. Thus, this SNP may not affect expression, but 
rather is specific to the JK*01W allele (Table 4.5).  
Most of the SNPs observed here required no further confirmation or validation due to 
high coverage (750X) and previous validation in the NCBI database (dbSNP). However, 
SNPs 810G>A and 588A>G required further analysis to confirm their associations 
(sections 4.3.5.1 and 4.3.5.2). With regard to SNPs in the JK introns, a high number of 
SNPs were distributed among the JK alleles. On average, there were 30 intronic SNPs 
in JK*A/JK*A, 50 in JK*A/JK*01W, 40 in JK*01W /JK*01W, 80 in JK*B/JK*01W, 70 
































(synonymous     
substitution) 




(synonymous     
substitution) 
 
JK*A/ JK*A 18 G/G (18) G/G (18) 
A/A (17) 
A/G (1) 
G/G (18) Jk(a+b-) (17) 











JK ⃰ 01W.01/ 
JK ⃰ B 
2 G/A (2) G/A (2) G/G (2) G/G (2) Jk (a+b+) (1) 
JK ⃰ 01W.01/ 
JK*A 
7 G/G (7) G/A (7) 
A/G (6) 
G/G (1) 
G/G (7) Jk(a+b-)(6) 
JK ⃰ 01W.01/ 
JK ⃰ 01W.01 
1 G/G (1) A/A (1) G/G (1) G/G (1) Jk(a+b-)(1) 
Table 4.4. NGS genotyping of 67 samples of differing JK phenotypes.  
67 different gDNA samples (59 of which were phenotyped by serology) were 
sequenced using NGS and JK-specific LR-PCR. All phenotyped samples showed 
complete concordance with the NGS genotyping data with the key JK*A/JK*B 
allele SNP (838G>A). Other exonic SNPs are: 130G>A, suggested to encode for 
the JK*01W allele (JK*01W.01); 588A>G, encoding for a synonymous 
substitution; and 810G>A, claimed to encode for a purported novel JK*B null 
allele. The SNP 810G>A did not appear to affect Jk
b
 antigenicity as it was 
expressed in 7 Jk a-b+ and 3 Jka+b+ samples. *Asterisks denote allele names that 
are the same as in the ISBT (Reid et al., 2012). 
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4.3.4.2 Assignment of JK allele-specific polymorphism patterns  
NGS extensive genotyping enabled analysis of both exonic and intronic SNPs, with the 
latter mainly correlating with JK*A, JK*B and JK*01W alleles. This allowed detection 
of allele-specific mutations, including SNPs and a deletion, which may form allele-
defining SNP patterns (‘fingerprints’) thus giving suggested reference sequences for the 
JK*A, JK*B and JK*01W alleles. This approach to define allele-specific SNP patterns 
(reference sequences) involved the comparison of NGS sequences to reference 
sequences in the human genome (hg19). Sequences of all homozygous-allele samples 
(for example JK*A/JK*A and JK*B/JK*B) were then compared to determine their 
reference sequence. Table 4.5 illustrates the allele-specific reference SNPs (allele-
specific) that define JK*A, JK*B and JK*01W alleles; these show a high degree of 
concordance to the JK genotype at the allele-defining SNP (838G>A, at location ch18: 
43319519, in exon 9) that encodes for Asp280Asn. As seen in Table 4.5, there are 
number of allele-specific SNPs in introns; in the case of JK*B, a single nucleotide 
deletion (G>Del) at location ch18: 43321558. These novel allele-defining patterns have 
not been described before in the literature. The suggested reference sequence patterns 
for JK*A and JK*B alleles are shown here in Table 4.5; multiple JK*A, JK*B alleles 
were immediately recognised and some had to be resequenced to eliminate errors (Table 
4.5). Errors were suspected due to their diverse zygosity of SNPs (compared to the 
proposed reference sequence) and also one sample did not match the phenotype at first 
(data not shown), which illustrates the feasibility of this approach.  
Although the reference sequence from the human genome (hg19) encodes Asp at the 
280 position of the JK*A allele, multiple intronic SNPs were seen here to be consistent 
with either JK*A, JK*B and JK*01W. This implies that the reference sequence from the 
human genome (hg19) was obtained from individuals of different JK genotypes. In 
addition, most samples (apart from those noted in Figure 4.11 legend) were found to 
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have a homozygous difference to several nucleotides in the reference sequence form the 
(hg19); this suggested that these uncommon SNPs (Figure 4.11A) were found during 
the assembly of human genome sequences. One of these SNPs was 43319359 C>T, 
located a short distance (160 bp) upstream of the JK*A/JK*B crucial SNP (838G>A). 
This SNP is noteworthy to point out, to avoid possible allelic dropout if this position 
was used within designed genotyping primer in the case of, for example, the current 
BGG platforms.  
All ten (7 JK*A/JK*01W, 2 JK*B/JK*01W and 1 JK*01W /JK*01W) samples shared 
the JK*01W allele as they carried the previously described SNP (130G>A); the 10 
samples  showed an almost identical pattern (a ‘specific fingerprint’) (Table 4.5), due to 
the zygosity of the SNPs defined by the NGS. Interestingly, this approach of extensively 
analysing allele-specific patterns revealed that the JK*01W sequence, in addition to its 
specific SNPs, appeared to resemble a hybrid sequence of JK*A/JK*B alleles. The 
resemblance of the JK*B allele can be seen in part of intron 7, exon 7, parts of intron 9 
and intron 10, while the remainder of the JK*01W allele appeared to be derived from 
JK*A (see Table 4.5 and Figure 4.11D). Furthermore, an intronic SNP located at 
position -46 from the 3’ end of intron 9 was described to be associated with JK*A 
(nucleotide A) while the JK*B and JK*01W carry (nucleotide G) (Wester et al., 2011, 
Irshaid et al., 2000, Daniels, 2013). However, this SNP was found here to be not 
completely allele-specific as it was heterozygous in 4 JK*A/JK*A samples and 1 
JK*B/JK*B sample whereas G/G in 1 JK*A/JK*A sample, 1 JK*A/JK*01W sample and 
1 JK*A/JK*B sample (data not shown in table 4.5). Figure 4.11 provides a graphical 










Table 4.5 NGS of 67 different JK samples, 59 of which were of known Jk phenotype. (NOTE: the table is on the next page). 
The table graphically represents the suggested reference SNPs of JK*A, JK*B and JK*01W (JK*01W.01). The JK*A-specific SNPs (forming a 
reference sequence and pattern) are shown in red; the reference JK*B SNPs and the deletion are shown in blue; and the SNPs defining the 
JK*01W allele (JK*01W.01) are shown in green (and are also highlighted in yellow). Homozygous mutations are represented by solid colour, 
whilst crossed colour represents heterozygous mutations. The major JK*A/JK*B SNP (838G>A) is highlighted in orange, while other key 
mutations (SNPs 588A>G and 810G>A) and the G deletion, at chromosomal location chr: 43321558, are highlighted in grey. Samples with no 
provided phenotype provided are ND (not defined). The position of each SNP is represented by their location on chromosome 18/hg19. The 3 
LR-PCR overlapping amplicons and their location are indicated as black boxes at the top. *Asterisks represent repeat sequence samples for 
confirmation. There are two apparent JK*A alleles (samples JK009. 04, 05, 11, 13 and 15 for one allele while sample JK009.10 for the other) 
that differ from the reference sequence. Sample JK009.32, sample JK009.39, samples JK009.35, 44 and 53 and sample JK009.52, on the other 
hand, differ from the reference JK*B allele sequence in terms of the intronic polymorphisms. The JK*Aw and JK*01W alleles are short form for 
the official ISBT allelic name of JK*01W.01. The number 009 was used in accordance with the number of the JK blood group system (ISBT 
number). Larger table in appendix B 
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rsID 3819179 28994270 7233769 7234310 10432193 11877062 11877086 9304321 9304322 9304323 17674580 12605147 8090908 2298720 3819178 12963324 17674709 10460036 8099449 9949609 16978474 8083653 3819177 692899 2298718 16978475 10775479 493363 11082466 9955503 11665385 473429 17675299 1058396 11660575 8086499 564409 565153 11357759 56044725 12962485 493262 1682392 4890588 17142 16809 3745006
G>A G>A A>G G>A T>C C>T C>A C>T G>T A>G T>C A>G A>G 130G>A G>C A>G C>G A>G T>C C>G C>G T>C T>C C>T 588A>G T>C G>A A/G C>T A>T G>A C>T 810G>A 838G>A A>G A>G C>G T>G G>Del A>G T/C G>A G>A C>T A>G A>G T>G
43304182 43304783 43306681 43306793 43307072 43307246 43307338 43308188 43308198 43308315 43309911 43310180 43310187 43310415 43310845 43310851 43311380 43311566 43311696 43313128 43314962 43315027 43316110 43316270 43316538 43317005 43317252 43317249 43317528 43318694 43318746 43319060 43319274 43319519 43320438 43321412 43320714 43320771 43321558 43321563 43322410 43323624 43325159 43327294 43329310 43329198 43329590
JK*Aweak JK*Aweak JK*Aweak JK*Aweak JK*Aweak Pro196Pro JK*Aweak JK*A/JK*B
Genotype exon 1 intron 1 intron 2 intron 2 intron 2 intron2 exon 3 intron 3 intron 3 intron 3 intron 3 intron 3 intron 3 exon 4 intron 4 intron 4 intron 5 intron 5 intron 5 intron 5 intron 6 intron 6 intron 6 intron 6 exon 7 intron 7 intron 7 Intron 7 intron 7 inton 7 intron 7 intron 7 exon 8 near Splice exon 9 intron 9 intron 9 intron 9 intron 9 intron 9 intron 9 intron 9 intron 9 intron 9 intron 9 intron 10 intron 10 intron 10
18 JK*A/JK*A SAMPLE NUMBER Phenotype
JK*A/JK*A JK009.01 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.02 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.03 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.04 ND G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/A A/A G/G G/G A/G C/C A/A T/T C/T C/C T/T T/T C/T A/A T/T G/G A/G C/C T/A G/G C/T G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/G
JK*A/JK*A JK009.05 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A C/C A/A A/A G/G G/G G/G C/C A/A T/T C/C C/C T/T T/T T/T A/A T/T G/G G/G C/C T/T G/G T/T G/G G/G A/A A/A G/G G/G G/G A/A C/C A/A A/A T/T G/G G/G G/G
JK*A/JK*A JK009.06 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.07 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.08 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.09 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.10 Jk(a+b-) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.11 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/A A/A G/G G/G A/G C/C A/A T/T C/C C/C T/T T/T C/T A/A T/T G/G A/G C/C T/A G/G C/T G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/G
JK*A/JK*A JK009.12 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.13 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/A A/A G/G G/G A/G C/C A/A T/T C/C C/C T/T T/T C/T A/A T/T G/G A/G C/C T/A G/G C/T G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/G
JK*A/JK*A JK009.14 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.15 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/A A/A G/G G/G A/G C/C A/A T/T C/C C/C T/T T/T C/T A/A T/T G/G A/G C/C T/A G/G C/T G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/G
JK*A/JK*A JK009.16 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.17 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
JK*A/JK*A JK009.18 Jk(a+b-) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/T A/A A/A G/G G/G A/A C/C A/A T/T C/C C/C T/T T/T C/C A/A T/T G/G A/A C/C A/A G/G C/C G/G G/G A/A A/A C/C T/T G/G A/A T/T G/G G/G C/C A/A A/A T/T
7 JK*A/JK*Aw
JK*A/JK*Aw JK009.19 Jk(a+b-) G/A G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/G A/A G/A G/G A/G C/C A/A T/T C/C C/G T/T T/T C/T A/G T/C G/A A/G C/T A/A G/G C/C G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/T
JK*A/JK*Aw JK009.20 ND G/A G/A A/A G/G T/T C/C C/C C/C G/G A/A T/C A/G A/A G/A G/G A/G C/C A/A T/T C/C C/G T/T T/T C/T A/G T/C G/A A/G C/T A/A G/G C/C G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/T
JK*A/JK*Aw JK009.21 Jk(a+b-) G/A G/A A/A G/G T/T C/C C/C C/C G/G A/A T/C A/G A/A G/A G/G A/G C/C A/A T/T C/C C/G T/T T/T C/T A/G T/C G/A A/G C/T A/A G/G C/C G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/T
JK*A/JK*Aw JK009.22 Jk(a+b-) G/A G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/G A/A G/A G/G A/G C/C A/A T/T C/C C/G T/T T/T C/T A/G T/C G/A A/G C/T A/A G/G C/C G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/T
JK*A/JK*Aw JK009.23 Jk(a+b-) G/A G/G A/A G/G T/T C/C C/C C/C G/G A/A C/C A/G A/A G/A G/G G/G C/C A/A T/T C/C C/G T/T T/T T/T G/G C/C A/A G/G T/T A/A G/G C/C G/G G/G A/A A/A G/G G/G G/G A/A C/C A/A A/A C/T G/G A/G T/T
JK*A/JK*Aw JK009.24 Jk(a+b-) G/A G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/G A/A G/A G/G A/G C/C A/A T/T C/C C/G T/T T/T C/T A/G T/C G/A A/G C/T A/A G/G C/C G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/T
JK*A/JK*Aw JK009.25 Jk(a+b-) G/A G/A A/A G/G T/T C/C C/C C/C G/G A/A T/C A/G A/A G/A G/G A/G C/C A/A T/T C/C C/G T/T T/T C/T A/G T/C G/A A/G C/T A/A G/G C/C G/G G/G A/A A/A C/G T/G G/G A/A T/C G/A G/A C/T A/G A/G T/T
1 JK*Aw/JK*Aw
JK*Aw/JK*Aw JK009.26 Jk(a+b-) A/A G/A A/A G/G T/T C/C C/C C/C G/G A/A C/C G/G A/A A/A G/G G/G C/C A/A T/T C/C G/G T/T T/T T/T G/G C/C A/A G/G T/T A/A G/G C/C G/G G/G A/A A/A G/G G/G G/G A/A C/C A/A A/A T/T G/G G/G T/T
2 JK*B/JK*Aw
JK*B/JK*Aw JK009.27 Jk(a+b+) G/A G/G A/G G/A T/C C/T C/A C/T G/T A/G C/C A/G A/G G/A G/C G/G C/G A/G T/C C/G C/G T/C T/C T/T G/G T/C A/A G/G T/T T/A G/A C/T G/G G/A A/G A/G G/G G/G G/Del A/G C/C A/A A/A T/T G/G G/G T/G
JK*B/JK*Aw JK009.28 ND G/A G/G A/G G/A T/C C/T C/A C/T G/T A/G C/C A/G A/G G/A G/C G/G C/G A/G T/C C/G C/G T/C T/C T/T G/G T/C A/A G/G T/T T/A G/A C/T G/G G/A A/G A/G G/G G/G G/Del A/G C/C A/A A/A T/T G/G G/G T/G
26 JK*B/JK*B
JK*B/JK*B JK009.29 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.30 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.31 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.32 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G A/G G/G G/G G/Del A/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.33 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.34 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.35 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T G/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.36 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/A A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.37 ND G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.38 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/A A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.39* Jk(a-b+) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.40 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.41 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.42 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.43 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.44 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T G/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.45 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/A A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.46 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.47 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.48 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/A A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.49 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/A A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.50 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.51 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.52 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T A/A G/G T/T T/T A/A T/T G/A A/A G/G A/G G/G G/G G/Del G/G T/C G/A G/A C/T A/G A/G T/G
JK*B/JK*B JK009.53 Jk(a-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T G/A G/G T/T T/T A/A T/T G/G A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
JK*B/JK*B JK009.54** (Jka-b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C C/C T/T G/G T/T G/A G/G T/T T/T A/A T/T G/A A/A G/G G/G G/G G/G Del/Del G/G C/C A/A A/A T/T G/G G/G G/G
13 JK* A/JK * B
JK* A/JK * B JK009.55* Jk(a+b+) G/G G/G G/G A/A C/C T/T A/A T/T T/T G/G C/C A/A G/G G/G C/C G/G G/G G/G C/C G/G C/C C/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/A G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.56 Jk(a+b+) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.57 Jk(a+b+) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.58* Jk(a+b+) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.59* Jk(a+b+) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/A A/A G/G G/G A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.60* Jk(a+b+) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A C/C A/A A/A G/G G/G G/G C/G A/G T/C C/G C/C T/C T/C T/T A/G T/T G/A G/G C/T T/T G/A T/T G/G G/A A/G A/G G/G G/G G/Del A/G C/C A/A A/A T/T G/G G/G G/G
JK* A/JK * B JK009.61 Jk(a+b+) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/A G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.62 ND G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.63 ND G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.64 Jk(a+b+) G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.65 Jk(a+b+) G/G G/G A/A G/G T/T C/C C/C C/C G/G A/A T/C A/A A/A G/G G/G A/G C/G A/G T/C G/G C/C C/C C/C T/T G/G T/T G/A G/G T/T T/T G/A C/T G/A G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/C A/G A/A T/T
JK* A/JK * B JK009.66 ND G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
JK* A/JK * B JK009.67 ND G/G G/G A/G G/A T/C C/T C/A C/T G/T A/G T/C A/A A/G G/G G/C A/G C/G A/G T/C C/G C/C T/C T/C C/T A/G T/T G/A A/G C/T T/A G/A C/T G/G G/A A/G A/G C/G T/G G/Del A/G T/C G/A G/A C/T A/G A/G T/G
Amplicon 1 covers from (chr18:43301432 - 43312443) including exon 1- part of intron 5
Amplicon 2 covers from (chr18:43310959 - 43322011) including exon 5 to part of intron 9
Amplicon 3 covers from (chr18:43318623 - 43333287) including part of intron 7 to downstream of exon 11
Amplicon 1 and 2 overlap by 1484 bp
Amplicon 2 and 3 overlap by 3388 bp
 
















Figure 4.11 Graphic illustration of the allele-specific SNPs forming reference JK*A, JK*B and JK*Aw allele sequences (‘fingerprints’). 
(NOTE: the figures 4.11 A, B, C and D are on the next pages). 
The genomic structure for the JK alleles taken from analysing the 67 different samples derived by NGS is shown here. The SNPs are denoted by 
vertical lines and their chromosomal locations on ch18: hg19 are shown. A shows the SNPs (homozygous) that are different from the reference 
sequence (hg19) in all samples, apart from those noted here: for example (A>G 43306891), in all samples except the following: (A>G 43306891 
(samples JK009.04/11/13/15/60 and 65 were heterozygous, while JK009.05 was homozygous A/A; C>T 43307455 (samples 
JK009.04/11/13/15/60 and 65 were heterozygous, while JK009.05 was homozygous C/C; G>A 43311483 (samples JK009.04/11/13/15/23/60 
and 65 were heterozygous, while JK009.05 was homozygous G/G; A>G 43313309 (samples JK009.04/11/13/15 and 60 were heterozygous, 
while JK009.05 was homozygous A/A; C>T 43319359 (samples JK009.04/11/13/15/60 and 65 were heterozygous, while JK009.05 was 
homozygous C/C; A>G 43329031 (sample JK009.65 was heterozygous). B and C show the JK*A and JK*B allele-specific SNPs obtained from 
analysing the NGS data of homozygous JK*A and JK*B samples. The majority of samples matched these ‘allele fingerprints’, which suggests 
that these sequences may be JK*A and JK*B reference sequences. The JK*A reference SNPs are shown in red while those for the JK*B allele 
are shown as blue lines. Blue arrow denotes the G deletion at chromosomal location 43321558. D shows the sequence of samples carrying the 
JK*01W allele, which suggests derivation of SNPs from JK*A (red) and JK*B (blue). Green lines represent JK*01W -specific SNPs. JK*Aw and 
JK*Aweak are written as short form for the official ISBT allelic name (JK*01W.01). ** The SNP 810G>A was found in ten samples carrying 




























D) JK*Aw (JK*01W) 
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4.3.5 cDNA analysis of JK 810G>A and 588A>G SNPs 
4.3.5.1 SNP 810G>A 
The SNP 810G>A is thought to encode for the synonymous substitution Ala270Ala 
(silent mutation), and is located at the second last nucleotide position of exon 8 (at the 
exon 8/intron 8 boundary) (Figure 4.12). Due to its location, this SNP was previously 
suggested to alter the expression of the Jk
b
 antigen by possibly disturbing the splice site 
(Henny et al., 2014). The authors found this SNP in two samples of Jk b- phenotype, but 
which carried the JK*B allele; this SNP was, therefore, characterised as comprising a 
novel JK*B allele, not previously reported in the BGMUT database (dbRBC, 2016). In 
contrast to this finding, 10/67 of samples which showed normal Jk
b
 expression with 
phenotype (7 Jk a-b+ and 3 Jka+b+) here were found to carry this particular SNP; 
moreover, these samples showed compatible genotypes (7 JK*B/JK*B and 3 
JK*A/JK*B). Thus, the findings here do not corroborate the previous study by Henny’s 
group (2014), thereby raising the question whether this SNP is indeed a silencing 
mutation. This was further investigated by examining RNA levels in these samples. For 
instance, analysis of mRNA would show whether any exon skipping had occurred, 
which may have led to downregulated or abolished expression of the Jk
b
 antigen. 
During these experiments, cDNA was synthesised from the RNA (section 2.3.4 and 
2.3.5) of 15/67 samples. The samples were of known phenotype (6 Jk a-b+, 5 Jk a+b+, 2 
Jk a+b-, 1 JK*A/JK*01W (Jk a+b-) and 1 JK*B/JK*01W (Jk a+b+)). Primers were used 
to amplify the selected areas of interest (exons 8 and 9) to analyse the SNP 810G>A in 
exon 8 and the (JK*A/JK*B) SNP 838G>A in exon 9 (section 2.3.3). This primer design 
allowed annealing within exons, as introns are naturally spliced out from RNA (Figure 
4.13). Figure 4.14 shows the amplified cDNA bands of the expected size (~237 bp). The 
cDNA amplicons were then sequenced using Sanger sequencing (see section 2.3.6). 
Only 1/15 samples with the phenotype Jk a+b+, JK*A/JK*B was found to be 
193 
 
heterozygous for both the 810G>A and 838G>A SNPs. This sample confirmed there 
was a restored a splice site sequence, spliced as expected, with no sign of exon skipping 
that could be silencing the Jk
b
 antigen, which was manifested by the phenotype Jk b+ 
(Figure 4.15). The data generated by Sanger sequencing matched with NGS data for 
JK*A/JK*B and serology (Jka+b+). Notably, the 5’ exonic reference sequence of JK at 
the exon/intron boundary appeared to be a GG-intron, which might not match the 




Figure 4.12 An IGV image illustrating the critical location of the 810G>A 
SNP in a JK sample.   
The SNP 810G>A is located at the exon 8/intron 8 boundary; the 3’ of exon 8 within the 
5’ splice site sequence. The location of the SNP is denoted with a split box (orange and 









Figure 4.14 The amplification of JK cDNA for splice site analysis 
Amplification of JK cDNA from two samples (JK009.55 and 34, respectively) is 
shown here as an example under the thermocycling conditions described in 
section 2.3.5. The amplicon size is 237bp, seen just above the 200bp ladder. 
Samples were loaded onto a 1.5% agarose gel and electrophoresed at 90V for 1 
hour. The TriDye
TM
 100bp was used as a marker of amplicon size. 
200 bp 
300 bp 
237 bp amplicon 
Figure 4.13 Primer design for amplification of SNPs 810G>A and 
838G>A. 
The above primer pairs were used: forward (red brackets) and reverse (blue 
brackets) to address the 810G>A and 838G>A SNPs. These primers were designed 
to anneal within exons instead of introns, as the latter are spliced out in mRNA 
synthesis. The forward primer annealed within exon 8 to cover 810G>A (red 






     
  
Figure 4.15 An electropherogram of 810G>A and 838G>A SNPs from Sanger sequencing of JK*A/JK*B cDNA.  
The sample JK009.55 was heterozygous for both the 810G>A and 838G>A SNPs. The introns between both exons 8 and 9 
were visibly normally spliced out, with no sign of exon skipping; thus, both SNPs were expressed and validate the provided 
phenotype (Jk a+b+) and genotype by NGS (JK*A/JK*B), without affecting the Jk
b
 expression. Image was obtained by Seq 
scanner 2. A red line split between exons 8 and 9.  
JK*A/JK*B  (838G>A) Het Exon 9 (810G>A) Het Exon 8 
Sample JK009.55 (Jk a+b+, JK*A/JK*B) 






Figure 4.16. An IGV image of the 810 G>A and 838 G>A SNPs and shows the splice site sequence between exon 8 and 9 of a 
JK*A/JK*B sample. 
A) The 3’ exonic reference sequence of JK at the exon 8/intron 8 boundary appeared to be GG-intron, which may not match the consensus sequence (AG-
intron) shown in B) red circle. B) the consensus splice site sequence is shown, where the underlined A can change to G. In addition, the consensus T in the 
intron is found as C in the JK reference sequence. Both SNPs are heterozygous in this sample. Encoding for the genotype JK*A/JK*B. 
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4.3.5.2 SNP 588A>G 
Sanger sequencing was used to sequence cDNA clones from JK samples carrying 
JK*B/JK*01W alleles (JK009.27 Jka+b+), using RT-PCR and primers annealing within 
exons 4-9 (Figure 4.17 and 4.18). This was conducted to ascertain whether the G588 
silent SNP was carried by both JK*B and JK*01W alleles as suggested by NGS 
genotyping data (Table 4.4 and 4.5), but not with the JK*A allele (the first two runs). As 
the NGS approach uses small fragments (200-400bp), assigning mutations as cis or 
trans (i.e. depending on which allele a mutation arises from compared to other 
mutations) is more difficult than with cloning methods, where plasmid DNA take only 
one cDNA molecule (in this case, cDNA of only one allele). The successful insertion of 
cDNA into plasmid DNA was confirmed using EcoRI restriction digest, where both 
uncut and cut plasmid DNA was seen (Figure 4.19). The Sanger sequence analysis 
confirmed the findings of NGS; that both alleles (JK*B and JK*01W) carry G588, while 
A838 and G130 were carried by the JK*B allele, and G838 and A130 were carried by 
the JK*01W allele. The nucleotide G810 in exon 8 was found in both alleles, which also 
confirms NGS data in that sample (Figure 4.20). This 588A>G SNP might not be 
involved in suppression of the Jk
a
 antigen as it was found in multiple samples carrying 
the JK*A allele (1/18 het in JK*A/JK*A, 1/13 hom in JK*A/JK*B and 1/7 hom 








Figure 4.17 The primer pairs designed to cover exon 4 to exon 9 for 588A>G SNP analysis. 
The primer pairs were designed to produce a cDNA amplicon of 864bp in size, which covers the following SNPs: 130G>A (JK*01W specific); 
588A>G; and 838G>A (JK*A/JK*B specific). This analysis determined whether 588A>G was associated with both JK*01W and JK*B alleles. 
The SNP 810G>A in exon 8 was also covered. The total distance across exons 4 to 9 is ~10kb in the JK gene which was covered in the NGS 
and LR-PCR analysis. JK*Aw is another name form for the allelic name (JK*01W). 
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Figure 4.18 JK cDNA amplicon (864bp) containing 
SNP 588A>G. 
The amplification of JK cDNA from 2 samples is 
shown here as an example (only sample A was used 
for downstream analysis due successful colony 
growth) under the  thermocycling conditions (in 
section 2.3.5).  The amplicon size is 864bp, seen 
around the 900bp ladder. Samples were loaded onto a 
1% agarose gel and electrophoresed at 90V for 1 
hour. The TriDye
TM









Figure 4.19 EcoRI restriction enzyme analyses for positive insertions.  
The cut plasmid DNA (linearised) is aligned along the 4kb marker (~ size of plasmid DNA used), 
while the uncut fragment migrated faster through the gel due to its circular compact shape (with 
some remaining open circular plasmid on top of the uncut due to handling). The GeneRuler
TM
1Kb 
Plus DNA ladder was used here as a marker of DNA size. 
A1) A plasmid DNA form a colony with unsuccessful cDNA insertion as no product was shown 
with EcoRI restriction digest. A2) cDNA was successfully inserted but the size of the insert was 
smaller (~500bp) than expected (864bp). (B)  This was due to the EcoRI recognition sequence 
(G^AATTC) located in the middle of the insert, dividing it into 449bp and 415bp fragments before 
and after the cut.  
A) 
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Figure 4.20 Electropherograms showing the association of SNP G588 with both JK*B and JK*01W alleles by 
Sanger sequencing of JK*B/JK*01W cDNA clones.  
A) cDNA clone of the JK*B allele confirmed presence of G588 in exon 7, G130 in exon 4 and A838 (specific for JK*B) in exon 
9. B) That from the JK*01W allele also confirmed presence of G588 in exon 7, along with A130 (JK*01W.01-specific) and 
G838 (specific for JK*A) in exon 9.  
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4.4 Discussion  
4.4.1 NGS of the JK library 
The construction of JK libraries for the NGS genotyping protocol involved various 
optimisation steps, in particular the LR-PCR conditions, purification and size-selection. 
The SPRIselect® reagent kit (Beckman Coulter, UK) was preferred for purification and 
size-selection over AMPure® XP beads Reagent and the Pippin Prep
TM
 instrument due 
to its cost-effectivity and time efficiency (it can be used for both purification and size 
selection) (see section 2.2.4.10). Briefly, each Pippin Prep
TM 
kit, which contains ten 
cassettes, is only capable of processing 4 samples per cassette and run, which takes 
about 1 hour and ten minutes. The kit costs £461 for
 
size selecting 40 samples (£11.53 
per sample) that in addition needs purification steps with AMPure® XP beads Reagent. 
On the other hand, SPRIselect® reagent kit, which is used for size selection and 
purification simultaneously, costs £696 for 60 ml, by which 120 samples can be 
processed (£5.80 per sample).  
4.4.2. Quality control of NGS data 
Quality control of NGS data was carried out to so as to assess the validity of data for 
downstream analysis. FastQC was used, which assesses sequence quality by providing a 
report of the library, based on a Phred score (Andrews, 2016). All JK sequences were 
shown to have high quality (according to the Phred score), with > 99% base call 
accuracy (1 in 1000 probability of an incorrect base call). In addition to this high quality 
score, a high mean coverage depth of 750X was shown, which increased the confidence 
in the data for downstream analysis, such as variant analysis (Sims et al., 2014). This 
coverage depth significantly exceeded that of previous high-throughput sequencing 
studies, such as those by Stabentheiner et al. (2011) and Fichou et al. (2014) groups. 
These studies relied on a 50X coverage depth for polymorphism analysis of the RHD 
gene and 15 blood group system genes, respectively. One explanation for the high 
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coverage depth seen here could be the use of only a fraction of the 316
TM
 chip capacity 
in each run; around 108 samples can be simultaneously sequenced for the entire JK gene 
and flanking regions, with total amplicon size (~37kb) in a single run using the 200 base 
reads with 50X coverage depth as used by Stabentheiner et al. (2011). Moreover, about 
540 JK samples can be sequenced in parallel per run if the 318
TM 
chip was used 
(applying the calculation in chapter 1). Using these chips allows simultaneous 
sequencing of a large number of samples, which drops the cost of sequencing. The cost 
of the NGS library preparation, which included three PCR reactions (for the 3 different 
amplicons), fragmentation, purification and quality check by Bioanalyzer 2100, for one 
JK sample was approximately £63.00. On the other hand, the cost of the sequencing run, 
using the 316
TM 
chips and including template preparation, was around £454.00. 
Therefore, the cost for sequencing one JK sample was approximately £4.20, which 
would be lower if a higher capacity chip was used. 
4.4.3 Validity of JK NGS genotyping. 
For the majority of the JK polymorphisms, no further validation approaches were 
conducted due to the high quality of data.  The base call accuracy was above 99% (~30 
Phred score), which was higher than the score of a previous study by Ajay’s group 
(2011; 20 Phred score), which aimed to establish a sequencing guide for data quality. 
Moreover, the high coverage depth supported the accuracy of the data. Moreover, the 
important JK*A/JK*B SNP (838A>G) observed from NGS showed complete 
concordance with the provided serology of the Jk
a/b
. Sanger sequencing, conducted to 
analyse two cases (sections 4.3.5.1 and 4.3.5.2), with SNPs 130G>A, 588A>G, 
810G>A and 838G>A involved, also showed complete concordance with NGS data, 




4.4.4 JK NGS-based genotyping 
Genotyping of the JK gene is suggested to be beneficial for elucidation of the molecular 
mechanisms of the various JK alleles, a number of which weaken or silence the Jk 
antigens (Reid et al., 2012). This also allows for more accurate prediction of the 
phenotypes resulting from these alleles, which should help prevent alloimmunisation – 
especially in transfusion-reliant individuals (Anstee, 2009, Lomas-Francis, 2007). 
Despite their high throughput capability, the current platforms that are based on 
microarray technology predict the phenotypes only of predefined SNPs (Hurd and 
Nelson, 2009) and are not able to detect rare or novel SNPs (not included in the 
platform) that may affect Jk antigenicity, leading to false interpretation of phenotype. 
One example of this is the previous study by Paris’ group (2014), in which a 96-well 
flexible microarray platform was designed for automated genotyping of four blood 
group systems (KEL, JK, FY and MNS). Despite the advantage of automation, which 
required only 8 hours to process 96 samples, the predicted phenotype of 3/960 samples 
(involved the KEL, JK and MNS systems) were revealed discordant with serology. The 
JK samples here were genotyped as JK*A/JK*B while the phenotype was Jk (a+b-), 
which was assumed that this was accounted for by a possible silencing polymorphism 
that disrupt the expression of Jk
b
 antigen that clearly was not included in the panel list 
of SNPs. Only 8 SNPs, including JK*A/JK*B 838 G>A were included for the 4 blood 
group systems, with the cost of genotyping of each SNP was below $2.60 (Paris et al., 
2014). Another example that displays the limitation of microarray-based high-
throughput genotyping, in terms of the restriction to predefined SNPs, was that of the 
Keller et al. (2014) study. In the study, disagreement between the serological phenotype 
and that predicted using HEA BeadChip (microarray-based platform) was demonstrated 
in 7/>60,000 JK samples (5 with Jk
b
 and 2 Jk
a
). These samples were further investigated, 
using DNA sequence analysis, in an attempt to resolve the mismatch. The phenotype of 
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all 5 samples with the Jk
b 
discrepancy were predicted from the genotyping to be Jk(b+), 
while the serology demonstrated no expression of the Jk
b
 antigen (Jk(b-), which 
appeared to be due to JK*B null alleles, following DNA sequencing analysis. Three 
samples carried the JK*02N.01 allele with the polymorphism IVS5-1g>a (one was 
homozygous), one carried JK*02N.10 (194G>A) and one carried JK*02N.09 (191G>A). 
The two samples showing a Jk
a
 mismatch were found to carry the JK*01W.01-specific 
SNP 130G>A, and a novel SNP (814>T, Leu272Phe) in exon 9. The latter was thought 
to hinder the PCR amplification or hybridisation to the JK*A/JK*B SNP (838G/A)-
specific probe, leading to the allelic drop. Although the number of the samples showing 
discrepancy was low (7/60,000), it is still considered a limitation of the microarray-
based genotyping when screening for rare or new SNPs, while the sequencing-based 
genotyping was used to resolve this issue that illustrated the advantages of the discovery 
mode (Keller et al., 2014). Another discrepancy between the serological phenotype of 
the Jk antigen and (HEA) BeadChip microarray-predicted phenotype was described by 
Casas and colleagues (2015). This retrospective study evaluated the importance of 
genotyping over serology in assigning the phenotype of 494 multiply-transfused (SC) 
patients and limiting alloimmunisation by comparing the historical phenotype with that 
predicted by microarray screening. One sample was phenotyped as Jk(b-) by both 
historical and repeat serology; however, the microarray-predicted genotype was Jk(b+), 
which was subsequently confirmed by sequencing and revealed that the JK*B allele 
carried the silencing 191G>A SNP. This suggested that this SNP was not covered by the 
microarray panel (Casas et al., 2015). As a result, it can be concluded that sequencing-
based genotyping is superior to microarray platforms in terms of providing more 
extensive genotyping and, thus, better prediction of the true phenotype. This project 
features the first NGS-based genotyping study of the JK gene, coupled with LR-PCR. 
Unlike other NGS genotyping approaches, such as AmpliSeq
TM,
 in which mostly the 
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coding regions are targeted, the protocol developed here provides comprehensive 
genotyping of all existing polymorphisms in the whole JK gene (exons, splice sites and 
introns) plus flanking regions, enabling better assessment of the gene. In addition, the 
size of the LR-PCR amplicons allows better association between the carried SNPs – 
particularly novel SNPs – and critical allele SNPs (especially the JK*A/JK*B SNP 
838G>A); i.e. cis/trans association, since LR-PCR amplicons are amenable to cloning 
(section 4.3.5.2). Moreover, the suggested reference JK alleles sequences were 
established here based on extensive genotyping of both exons and introns by NGS 
(section 4.3.4.1). 
 
4.4.4.1 Genotyping of JK SNPs in exons 
Out of the 67 samples, 59 were of known serological phenotype and were in 
concordance with the NGS genotyping data of key JK allele SNPs (JK*A/JK*B 
838G>A, and JK*01W 130G>A). The variant analysis, which included SNP and amino 
acid locations, was based on the JK reference sequence associated with NCBI accession 
number NM_001146036.2; in contrast to that suggested in Reid et al (2012) with 
accession number NM_015865. The reason for this is the corroboration between the 
studies showing that JK gene contains 11 exons (Westhoff and Reid, 2004, Lucien et al., 
1998) and the 11 exon reference sequence NM_001146036.2; on the other hand, the 
NM_015865 reference sequence revealed only 10 exons. In addition, the location of the 
two critical SNPs (JK*A/JK*B 838G>A and JK*01W.01 130G>A) in the reference 
sequence used here were in concordance with the locations previously described (exon 9 
and 4, respectively) (Daniels, 2013, Wester et al., 2011), unlike in the transcript variant 
associated with NM_015865 (exon 8 and 3). Despite these differences, the NCBI 
database confirms that both reference sequences encode the same isoform of Jk antigen 
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(urea transporter) (NCBI, 2016b). 
 SNP 130 G>A, described to be JK*01W.01-specific and suppress Jk
a
 expression 
(Wester et al., 2011), was shared among 11/134 alleles, at a frequency of around 8% - 
double that previously observed in 300 Swedish samples (Wester et al., 2011). However, 
the provided serological phenotype showed normal expression of Jk
a
, which may be due 
to the inclusion of weak expression into the positive category. However, in the study by 
Wester et al. (2011), other factors than this SNP (130G>A) were suggested to reduce 
expression of the Jk
a
 antigen, as two samples (homozygous and heterozygous 130G>A) 
were shown to react strongly in the haemagglutination assay. Nevertheless, this SNP 
may play a role in Jk
a 
suppression, as six of samples carrying this SNP showed 
decreased reactivity in the haemagglutination assay and two, tested with flow cytometry, 
showed lower expression of Jk
a
 antigens. However, it is possible that other SNPs 
located in regions (exonic or promoter) not covered in the previous study may have 
exerted an effect on Jk
a
 expression. A silent mutation (588A>G) was found to be carried 
in all NGS-analysed samples containing JK*01W.01 (JK*01W) alleles (11 haplotypes); 
this mutation is suggested to also be JK*B-specific, along with an intronic SNP at 
position -46(G) from the 3’ end of intron 9 (Wester et al., 2011, Irshaid et al., 2000, 
Daniels, 2013). Results from Sanger sequencing the cDNA clones confirmed these 
findings; however, the JK*01W was concluded to differ from the JK*A allele by at least 
three SNPs: (130G>A), and two SNPs probably specific to JK*B. The SNP 588A>G 
was found also carried by the JK*A allele (3 haplotypes); thus, it appeared to be neither 
weakening expression of Jk
a
 antigen nor JK*B-specific. Similarly, the SNP in intron 9 
(position -46 G from the 3’ end) was found heterozygous in 4 JK*A/JK*A, G/G in 1 
JK*A/JK*A, JK*A/JK*01W and 1 JK*A/JK*B sample. Another SNP in exon 1 (G>A), 
at chromosomal location ch18: 43304182, was found in all samples carrying the 
JK*01W allele (Table 4.5; however, due to its location in the untranslated exon (1), the 
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SNP did not encode a ATG codon, but rather, produced a synonymous substitution 
(Arg-Arg) which did not to affect expression. However, this substitution may have 




SNP 810G>A was previously found in the second last nucleotide in exon 8 (at the exon 
8/intron8 boundary) and was suggested to exert a silencing effect on the expression of 
Jk
b
 antigens (Henny et al., 2014). The authors found this SNP in two (Jk a+b-) samples 
and defined it as a novel JK*B Null allele, since the SNP 810G>A was not already 
recorded in the BGMUT (Henny et al., 2014). However, NGS sequencing of JK 
samples here revealed that this SNP had no effect on Jk
b
 antigen expression, as the 
predicted phenotype (which matched serology) showed positive expression in all 10 
samples carrying that SNP. In addition, cDNA Sanger sequencing confirmed this, as no 
effect of the SNP was found (section  4.3.5.1) and intron 8 was spliced correctly, while 
splice site sequence seen in exon8/intron 8 boundary was described before (Lucien et al., 
1998). In conclusion, this reported novel JK*B Null allele (carried in JK*B; Henny et al., 
2014) is shown here to have no effect on expression of Jk
b
 antigen.  
4.4.4.2 JK polymorphism patterns and assignment of JK*A, JK*B and JK*01W 
allele reference sequences (‘fingerprints’) 
The extensive sequencing of the complete JK gene by NGS enabled the analysis of 
intronic SNPs and their correlation with key allele-defining exonic SNPs, such as 
JK*A/JK*B (838G>A) and JK*01W (130G>A). Despite the large number of intronic 
SNPs found here, those closely correlated with key exonic SNPs in homozygous 
JK*A/JK*A, JK*B/JK*B and JK*01W/JK*01W samples were thoroughly analysed. This 
allowed detection of novel allele-defining SNPs (which included G deletion 43321558 
in JK*B), based on which suggested allele-specific patterns (‘fingerprints’) of JK*A, 
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JK*B and JK*01W reference sequences were established (Table 4.5 and Figure 4.11). 
The benefit of this assignment of unique patterns provides insight into the evolution of 
alleles and their variants (intronic or exonic); for example the discovery of novel SNPs 
from which JK alleles may have arisen. This approach of analysing and associating 
intronic SNPs to alleles yielded interesting findings regarding the JK*01W allele, the 
sequence of which appeared to evolve from or resemble an undescribed hybrid 
JK*A/JK*B gene sequence – a phenomenon that has been described before in other 
blood group systems, such as ABO (Storry and Olsson, 2004), (Table 4.5 and Figure 
4.11). The JK*01W allele specific polymorphisms (illustrated in green in Table 4.5 and 
Figure 4.11) might have evolved on a hybrid JK*A/JK*B backbone. In addition, a 
number of JK*A and JK*B alleles in samples (Table 4.5) showed some degree of 
diversity from the suggested reference sequence to generate multiple alleles.  This 
comprehensive analysis showed that the human genome (hg19) may contain uncommon 
variants, since most of the samples were homozygous different (legend of Figure 4.11). 
Also, it is worth noting that one of those SNPs (43319359 C>T) is closely located 
(160bp) upstream of the JK*A/JK*B key SNP (838G>A), possibly accounting for the 
allelic dropout in genotyping platform based on primers designed at this position, such 
as microarray platforms. Accordingly, this would urge caution when designing 
JK*A/JK*B genotyping primers to avoid amplification failure due to SNPs in the primer 
binding sites. In addition, it is suggested to be good practice to sequence a large number 
of samples using NGS for different blood group genes to investigate and catalogue 
polymorphisms close to critical SNP positions so that these can be taken into 
consideration whilst designing genotyping primers. One example of allelic dropout due 
to intronic SNPs was described in a study by Mullins et al. (2007), the goal of which 
was to develop a sequencing assay for genotyping of cadherin 1 (CDH1) gene. The 
authors reported that the allelic dropout, characterised by a (2398delC) in exon 15, was 
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because of a SNP located in intron 15 within the primer binding site (Mullins et al., 
2007). As a consequence, this would provide a false negative result, which was also 
reported by another study that reported the possibility of allelic dropout due to intronic 
SNPs that prevent the discovery of long QT syndrome (LQTS) causing mutations 
(Tester et al., 2006). Therefore, polymorphisms in introns should be taken into account 
during designing primers. 
In summary, NGS showed clear superiority over other high-throughput genotyping 
microarray-based methods, since all existing polymorphisms, without the predefined 
SNPs constraints, were revealed here. SNPs in exons were correlated here with intronic 
SNPs, which was beneficial in studying the phenotype and evolution of the blood group 
gene system. In addition, alleles differing form the suggested reference sequences may 
require further attention for their role in antigenicity. These allele-specific fingerprints 
may be shared with software developers to establish more detailed interpretation of the 
genotype and predicted phenotype of JK and other blood genes. Moreover, this 
approach would greatly help solve unusual data and discrepancies in samples, so as to 
enable correct identification of causative SNPs. Finally, NGS-based genotyping of the 
JK gene has provided insight into the molecular basis of Jk antigen expression, which 
can be applied to other blood group systems, contributing greatly towards the safety of 









Chapter 5  




ABO (ABO/ISBT 001) is considered the most clinically significant blood group system 
in transfusion medicine and transplantation, as naturally occurring ABO antibodies can 
induce a rapid transfusion reaction if the mismatched ABO blood type is transfused into 
a patient (Yamamoto, 2004). The ABO gene, which comprises 7 exons (Yamamoto et 
al., 1995), indirectly generates synthesis of A and B antigens by encoding the 
glycosyltransferases: N-acetylgalactosaminyltransferase (GTA) and 
galactosyltransferase (GTB), which catalyse expression of these antigens (Daniels, 
2013). ABO is one of the most complex and polymorphic blood group genes with an 
ever-increasing number of alleles as in four years from 2012 (Patnaik et al., 2012) to 
2016, an increase of 109 new ABO alleles have been identified and listed in the 
BGMUT database (dbRBC, 2016), with many others likely remaining unidentified nor 
listed (Lang et al., 2016). These alleles have resulted from various polymorphisms – 
such as, single nucleotide polymorphisms (SNPs) and deletions – within exonic or other 
parts of the ABO gene, including intronic regions. Notably, a number of these 
polymorphisms might not only alter the specificity of the enzymes but also suppress 
expression of ABO antigens (Sano et al., 2012, Reid et al., 2012). ABO serological 
typing has yielded some discrepancies, for which reason genotyping has been used as a 
more reliable tool for prediction of the ABO phenotype, thereby ensuring safe blood 
transfusion. Genotyping of the whole ABO gene (molecular information across the 
exons and introns) allows identification and assessment of hybrid, rare and novel alleles 
(Thuresson et al., 2012, Huh et al., 2011) and allele evolution studies (Avent et al., 
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2015). Moreover, a high-throughput genotyping approach like NGS is required to 
address the increasing number of new ABO alleles identified in individuals. The 
commercially available high-throughput genotyping platforms, such as microarrays, 
have the disadvantage of only assessing known polymorphisms, thereby preventing 
discovery of new or rare mutations and resulting alleles (Tilley and Grimsley, 2014). In 
contrast, NGS is a powerful genotyping platform which enables high-throughput 
screening and discovery of new mutations; thus, it overcomes the obstacles of 
microarray-based genotyping technology. Accordingly, NGS allows comprehensive 
analysis of the frequency, evolution of alleles and allelic markers which enables better 
elucidation of complex blood group systems such as ABO. 
 
5.2 Aim of the study 
Following the feasibility of the NGS approach for genotyping of FY and JK blood group 
genes in previous chapters, the NGS approach together with long-range polymerase 
chain reaction (LR-PCR) will be used here for genotyping of the ABO blood group gene. 
The entire ABO gene will be sequenced here, including all 7 exons, introns and flanking 
regions. Previous genotyping studies only sequenced exons 6 and 7 (Lang et al., 2016) 
or left out the large intron 1 (Huh et al., 2011, Thuresson et al., 2012); in contrast, 
sequencing the entire gene here will enable a more comprehensive genotyping of ABO, 
which will allow identification of rare or novel polymorphisms (including intronic) with 








5.3.1 LR-PCR of the ABO gene  
A total of 47 samples were used for NGS genotyping of the entire ABO gene including 
flanking regions (Table 2.3). The ABO serological phenotype (A, B, O or AB) was 
provided for all samples and used as a basis for their selection (Table 5.1). Four primer 
pairs were designed using Primer3 and the NCBI database (NCBI, 2016c)(NCBI, 2016c) 
(see section 2.2.4.1, Table 2.3 for more details about the primer pairs), resulting in four 
overlapping amplicons covering the entire ABO gene and outer regions (Figure 5.1). For 
the amplification of the first ABO area (the upstream region, exon 1 and part of intron 1), 
two primer pairs (1A and 1B; section 2.2.4.1) were used. Initially, several samples were 
not successfully amplified by primer pair 1A, which were adapted from the study by 
Huh et al. (2011), likely due to polymorphisms around the primer binding site (section 
5.3.4.2); therefore, primer pair 1B was designed to amplify the rest of samples. For LR-
PCR amplification using these primer pairs (1A or 1B), the Phusion Flash High-Fidelity 
PCR Master Mix (Thermo Scientific, Leicestershire, UK) was used under 
thermocycling conditions adapted from Huh et al. (2011), as shown in Table 2.7 in 
Chapter 2. Amplicons 2, 3 and 4 were amplified using the LongAmp® Hot Start Taq 
Master Mix (New England BioLabs Inc, Herts, UK) under thermocycling conditions 
shown in Table 2.6 in Chapter 2. Figure 5.2 shows examples of PCR amplicons of ABO, 
which were loaded onto 1% agarose gels and separated by electrophoresis (see section 
2.2.4.3). Amplicons were then purified using the magnetic bead technique (section 
2.2.4.4) and subsequently quantified using the Qubit® 2.0 Fluorometer with Broad 
range (BR) assay Kit (InvitrogenTM, Paisley,UK) to ensure the 100 ng concentration 
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Figure 5.1 Four overlapping LR-PCR amplicons covering the entire ABO gene. 
The ABO gene is approximately 20039 bp (according to NCBI GenBank) in size, comprising 7 exons (shown here as boxes) and 6 introns (shown here as a 
fine line). The overlapping amplicons 1A (6260bp) or 1B (7017bp), 2 (9188bp), 3 (10354bp) and 4 (9628bp) cover the entire gene plus the up-/down 
stream flanking regions. The key polymorphisms, most of which encode for a single amino acid change A
1
 (A101) from B (B101) allele (Gly268Ala, 
Leu266Met, Gly235Ser, and Arg176Gly), (1061delC and Pro156Leu) are associated with A
2
 (A102) allele, the 261delG are with O
1 
(O01), which is also 
associated with (O02) allele along with Pro74Ser, Arg63His and Val36Phe. The exons are shown in reverse order here due to the anti-sense direction of the 





Table 5.1 The serology information of all 47 blood samples provided by the National Health Service Blood and Transplant (NHSBT; 
Filton, Bristol UK). * denotes the working sample ID. The ABO001 number, which is the ISBT number assigned for the ABO blood group 
system (Daniels, 2013, Reid et al., 2012), is used here to name the samples accordingly for ABO NGS genotyping. 
Sample 
number 









ABO001.01 3 A ABO001.21 RN O ABO001.41 109 AB 
ABO001.02 4 A ABO001.22 R9 O ABO001.42 111 AB 
ABO001.03 7 A ABO001.23 130 O ABO001.43 112 AB 
ABO001.04 25 A ABO001.24 19 O ABO001.44 114 AB 
ABO001.05 40 A ABO001.25 26 O ABO001.45 115 AB 
ABO001.06 73 A ABO001.26 28 O ABO001.46 118 AB 
ABO001.07 44 A ABO001.27 57 B ABO001.47 119 AB 
ABO001.08 64 A ABO001.28 8 B    
ABO001.09 72 A ABO001.29 60 B    
ABO001.10 RL A ABO001.30 32 B    
ABO001.11 RH A ABO001.31 56 B    
ABO001.12 11 O ABO001.32 62 B    
ABO001.13 17 O ABO001.33 67 B    
ABO001.14 50 O ABO001.34 RP B    
ABO001.15 66 O ABO001.35 R7 B    
ABO001.16 10 O ABO001.36 101 B    
ABO001.17 12 O ABO001.37 103 B    
ABO001.18 29 O ABO001.38 125 B    
ABO001.19 38 O ABO001.39 131 B    







Figure 5.2 Four LR-PCR amplicons covering the whole ABO gene. 
Four LR-PCR amplicons were used to amplify the entire ABO gene for each sample. The amplicons are the product of primer pairs 1A (6260bp) or 1B (7017bp), 2 
(9188bp), 3 (10354bp) and 4 (9628bp). Here, examples of amplicons are shown aligned to the DNA marker.  Amplicon 1A from sample A (the ID of the sample 
was R8, phenotype O) was unsuccessfully amplified, was not used in genotyping, but was successfully amplified from sample B(ABO001.10). Example of 
successful amplification of Amplicons 1B, 2 and 3 are shown. Successful amplification of 2 samples using primer pair 4 is shown. All amplicons were 
electrophoretically separated on 1% agarose gel at 80 V for 1 hour and 40 minutes. 
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5.3.2 NGS of the ABO gene 
5.3.2.1 ABO purified fragmented library  
Following amplicon purification and quantitation, the NGS sequencing libraries were 
fragmented by enzymatic shearing using the Ion Xpress
TM
 Plus Fragment Library Kit 
(section 2.2.4.6). The 4 amplicon-pool (100ng) from each sample were enzymatically 
fragmented for 8 minutes, which enabled a wide fragment size distribution and 
sufficient yield (peak) around 200-300bp. Subsequently, samples were purified using 
SPRIselect® reagent kit (Beckman Coulter, UK) (section 2.2.4.6).  
The outcome of the fragmentation (fragment size distribution) was assessed by the 
Agilent® 2100 Bioanalyzer and Agilent High Sensitivity DNA Kit (Agilent 
Technologies UK Limited). Figure 5.3 illustrates the size distribution outcome of the 
purified fragmented ABO sequencing library.
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Figure 5.3 An electropherogram of a purified fragmented ABO DNA library (consists of a pool of four ABO amplicons). 
An ABO sample was fragmented using the Ion Xpress
TM
 Plus Fragment Library Kit for 8 minutes. A wide fragment size distribution 
can be seen with a peak around 200-300bp (marked by a blue arrow), which is recommended for the 200bp read length on the Ion 
PGM
TM
. The green number (35bp) is the lower marker and the purple number (10380bp) is the upper marker. Results shown were 
obtained using the 2100 Bioanalyzer® instrument. The raw trace from the 2100 Bioanalyzer® instrument is shown in the appendix B. 
 





5.3.2.2 Ligation of barcoded adapters (ABO purified-ligated library) 
Following fragmentation and purification, samples were ligated with barcoded adapters 
(P1 and Ion Xpress
TM 
Barcode X adapter, provided in the Ion Xpress
TM
 Barcode 
adapters Kit), catalysed by DNA ligase. The ligated libraries were then purified using 
SPRIselect® reagent kit before assessing the ligated-purified libraries by Agilent® 2100 
Bioanalyzer and the Agilent High Sensitivity DNA Kit (Agilent Technologies UK 
Limited) (section 2.2.4.9). Figure 5.4 illustrates the size distribution of an ABO sample 
sequencing library after ligation. 
 
5.3.2.3 Size selection 
The ligated libraries were then size-selected to provide a suitable size range (around 
200bp) for the Ion PGM
TM
 Template OT2 200 kit. In the process of sequencing 47 
samples, 3 separate sequencing experiments were conducted, in all of which the 
SPRIselect
®
 was used for size selection (section 2.2.4.10). Figure 5.5 shows an ABO 
sample that was size-selected by SPRIselect
®
. Next, the concentrations of the size-
selected libraries were obtained and calculated using the 2100 Bioanalyzer
®
 instrument 
(section 2.2.4.11) for the purpose of template preparation (section 2.2.5), prior to 
sequencing using the Ion Torrent PGM
TM






Figure 5.4 Two electropherograms of an ABO sample library. 
A) Fragmented-purified library with a peak around 200-300bp. 
B) Fragmented-ligated purified library with the peak shifted to the right (due to adapter ligation, represented 
by an increase in size). 
The green number (35bp) is the lower marker and the purple number (10380bp) is the upper marker. Results 
shown were obtained using the 2100 Bioanalyzer® instrument. The raw trace from the 2100 Bioanalyzer® 
instrument is shown in the appendix B. 
 
A) Fragmented-purified library 






Figure 5.5 An electropherogram of a size-selected ABO sequencing library by SPRIselect
®
. 
An ABO sequencing library was size-selected using SPRIselect
®
 magnetic beads. A peak around 200 bp (215-227bp) was achieved. 
The green number (35bp) is the lower marker and the purple number (10380bp) is the upper marker. Results shown were obtained 





5.3.3 NGS data quality control 
5.3.3.1 Sequencing data summary report  
Sequencing of the 47 ABO samples was conducted in 3 separate experiments using Ion 
PGM
TM
, the raw data of which was then processed by the Torrent suite server, to 
produce a summary run by Torrent Suite
TM
 Software Version 4.4. The average total 
usable reads generated from the 47 ABO samples was 3,399,21, with a mean coverage 
depth of 650X. A summary of the sequencing report is shown in Table 5.2 and a 
representative ABO sequencing experiment brief report is depicted in Figure 5.6. In this 
sequencing report, the ISP loading density for the 316
TM
 chip was 74%, with 26% of the 
wells remaining empty. The total number of reads usable for downstream analysis was 
~3.7 million. These reads were obtained following well classification and made up 80% 
of the total reads containing library ISPs. Also, these ISPs underwent filtration to 
remove polyclonal ISPs (13%), test fragments (1%), adapter dimer (3%) and low 
quality ISPs (5%). The mean read length was 145bp (Figure 5.6). 
Table 5.2 A summary of the Ion PGM
TM
 sequence output for the 47 ABO samples, 
processed in 3 separate runs. *Samples were not genotyped due to issues, such as 











































Figure 5.6 A summary report for a single ABO library sequencing run. 
A) 74% of chip wells contained the ISPs. The colour represents the loading percentage of ISP across the 316
TM
 chip  plate surface. 
 B) The total number of usable reads is 3,723,345, which are provided after trimming and filtration from empty wells, non-templated, polyclonal reads and low 
quality ISPs. 80% of ISPs was obtained by dividing these reads by the total number reads containing the library ISPs (4,648,719). The live/enrichment 
percentage is 100%, which indicates that ISPs contain a strong sequence signal from the test fragment and template library. 
C) A histogram shows a mean reading length of 145bp. The read count is displayed in the y-axis, while the read length, in bp, is 
     shown on the x-axis. 
 




5.3.3.2 NGS data quality control 
The quality of NGS data is important for further analysis, which includes genotyping. 
The quality and the mean coverage depth (~650X) of libraries were analysed using the 
Ion Torrent Suite
TM
 plugins: coverage analysis and FastQC. The mean coverage depth 
was high (650X), which increased the confidence for variant calling. The per base and 
per sequence quality were in turn assessed by FastQC according to the Phred score, 
which is a measure logarithmically related with the base calling error probability and is 
used to assess the quality of bases generated from automated sequencing (Ewing et al., 
1998).  
 
5.3.3.2.1 Per base sequence quality  
Figure 5.7 demonstrates the ABO sequence quality (the base pairs sequenced) according 
to the Phred score. The mean quality score here was ~29-30, which then gradually 
decreased towards the end of sequencing; this phenomenon has been described before as 
a normal observation in high-throughput platforms (Andrews, 2016). This mean quality 
score range indicated a high base call accuracy (> 99% to 99.9%) with a probability of 1 
in 1000 of incorrect base call. The quality of the samples in all three runs was 




Figure 5.7 The Phred quality score across all bases of a single representative ABO sample. 
The x-axis represents the position of bases in the read, while the Phred score is displayed on the y-axis. The three-colour background divides 
the y-axis into three regions of different quality levels, according the Phred score: very good (green), reasonable (orange) and poor quality 
base calling (red). The yellow boxes represent a BoxWhisker-type plot for each position with a 25-75% interquartile range. Upper and lower 
whiskers represent the 10% and 90% points. The blue line represents the mean value of the base call quality (29-30), which indicates ~ 99.9% 













5.3.3.2.2 Per sequence quality score 
The quality of the sequences was also assessed using FastQC (see Figure 5.8 for an 
example). Here, the mean sequence quality of ABO was high, with most sequence reads 
achieving a Phred quality score of 30, in accordance with the previous section 
(5.3.3.2.1). The quality of all three ABO runs was comparable (above 99% base call 
accuracy, according to the Phred score; Table 5.3). As a result, these high quality 
parameters, along with the coverage depth, provide confidence in the ABO NGS data for 
further analysis. 
 
Table 5.3 Summary of the sequencing quality of the three ABO NGS experiments. 
All runs achieved a base call accuracy of ~ 99.9%.  





 29-30 29-30 
2
nd
 29-30 30 
3
rd
 29-30 30 




Figure 5.8 The mean quality score of ABO sequences generated from a single sample. 
The mean quality score (Phred score, x-axis) of the sequences across the number of reads (y-axis) is shown. The mean 
quality score for most of the sequences was 30 (Phred score), which indicates high quality of generated reads with an 















5.3.4 NGS sequence visualisation 
The IGV software (version 2.3) was used to visualise the ABO sequencing data, which 
was aligned to the ABO reference sequence in the human genome (hg19) and associated 
with the mRNA accession number (NM_020469.2). Different aspects were assessed 
using this tool: the integrity of the sequence (full coverage across the ABO gene) and the 
coverage depth. Moreover, other obtained genomic information included mutations, 
such as SNPs, deletions, insertions, as well as the zygosity and chromosomal location of 
mutations, in addition to the correlation with amino acid locations. This information, 
together with genotyping software, such as Ion Reporter
TM
, enables a comprehensive 
and efficient analysis of ABO. Figure 5.9 illustrates an ABO sample (phenotyped as A, 
genotyped as A201(ABO*A2.01)/O75) sequence of the entire gene and flanking regions, 
which reflects the integrity of the library preparation and the primer specificity.  
  
ABO 
Figure 5.9 An IGV image illustrating the full coverage of the sequencing data from 
one ABO sample. 
The reference ABO gene is fully covered and aligned by the sequencing reads. The coverage 
depth is shown on top (which appears  in the software when the arraow is pointed at it). 
Coloured bars represent SNPs across the gene. The complete coverage enables the analysis of 




5.3.4.1 Observations on the ABO reference sequence  
The analysis of the ABO sequence data, including the visualisation, revealed a number 
of observations with regards to the ABO reference sequence. The ABO reference gene 
sequence is displayed from right to left (an anti-sense direction), which should be taken 
into account when analysing SNPs. Figure 5.10 is an example issue the anti-strand ABO 
reference gene sequence poses when analysing the consensus 467C>T missense 
mutation, which encodes the amino acid change Pro156Leu. In the IGV, the SNP is 
observed as G>A instead of C>T, as a result of the anti-sense direction of the ABO 
sequence, which had to be flipped to reveal the reference nucleotide (C). Consequently, 
the mutation codon needs to read in the opposite direction (right to left) in the reverse-
complement sequence. This issue was overcome manually (Figure 5.10) and the 
genotyping software Ion Reporter
TM
 provided a neutralised annotation (section 5.3.5). It 
was also noticed that the ABO reference sequence derived from the human genome 
(hg19) was assembled from regions of two O allele sequences (contigs). Exons 1 to 5 
seemed to correspond to the ABO*O.01.02 (O02/O
1v
) allele as the amino acids Phe36, 
His63 and Ser74 were encoded, in contrast to the suggested consensus allele 
ABO*A1.01 (A101) encoding for Val36, Arg63 and Pro74. On the other hand, exons 6 
and 7 represent the sequence of allele ABO*O.01.01 (O01/O
1
), as there was a (261G) 
deletion in exon 6 of the reference sequence from hg19, while exon 7 was identical to 
that of the ABO*A1.01 allele. Consequently, an insertion of G at this location 
(chr9:136132908-136132909) was noticed in samples carrying the A and B alleles, 
while samples with the O01 allele showed no change from the reference sequence. The 
same was seen with the ABO reference sequence from the human genome reference 
sequence (hg38), where there was a 261G deletion in exon 6.  Table 5.4 lists the 
differences between the ABO reference sequence and sequences of hg19 and the 
consensus ABO*A1.01 (A101) RefSeqGene, NG_006669.1. Figure 5.11 shows an 
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Figure 5.10 IGV visualisation analysis of ABO sequencing data of a single sample. 
A) The orientation of the ABO reference gene is right to left (against the direction of the 
chromosome). Exon 7 is shown on the left through to exon 1 on the right. 
B) A heterozygous SNP at the chromosomal location chr9:136131651 is shown as 467G>A, 
whereas the consensus is 467C>T. This is because the ABO reference sequence is illustrated 
as anti-sense strand.  
C) The reference sequence was intentionally complemented to reveal the nucleotide in the 
sense strand, the consensus i.e. nucleotide C. The mutation is C>T but the sequencing data 
cannot be visually altered so the T cannot be shown, the mutation still looks like A.  Note: 
the codon sequence should also be read from right to left (CCG Pro) instead of (GCC Ala). 









Figure 5.11 illustrations regarding the ABO reference sequence.  
A) an alignment of the ABO reference sequence from hg19 (Query, NC_000009.11: 
136130563-136150630) and the (sbjct, NG_006669.1) consensus NCBI own reference 
sequence (ABO*A1.01) revealed a G deletion (shown as a C here, due to anti-sense direction) 
in the query,  represented by the red arrow. 
B) A G deletion in the ABO reference sequence from the hg38 (query, NC_000009.12: 
133255176-133275214) was observed when aligned with the NCBI reference sequence 
(RefSeqGene, NG_006669.1).  
The alignment was conducted using the NCBI Blast tool.  
C) An IGV visualisation analysis of an ABO sample (with serological phenotype AB) shows  
homozygous insertion of G (denoted by purple bars) at the chromosomal location 
chr9:136132908-136132909. The insertion is noticed as the reference sequence lacks the G at 
this location, which represents the sequence of O01 allele.  Conventionally, the 
261Gdeletion (O01) leads to a frame shift that alters the amino acid sequence from 88 







Table 5.4 The differences in polymorphisms between the reference sequence in hg19 and the agreed consensus sequence (ABO*A1.01) from the 
NCBI.  
 A) In exon 3, the amino acid Phe36 is seen in the hg19 ref sequence, His63 in exon 4 and Ser74 in exon 5. The opposite was found in the consensus 
sequence from NCBI (RefSeqGene, NG_006669.1). *Nucleotide 261G was found in exon 6 of the consensus sequence, but was absent in the reference 
sequence of both hg 19 and 38 (thus, an insertion is seen when aligning samples carrying A and B alleles. B) The reference sequences from hg 19 and 38 
show His instead of Thr at location 99 due to single nucleotide shift to the right as a result of the G deletion in the hg19 reference sequence (ACA/Thr to 
TAC/His). *** The location of amino acids were slightly shifted in exon 7 but were neutralised using the Seattle online tool. In addition, the nucleotide 
numbers were changed by one nucleotide in exon 7. As a result, the reference sequence in hg 19 was suggested to be mixed between O02(ABO*O.01.02) 




  Exon 2 Exon 3 Exon 4 Exon 5 Exon 6         Exon 7 














88fs 118 stop 261delG 
Pro354fs/1061delC, Leu310 930G>A, 
Tyr309Cys 926A>G, Val277Met/829G>A, 
Gly268Ala 803G>C, Gly268Arg 802G>A, 
Leu266Met 796C>A, Pro257   771C>T, 
Ile256  768C>A, Gly235Ser 703G>A, Pro227 
681G>A, His219 657C>T, Phe216Ile 
646T>A, Arg199Cys 595C>T, Trp181stop 
542G>A, Arg176Gly 526C>G, Pro156Leu 













Pro88fs 118 stop 
261insG* 
His99Arg 296A>G ** 
 The amino acid locations slightly shifted, 
although neutralised*** 
 All nucleotide positions minus 1, e.g. 
Val277Met/828G>A, Gly268Ala 802G>C, 






5.3.4.2 Observations on the ABO amplicons  
Four primer pairs (4 amplicons) were used to amplify the ABO gene; however, 
amplicon 1A, which covered the region ~5kb upstream of and including exon 1, and 
part of intron 1, was not amplified in a number of samples of different phenotypes and 
thus alleles (Figure 5.12). As a result, another amplicon (primer pair/1B) was designed 
in order to overcome this issue, which lead to successful subsequent amplification of 
samples processed in the runs after the 1
st
. In the 1
st
 run, all samples were sequenced by 
NGS, including those not amplified by primer pair 1A, to establish why there was 
failure to amplify in certain samples. The IGV visualisation investigation revealed SNPs 
around the 1A primer binding site, which may have accounted for the amplification 
failure. Table 5.5 lists SNPs from samples of different ABO genotype/phenotype, some 
of which were not amplified by 1A.  ABO samples carrying the A, B alleles revealed the 
SNP A>G (ch9:136149500) at the binding site of the 13
th
 nucleotide (T) of the reverse 
primer. In addition, one B sample, one AB sample and O phenotype samples also 
displayed a SNP, T>A located at ch9:136155720, at the first nucleotide adjacent to the 
3' end of the forward primer (Table 5.5). With regard to amplicon 2, at least five 
samples of AB and 1 sample O phenotype were not successfully amplified, despite there 





Table 5.5 The SNPs found around the 1A primer pair binding sites in examples of ABO 
samples with different phenotype. 
Examples of ABO samples that showed unsuccessful PCR amplification of the amplicon 1A and 
carry SNPs that may have hindered amplification. SNP 136149500 (A>G) was found in samples 
of phenotype/genotype A, B and AB, while SNP 136155720 (T>A), at the 1
st
 nucleotide 
adjacent to the 3’ end of the reverse primer was found in samples of B, AB and O phenotype. * 
3/4 B and 2/2 A samples were NGS sequenced successfully with primer pair 1B. Het, 


















4 4 Het 1 Het 
A*/(A102/O02) and 
(A201/A201)* 
2 1 Het, 1 Hom none 
AB 1 1 Het 1 Hom** 
O 2 none 2 Hom 
     
Amplified 
B 5 None none 
A 3 None none 
O 5 None none 
Figure 5.12 IGV image of an ABO sample of phenotype O where coverage of areas 
by amplicon 1A failed. 
Part of intron 1- exon 1 and upstream area covered by the 1A primer pair showed no 
coverage of the sequence. This is due to failed PCR amplification, likely as a result of 
SNPs present at the primer binding sites.   
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5.3.5 Variant analysis and genotyping   
The sequencing data generated from the Ion PGM
TM
 was analysed using a combination 
of tools to enable accurate variant annotation. The Ion Suite
TM
 plugin Variant Caller 
was used for mutation annotation, analysis of zygosity and production of VCF files, 
which were used in other variant annotation software for confirmation. The VCF files 
were uploaded to the online annotation online platform, SeattleSeq Annotation 137, 
which provided a wide range of information based on the NCBI database, including 
mutation chromosomal location, type of mutation, the number of nucleotides and the 
amino acid change and the rsID for a known mutation in the NCBI dbSNP database. 
Most of the variant analysis was conducted using the Ion Reporter
TM
 5.0 software 
(which only supports hg19 so far) to which the VCF files were also uploaded. This 
software provides extensive information, such as mutation type (single nucleotide 
variant/SNP or indel), mutation effect (missense or synonymous), mutation location 
(exon or intron), name of the gene, chromosomal location and rsID in dbSNP. The files 
can also be converted into different formats, such as PDF or Excel sheets. Moreover, 
this software overcame the aforementioned issues regarding anti-sense direction SNPs 
visualised using the IGV and provided the consensus SNP based on the NCBI database, 
which greatly simplified variant analysis. Regarding the issue of the nucleotide and 
amino acids shift arising from a shift in the O allele reference, the rsID and 
chromosomal location of the mutation was used to obtain the consensus order from the 
NCBI database, which was for genotyping of ABO samples in this study.  Figure 5.13 
shows part of the report from analysis of a sample with B phenotype and 
B101(ABO*B.01)/O01(ABO*O.01.01) genotype, generated by the the Ion Reporter
TM
 







Figure 5.13 A section of the report generated by the Ion Reporter
TM
 showing genotyping analysis of an ABO sample with B 
phenotype and B101(ABO*B.01)/ O01(ABO*O.01.01) genotype. 
The highlighted polymorphism is used as an example 
A) The chromosomal location of each variant, the type of mutation, reference and allelic nucleotide and zygosity are shown. The SNP or SNV at 
chr9:136131322 is shown as G>T heterozygous, which is different from the consensus SNP in the NCBI database. 
B) Gene name, reference number, location of the mutation (exonic or intronic), the mutation effect, exon number and amino acid change are 
shown. Note that the SNP (marked) has been converted to the consensus SNP C>A.  
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5.3.6 ABO genotyping results from NGS  
Extensive genotyping of the ABO gene using NGS allows identification of known 
common and rare mutations and discovery of novel mutations, which offers significant 
advantage over array based methods. The genotyping results and the interpretations of 
the SNPs and the amino acid changes were conducted according to the consensus 
reference sequence in the NCBI database (as if the NGS data were aligned against A101 
(ABO*A1.01)) in order to be in line with conventional analysis. The results from 47 
sequenced samples revealed various mutations, including SNPs and indels, both in 
exons (one novel) and introns of ABO. The genotypes of samples were then correlated 
with the phenotypes determined by serology (NHSBT). It is worth noting that the 
terminology used to describe ABO alleles here will be mainly the same as that used in 
dbRBC (Blood Group Antigen Gene Mutation Database), only for simplification 
reasons, for example A101 for ABO*A1.01 ISBT name, although in some cases the 
latter will be used for clarification. 
 
5.3.6.1 ABO mutations in exons   
NGS data revealed several mutations in exons of different ABO alleles, including rare 
and novel SNPs, in various ABO phenotypes (A, B, O and AB) (Table 5.6). The 
provided phenotypes of the samples sequenced were as follows: 11 A, 13 B, 15 O and 8 
AB. The NGS genotyping data matched these phenotypes and, in addition, offered more 
detail on predicted A and A 2 phenotype. 
Regarding samples of A phenotype, 9/11 samples were heterozygous with O alleles 
(Table 5.6 A). The common A101 allele was heterozygous with O01 (A101/O01) in one 
sample and with O26 in two samples; the latter allele is similar to O01 but features a 
silent mutation (768C>A) (Hosseini-Maaf et al., 2005, Roubinet et al., 2001). Two 
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samples carried the A101 allele together with the common O02 allele, which carries 
nine SNPs across exons 3, 4, 5, 6 and 7, in addition to the 261 G deletion (Reid et al., 
2012) (Table 5.6). An allelic combination of A101/O063 was found in one sample; the 
O63 allele is rare, according to dbRBC (BGMUT), and contains a unique SNP 103G>A 
(the frequency of which is 0.02 % in Europe), according to the NCBI database and the 
1000 genomes (NCBI, 2016a). This allele is listed in the Antigen Gene Mutation 
Database (BGMUT, dbRBC) by Stabentheiner et al. in an unpublished report  as stated 
in BGMUT). The molecular basis of the O63 allele is similar to that of the O02 allele, 
except with the addition of a missense 103G>A SNP encoding amino acid change 
Gly35Arg. One sample was found to carry the A102 allele with the 467C>T SNP 
(Pro156Leu), which is common among Asians (Reid et al., 2012). Four samples carried 
the A201 allele (1 homozygous and 3 heterozygous), which differs from the A101 allele 
by a 467C>T SNP (Pro156Leu) in exon 7 and a 1061C deletion codon directly adjacent 
to the translation stop codon (TGA). Consequently, the gene product of this mutation 
(GTA) has an extra 21 amino acids at the C-terminus, reflecting disruption of the stop 
codon (Yamamoto et al., 1992). Three samples were heterozygous for A201; one carried 
the A101 allele and two carried O75 and O03, respectively. The O03 allele lacks the 
216G deletion but contains 5 SNPs, 4 of which lead to amino acid changes in exon 7 
(Gly268Arg and Arg176Gly) and exons 5 and 2 (Pro74Ser and Arg18Leu, respectively) 
(Reid et al., 2012). The O75 allele is similar to the O02 allele, with the addition of a rare 
SNP (542 G>A; 0.02% frequency in Europe, according to NCBI/1000 genome) which 
changes Trp181 into a stop codon. As a result, the suggested phenotypes of A samples 
according to the genotyping were:  8 A1 and 3 A2.  
With regard to the samples of O phenotype, several O alleles were found.  The O01 
allele was homozygous in 6/15 samples and heterozygous in 3 samples; the O02 allele 
was homozygous in one sample and heterozygous in one sample; the O03 allele was 
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heterozygous in two samples; and the O26 allele was heterozygous in two samples. 
Other rare O alleles were found in heterozygous samples: O28, which is similar to O01 
except for a rare (926A>G, exon 7) SNP (Roubinet et al., 2001) with frequency of a 
little over 0% in Europe (according to NCBI); O63; O73, which differs from O02 by 1 
missense SNP (595 C>T/Arg199Cys) in exon 7 with 220C (not carrying the O02 SNP 
220C>T), and O75 allele. Interestingly, a suggested novel O allele was found in one 
sample with a heterozygous missense SNP 482G>A (Arg161His) in exon 7. Although 
this SNP has been listed and validated in NCBI dbSNP, with frequency of 0% in Europe, 
it has not been allocated to an ABO allele as it is not listed in the dbRBC database 
(BGMUT) of 381 alleles (accessed July 2016).  
In all the 13 B phenotype samples, B101 was found heterozygous, which differs from 
the A allele by seven SNPs: in exon 6, 526C>G (Arg176Gly); in exon 7 703G>A 
(Gly235Ser), 796C>A (Leu266Met) and 803G>C (Gly268Ala). The SNPs 297A>G 
(exon 6), 657C>T and 930G>A (exon 7) are silent mutations, while the others are 
missense mutations. Of the 13 B samples, 9 were heterozygous for the O01 allele, 2/13 
were heterozygous with O02 and the rest carried O63 and O75.  
Regarding samples of AB phenotype (8/47), the genotypes for 7 were A201/B101 and 
one was A101/B101, leading to the 7 samples of A2B phenotype and 1 of A1B 
phenotype.  
These mutations observed from the NGS genotyping required no further confirmation as 
data showed high coverage depth (650X) and quality; moreover, all identified mutations 
were reported and validated in the NCBI (dbSNP) with corresponding alleles listed in 








Table 5.6 NGS genotyping of 47 samples of different ABO phenotypes. (Note: 
samples of the same phenotype were grouped in tables in the next pages). 
The 47 samples (all with provided serological phenotypes) were sequenced by ABO-
specific LR-PCR. The samples were ordered according to the phenotype: as A, O, B and 
AB. The genotyping results, shown for all 7 exons of the ABO gene, revealed several 
rare O alleles, such as O26, O28, O63, O73 and O75, in addition to a possible novel O 
allele (found in an O phenotype sample) with a missense SNP 482G>A (Arg161His). 
The underlined mutations relate to those underlined alleles. The NHSBT provided and 
predicted phenotypes according to the genotyping are shown, which matched apart from 
the more detailed phenotype of A2 and A2B, which were revealed by NGS genotyping. 
The allele names were in accordance with dbRBC and ISBT (in brackets). The 
















Possible Genotype Exon 2 Exon 3 Exon 4 Exon 5 Exon 6         Exon 7 
01,02 A/A1 A101(ABO*A1.01)/O26     88fs 261delG (Het) Ile256  768C>A (Het) 






Arg63 189C>T (Het), 








Pro257 771C>T (Het), 
Pro227 681G>A (Het), 
Phe216Ile 646T>A (Het) 
05 A/ A1 
A101(ABO*A1.01)/ 
O01(ABO*O.01.01) 
    261delG (Het)  






Arg63 189C>T (Het), 








Pro257 771C>T (Het), 
Pro227 681G>A (Het), 
Phe216Ile 646T>A (Het), 
Pro156Leu 467C>T (Het) 





Arg63 189C>T (Hom), 








Pro257 771C>T (Het), 
Pro227 681G>A (Het), 




     
1061delC (Het), Pro156Leu 
467C>T (Het) 
09 A/A2 A201(ABO*A2.01)/O75  
Val 36Phe 
106G>T (Het) 
Arg63 189C>T (Het), 









Pro257 771C>T (Het), 
Pro227 681G>A (Het), 
Phe216Ile 646T>A (Het), 
Trp181stop 542G>A (Het), 




     
1061delC (Hom), 
Pro156Leu 467C>T (Hom) 












1061delC (Het), Pro156Leu 
467C>T (Het), Gly268Arg 










Possible Genotype Exon 2 Exon 3 Exon 4 Exon 5 Exon 6         Exon 7 
12 O O63/O (NOVEL)  









Thr99 297A>G (Het), 
88fs 261delG (Hom) 
Val277Met/829G>A (Het), 
Pro257 771C>T (Het), 
Pro227 681G>A (Het), 
Phe216Ile 646T>A (Het), 







    88fs 261delG (Hom)  












Thr99 297A>G (Het), 
88fs 261delG (Hom) 
Val277Met/829G>A (Het),  
Pro257 771C>T (Het), 
Pro227 681G>A (Het), 
Phe216Ile 646T>A (Het), 
Trp181stop 542G>A (Het) 













Thr99 297A>G (Hom), 
88fs 261delG (Hom) 
Val277Met/829G>A (Hom), 
Pro257 771C>T (Hom), 
Pro227 681G>A (Hom), 
Phe216Ile 646T>A (Hom), 
Arg199Cys 595C>T (Het) 










Thr99 297A>G (Het), 
88fs 261delG (Hom) 
Val277Met/829G>A (Het),  
Pro257 771C>T (Het), 
Ile256  768C>A (Het),  
Pro227 681G>A (Het), 











Thr99 297A>G (Het), 
88fs 261delG (Het) 
Tyr309Cys 926A>G (Het) 
Gly268Arg 802G>A 












Thr99 297A>G (Het), 
88fs 261delG (Het) 
Gly268Arg 802G>A (Het) 


















Thr99 297A>G (Hom), 
88fs 261delG (Hom) 
Val277Met/829G>A (Hom), 
Pro257 771C>T (Hom), 
Pro227 681G>A (Hom), 










Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 
27, 28, 29, 30, 






   
Thr99 297A>G 
(Het), 88fs 261delG 
(Het) 
Leu310 930G>A (Het), Gly268Ala 
803G>C (Het), Leu266Met 796C>A 
(Het), Gly235Ser 703G>A (Het), 






Val 36Phe 106G>T (Het), 








(Hom), 88fs 261delG 
(Het) 
Leu310 930G>A (Het), 
Val277Met/829G>A (Het), 
Gly268Ala 803G>C (Het), 
Leu266Met 796C>A (Het), Pro257 
771C>T (Het), 
Gly235Ser 703G>A (Het), 
Pro227 681G>A (Het), His219 
657C>T (Het), 

















Leu310 930G>A (Het), 
Val277Met/829G>A (Het), Gly268Ala 
803G>C (Het), Leu266Met 796C>A 
(Het), Pro257 771C>T (Het), 
Gly235Ser 703G>A (Het), Pro227 
681G>A (Het), His219 657C>T (Het), 
Phe216Ile 646T>A (Het), Trp181stop 
542G>A (Het), Arg176Gly 526C>G 
(Het) 
 












(Hom), 88fs 261delG 
(Het) 
Leu310 930G>A (Het), 
Val277Met/829G>A (Het), 
Gly268Ala 803G>C (Het), 
Leu266Met 796C>A (Het), Pro257 
771C>T (Het), 
Gly235Ser 703G>A (Het), Pro227 
681G>A (Het), His219 657C>T (Het), 











Possible Genotype Exon 2 Exon 3 Exon 4 Exon 5 Exon 6         Exon 7 
40, 41, 42, 43, 








Leu310 930G>A (Het), 
Gly268Ala 803G>C (Het), 
Leu266Met 796C>A (Het), 
Gly235Ser 703G>A (Het), His219 
657C>T (Het), Arg176Gly 







    
Thr99 297A>G 
(Het) 
Leu310 930G>A (Het), 
Gly268Ala 803G>C (Het), 
Leu266Met 796C>A (Het), 
Gly235Ser 703G>A (Het), His219 
657C>T (Het), Arg176Gly 
526C>G (Het),  
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5.3.6.2 ABO mutations in introns    
NGS genotyping revealed all existing ABO gene mutations, including those in introns 
and flanking regions. This may be useful in studies of allele evolution and forensics for 
better resolution of the molecular basis of the ABO allele. A significant number of 
intronic SNPs and indels were found, with an average of 74 mutations in samples of A 
phenotype, 59 in O, 79 in B and 96 in AB. Correlation of these intronic mutations with 
the allele-defining exonic SNPs in our samples was challenging, especially when this 
task was carried out mostly manually. The reason for this was the small number of 
samples carrying homozygous alleles: 1 (A201/A201), 6 O01 and 1 O02. Table 5.7 lists 
the intronic mutations analysed across the ABO gene. The analysis of the intronic 
mutations was (green for homozygous match the reference, orange homozygous 
different and crossed blue heterozygous). The reference sequence is suggested to 
represent both O01 and O02, which was seen in intronic and exonic mutations. Aligning 
the samples with homozygous O alleles (O01 or O02) (Table 5.8) showed this 
phenomenon, as in intron 4 there were insertions of a C nucleotide and an extra 13bp at 
chromosomal positions chr9:136133583 and 136135138-chr9:136135150, respectively. 
While this region of the reference sequence was in concordance with the O02 allele, the 
sample of O02/O02 genotype showed no difference. In contrast, O01/O01 samples 
showed a homozygous deletion which was not shown in the reference sequence. There 
was also a CCC insertion at chr9:136133381-83 in intron 5 along with intronic SNPs 
within intron 2-5 and intron 6-7 (Table 5.7 and 5.8). From Table 5.8, it can be seen that 
there is correlation of intronic SNPs across the gene, especially in introns 3 to 6, with 
homozygous samples containing O01 and O02 alleles, while sample ABO001.14 
(O01/O75) represented the heterozygous sample. On the other hand, an 8 nucleotide 
deletion was detected in chr9:136139908-136139915 in intron 1 in all samples with A 
alleles (A1 and A2) (11 A phenotype samples and 8 AB phenotype samples). Only 
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samples carrying the A allele were different to the reference sequence; samples 
ABO001.8 and .10 were homozygously different as the genotype were (A101/A201 and 
A201/A201, respectively) (Table 5.7).  With regards to O alleles, the pattern of the 
intronic SNPs show similarity of O26 and O28 alleles heterozygous with O01, while 
O63, -68, -73, and -75 were similar to O02 (Table 5.7), which illustrates the benefit of 
this approach in analysing the evolution of ABO alleles. A 22 bp deletion was found in 
samples carrying the A201 allele (homozygous in samples ABO001.08, .10 and .11) and 
heterozygous in sample ABO001.09). All samples the with AB phenotype (7 A2B and 1 
A1B) were homozygous for this deletion, which also applies to 2 intronic SNPs (in chr9: 
136145118 and 13614597 adjacent to this deletion). Nevertheless, this deletion and the 
intronic SNPs were absent in other samples of A, B and O phenotype, which might 
suggest the possibility of an allelic dropout in amplicon 2 during the PCR amplification. 
However, analysis of all 47 samples for polymorphisms around the primer pair sites for 
amplicon 2 showed no visible SNPs, which suggested that the amplification conditions 
might need optimisation.  
The upstream area that includes the CBF/NF-Y transcription factor binding site with 
four (43 bp) repeats about 3.8kb upstream from the start codon was analysed. The 43 bp 
sequence is ACCCCAGCCAATAGGGGAAGGACACAGAAACAGAAACTGCGTT 
(Kominato et al., 1997, Irshaid et al., 1999). The four repeats of the 43 bp sequence 
were all covered  by the NGS sequence data for all samples irrespective of phenotype. 
There were 2 SNPs in the nt. 41 in 2 repeats were inconsistent between different ABO 
alleles. The
 
first repeat appeared to carry C in nucleotide 41 in the reference sequence 
(chromosomal location ch9: 136154433), which suggested to be O02. This is seen in 
sample ABO001.26 with genotype O02(ABO*O.01.02)/O02(ABO*O.01.02) with no 
change from the reference allele (Table 5.9). However, there was no consistency with 
other alleles, A, B and O01 (Table 5.9). Another SNP (G>A), which has been described 
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before (Irshaid et al., 1999) to be carried in A101/A101 or A101/O02 genotype samples, 
was found in 6/11 samples of A phenotype but not with complete consistency as it was 
seen in samples ABO001.03 and .04 samples: these samples are of the same suggested 
genotype (A101(ABO*A1.01)/O02(ABO*O.01.02), but only the latter was heterozygous 
with the SNP. In addition, this SNP was not found in sample ABO001.26, the genotype 
of which (O02/O02) may contradict the association of this SNP with the O02 allele, as 
previously described (Irshaid et al., 1999). This SNP was not found in samples of B 
phenotype, but was heterozygous in 2/8 AB samples (A2B and A1B). This approach 
may thus reveal more specific intronic polymorphisms if applied in more samples with 










Table 5.7 NGS genotyping of 47 ABO samples (all provided with serological 
phenotype) (Note: the table is distributed on the next pages due to its size).  
A graphical illustration of the various mutations found in the ABO samples from 
NGS genotyping. The green represents homozygous resemblance to the reference; 
orange represents homozygous difference to the reference; while the crossed blue 
represents heterozygosity. Polymorphisms in exons are coloured grey, while red 
represents the rare mutation listed in the dbRBC and (NCBI/1000 genome), the rsID 
for which is shown above the polymorphisms. The yellow highlighted line is the 
consensus annotation. The four overlapping amplicons are shown as blue bars on 
the top. Due to the lack of the number of homozygous samples, the correlation study 
of these SNPs with the alleles was challenging.  Larger tables in appendix B. 
248 
 
62641785 62641786 62641788 56392308 8176749 56346931 8176748 8176747 41302905 8176746 8176745 8176744 8176743
frameshiftDeletion Synonymous Missense Missense Missense Missense Missense Synonymous Synonymous Missense
EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7
 Utr-3 down stream Utr-3 down stream Utr-3 down stream 1060_1060delC
chr9:136130669 chr9:136130677 chr9:136130689 chr9:136131057 chr9:136131188 chr9:136131192 chr9:136131289 chr9:136131315 chr9:136131316 chr9:136131322 chr9:136131347 chr9:136131350 chr9:136131415
A>G A>G T>C Pro354fs/1061delC Leu310 930G>A Tyr309Cys 926A>G Val277Met/829G>A Gly268Ala 803G>C Gly268Arg 802G>A Leu266Met 796C>A Pro257   771C>T Ile256  768C>A Gly235Ser 703G>A
(Pro353fs/1060_1060delC)  Leu310 929G>A Tyr308Cys 925A>G (Val276Met/828G>A) Gly267Ala 802G>C Gly267Arg 801G>A Leu265Met 795C>A    Pro257 (770C>T) Ile256  767C>A Gly234Ser 702G>A
NGS NGS
Run POSSIBLE PHENOTYPE POSSIBLE GENOTYPE 
1st ABO001.01 A1 A101(ABO*A1.01)/O26 A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/A G/G
1st ABO001.02 A1 A101(ABO*A1.01)/O26 A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/A G/G
1st ABO001.03 A1 A101(ABO*A1.01)/O02(ABO*O.01.02) A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
1st ABO001.04 A1 A101(ABO*A1.01)/O02(ABO*O.01.02) A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
1st ABO001.05 A1 A101(ABO*A1.01)/O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
2NDRUN ABO001.06 A1 A102(ABO*A1.02)/ O02(ABO*O.01.02) A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
2NDRUN ABO001.07 A1 A101(ABO*A1.01)/O63 A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
2NDRUN ABO001.08 A1 A101(ABO*A1.01)/ A201(ABO*A2.01) A/A A/A T/T C/1061delC G/G A/A G/G G/G G/G C/C C/C C/C G/G
1st ABO001.09 A2 A201(ABO*A2.01)/O75 * A/G A/G T/C C/1061delC G/G A/A G/A G/G G/G C/C C/T C/C G/G
2NDRUN ABO001.10 A2 A201(ABO*A2.01)/ A201(ABO*A2.01) A/A A/A T/T 1061delC /1061delC G/G A/A G/G G/G G/G C/C C/C C/C G/G
2NDRUN ABO001.11 A2 A201(ABO*A2.01)/ O03(ABO*O.02.01) A/A A/A T/T C/1061delC G/G A/A G/G G/G G/A C/C C/C C/C G/G
1st ABO001.12 O O63/O( NOVEL ) A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
1st ABO001.13 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
1st ABO001.14 O O01(ABO*O.01.01)/O75* A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
1st ABO001.15 O O02(ABO*O.01.02)/O73 G/G G/G C/C C/C G/G A/A A/A G/G G/G C/C T/T C/C G/G
2NDRUN ABO001.16 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
2NDRUN ABO001.17 O O26/O68(ABO*O.02.17.1) A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/A G/G
2NDRUN ABO001.18 O O03(ABO*O.02.01)/O28 A/A A/A T/T C/C G/G A/G G/G G/G G/A C/C C/C C/C G/G
2NDRUN ABO001.19 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
2NDRUN ABO001.20 O O01(ABO*O.01.01)/O75* A/G A/G T/T C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G
2NDRUN ABO001.21 O O01(ABO*O.01.01)/ O03(ABO*O.02.01) A/A A/A T/T C/C G/G A/A G/G G/G G/A C/C C/C C/C G/G
2NDRUN ABO001.22 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
3RD ABO001.23 O O01(ABO*O.01.01)/O26 A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/A G/G
3RD ABO001.24 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
3RD ABO001.25 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G
3RD ABO001.26 O O02(ABO*O.01.02)/ O02(ABO*O.01.02) G/G G/G C/C C/C G/G A/A A/A G/G G/G C/C T/T C/C G/G
1st ABO001.27 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.28 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.29 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.30 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.31 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.32 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.33 B B101(ABO*B.01)/ O63 A/G A/G T/T C/C G/A A/A G/A G/C G/G C/A C/T C/C G/A
2NDRUN ABO001.34 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
2NDRUN ABO001.35 B B101(ABO*B.01)/ O75 A/A A/A T/T C/C G/A A/A G/A G/C G/G C/A C/T C/C G/A
3RD ABO001.36 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.37 B B101(ABO*B.01)/ O02(ABO*O.01.02) A/G A/A T/T C/C G/A A/A G/A G/C G/G C/A C/T C/C G/A
3RD ABO001.38 B B101(ABO*B.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.39 B B101(ABO*B.01)/ O02(ABO*O.01.02) A/G A/A T/T C/C G/A A/A G/A G/C G/G C/A C/T C/C G/A
3RD ABO001.40 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.41 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.42 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.43 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.44 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.45 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.46 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01) A/A A/A T/T C/1061delC G/A A/A G/G G/C G/G C/A C/C C/C G/A
3RD ABO001.47 AB/A1B A101(ABO*A1.01)/ B101(ABO*B.01) A/A A/A T/T C/C G/A A/A G/G G/C G/G C/A C/C C/C G/A
Utr-3 down stream
8176742 8176741 8176740 8176739 55727303 7853989 1053878 8176738 8176737 8176736 7873416 7873522 7873634 7873635 8176732 8176731 8176727 2073824 8176726
Synonymous Synonymous Missense Missense Nonsense Missense Missense Missense
EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6
chr9:136131437 chr9:136131461 chr9:136131472 chr9:136131523 chr9:136131576 chr9:136131592 chr9:136131651 chr9:136131636 chr9:136131783 chr9:136131785 chr9:136131846 chr9:136131905 chr9:136132010 chr9:136132012 chr9:136132303 chr9:136132350 chr9:136132570 chr9:136132633 chr9:136132608
Pro227 681G>A  His219 657C>T Phe216Ile 646T>A Arg199Cys 595C>T Trp181stop 542G>A      Arg176Gly 526C>G Pro156Leu 467C>T Arg161His 482G>A G>A A>G A>G A>G A>G A>G T>C A>G C>T T>C G>A
Pro 227(680G>A)    His219 656C>T Phe215Ile 645T>A Arg198Cys 594C>T Trp180stop 541G>A Arg175Gly 525C>G Pro155Leu 466C>T Arg160His 481G>A
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/G T/T A/A C/C T/T G/G
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/G T/T A/A C/C T/T G/G
G/A C/C T/A C/C G/G C/C C/C G/G G/A A/G A/G A/G A/G G/G T/C A/G C/T T/C G/A
G/A C/C T/A C/C G/G C/C C/C G/G G/A A/G A/G A/G A/G G/G T/C A/G C/T T/C G/A
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/G T/T A/A C/C T/T G/G
G/A C/C T/A C/C G/G C/C C/T G/G G/A A/G A/G A/G A/G G/G T/C A/G C/T T/C G/A
G/A C/C T/A C/C G/G C/C C/C G/G G/A A/G A/G A/G A/G G/G T/C A/G C/T T/C G/A
G/G C/C T/T C/C G/G C/C C/T G/G G/G A/A A/A A/A A/A G/G T/T A/A C/C T/T G/G
G/A C/C T/A C/C G/A C/C C/T G/G G/A A/G A/G A/G A/G G/G T/C A/G C/T T/C G/A
G/G C/C T/T C/C G/G C/C T/T G/G G/G A/A A/A A/A A/A G/G T/T A/A C/C T/T G/G
G/G C/C T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/A C/C T/A C/C G/G C/C C/C G/A G/A A/G A/G A/G A/G A/G T/C A/G C/T T/C G/A
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
G/A C/C T/A C/C G/A C/C C/C G/G G/A A/G A/G A/G A/G A/G T/C A/G C/T T/C G/A
A/A C/C A/A C/T G/G C/C C/C G/G A/A G/G G/G G/G G/G G/G C/C G/G T/T C/C A/A
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
G/A C/C T/A C/C G/G C/C C/C G/G G/A A/G A/G A/G A/G A/G T/C A/G C/T T/C G/A
G/G C/C T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
G/A C/C T/A C/C G/A C/C C/C G/G G/G A/G A/G A/G A/G A/G T/C A/G C/T T/C G/A
G/G C/C T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
G/G C/C T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G
A/A C/C A/A C/C G/G C/C C/C G/G A/A G/G G/G G/G G/G G/G C/C G/G T/T C/C A/A
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/A C/T T/A C/C G/G C/G C/C G/G G/A A/G G/G G/G G/G G/G T/C G/G C/T C/C G/A
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/A C/T T/A C/C G/A C/G C/C G/G G/A A/G G/G G/G G/G G/G T/C G/G C/T C/C G/A
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/A C/T T/A C/C G/G C/G C/C G/G G/A A/G G/G G/G G/G G/G T/C G/G C/T C/C G/A
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G A/G T/T A/G C/C T/C G/G
G/A C/T T/A C/C G/G C/G C/C G/G G/A A/G G/G G/G G/G G/G T/C G/G C/T C/C G/A
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/T G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
G/G C/T T/T C/C G/G C/G C/C G/G G/G A/A A/G A/G A/G G/G T/T A/G C/C T/C G/G
Amplicon 4     chr9:136124 605+136134232




2073825 8176720 8176719 8176718 8176717 8176715 8176714 66882853 512770 8176712 641959 641943 517414 626792 625593
 Missense (Synonymous) Frameshift_stop Missense
Intron 6 EXON 6 EXON 6 Intron 5 Intron 5 Intron 5 Intron 5 Intron 5 EXON 5 Intron 4 Intron 4 Intron 4 Intron 4 Intron 4 Intron 4
chr9:136132707 chr9:136132873 chr9:136132908-136132909 chr9:136132957 chr9:136133034 chr9:136133148 chr9:136133178 chr9:136133381-83 chr9:136133506 chr9:136133583 chr9:136133699 chr9:136133714 chr9:136134034 chr9:136134864 chr9:136135096
T>A Thr99 297A>G 88fs 118 261delG G>A C>A A>G C>T WOULD BE INS IN O ALLELE Pro74Ser 220C>T C>Del G>T C>T T>C G>T T>C
His99Arg 296A>G Val87_Pro88fs 118 stop 260_261insG CCC>Del Ser74Pro 220T>C
Pro 74(C/C)This means as in A allele 
T/T A/A (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/A (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A A/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/A A/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/A (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A A/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/A A/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/A INS/INS (G/G) G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A A/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/A INS/INS (G/G) G/G C/C G/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C G/G C/C CCC/DEL C/T C/DEL G/T C/T C/C T/T C/C
T/A A/G no insertion (del/del) G/A C/A A/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A A/G no insertion (del/del) G/A C/A A/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
A/A G/G no insertion (del/del) A/A A/A G/G T/T CCC/CCC C/T C/C G/G C/C T/T G/G T/T
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A A/G no insertion (del/del) G/A C/A A/G C/T CCC/DEL C/C   T/T C/DEL G/T C/T T/C G/T T/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C CCC/DEL C/T C/DEL G/T C/T C/C T/T C/C
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A A/G no insertion (del/del) G/A C/A A/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C CCC/DEL C/T C/DEL G/T C/T C/C T/T C/C
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/A no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
A/A G/G no insertion (del/del) A/A A/A G/G T/T CCC/CCC T/T    C/C C/C G/G C/C T/T G/G T/T
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A G/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A G/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A G/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/G (insG/-) delG/G G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/A G/G (insG/-) delG/G G/A C/A G/G C/T CCC/DEL C/T C/DEL G/T C/T T/C G/T T/C
T/T A/G INS/INS (G/G) G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C G/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C G/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C G/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C A/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
T/T A/G INS/INS (G/G) G/G C/C G/G C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C
Amplicon 3 chr9:136132466
NGS NGS
Run POSSIBLE PHENOTYPE POSSIBLE GENOTYPE 
1st ABO001.01 A1 A101(ABO*A1.01)/O26
1st ABO001.02 A1 A101(ABO*A1.01)/O26
1st ABO001.03 A1 A101(ABO*A1.01)/O02(ABO*O.01.02)
1st ABO001.04 A1 A101(ABO*A1.01)/O02(ABO*O.01.02)
1st ABO001.05 A1 A101(ABO*A1.01)/O01(ABO*O.01.01)
2NDRUN ABO001.06 A1 A102(ABO*A1.02)/ O02(ABO*O.01.02)
2NDRUN ABO001.07 A1 A101(ABO*A1.01)/O63
2NDRUN ABO001.08 A1 A101(ABO*A1.01)/ A201(ABO*A2.01)
1st ABO001.09 A2 A201(ABO*A2.01)/O75 *
2NDRUN ABO001.10 A2 A201(ABO*A2.01)/ A201(ABO*A2.01)
2NDRUN ABO001.11 A2 A201(ABO*A2.01)/ O03(ABO*O.02.01)
1st ABO001.12 O O63/O( NOVEL )
1st ABO001.13 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
1st ABO001.14 O O01(ABO*O.01.01)/O75*
1st ABO001.15 O O02(ABO*O.01.02)/O73
2NDRUN ABO001.16 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.17 O O26/O68(ABO*O.02.17.1)
2NDRUN ABO001.18 O O03(ABO*O.02.01)/O28
2NDRUN ABO001.19 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.20 O O01(ABO*O.01.01)/O75*
2NDRUN ABO001.21 O O01(ABO*O.01.01)/ O03(ABO*O.02.01)
2NDRUN ABO001.22 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
3RD ABO001.23 O O01(ABO*O.01.01)/O26
3RD ABO001.24 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
3RD ABO001.25 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
3RD ABO001.26 O O02(ABO*O.01.02)/ O02(ABO*O.01.02)
1st ABO001.27 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.28 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.29 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.30 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.31 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.32 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.33 B B101(ABO*B.01)/ O63
2NDRUN ABO001.34 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.35 B B101(ABO*B.01)/ O75
3RD ABO001.36 B B101(ABO*B.01)/ O01(ABO*O.01.01)
3RD ABO001.37 B B101(ABO*B.01)/ O02(ABO*O.01.02)
3RD ABO001.38 B B101(ABO*B.01)/ O01(ABO*O.01.01)
3RD ABO001.39 B B101(ABO*B.01)/ O02(ABO*O.01.02)
3RD ABO001.40 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.41 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.42 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.43 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.44 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.45 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.46 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.47 AB/A1B A101(ABO*A1.01)/ B101(ABO*B.01)
111705520 549331 549443 549446 624601 574347 575259 579622 688976 8176696 687621 687289 55876802 673578 672316 149092047
Synonymous Missense Missense Missense Missense
Intron 4 Intron 4 EXON 4 EXON 4 Intron 3 Intron 3 Intron 3 Intron 3 EXON 3 EXON 3 Intron 2 Intron 2 EXON 2 Intron 1 Intron 1 Intron 1
13bp  
chr9:136135138-chr9:136135150 chr9:136135195 chr9:136135237 chr9:136135238 chr9:136135365 chr9:136135659 chr9:136135752 chr9:136136242 chr9:136136770 chr9:136136773 chr9:136137065 chr9:136137106 chr9:136137547 chr9:136137857 chr9:136138125 chr9:136139908-chr9:136139915 
WOULD SEE INS13 IN SOME O ALLELE C>G  Arg63 189C>T  Arg63His 188G>A T>C G>A C>T T>C Val 36Phe 106G>T Gly35Arg 103G>A T>C C>T Arg18Leu 53G>T
13bp Del CGAAGACAGGTGTG/C His63 189T>C His63Arg 188A>G Phe36Val  106T>G Gly35Arg 103G>A Arg18Leu 53G>T C>A C>A CTTTGACGG Del 8 bp/C  ( COULD BE insersion in SOME O allele) 
(GCTTCTGTCCACAC)/G
C/C means no change from Aallele Arg 63 G/G means no change from A allele G/G means nno change from A allele
DEL/DEL    INS13BP/INS13BP C/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP C/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A 8 BP DEL/C
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G C/A C/A 8 BP DEL/C
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G C/A C/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP C/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A 8 BP DEL/C
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G A/A C/A 8 BP DEL/C
G/DEL 13BP (G/INS 13 BP) C/G T/T C/C G/A T/C G/A C/T T/C G/T G/A T/C C/T G/G C/A C/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/DEL (INSERTION IN O REF ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G C/A C/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/DEL (INSERTION IN O REF ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/T C/A C/A 8 BP DEL/C
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/A T/T C/C G/G C/A C/A C/C NO DEL/NO DEL  ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/T C/C G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
C/C         NO DEL C/C T/T  C/C A/A  G/G T/T G/G C/C T/T T/T  G/G G/G T/T C/C G/G C/C C/C C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/T C/C G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/T C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/T C/C G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/T C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
C/C         NO DEL C/C T/T  C/C A/A  G/G T/T G/G C/C T/T T/T  G/G G/G T/T C/C G/G C/C C/C C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/A T/C C/T G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G T/C C/T G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
G/DEL 13BP (G/INS 13 BP) C/G C/T G/A T/C G/A C/T T/C G/T G/G T/C C/T G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE)
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C
DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A C/C A/A T/T C/C G/G  T/T G/G C/C T/T G/G A/A A/A 8 BP DEL/C





























































Run POSSIBLE PHENOTYPE POSSIBLE GENOTYPE 
1st ABO001.01 A1 A101(ABO*A1.01)/O26
1st ABO001.02 A1 A101(ABO*A1.01)/O26
1st ABO001.03 A1 A101(ABO*A1.01)/O02(ABO*O.01.02)
1st ABO001.04 A1 A101(ABO*A1.01)/O02(ABO*O.01.02)
1st ABO001.05 A1 A101(ABO*A1.01)/O01(ABO*O.01.01)
2NDRUN ABO001.06 A1 A102(ABO*A1.02)/ O02(ABO*O.01.02)
2NDRUN ABO001.07 A1 A101(ABO*A1.01)/O63
2NDRUN ABO001.08 A1 A101(ABO*A1.01)/ A201(ABO*A2.01)
1st ABO001.09 A2 A201(ABO*A2.01)/O75 *
2NDRUN ABO001.10 A2 A201(ABO*A2.01)/ A201(ABO*A2.01)
2NDRUN ABO001.11 A2 A201(ABO*A2.01)/ O03(ABO*O.02.01)
1st ABO001.12 O O63/O( NOVEL )
1st ABO001.13 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
1st ABO001.14 O O01(ABO*O.01.01)/O75*
1st ABO001.15 O O02(ABO*O.01.02)/O73
2NDRUN ABO001.16 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.17 O O26/O68(ABO*O.02.17.1)
2NDRUN ABO001.18 O O03(ABO*O.02.01)/O28
2NDRUN ABO001.19 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.20 O O01(ABO*O.01.01)/O75*
2NDRUN ABO001.21 O O01(ABO*O.01.01)/ O03(ABO*O.02.01)
2NDRUN ABO001.22 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
3RD ABO001.23 O O01(ABO*O.01.01)/O26
3RD ABO001.24 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
3RD ABO001.25 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
3RD ABO001.26 O O02(ABO*O.01.02)/ O02(ABO*O.01.02)
1st ABO001.27 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.28 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.29 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.30 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.31 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.32 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.33 B B101(ABO*B.01)/ O63
2NDRUN ABO001.34 B B101(ABO*B.01)/ O01(ABO*O.01.01)
2NDRUN ABO001.35 B B101(ABO*B.01)/ O75
3RD ABO001.36 B B101(ABO*B.01)/ O01(ABO*O.01.01)
3RD ABO001.37 B B101(ABO*B.01)/ O02(ABO*O.01.02)
3RD ABO001.38 B B101(ABO*B.01)/ O01(ABO*O.01.01)
3RD ABO001.39 B B101(ABO*B.01)/ O02(ABO*O.01.02)
3RD ABO001.40 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.41 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.42 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.43 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.44 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.45 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.46 AB/A2B A201(ABO*A2.01)/ B101(ABO*B.01)
3RD ABO001.47 AB/A1B A101(ABO*A1.01)/ B101(ABO*B.01)
673578 672316 149092047 643434 574311 494242 2769071 57738738 677355 476410 505922 566183 568203 552148 651007
Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 UPSTREAM ~2KB UPSTREAM ~2KB UPSTREAM ~3KB UPSTREAM ~4KB
 
chr9:136137857 chr9:136138125 chr9:136139908-chr9:136139915 chr9:136142355 chr9:136144110 chr9:136145118 chr9:136145974 chr9:136145994-chr9:136146015 chr9:136146046 chr9:136148368 chr9:136149229 chr9:136151198 chr9:136151445 chr9:136153481 chr9:136153875
C>A C>A CTTTGACGG Del 8 bp/C  ( COULD BE insersion in SOME O allele) C>T C>T G>A T>C22 bp DelAAGAAGGGAAATTAATAAATATT/A ( In O allele you would see insertion)C>T C>G A>G T>C T>G A>G G>A
A/ A/A 8 BP DEL/C C/T T/T G/G T/T NO DEL/NO DEL C/C C/C A/G C/C G/G G/G G/G
A/ A/A 8 BP DEL/C C/T T/T G/G T/T NO DEL/NO DEL C/C C/C A/G C/C G/G G/G G/G
C/A C/A 8 BP DEL/C C/T C/C G/G T/T NO DEL/NO DEL C/C C/C A/A T/C T/G A/G G/G
C/A C/A 8 BP DEL/C C/T C/C G/G T/T NO DEL/NO DEL C/C C/C A/G T/C T/G A/G G/A
A/A A/A 8 BP DEL/C C/T T/T G/G T/T NO DEL/NO DEL C/C C/C A/G C/C G/G G/G G/G
A/A C/A 8 BP DEL/C C/T C/C G/G T/T NO DEL/NO DEL C/C C/C A/G T/C T/G A/G G/A
C/ C/A 8 BP DEL/C C/T C/C G/G T/T NO DEL/NO DEL C/C C/C A/G T/C T/G A/G G/A
A/A A/A 8 BP DEL/DEL (INSERTION IN O REF ALLELE) T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/A
C/A C/A 8 BP DEL/C C/T C/T G>A T/C A/22BP DEL (MEANS INS IN A ALLELE (A2) C/T C/G A/G T/T T/T A/A G/G
A/A A/A 8 BP DEL/DEL (INSERTION IN O REF ALLELE) T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
C/A C/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G A/G C/C G/G G/G G/A
C/A C/A C/C NO DEL/NO DEL  ( MEANS INS IN O ALLELE) C/C C/C G/G T/T NO DEL/ NO DEL C/C C/C A/A T/C T/G A/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C G/G A/A C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C C/G A/A C/C G/G G/G G/G
C/C C/C C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C C/C G/G T/T NO DEL/ NO DEL C/C C/C A/A T/T T/T A/A G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C C/C A/G C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C C/C G/G T/T NO DEL/ NO DEL C/C C/C A/A T/C T/G A/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C C/C A/A C/C G/G G/G G/A
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C C/G A/A C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C C/T G/G T/T NO DEL/ NO DEL C/C C/G A/A T/C T/G A/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C G/G A/A C/C G/G G/G G/A
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C G/G A/A C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C C/G A/A C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C G/G A/A C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL C/C C/C A/A C/C G/G G/G G/G
C/C C/C C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C C/C G/G T/T NO DEL/ NO DEL C/C C/C A/A T/T T/T A/A G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C G/G A/A C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C C/C A/G C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C C/C A/G C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C G/G A/G C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C G/G A/G C/C G/G G/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C G/G A/G C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T C/C G/G T/T NO DEL/ NO DEL C/C C/C A/A T/C T/G A/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C G/G A/G C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T C/C G/G T/T NO DEL/ NO DEL C/C C/C A/G T/C T/G A/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C C/C A/G C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T C/C G/G T/T NO DEL/ NO DEL C/C C/C A/G T/C T/G A/G G/G
A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL C/C C/C A/G C/C G/G G/G G/G
C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T C/C G/G T/T NO DEL/ NO DEL C/C C/C A/G T/C T/G A/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/A
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/G
A/A A/A 8 BP DEL/C T/T T/T A/A C/C 22bp DEL/DEL T/T G/G G/G C/C G/G G/G G/A
Amplicon 2 chr9:136140844-136150031
1B      chr9:136148978-136155994
1A     chr9:136149487-136155746
amplicons 3 and 2 1975bp overlap
amplicons 2 and 1B 1053bp overlap amplicons 2 and 1A 544bp overlap






Table 5.8 NGS genotyping of homozygous O allele samples (Note: the table is 
on the next pages due to its size).  
A graphical illustration of the correlation of intronic polymorphisms with 
homozygous O alleles obtained from the analysis of the NGS data. The 
polymorphisms of 6 O01 homozygous and 1 O01/O26 alleles (of which the latter 
resembles O01) are shown to be correlated. A O02 homozygous sample was also 
displayed. One sample of genotype O01/O75, the latter allele resembles O02, was 
compared to the homozygous samples, which shows the heterozygosity of the 
polymorphisms. The correlation was mainly in the intronic polymorphisms in 
intron 3-6. The green represents homozygous resemblance to the reference; orange 
represents homozygous difference to the reference; while the crossed blue 
represents heterozygosity. Polymorphisms in exons are coloured grey, while red 
represents the rare mutation listed in the dbRBC and (NCBI/1000 genome), the 
rsID for which is showed above the polymorphisms. The yellow highlighted line 
is the consensus annotation. Larger tables in appendix B. 
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62641785 62641786 62641788 56392308 8176749 56346931 8176748 8176747 41302905 8176746 8176745 8176744 8176743 8176742 8176741
frameshiftDeletion Synonymous Missense Missense Missense Missense Missense Synonymous Synonymous Missense Synonymous Synonymous 
EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7
Utr-3 down stream Utr-3 down stream Utr-3 down stream 1060_1060delC
chr9:136130669 chr9:136130677 chr9:136130689 chr9:136131057 chr9:136131188 chr9:136131192 chr9:136131289 chr9:136131315 chr9:136131316 chr9:136131322 chr9:136131347 chr9:136131350 chr9:136131415 chr9:136131437 chr9:136131461
A>G A>G T>C Pro354fs/1061delC Leu310 930G>A Tyr309Cys 926A>G Val277Met/829G>A Gly268Ala 803G>C Gly268Arg 802G>A Leu266Met 796C>A Pro257   771C>T Ile256  768C>A Gly235Ser 703G>A Pro227 681G>A  His219 657C>T
(Pro353fs/1060_1060delC)  Leu310 929G>A Tyr308Cys 925A>G (Val276Met/828G>A) Gly267Ala 802G>C Gly267Arg 801G>A Leu265Met 795C>A    Pro257 (770C>T) Ile256  767C>A Gly234Ser 702G>A Pro 227(680G>A)    His219 656C>T
ABO001.23 O O01(ABO*O.01.01)/O26 A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/A G/G G/G C/C
ABO001.13 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G G/G C/C
ABO001.16 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G G/G C/C
ABO001.19 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G G/G C/C
ABO001.22 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G G/G C/C
ABO001.24 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G G/G C/C
ABO001.25 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) A/A A/A T/T C/C G/G A/A G/G G/G G/G C/C C/C C/C G/G G/G C/C
ABO001.26 O O02(ABO*O.01.02)/ O02(ABO*O.01.02) G/G G/G C/C C/C G/G A/A A/A G/G G/G C/C T/T C/C G/G A/A C/C
ABO001.14 O O01(ABO*O.01.01)/O75* A/G A/G T/C C/C G/G A/A G/A G/G G/G C/C C/T C/C G/G G/A C/CUtr-3 down stream
8176740 8176739 55727303 7853989 1053878 8176738 8176737 8176736 7873416 7873522 7873634 7873635 8176732 8176731 8176727 2073824 8176726 2073825 8176720
Missense Missense Nonsense Missense Missense Missense  Missense (Synonymous)
EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 EXON 7 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 Intron 6 EXON 6
chr9:136131472 chr9:136131523 chr9:136131576 chr9:136131592 chr9:136131651 chr9:136131636 chr9:136131783 chr9:136131785 chr9:136131846 chr9:136131905 chr9:136132010 chr9:136132012 chr9:136132303 chr9:136132350 chr9:136132570 chr9:136132633 chr9:136132608 chr9:136132707 chr9:136132873
Phe216Ile 646T>A Arg199Cys 595C>T Trp181stop 542G>A      Arg176Gly 526C>G Pro156Leu 467C>T Arg161His 482G>A G>A A>G A>G A>G A>G A>G T>C A>G C>T T>C G>A T>A Thr99 297A>G
Phe215Ile 645T>A Arg198Cys 594C>T Trp180stop 541G>A Arg175Gly 525C>G Pro155Leu 466C>T Arg160His 481G>A His99Arg 296A>G
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
T/T C/C G/G C/C C/C G/G G/G A/A A/A A/A A/A A/A T/T A/A C/C T/T G/G T/T A/A
A/A C/C G/G C/C C/C G/G A/A G/G G/G G/G G/G G/G C/C G/G T/T C/C A/A A/A G/G
T/A C/C G/A C/C C/C G/G G/A A/G A/G A/G A/G A/G T/C A/G C/T T/C G/A T/A A/G
8176719 8176718 8176717 8176715 8176714 66882853 512770 8176712 641959 641943 517414 626792 625593 111705520 549331 549443 549446
Frameshift_stop Missense Synonymous Missense
EXON 6 Intron 5 Intron 5 Intron 5 Intron 5 Intron 5 EXON 5 Intron 4 Intron 4 Intron 4 Intron 4 Intron 4 Intron 4 Intron 4 Intron 4 EXON 4 EXON 4
13bp 
chr9:136132908-136132909 chr9:136132957 chr9:136133034 chr9:136133148 chr9:136133178 chr9:136133381-83 chr9:136133506 chr9:136133583 chr9:136133699 chr9:136133714 chr9:136134034 chr9:136134864 chr9:136135096 chr9:136135138-chr9:136135150 chr9:136135195 chr9:136135237 chr9:136135238
88fs 118 261delG G>A C>A A>G C>T WOULD BE INS IN O ALLELE Pro74Ser 220C>T C>Del G>T C>T T>C G>T T>C WOULD SEE INS13 IN SOME O ALLELE C>G  Arg63 189C>T  Arg63His 188G>A
Val87_Pro88fs 118 stop 260_261insG CCC>Del Ser74Pro 220T>C 13bp Del CGAAGACAGGTGTG/C His63 189T>C His63Arg 188A>G
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) G/G C/C A/A C/C DEL/DEL C/C   T/T DEL/DEL T/T T/T C/C T/T C/C DEL/DEL    INS13BP/INS13BP G/G C/C   T/T G/G  A/A
no insertion (del/del) A/A A/A G/G T/T CCC/CCC T/T    C/C C/C G/G C/C T/T G/G T/T C/C         NO DEL C/C T/T  C/C A/A  G/G






494242 2769071 57738738 677355 476410 505922
Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1
`                                           THE snp AT 41 NULEOTIDE OF ONE REPAT IS 136154433 C>G
chr9:136145118 chr9:136145974 chr9:136145994-chr9:136146015 chr9:136146046 chr9:136148368 chr9:136149229
G>A T>C 22 bp DelAAGAAGGGAAATTAATAAATATT/A ( In O allele you would see insertion)C>T C>G A>G
G/G T/T NO DEL/ NO DEL C/C C/G A/A
G/G T/T NO DEL/ NO DEL C/C G/G A/A
G/G T/T NO DEL/ NO DEL C/C C/C A/G
G/G T/T NO DEL/ NO DEL C/C C/G A/A
G/G T/T NO DEL/ NO DEL C/C G/G A/A
G/G T/T NO DEL/ NO DEL C/C G/G A/A
G/G T/T NO DEL/ NO DEL C/C C/C A/A
G/G T/T NO DEL/ NO DEL C/C C/C A/A
G/G T/T NO DEL/ NO DEL C/C C/G A/A
 
624601 574347 575259 579622 688976 8176696 687621 687289 55876802 673578 672316 149092047 643434 574311 494242 2769071 57738738
Missense Missense Missense
Intron 3 Intron 3 Intron 3 Intron 3 EXON 3 EXON 3 Intron 2 Intron 2 EXON 2 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1 Intron 1
 
chr9:136135365 chr9:136135659 chr9:136135752 chr9:136136242 chr9:136136770 chr9:136136773 chr9:136137065 chr9:136137106 chr9:136137547 chr9:136137857 chr9:136138125 chr9:136139908-chr9:136139915 chr9:136142355 chr9:136144110 chr9:136145118 chr9:136145974 chr9:136145994-chr9:136146015
T>C G>A C>T T>C Val 36Phe 106G>T Gly35Arg 103G>A T>C C>T Arg18Leu 53G>T
Phe36Val  106T>G Gly35Arg 103G>A Arg18Leu 53G>T C>A C>A CTTTGACGG Del 8 bp/C  ( COULD BE insersion in SOME O allele) C>T C>T G>A T>C 22 bp DelAAGAAGGGAAATTAATAAATATT/A ( In O allele you would see insertion)
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/T T/T G/G T/T NO DEL/ NO DEL 
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
C/C A/A T/T C/C G/G  T/T G/G T/T C/C G/G A/A A/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
T/T G/G C/C T/T T/T  G/G G/G T/T C/C G/G C/C C/C C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C C/C G/G T/T NO DEL/ NO DEL 
T/C G/A C/T T/C G/T G/G T/T C/C G/G C/A C/A C/C NO DEL/NO DEL ( MEANS INS IN O ALLELE) C/C T/T G/G T/T NO DEL/ NO DEL 
ABO001.23 O O01(ABO*O.01.01)/O26
ABO001.13 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
ABO001.16 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
ABO001.19 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
ABO001.22 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
ABO001.24 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
ABO001.25 O O01(ABO*O.01.01)/ O01(ABO*O.01.01)
























ID Phenotype Genotype 
nt 41 1st 
repeat* 
nt 41 4th 
repeat** 
ABO001.01 A1 A101(ABO*A1.01)/O26 C G 
ABO001.02 A1 A101(ABO*A1.01)/O26 C G 
ABO001.03 A1 A101(ABO*A1.01)/O02(ABO*O.01.02) C G 
ABO001.04 A1 A101(ABO*A1.01)/O02(ABO*O.01.02) C G/A HET 
ABO001.05 A1 A101(ABO*A1.01)/O01(ABO*O.01.01) C G/A HET 
ABO001.06 A1 A102(ABO*A1.02)/ O02(ABO*O.01.02) C G/A HET 
ABO001.07 A1 A101(ABO*A1.01)/O63 C G/A HET 
ABO001.08 A1 A101(ABO*A1.01)/ A201(ABO*A2.01) G G/A HET 
ABO001.09 A2 A201(ABO*A2.01)/O75* C G 
ABO001.10 A2 A201(ABO*A2.01)/ A201(ABO*A2.01) G G 
ABO001.11 A2 A201(ABO*A2.01)/ O03(ABO*O.02.01) C/A Het G/A HET 
     
ABO001.12 O O63/O(NOVEL) C G 
ABO001.13 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) G G 
ABO001.14 O O01(ABO*O.01.01)/O75* C G 
ABO001.15 O O02(ABO*O.01.02)/O73 C G 
ABO001.16 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) G G 
ABO001.17 O O26/O68(ABO*O.02.17.1) C G 
ABO001.18 O O03(ABO*O.02.01)/O28 C/A HET G/A HET 
ABO001.19 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) C/G HET G 
ABO001.20 O O01(ABO*O.01.01)/O75* C/G HET G 
ABO001.21 O O01(ABO*O.01.01)/ O03(ABO*O.02.01) C/A HET G/A HET 
ABO001.22 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) G G 
ABO001.23 O O01(ABO*O.01.01)/O26 C G 
ABO001.24 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) G G 
ABO001.25 O O01(ABO*O.01.01)/ O01(ABO*O.01.01) G G 
ABO001.26 O O02(ABO*O.01.02)/ O02(ABO*O.01.02) C G 
     
ABO001.27 B B101(ABO*B.01)/ O01(ABO*O.01.01) G G 
ABO001.28 B B101(ABO*B.01)/ O01(ABO*O.01.01) C/G HET G 
ABO001.29 B B101(ABO*B.01)/ O01(ABO*O.01.01) C/G HET G 
ABO001.30 B B101(ABO*B.01)/ O01(ABO*O.01.01) G G 
ABO001.31 B B101(ABO*B.01)/ O01(ABO*O.01.01) G G 
ABO001.32 B B101(ABO*B.01)/ O01(ABO*O.01.01) G G 
ABO001.33 B B101(ABO*B.01)/ O63 C/G HET G 
ABO001.34 B B101(ABO*B.01)/ O01(ABO*O.01.01) G G 
ABO001.35 B B101(ABO*B.01)/ O75 C/G HET G 
ABO001.36 B B101(ABO*B.01)/ O01(ABO*O.01.01) C/G HET G 
ABO001.37 B B101(ABO*B.01)/ O02(ABO*O.01.02) C/G HET G 
ABO001.38 B B101(ABO*B.01)/ O01(ABO*O.01.01) G G 
ABO001.39 B B101(ABO*B.01)/ O02(ABO*O.01.02) C/G HET G 
     
ABO001.40 A2B A201(ABO*A2.01)/ B101(ABO*B.01) G G 
ABO001.41 A2B A201(ABO*A2.01)/ B101(ABO*B.01) G G 
ABO001.42 A2B A201(ABO*A2.01)/ B101(ABO*B.01) G G 
ABO001.43 A2B A201(ABO*A2.01)/ B101(ABO*B.01) G G 
ABO001.44 A2B A201(ABO*A2.01)/ B101(ABO*B.01) G G 
ABO001.45 A2B A201(ABO*A2.01)/ B101(ABO*B.01) C/A HET G/A HET 
ABO001.46 A2B A201(ABO*A2.01)/ B101(ABO*B.01) G G 
ABO001.47 A1B A101(ABO*A1.01)/ B101(ABO*B.01) C/A HET G/A HET 
Table 5.9 The analysis of minisattelite repeats 3.8kb upstream of the start codon of ABO. 
Four repeats were covered by the NGS data from all ABO samples with different ABO phenotypes.  
There was a SNP in nt. 41 in the first and fourth repeats, at chromosomal locations chr9: 
136154433* and 136154304**, respectively.  
The repeat sequence is  ACCCCAGCCAATAGGGGAAGGACACAGAAACAGAAACTGCGTT, 






5.3.7 Validity of NGS data 
The variant analysis from the NGS data is valid and need no further validation due to 
the high quality, coverage depth and all SNPs were reported to the dbSNP database. 
However, at the beginning this project (first NGS ABO run), the SNPs in exons 3, 4 and 
6 were investigated and confirmed by Sanger sequencing. Primers were designed to 
amplify around SNPs in exon 3 (103G/A, 106G/A), exon 4 (188G/A, 189C/T) and exon 
6 (297A/G). These SNPs were selected for confirming the NGS of ABO run; 103 G/A 
was a rare SNP and the rest were randomly selected. The primers used for amplification 
of these SNPs are listed in Table 2.13; with thermocycling conditions described in 






















189 C/T   
297 G/A 
Figure 5.14 Sanger sequencing of a number of SNPs to confirm NGS data of one sample. 
Several SNPs identified by NGS genotyping of samples of O phenotype (ABO001.12 shown here) were investigated by Sanger 
sequencing for confirmation of the integrity of NGS SNP data.  All SNPs were heterozygous and matched NGS genotyping data. The 




5.4.1 ABO NGS genotyping with LR-PCR 
ABO genotyping is a valuable, complementary approach to serology, especially to 
elucidate discrepancies, and overall leading to better determination of the ABO status of 
donors and patients to ensure safer clinical transfusion. The causes of the discrepancies 
may be due to weak expression alleles or hybrid alleles. Ax alleles may be mistyped as 
O group due to low reactivity with anti-A, while the serum contains anti-A1 (Olsson et 
al., 2001, Daniels, 2013). Hosseini-Maaf et al. (2005) illustrated an example of solving 





 alleles. However, they manifested discrepancies which led 
to serological mistyping, one case of which was typed as Aweak due to weak reactivity 
with anti-A/B and an absence of anti-A. DNA sequencing analysis of this individual 
revealed the conventional O02 genotype, with O
2
-like polymorphisms and additional 
SNPs 649C>T and 689G>A – which were novel at the time of the study (Hosseini-Maaf 
et al., 2005). The majority of ABO genotyping studies have relied on methods such as 
sequence-specific primer (SSP) PCR, the output of which are insufficient for extended 
genotyping of transfusion units that are high in demand (Flegel et al., 2015). Moreover, 
other high-throughput approaches, such as microarrays, are only capable of revealing 
known ABO alleles (Avent et al., 2007, Avent et al., 2015). As a result, novel alleles are 
likely to be missed, which are increasing significantly as reported in the study of Lang 
et al. (2016), which used the NGS approach to genotype ABO samples and estimate the 
frequency of ABO alleles in a German population. Although only exons 6 and 7 were 
sequenced in Lang’s study, a suggested 287 novel alleles were found and were not 
previously described in the BGMUT (which in turn reported an additional 95 new 
alleles four years since the publication of (Patnaik et al., 2012). A considerable number 
of ABO genotyping studies focused only on exons 6 and 7 (Lang et al., 2016, Taki and 
258 
 
Kibayashi, 2014, Hosoi, 2008), as these exons are thought to carry the majority of the 
ABO coding sequence (Daniels, 2013). However, it is argued that genotyping all exons 
and introns allows for more accurate assessment and prediction of the ABO phenotype 
and thus promotes safer transfusion practice and forensic application; this is especially 
relevant to subgroups or other ABO alleles, such as O02, new alleles or hybrid alleles 
carrying various polymorphisms across the ABO gene (Huh et al., 2011). In the exon 6 
and 7 restricted Lang et al (2016) study, it has been stated that high resolution 
genotyping would have been obtained if the rest of the gene was sequenced since 
multiple alleles were not covered, such as ABO*Aw.13.01.1 which differed from the 
ABO*A1.01 by a SNP in exon 1 (Lang et al., 2016).  
Here, the high-throughput NGS approach was used to extensively genotype the entire 
ABO gene, including all 7 exons, introns and the flanking regions (up to 5kb upstream). 
This protocol ensures that all existing and potential novel polymorphisms are covered, 
enabling maximally thorough analysis of ABO molecular biology and, thus, better 
insight into the phenotype. The NGS protocol here was coupled with LR-PCR to yield 4 
overlapping amplicons, which were used to amplify the entire ABO gene. Using a small 
number of primer pairs for PCR amplification is more time- and cost-effective and 
carries a lower risk of error and is less labour intensive. In a previous study by Huh et al. 
(2011), there were 31 sequencing reactions in total that required more than 17 
sequencing primer pairs, in addition to two long amplicons, to genotype the ABO gene 
with the exclusion of intron 1 (~13 kb). Here, the entire ABO gene, including flanking 
regions, was successfully amplified by NGS of four LR-PCR-produced amplicons. 
Using only four amplicons increased the likelihood of successful amplification, as there 
would likely be fewer polymorphisms surrounding primer binding areas; this is 
especially true for highly polymorphic areas, such as in exon 7 of ABO. This was 





(in which multiplex PCR is used) to sequence the coding regions of genes and intron-
exon boundaries of 15 blood group systems. The amplification of several areas 
including exons 1-4 was unsuccessful, most likely as a result of homopolymers and GC-
rich sequences, especially around exon 1 and upstream regions, which would have 
required nonstandard amplification conditions (Fichou et al., 2014).  
5.4.2 Quality control of NGS data  
The quality of the NGS data was assessed via FastQC, along with the coverage depth 
analysis, based on the Phred score. The quality of data was found to be high (>99% base 
call accuracy, with a 1 in 1000 probability of an incorrect base call) and there was a 
good mean coverage depth of 650X, which significantly exceeds that suggested to be 
sufficient for accurate variant calling (30X)  (Tilley and Grimsley, 2014). This increases 
confidence in the NGS data for downstream analysis (Sims et al., 2014). The high 
coverage seen here is thought to be attributed to only using part of the 316
TM
 chip 
capacity for each ABO experiment, as 111 samples can be simultaneously sequenced for 
the entire ABO gene (~ 36kb amplicon size) by this chip at a coverage of 50X. The 
output can be further increased using higher capacity chips and would decrease the 
sequencing cost of the entire ABO gene. The library preparation cost for one ABO 
sample was ~£69, while the cost of sequencing run of one sample was ~£4. Using 
higher capacity chips, for example 318
TM
, would allow sequencing of 555 ABO samples 
at once at a cost of ~£1. As a result, the high throughput capability of the NGS would 
eventually lead to a drop in the costs of blood group gene genotyping and might 
promote its use in more clinical laboratories in the future. The impact of implementing 
the NGS approach on reducing the costs of genotyping has been pointed out, as in a 
study of typing HLA alleles by NGS high-throughput platform (Illumina MiSeq) that 
led to a reduction of the costs by more than 50% compared to Sanger sequencing; 
moreover, the NGS data was in complete concordance with results obtained from 
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Sanger sequencing (Lange et al., 2014). 
 
5.4.3 Validity of ABO NGS 
The validity of NGS genotyping of blood groups here has already been discussed in the 
previous two chapters (FY 3.4.3 and JK 4.4.3). Similarly, the genotyping data quality 
for ABO was high here, as assessed by FastQC and coverage depth. In addition, there 
was a complete concordance of the  phenotype from the serological approach with that 
suggested from the NGS, in fact the NGS provided more detailed and accurate 
phenotype (for example, the serological phenotype was AB while that of the NGS was 
A2B). Moreover, the polymorphisms found were already reported in the dbRBC 
database. Nevertheless, despite these parameters that illustrated the validity of the ABO 
NGS data, Sanger sequencing was used for a number of SNPs, which were found at the 
beginning of this study, for their confirmation and this data was in agreement with NGS 
output (section 5.3.7). 
5.4.4 NGS ABO library 
The first step to constructing ABO libraries for NGS genotyping of the whole gene was 
PCR amplification of four long amplicons. Some difficulties were encountered when 
amplifying the amplicon covering the region upstream-exon 1 and part of intron 1 in 
samples of various phenotype and thus genotype (section 5.3.4.2), which required 
another primer pair to be used. Visualisation analysis of amplicons that failed PCR 
amplification but were sequenced regardless revealed SNPs surrounding primer binding 
sequences, which may have perturbed amplification as these SNPs were not found in 
samples that were successfully amplified (Table 5.5). Correlation of these SNPs with 
ABO alleles was not confirmed, although SNP 136149500 A>G was found to be 
homozygous in the A201/A201 sample. Analysing more samples, especially ones with 
homozygous alleles, would allow correlation of SNPs with the alleles; moreover, further 
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analysis, such as Sanger sequencing, of the primer binding sites would be useful, for 
instance, to explain the lack of coverage at the first nucleotide attaching the reverse 1A 
primer in our study. It is advised to avoid these SNPs when designing primers, which 
was the strategy for the design of primer pair 1B here. Another possible reason for the 
failure of amplification may be a GC-rich area around exon 1, which may require 
nonstandard amplification conditions as has been mentioned (Fichou et al., 2014). It is 
worth paying attention to this area in future ABO studies when optimising amplification 
conditions. With regard to amplicon 2, which mostly covers intron 1, there were a few 
samples that failed to be amplified or very small amplification was noticed (faint bands); 
thus, the corresponding area was not covered by NGS. It is unclear why this region 
displayed amplification problems, as visualisation analysis showed no signs of 
polymorphisms around the primer binding areas (which were covered by NGS), yet the 
middle of the amplicon was not sequenced (covered). Possible reasons could be a high 
GC-content which needs optimisation of PCR conditions; however, since the majority 
of samples were amplified, another reason could be the presence of homopolymer 
sequences across the ABO gene (repeats of the same base in the sequence) as previously 
suggested by Fichou et al. (2014). These homopolymers could affect amplification and 
also NGS sequencing by the Ion PGM
TM 
 platform, leading to errors (Loman et al., 2012, 
Fichou et al., 2014, Bragg et al., 2013, Quail et al., 2012). 
With regard to the ABO library processing, the purifcation and size selection was 
conducted by SPRIselect® reagent kit, which is cost effective and less time consuming 
compared to Pippin Prep
TM 
instrument (section 2.2.4.10). 
5.4.5 NGS data analysis (ABO reference sequence) 
According to the ISBT and NCBI databases, the A101 allele is a consensus reference 
sequence against which the variants are annotated (Reid et al., 2012). However, this is 
likely to be developed by the NCBI database project (RefSeqGene) used for 
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conventional annotations which is stated to be developed with the consultation of the 
gene-specific experts (NCBI website). It was found here that the hg 19 reference 
sequence of the ABO resembled a combination of two alleles (O01 and O02) (see 
section 5.3.4.1), with a deletion (261delG) in the reference sequence both in hg19 and 
hg38. This issue with the hg19 ABO reference sequence was previously noted by Lane 
et al. (2016), whose study involved red cell antigen prediction from whole genome 
sequencing (Lane et al., 2016). As a result, a G insertion would be in samples 
containing A and B alleles (and this has been observed), thus causing downstream 
nucleotide changes and resulting amino acid location shift that needs to be noted. 
However, here NGS variant analysis against the NCBI RefSeqGene (A101) was not 
feasible as the chromosomal locations of the polymorphisms may not be accurate as the 
sequence has different coordinates to that of hg19 or hg38. Consequently, NGS data 
was aligned against the hg 19 reference sequence for several reasons: to be consistent 
throughout this project (FY and JK was analysed against hg19); it has been utilised by 
previous NGS studies (Rieneck et al., 2013, Fichou et al., 2014, Lane et al., 2016); and 
to be consistent with data analysis software (Ion Reporter
TM
,  most updated version), 
which is based on hg19. Moreover, it is worth noting that the visualisation analysis of 
ABO was challenging due to its anti-sense direction (section 5.3.4.1), which may lead to 
false annotation. Nevertheless, Ion Reporter
TM
 reports SNPs in the sense direction and 








5.4.6 Genotyping of the ABO gene  
5.4.6.1 Polymorphisms in exons 
NGS genotyping of the 47 ABO samples, all of which were serologically phenotyped, 
revealed numerous exonic and intronic polymorphisms which accounted for different 
ABO alleles (Table 5.6 and 5.7).  NGS also provided more detail on sample phenotype 
(e.g. A1 and A2) than serology. Genotyping of samples of A phenotype revealed a 
comparable frequency of A2 phenotype compared with those previously reported. Here, 
the A2 phenotype frequency among 11 samples with A phenotype was 27% with 5 A2 
haplotype. This is a slightly higher frequency than that described in a study that 
illustrated the distribution ABO allele frequency in England, with the A2 phenotype 
representing 22% of the A phenotype samples (Ikin et al., 1939, Daniels, 2013). The 
possible reason for this increase could be due to the small number of samples of A 
phenotype being analysed here, as the study by Ikin et al. (1939) analysed 1546 samples 
of A phenotype, upon which the frequency was provided. On the other hand, the 
frequency of the A2 phenotype among the samples analysed in this project was similar 
to that found in a previous study that genotyped 34 A phenotype samples from 
Birmingham, England (finding that ~70% and 30% were A1 and A2, respectively) 
(Procter et al., 1997). Likewise, in the same study, the ABO blood group genotyping of 
A phenotype samples (63/146) from random renal donors revealed a comparable 
frequency (76% and 24% for A1 and A2, respectively). 
With regard to samples of O phenotype, NGS identified rare polymorphisms that 
generated O alleles (section 5.3.6.1 and Table 5.6) previously reported in publications 
or in the BGMUT database. One of the O alleles identified here is suggested to be novel 
(0% frequency in Europe) and carries a missense SNP (482 G>A, Arg161His) in exon 7. 
Although this SNP has been reported and validated by the NCBI dbSNP database, it has 
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yet to be allocated to an ABO allele listed in BGMUT.  For samples of B phenotype, 
there was complete concordance between NGS data and serology. Regarding the 
frequency of the samples with the AB phenotype, samples with A2B phenotype showed 
higher frequency than A1B phenotype. According to genotyping data, the majority of 
the samples (7/8; 87.5%) were of A2B phenotype – a significantly higher frequency than 
reported in English donors (~19.5%, 22 out of 113 donors with AB phenotype) by Iken 
et al. (1939) (Ikin et al., 1939, Daniels, 2013).  The possible reason for this finding may 
be the small number of samples (8 AB samples) used here, which may have resulted in 
invalid representation of allele frequency in a population compared to the study of Iken 
et al (1939), in which the analysis of 113 A phenotype individuals was conducted. The 
results here are therefore likely a coincidence, the 7 randomly selected samples 
happened to carry the A2B antigens. The A2B phenotype samples were observed at a 
higher frequency than A1B phenotype samples in an early study by Procter et al. (1997), 
in which 63% of the samples of AB phenotype (8 AB phenotype samples/146 total 
samples) from renal donors were A2B and 37% were A1B. Accordingly, sequencing 
large number of samples would provide better illustration of the phenotypes and thus 
allele frequencies in different populations, which is feasible by the high-throughput 
NGS capability. Lastly, the majority of our samples were heterozygous, in agreement 








5.4.6.2 Polymorphisms in introns and upstream regions 
The ABO NGS genotyping approach used here enabled analysis of all existing 
polymorphisms across the gene, including those in introns and upstream areas. There 
are several suggested benefits to analysing intronic polymorphisms, namely it yields 
information on gene and allele evolution and hybrid alleles. The latter was observed 
here with respect to the hg 19 ABO reference allele (Table 5.8) and in a previous study 
of the Bw26 allele, which revealed a hybrid sequence of O03 and B101 alleles in both 
introns and exons (Thuresson et al., 2012), thereby providing more accurate genotyping 
data that might help in the forensic analysis of the ABO genotyping (Huh et al., 2011, 
Avent et al., 2015). Here, all introns were genotyped, including intron 1 (~13 kb) which 
was not covered in the previous entire ABO genotyping study (Huh et al., 2011). The 
analysis of intron 1 is suggested to be beneficial for studying the expression of ABO 
antigens on the surface of red cells, as it has been reported to contain sequences (5.6-6.1 
kb from the translation initiation site) suggested to be erythroid specific enhancer 
elements that plays a role in GATA-1 transcription factor binding. The deletion of 
which was previously shown to be associated with a Bm phenotype with no erythroid B 
antigen expression on red cells while B antigen found in saliva (Sano et al., 2012). 
However, it is worth noting to consider intronic SNPs when designing primers as they 
may affect the success of amplification, as seen with ABO amplicons 1A and 1B here 
(section 5.3.4.2), and would result in allelic dropout.  
A high number of intronic SNPs was found here across different ABO alleles; however, 
not all of these SNPs underwent correlation analysis with alleles, due to time constraints 
since it was done manually (section 5.3.6.2). The attempt to establish a specific set of 
intronic polymorphisms, as done with the JK alleles (section 4.4.4.2), was challenging 
due to the fact that the majority of samples were heterozygous with an O allele, despite 
the phenotype similarity. Thus, future NGS sequencing studies should involve more 
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ABO samples with homozygous alleles, such as A101/A101, to study correlation of 
alleles with intronic polymorphisms. This would be important, as polymorphisms in 
ABO introns have previously shown use as allelic markers along with exonic SNPs 
(Hosseini-Maaf et al., 2003). Otherwise, the technology of the single molecule 
sequencing may circumvent this issue with regard to the assignment of polymorphisms 
to corresponding alleles but it was beyond the remit of this project (see section 6.4). 
This was observed here during analysis of samples homozygous for the O allele; 
although, the number of these samples was small. Nevertheless, there were various 
instances of observed complete correlations between intronic SNPs and alleles, such as 
the 13bp insertion in intron 4 of the O02 allele and from exons 3 to 7, including the 
introns between, with O01 and O02 alleles were noticed (Table 5.8). A complete 
correlation of alleles with SNPs in intron 1 was not seen here, however, which could be 
due to the limited number of intronic SNPs analysed in this area. As the correlation of 
intronic SNPs analysis was carried out manually, the comprehensive intronic SNPs 
analysis (more than 70 SNPs) in the 13kb intron 1, was challenging and  time 
consuming; therefore, more efficient analysis in the future may lead to better correlation 
data. Interestingly, analysis of rare O alleles, which resembled either O01 (O26 and O28) 
or O02 (O63, O68, O73 and O75), was suggestive of allele evolution.  
As in the analysis of the NGS data regarding the polymorphisms in the exons, NGS 
analysis of introns illustrates zygosity, which is used to evaluate the specificity and 
correlation to alleles. This was seen in the analysis of the homozygous O alleles analysis 
with the O01/O75, which was used as heterozygous sample. However, in the samples 
with AB phenotype there was an unclear situation in that none sense zygosity  pattern 
was seen around the area covered by amplicon 2, particularly around the 22 bp deletion 
chr9:136145994-chr9:136146015 (Table 5.7) in intron 1. Instead of heterozygous, AB 
phenotype samples were homozygous difference to the reference in that area, whereas 
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no observed change was seen in all B and A1, although those with A2 phenotype were 
similar to that in the AB phenotype samples. There were no visible polymorphisms that 
may have led to allelic dropout (which is more likely in the A101 and B alleles) seen 
here when analysing primer binding sites of amplicon 2. Thus, the reasons for 
unsuccessful amplification of this amplicon here are unclear and it may be worth 
revisiting the design of primer pairs and amplification conditions in addition to 
sequence and analyse more samples with AB phenotype in the future. 
Moreover, it is worth conducting a more thorough investigation of intron 1 in the future. 
With regard to the analysis of the upstream area, there was no correlation between the 
number of repeats of the CBF/NF-Y transcription factor binding site and the ABO 
alleles, as all four copies were present in all alleles. This finding contradicts the 
suggested description of the alleles correlation with the number of copies carried in 
which all (4 copies) are found in A2, B, O
1





 alleles. This suggestion was depending on the PCR-product fragment size and 
number of bands that was amplified followed by sequencing (Irshaid et al., 1999). 
Therefore, these findings merit further investigation in the future, as there are 
conflicting views in the literature on the effect of variations in this area on the ABO 
antigen expression, especially in homozygous ABO samples. In 2007 a study suggested 
a reduced B antigen expression due to variations in the CBF/NF-Y region (Seltsam et al., 
2007). Another study contradicts this assumption by arguing that the number of repeats 
does not affect transcription, which was normal, in Bw26 alleles, whereas reduced 






In conclusion, used together with LR-PCR, the NGS approach enabled comprehensive 
genotyping of the ABO gene. In this study, the entire ABO gene plus outer regions were 
sequenced, which enables identification of all known, rare and novel polymorphisms 
across the gene and therefore permits the study of new alleles. The high-throughput and 
discovery capabilities of NGS genotyping opens an avenue for a variety of future 
investigations with regard to the ABO gene; these may help elucidate unusual cases, 
such as hybrid and low frequency alleles, and solve any discrepancies between the ABO 
genotype and serological phenotype. It is, therefore, concluded here that NGS is a 
potentially reliable and feasible platform for genotyping complex blood groups such as 
ABO. In addition, as NGS technology and data analysis software continually improve, it 
is likely that this tool may in the near future become commonplace in the clinic for the 













Chapter 6  
General Discussion and Conclusion 
 
The determination of some blood groups in individuals is essential for the safety of 
blood transfusion. Mismatched exposure to blood group antigens leads to 
alloimmunisation that may result in transfusion reactions. Correctly matched blood units 
are crucial for patients, especially those who require multiple blood transfusions for 
survival, such as those with sickle cell disease (SCD). The occurrence of 
alloimmunisation is frequent among SCD patients receiving blood units that do not 
undergo extended blood group antigens matching (Chou and Westhoff, 2011). As a 
consequence, the possibility of HTR, as well as the difficulty in finding compatible 
RBC units for subsequent transfusion, which might risk the recipient’s life, pose great 
challenges in the successful management of such patients (Bakanay et al., 2013). Also, 
Alloimmunisation occurs in pregnancy in cases, such as  fetomaternal haemerhage. 
Comprehensive and extended blood group antigen typing is therefore crucial and has, in 
fact, been shown to reduce the incidence of alloimmunisation (Chou and Westhoff, 
2011). Serological typing might be insufficient for accurately defining blood group 
phenotypes in multiply transfused patients, especially if they have recently received 
transfusions, owing to the possibility of persistence of circulatory RBCs of the donor 
(Castilho et al., 2002). In addition, serological typing for an extended range of clinically 
significant blood group antigens would be expensive, particularly if applied to cover 
large numbers of donors and recipients (an example is provided in section 6.6). BGG is 
capable of overcoming the limitations of serology. Nevertheless, the commercially 
available BGG platforms have certain drawbacks, such as low throughput (except 
micro-array-based technology) and inability to define novel or rare alleles which are not 
included in the assay design. Accordingly, the emerging alleles, including those 
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affecting the phenotype that could be clinically significant, cannot be detected with 
these platforms. The NGS approach circumvents these issues by not only addressing the 
large demand on BGG applications with the ability for high-throughput genotyping but 
also making available the discovery mode based on its sequencing-based genotyping 
that defines all polymorphisms irrespective of their mechanisms, describing all alleles 
(known, rare and novel) found in samples (Avent et al., 2015). In this PhD project, an 
NGS approach was coupled with LR-PCR to assess the feasibility of NGS in 
genotyping blood groups.  
6.1 NGS with LR-PCR  
The ability of NGS-based genotyping of blood groups to define rare and novel alleles 
allows more comprehensive and accurate prediction and representation of the phenotype 
than currently possible. This makes this approach superior to those platforms based on 
predefined SNPs, which might falsely predict a positive phenotype encoded by rare or 
novel silencing or weakening alleles that are not included in the assay. One example of 
this situation is illustrated in (section 3.4.5), in which a discordant of the predicted 
phenotype by the HEA BeadChip assay Fy(b+) with that of serology Fy(b-). A 
sequencing approach confirmed a missense mutation in exon 2 895G>A (Ala299Thr), 
which was suggted to be a new silencing SNP that was not covered in the array based 
platform (Westoff et al., 2014).  
The NGS approach was coupled with the LR-PCR method, rather than the AmpliSeq
TM
 
technology, to develop a protocol for comprehensive BGG. The LR-PCR approach was 
used over AmpliSeq
TM
 technology for several reasons. The AmpliSeq
TM
 technology 
used with the Ion Torrent NGS platform is based on a customised panel of multiplex 
primers provided by the company by using Ion Ampliseq
TM
 Designer to generate a large 
number of amplicons of targeted areas in various blood group genes. Therefore, despite 
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its ability for high-throughput and sequencing-based genotyping that allows discovery 
of novel polymorphisms, this approach raises some constraints due to the fact that only 





 technology has been previously used to genotype (only 
the exons) of 11 blood group genes (Halawani, 2015). It has been pointed out that the 
NGS with AmpliSeq
TM
 technology protocol was simpler in terms of the library 
preparation, in which no fragmentation nor purification was needed. However, a large 
number of primer pairs were designed to cover the targeted regions in that study; for 
example, 6, 9 and 11 amplicons were needed to cover only the exons of FY, JK and 
ABO, respectively. As a result, amplicon coverage might be affected by the failure of 
amplification targets of a number of primers due to polymorphisms at the primer-
binding sites. In addition, the designed primers might not have sufficient and accurate 
specificity. This, in fact, was evident since several regions of blood groups were not 
covered; for example, two regions of exon 7 of ABO were missed. In addition, the 
designed primers provided in the panel failed to distinguish the homology between the 
RHD and RHCE genes by misaligning a SNP for RHCE to RHD, which was suggested 
to be due to the lack of specificity in the primer design. The latter issue was addressed 
by designing gene specific primers with the LR-PCR approach, coupled with NGS 
(Halawani, 2015, Avent et al., 2015). Similar issues were encountered in the 2014 study 
by Fichou et al, in which AmpliSeq
TM
 technology was used with a designed panel to 
generate 417 amplicons (16, 31 and 16 for FY, JK and ABO, respectively) for 
genotyping the coding and untranslated regions of 18 blood group genes involved in 15 
blood group systems. The authors mentioned difficulties in genotyping with only 86% 
of the coding regions being covered, especially for the ABO gene, where several exons 
were not covered (1 and 4), whilst irrelevant sequences were obtained for the remaining 
exons. In addition, the designed panel of primers failed to cover and distinguish 
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homologous genes, for example RHD and RHCE. This has also been pointed out to 
have been solved by LR-PCR with specific primers (Fichou et al., 2014). Accordingly, 
NGS with LR-PCR was used here to sequence the complete gene, including splice sites, 
introns and flanking regions, which provides an extensive genotyping and analysis of 
the blood group genes.  
To our knowledge, this is the first NGS-based genotyping with LR-PCR of the blood 
group genes FY, JK and ABO, although LR-PCR was used before in a FY sequencing 
study but not with NGS technology (Schmid et al., 2012). Since complete coverage of 
the sequence across the gene can be visualised by the IGV system, an overview of 
polymorphisms in critical areas, such as exons and splice sites, can be rapidly obtained. 
Further investigation will then be considered, depending on the knowledge of the 
critical molecular locations of the genes. Polymorphisms across the genes were 
analysed, starting with those in the exons.  
6.1.1 NGS data quality  
The overall quality of the NGS data from genotyping all three genes was high. 
According to the Phred score, the base call accuracy was more than 99%, with a 1 in 
1000 probability of an incorrect base call. In addition, the coverage depth (for example, 
5600x for FY genotyping), which is suggested to increase the confidence for variant 
analysis results, was significantly higher than pointed out to be sufficient (30x) (Tilley 
and Grimsley, 2014). 
6.2 Polymorphisms in Exons  
The entire FY gene was extensively genotyped by NGS with LR-PCR, using only one 
single amplicon to cover exons, intron and promoter region. All exonic polymorphisms 
in the samples were revealed. The NGS genotyping data matched and confirmed the 
phenotypes of FY alleles FY*A, FY*B and FY*02(Null) in terms of the crucial SNPs 
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previously described (Reid et al., 2012). For example, the crucial SNP for FY*A/FY*B 





phenotype. The 298G>A encoding Ala100Thr aa change, which occurs on the FY*B 
allele background since none of FY*A/FY*A samples showed this SNP, was commonly 
found in our samples (16/53); as stated before, this alone is not expected to affect the 
Fy
b
 expression (Olsson et al., 1998). 
The NGS genotyping of the JK was feasible and allowed extensive analysis across the 
gene. NGS genotyping data of the key JK allele SNP (JK*A/JK*B 838G>A) was in 
concordance with the provided serological phenotype. The SNP 130G>A, which was 
described to be specific to the JK*01W.01 allele associated with a weaken expression of 
Jk
a
, was found to be heterozygous in 7 JK*A/ JK*01W.01, 2 in JK*B/ JK*01W.01 and 1 
homozygous JK*01W.01/ JK*01W.01 samples. With regard to the expression of Jk
a
, the 
phenotype in the samples appeared not be affected by the SNP. Although it could be 
argued that even weak expression is recorded as positive with the system used by the 
sample provider, it was found that two samples with this SNP (homozygous and 
heterozygous, respectively) reacted strongly in the haemoagglutination assay (Wester et 
al., 2011). Therefore, it was speculated that this SNP 130G>A might not be the only 
factor in reducing Jk
a
 expression; other polymorphisms located elsewhere across the 
gene that were not observed in Wester’s et al (2011) study might also play a role in 
bringing about the reduced expression. The approach of NGS and LR-PCR used in the 
present project might be a great candidate for the investigation in determining these 
polymorphisms since the entire gene and flanking region is covered by only three 
amplicons. Accordingly, samples with discrepant phenotype or weak expression (weak 
Jk
a
 expression in this case) can be sequenced, and critical areas such as splice sites, 
introns and upstream region, which contain erythroid-specific GATA-1 transcription 
factor binding sites (section 1.7.1), can be analysed. The ability of high-throughput 
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screening allows for the analysis of a large number of such samples to define the 
weakening allele-specific polymorphisms. The visualisation of the NGS sequence 
across the gene allows rapid identification of polymorphisms within significant 
locations. The SNP 810G>A locates in the second last nucleotide in exon 8 (exon 
8/intron 8 boundary), which might raise the concern about affecting the splicing. In fact, 
this has been pointed out in a study that suggested the silencing effect of this SNP on 
the Jk
b
 expression resulting from the association with a novel JK*B Null allele (Henny 
et al., 2014). However, all samples carrying this SNP showed no effect on the 
expression of the Jk
b
 (phenotype Jk b+), in addition to the confirmation obtained from 
the cDNA Sanger sequencing that showed a correct splice out of intron 8. 
The LR-PCR coupled with NGS approach was also feasible to comprehensively 
genotype ABO, including all 7 exons, introns and flanking regions. This is different 
from other studies that either sequenced some of the exons or neglected intron 1, 
possibly due to its large size (see chapter 5). This allows accurate elucidation of the 
molecular basis of the various ABO alleles, identifying rare, novel polymorphisms or 
hybrid alleles that would enable better prediction of the phenotype. An example of the 
benefits of genotyping the entire ABO gene and not only exons 6 and 7 is the definition 
of the O02 allele since it carries polymorphisms in different exons, including 3 and 4, 
across the gene. Several rare alleles and one novel O allele were identified using the 
NGS and LR-PCR approach with only four long amplicons. Using a small number of 
primer pairs for PCR amplification is time- and cost-effective and possibly carries a low 
risk of error and is less labour intensive, especially if accompanied with robotic 
automated PCR set up. In addition, the likelihood for successful PCR amplification with 
the use of a small number of primer pairs is greater compared to the case with the use of 
a large number of primer pairs, which increases the chances of encountering 
polymorphisms at the binding sites (Mullins et al., 2007). This is particularly relevant in 
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the case of genes with a complex and highly polymorphic molecular basis such as ABO, 
which should be taken into consideration while designing primers. In addition, the 
upstream area/exon 1/intron 1 were found to be more complex for amplification than the 
rest; this necessitated the redesigning of another amplicon to address this issue, which 
has been reported to be problematic and might need nonstandard conditions for 
amplification (Fichou et al., 2014) (see chapter 5). Another benefit of the approach of 
sequencing the entire ABO gene by the NGS technology followed by comprehensive 
analysis and visualisation is the identification of hybrid alleles. Interestingly, the 
reference sequence from hg19 and hg38 were not only found to carry a 261delG 
polymorphism but also the sequence from hg19 resembled a combination of two alleles 
(O01 and O02). This issue was also reported recently and should be taken into 
consideration during analysis in the future (Lane et al., 2016). The frequency of the 
predicted A2B phenotype was found to be relatively high which could be inaccurate and 
requires larger samples to assign the frequency (section 5.4.6.1).The A2B phenotype 
frequency among AB phenotype samples in this project was higher (87.5%) than A1B 
samples, which was also seen by study that illustrated a frequency of 63% and 37% for 
A2B and A1B, respectively among (8 AB samples) (Procter et al., 1997). On the other 
hand, the frequency of  A2B was (~19.5%, 22 out of 113 donors with AB phenotype) in 
the study of (Ikin et al., 1939). 
6.3 The Intronic Polymorphisms 
The NGS approach applied here involved sequencing the introns and flanking regions to 
enable an extensive analysis of polymorphisms across the gene. The NGS data revealed 
a large number of intronic SNPs, for example up to 80 SNPs in the JK*A/JK*B samples. 
Although it might be argued that intronic polymorphisms, especially SNPs, might not 
affect the protein sequence and thus affect the expression of anitgens, several benefits 
have been obtained with the approach of analysing the intronic polymorphisms. It has 
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been suggested that the knowledge of molecular background, including information 
from introns and flanking regions, for weakening or silencing alleles is important to 
determine the causative factors of these alleles, where intronic/flanking region 
polymorphisms may play a major and/or cumulative role in terms of expression (Avent 
et al., 2015). For example, a deletion in intron 1 at (5.6–6.1 kb from the translation 
initiation site) is reported to abolish the expression of B antigen from the RBCs, which 
is suggested to be associated with Bm phenotype, while an intronic SNP 190C>T has 
been suggested to play a cumulative role in the reduced expression of Fy
b
 (Gassner et 
al., 2000, Sano et al., 2012) 
In addition, intronic SNPs, along with those key allele defining SNPs in exons, might be 
used to distinguish between alleles more accurately. In fact, allele-specific intronic 
polymorphisms were described here after analysing homozygous samples, especially, 
those for JK alleles (JK*A, JK*B and JK*01W [JK*01W.01]), which might be 
considered the reference sequences for those alleles (see section 4.3.4.2, Table 4.5 and 
Figure 4.11). Consequently, variation from these sequences might indicate different 
alleles. Another example of the correlation of the intronic SNPs with the alleles was 
noted for the homozygous O alleles (Table 5.8).  
Additionally, the intronic polymorphisms analysis approach may provide an insight into 
the allele evolution and hybrid alleles. An interesting example was the illustration of the 
JK*01W.01 that appears to evolve from a hybrid JK*A/JK*B allele sequence, with the 
JK*01W.01-specifc polymorphisms being evolved on a hybrid JK*A/JK*B backbone 
(Table 4.5 and Figure 4.11). The hybrid sequence of the hg19 ABO reference sequence 
was also observed during the comprehensive analysis (exons, introns) of the O alleles 
(Table 5.8). In addition, various O alleles described here might be evolved from either 
O01 (O26 and O28) or O02 (O 63, O68, O73 and O75) alleles (section 5.3.6.2).  
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Moreover, cataloguing and acknowledging the intronic SNPs is recommended during 
the designing of primers, particularly those adjacent to key allele-specific SNPs. Such 
SNPs that might be around the primer-binding sites may hinder the amplification, which 
might cause an allelic dropout. One example of such a SNP is a C>T change found to be 
closely located (160 bp) upstream of the crucial JK*A/JK*B SNP (838G>A) (Section 
4.3.4.2). In addition, intronic analysis revealed that the hg19 reference sequence might 
carry uncommon SNPs, with samples exhibiting a homozygous difference (section 
3.4.4.2 and Figure 4.11).  
Also, as is the case with exons, intronic SNPs might guide in the determination of 
zygosity, which might illustrate the correlation of polymorphisms to alleles, as seen in 
the case of the O01/O75 sample that was used as the heterozygous sample (Table 5.8).  
 
6.4 Cis or Trans? (Assignment of haplotype) 
The current NGS platforms are designed to sequence small fragments of the DNA; for 
example, the Ion PGM
TM
 can sequence 200–400 bp fragments. Accordingly, the 
allocation of a polymorphism, especially novel weakening or silencing, to a particular 
allele could be challenging. In other words, the definite assigment whether the 
polymorphism is in cis or trans to other polymorphisms may be difficult, since the 
fragmentation of the target (here, DNA) into small fragments may shatter those SNPs 
from the actual carrying allele. The LR-PCR approach is amenable for cloning into 
vectors for cis/trans assessment of novel mutations since vectors can hold inserts up to 
10–42 kb (Casali. and Preston, 2003, Promega, 2016). However, allele-specifc LR-PCR 
might be applied to define alleles. Futhermore, advances in the sequencing technology 
have led to the emergence of the single molecule sequencing approach that allows 
single molecule sequencing of considerably long reads of 50 kb to 200 kb (or 
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theoretically any size) for PacBio and ONT MinION, respectively (Goodwin et al., 
2016). Accordingly, this read length is possibly greater than all blood group genes and 
hence would be useful to assign the cis/trans location of polymorphisms, while 
eliminating the need for laborious gene cloning (Avent et al., 2015). 
 
6.5 Data analysis 
The software packages that were utilised for the NGS data analysis for genotyping and 
subsequent phenotype prediction are user friendly and do not require extensive 
knowledge of bioinformatics. On the other hand, fundamental and basic knowledge of 
the blood group systems, especially the molecular basis of the alleles and the 
correspondent blood group antigens, is crucial. Moreover, the depth and complexity of 
the analysis depends on the application needed, for instance whether only 
polymorphisms in coding regions or all those found across the entire gene, including 
introns and regulatory regions are needed.  
In this investigation, the comprehensive data analysis was complex and time consuming 
since intronic polymorphisms were analysed, for example, to assign the correlation with 
blood group alleles and thus the effect on the antigenicity. This might not be feasible if 
NGS-based genotyping, which generates enormous number of data, would be applied 
routinely on genotyping donors and patients. To my knowledge, there is no dedicated 
software for the interpretation of NGS data for comprehensive BGG, although software 
for blood group phenotype prediction from NGS data has recently emerged but they 
might not provide extensive analysis (Giollo et al., 2015). Therefore, it would be 
worthwhile to establish a collaboration between experts in the blood transfusion science 
field and software developers to establish software packages that address the necessary 
applications. For example, the JK allele-specific coloured patterns (Table 4.5) described 
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here could be adopted to establish a rapid allele identification and phenotype prediction 
for scoring NGS data from samples automatically, in which polymorphisms, in both 
coding and non-coding areas, are rapidly called and interpreted. In addition, a rapid 
approach of interpreting the polymorphisms across the gene of different samples can be 
automatically and rapidly aligned and categorised among the samples and the reference 
sequence. The sheer volume of data generated from the NGS genotyping may raise 
concerns about the storage and analysing ability. This has prompted the development of 
cloud storage and computing that is suggested to address such concerns (Onsongo et al., 
2014, Shanker, 2012, Bhuvaneshwar et al., 2015). 
6.6 NGS costs 
The NGS, with its large-scale and high-resolution genotyping, might replace the 
commercially available microarray-based platforms since it is not only cheaper but also 
precludes the constraints on the limited number of alleles that can be defined (Avent et 
al., 2015). With regard to serological testing, it has been reported that the costs of high-
resolution testing, on average, were $195 (£149.49) per patient, while those with 
complex cases, such as autoimmune haemolytic anaemia, were on average of $1490 
(£1142.24) per patient (Mazonson et al., 2014). On the other hand, the process of NGS 
extensive genotyping, from the library to the results of sequencing required £50.6, £67 
and £73 per sample for FY, JK and ABO. The sequencing costs are dependent on the 
throughput and the reagents for each platform. The cost of the sequencing per sample 
drops significantly in higher throughput approaches (section 5.4.2). In addition to the 
reduction in the costs of the actual extensive genotyping, including all polymorphisms, 
high–throughput genotyping would eventually bring about a reduction in the cases of 
transfusion complications (since the frequency of alloimmunisation would decline) and 
preclude the unnecessary administration of prophylaxis to mothers, whose foetuses are 
not in danger of HDFN, although LR-PCR may not be feasible for cffDNA genotyping, 
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due to the size of the cffDNA (Avent, 2009, Finning et al., 2008).   
6.7 Future advancements in NGS technology 
NGS technology is undergoing continuous development in various aspects, for instance, 
speed, throughput, and automation of sample processing (such as DNA library 
preparation). These might help and simplify the implementation of large-scale routine 
BGG that is in high demand (Avent, 2009). An example of the approaches towards 
automation for the library preparation is SPRIworks system I by Beckman Coulter, 
which is designed for automated library preparation, in terms of adapter ligation, size 
selection and purification, which is attached with an automated nucleic acid extractor 
(SPRI-TE) (https://www.beckmancoulter.com). In addition, the Ion Torrent Chef
TM
 
system (from Thermo Fisher Scientific) was developed recently for automated template 
preparation and loading the samples into the chip automatically. It can also be involved 
in the library preparation of the AmpliSeq
TM
 technology 
(https://www.thermofisher.com). These advancements, which are continously 
improving, might help reduce the labour intensive and inconsistency of processing a 
large number of samples for the high-throughput NGS platforms. 
There have been several advancements in terms of the throughput that allows a 
significant number of samples and large targets, such as all blood group genes or whole 
genome to be simultaneously sequenced, which also reduces time and costs. Ultra-high-
throughput platforms have been described. Examples of such platforms are Illumina 
HiSeq X and the single-molecule Oxford Nanopore PromethION with throughput 
capacity of up to 900 Gb and 4 Tb, respectively, while the cost has been reported to be 
only $1000 per genome with the former platform (Tilley and Grimsley, 2014, Goodwin 
et al., 2016). Accordingly, great benefits can be achieved, such as the possibility of 
sequencing donors and patients for all blood group genes simultaneously. One approach 
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could be the designing of an expanded panel with multiplex primers (providing 
improved specificity) to sequence all blood group genes, including exons, introns and 
regulatory regions, to enable accurate phenotype prediction. It has been pointed out that 
all blood group genes with regulatory regions comprise only a fraction of the human 
genome (~150 kb) (Tilley and Grimsley, 2014), whereby a significant number of 
samples can be simultaneously sequenced by continually developing throughput 
platforms. Furthermore, due to the continuous advancement in the throughput, the 
whole genome sequencing of individuals (donors and patients) might become the 
conventional approach applied from birth in the future. Accordingly, all the molecular 
information might be available for accurate phenotype prediction without the need for 
further expenses in investigation (Tilley and Grimsley, 2014). In addition, the high-
throughput platforms, especially those for single molecule sequencing, might provide 
more accurate and refined molecular bases of the blood groups alleles and allow better 













6.8 Future work  
With regard to ABO analysis, more homozygous alleles (for example A101/A101) may 
be sequenced in the future for correlation assignment of polymorphisms with alleles. In 
addition, more samples with AB phenotypes could be sequenced to assign the frequency 
of the A2B phenotypes since the number of samples in this investigation may have been 
inadequate for frequency assessment. Furthermore, the area covered by amplicon 2 (in 
intron 1) of the ABO gene might be revisited in terms of redesigning the primers and 
sequencing more AB samples to investigate the causative factors for the unusual 
observation (section 5.4.6.2). Moreover, the upstream region that includes the CBF/NF-
Y transcription factor binding site might be revisited by other methods, for example, 
Sanger sequencing to investigate the number of copies of the (43-bp repeats) associated 
with ABO alleles. Furthermore, with the advances in the NGS data analysis software 
packages and the development of an extensive BGG specific software, a thorough 
analysis and scoring of the intronic polymorphisms, especially that in intron 1, can be 
accomplished in an easier and possibly automated fashion, considering an increase in 
the number of samples analysed in the future. With regard to JK, FY and ABO 
genotyping, samples with discrepant or weak phenotypes can be genotyped by LR-PCR 
to thoroughly investigate the polymorphisms across the genes, including flanking 
regions, and to investigate the causative factors, especially if encoded by rare or novel 
alleles with unknown molecular bases. This is because the NGS-based genotyping has 
no constraints in terms of only known SNPs. Moreover, single molecule platforms 










6.8.1 Allele classification system  
The comprehensive genotyping analysis (including the analysis of intronic 
polymorphisms) of homozygous samples defined the JK allele specific-patterns, thus 
suggesting reference sequences for JK*A, JK*B and JK*01W.01. Samples with 
sequence patterns that are different from the suggested reference sequence are 
considered different alleles. Accordingly, it is essential that a classification system for 
allele terminology is devised. Figure 6.1 illustrates an example of the suggested 
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Figure 6.1 Different JK*A alleles based on the intronic polymorphism patterns. 
Different JK*A alleles are described here based on the distinct polymorphism patterns, upon which representative terminology is 
suggested. For example, JK*01.01 is suggested for the reference JK*A reference sequence whereas JK*01.02 and JK*01.03 for the 
other JK*A alleles that differ from the reference. The allele assignment JK*01.01,02 and 03 was based on the frequencies (6 JK*01.02,  







6.9 Conclusion  
NGS has been shown to be a feasible approach for comprehensively genotyping the 
blood group genes FY, JK and ABO in addition to other genes, namely KEL, RHD and 
RHCE, which have been previously sequenced with a similar approach (NGS with LR-
PCR) (Avent et al., 2015). NGS-based genotyping allows an accurate reflection and 
prediction of the phenotype from the genotype by providing the entire encoding 
molecular sequence responsible for antigen expression for the specialists to analyse. 
Accordingly, the elucidation of the unusual cases, such as those with hybrid and novel 
alleles can be feasible. The mass-scale accurate genotyping of donors allows improved 
blood transfusion safety with better inventory of matched blood units and thereby 
minimises alloimmunisation and HTR. It is predicted that NGS-based genotyping will 
replace not only microarray-based genotyping but also serology in the blood group 
typing of individuals, with great advancements in technology and molecular knowledge 
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Transfusion Society (BBTS) for the following work: 
Altayar, M.A., Madgett, T.E., Kiernan, M., Halawani, A.J., Avent, N.D. (2016). Next 
generation sequencing of JK (SLC14A1) gene reveals higher frequency of variant alleles, 
novel allele-defining SNPs (allele reference fingerprints) and reassignment of a 
purported JKnull allele. Transfusion Medicine, 26, suppl. 2, 3-24. 
Antigens of the Jk system are among causes of alloimmunisation. The number of alleles 
of this clinically significant blood group is increasing. Commercially available high-
throughput Blood group genotyping (BGG) platforms are based on pre-defined 
polymorphisms. Next generation sequencing (NGS) circumvents this issue by operating 
in a discovery mode. We describe an NGS-based method for high-throughput, rapid and 
extensive genotyping of JK. Ion Torrent Personal Genome Machine (PGM
TM
) was used 
to optimise the method for sequencing the entire JK gene plus flanking regions with 
Long-range PCR (LR-PCR). DNA libraries were prepared from 67 JK DNA samples 
with 3 LR-PCRs. Samples were loaded onto a 316 chip for sequencing. Sequencing data 
were aligned to the gene reference sequence and analysed by software packages, such as 
Ion Torrent Suite
TM 
plugins. Sanger sequencing of cDNA and cDNA clones was used 
for confirmation. The analysis of millions of reads generated with coverage depth of 700x 
showed: JK*01W allele (130G>A) is common (10/67) with normal antigenicity. Silencing 
polymorphism (810G>A) leading to purported JK*B null allele maintains AG splice site and Jk
b
 
antigenicity (10/67). Intronic mutation analysis revealed novel allele-defining SNPs and a 
(G>Del) deletion, giving JK*A, JK*B and JK*01W novel reference allele sequence fingerprints, 
plus two new JK*A alleles were found. We found undescribed interactions between JK*A-JK*B 
allele sequences suggesting the JK*01W allele sequence arose from hybrid JK*A-JK*B gene 
sequence. C>T SNP, located 160bp upstream of the JK*A/JK*B critical polymorphism 838G>A, 
may lead to allelic dropout during BGG. Similarly, 53 FY and 45 ABO samples were processed 
revealing novel findings, such as 103G>A (Gly35Arg) in ABO.NGS can extensively 
genotype JK and other blood group genes including introns to define all existing and 
novel mutations. Thus, NGS will supplant array-based genotyping platforms and 








N. D. Avent, T. E. Madgett, A. J. Halawani, M. A. Altayar, M. Kiernan, A. J. Reynolds, 
& X. Li. (2015). Next-generation sequencing: academic overkill or high-resolution 
routine blood group genotyping? ISBT Science Series, 10, suppl. 1, 250-256. 
Blood group genotyping (BGG) has been in routine clinical practice ever since the 
molecular determination of blood groups was achieved, during the early to mid 1990s. 
These early methods were dependent on allele-specific PCR to detect simple single 
nucleotide polymorphisms (SNPs) responsible for blood group expression. As our 
knowledge regarding the molecular background of blood groups advanced, so did the 
numbers of SNPs requiring detection which necessitated the switch from allele-specific 
PCR to array-based technology, notably slide and bead-based approaches. All these 
methods thus described are totally dependent on the predefined genetic basis of each 
SNP. Hybrid blood group genes (as found in RH, ABO and MNS systems) are difficult 
to define by all of these aforementioned techniques. With the arrival of cheap next-
generation sequencing (NGS) approaches in the past 5 years, we have conducted long-
range PCR (LRPCR) coupled with NGS determination of the major blood group genes. 
By analysis of these data using an Ion Torrent Personal Genome MachineTM 
(PGMTM), it is readily apparent that NGS can highly effectively be applied with high 
resolution to blood grouping at costs no more than current array-based platforms. 
However, the complexity of the data obtained need careful filtering for effective clinical 
utilization, but provides useful insight on the evolution of blood groups and their 
environmental impacts which will be of undoubted value as an academic exercise, but 
of minimal cost (if any) to the original testing. 
 
M. Altayar, A. Halawani, M. Kiernan, A. Reynolds, N. Kaushik, T. Madgett & N. 
Avent (2013) Next Generation Sequencing of ABO, Duffy and Kidd Blood Group 
Genotyping. Transfusion Medicine, 23, suppl. 2; 30-71. 
 
Blood group Genotyping (BGG) has become well established in transfusion medicine. 
However, all current technologies are based on pre-existing knowledge of known 
polymorphisms. Next generation sequencing circumvents this requirement and adopts a 
discovery mode,which is important, as almost every new BGG project reveals new 
alleles. NGS has become high-throughput, rapid and accurate. Also, costs have 
significantly reduced in the past five years. In this pilot study, Ion Torrent Personal 
Genome Machine (PGM) sequencer was used to optimise and develop a reliable 
protocol for sequencing the entire Duffy, ABO and Kidd blood group genes including 
flanking regions. A DNA library was prepared from randomly selected DNA samples. 
Duffy, ABO and Kidd geneswere targeted by long-range PCR, enzymatic amplicon 
fragmentation before ligation with barcoded adapters and size selection. Templates were 
immobilised on beads, then clonally amplified using emulsion PCR. Sequencing 
revealed millions of reads that were then aligned to the reference gene sequences. 
Variants were visualised with two software packages, CLC workbench and Integrative 
Genomics Viewer (IGV). Initial Bioinformatics analysis of Duffy gene samples 
revealed all genotypes matched phenotype, however a number of SNPs (single 
nucleotide polymorphisms) were identified in exons 1,2 and intron1 and under 
investigation. We also identified that a significant number of the FY genes sequenced 
(5/12) encoded the previously described Ala100Thr mutation. The samples concerned 
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were FY (a-b+) (3 of 4) (1 homozygous and 2 heterozygous), FY (a+b-) (0 of 1) and FY 
(a+b+) (2/7) both heterozygous). We therefore conclude that the Ala100Thr mutation is 
much more frequent than previously described. We suggest that NGS will supplant 
other genotyping platforms in the near future and will potentially become the 
methodology of choice for genotyping patients and donors. 
 
A. J. Halawani, Altayar, M. A., M. Kiernan, N. Kaushik, A. Reynolds, T. Madgett & N. 
Avent (2013) Comprehensive Genotyping for Kell and Rh Blood Group Systems by 
Next-generation DNA Sequencing. Transfusion Medicine 23, suppl. 2; 30-71. 
 
Blood group genotyping (BGG) has emerged as a core technique in transfusion edicine 
and has impacted on the clinical management of multi-transfused patients. The vast 
ajority of these technical platforms require previous knowledge of the blood group 
polymorphisms under investigation. Next-generation sequencing (NGS) has emerged as 
a powerful replacement technology to genotyping single nucleotide polymorphisms 
(SNP), insertion/deletion (indels) and gene rearrangements. We have used NGS to 
define Rh and Kell alleles by amplification of the entire genes (KEL RHD,and RHCE). 
DNA was extracted from 14 random blood donor samples. Two primer pairs were 
designed to amplify the entire KEL gene using long-range polymerase chain reaction 
(LR-PCR). The sequencing library was constructed by fragmenting the DNA, ligating 
into barcoded adaptors and size selected using SPRIselect magnetic beads. The 
sequencing template was then immobilised to sphere particles that clonally amplified 
using emulsion PCR, emulsion breaking and enrichment for positive sphere particles. 
Finally, the sequencing reaction was loaded into a chip and sequenced on the Ion 
Torrent Personal Genome Machine (PGM) that generating 2·6 million reads. Data was 
analysed using CLC Genomics workbench Version 6·0.4. Data from the serological 
testing was confirmed by NGS. Two samples were typed serologically as K antigen and 
four as Kpb and this was confirmed by NGS as an initial genotype as [K antigen, 
Thr193Met (578C>T), heterozygous SNP 53·4% and 46·3%, respectively] and Kpb 
(Arg281, 841C and 842G). Moreover, one sample was found to be Kpa Arg281Trp 
(841C>T). Genotyping will be performed for all the antigens of Kell blood group 
system that encode the following antigens: (K/k, Kpa/Kpb/Kpc, Jsa /Jsb, K11/K17, K12, 
K13, K14/K24, VLAN/VONG, K18, K19, Km, K22, TOU, RAZ, KALT, KTIM, 
KYO/KYOR, KUCI, KANT, KASH, KELP, KETI and KHUL). NGS using LR-PCR 
approach offers a powerful technique enabling users to investigate comprehensive 
screening of all the Kell and Rh antigens. Similar approaches are in progress to define 
Rh alleles and that will reveal their variants in respect of the hybrid genes. 
 
Altayar, M. A., Halawani, A. J., Kiernan, M., Reynolds, A. J., Kaushik, N., Madgett, T. 
E. & Avent, N. D. (2014). Extensive Genotyping of Blood Groups Duffy, Kidd and 
ABO by Next-generation Sequencing. Vox Sang, 107, suppl. 1, 57-248. 
 
The determination of the blood groups present in an individual attains a great clinical 
importance for the purposes of blood transfusion and transplantation. Blood group 
genotyping (BGG) has become well established in transfusion medicine. However, all 
current technologies are based on pre-defined knowledge of known polymorphisms. 
The approach of Next Generation Sequencing (NGS) circumvents this requirement and 
adopts a discovery mode, which is important, as almost every new BGG project 
discovers new alleles. NGS is capable of producing high-throughput, rapid and accurate 
data that results in extensive and detailed genotyping. Also, costs have considerably 
reduced in the past years. In this pilot study, Ion Torrent Personal Genome Machine 
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(PGMTM) sequencer was used to optimise and develop a reliable protocol for 
sequencing the entire Duffy (DARC), Kidd (SLC14A1) and ABO blood group genes 
including flanking regions. First, a DNA library was prepared from 12 randomly 
selected DNA samples. DARC, SLC14A1 and ABO genes were targeted by long-range 
PCR, enzymatic amplicon fragmentation before ligation with barcoded adapters and 
size selection. Templates were immobilised on beads, then clonally amplified using 
emulsion PCR. Then, up to 20 samples from FY and JK samples were selected with 
certain serology for sequencing. The reason for this is to seek the possibility that those 
serologically typed as negative for a particular blood group are actually genotypically 
weak positive. Sequencing revealed millions of reads with great coverage depth that 
were then aligned to the reference gene sequences. Variants were analysed and 
visualised with software packages, Ion Torrent SuiteTM plugins, CLC Genomic 
Workbench, Integrative Genomics Viewer (IGV) and SeattleSeq Annotation 138 
website. Initial bioinformatics analysis of samples for the DARC and SLC14A1 genes 
revealed various single nucleotide polymorphisms (SNPs) in exons encoding for amino 
acid changes, such as (Gly42Asp and Ala100Thr in DARC) and (Asp280Asn, 
Ala270Ala and Glu44Lys in SLC14A1). In the FYsamples sequenced, a significant 
number (5/12) encoded the Ala100Thr mutation. In addition, the Allele JK ⃰ 01W.01 
(associated with Jka+w) was found with a frequency of 8%.A great number of 
polymorphisms (SNPs and Indel) were found in introns in JK samples (ranging from 52 
to122) and in FY samples (ranging from 2 to 4). An example of one of these SNPs is 
chromosomal position 43319274 in the SLC14A1 gene, close to the splice site region of 
exon 8. Interestingly, sets of intronic polymorphisms present differently among samples 
with same phenotype. Therefore, the intronic polymorphisms are possibly unique to 
individuals or families. The ABO sequencing is in progress. We suggest that NGS 
shows the capability of the comprehensive sequencing of blood group genes and will 
supplant other genotyping platforms in the near future, becoming the potential 
methodology of choice for genotyping patients and donors. 
 
Halawani, A. J., Altayar, M. A., Kiernan, M., Reynolds, A. J., Kaushik, N., Madgett, T. 
E. & Avent, N. D. (2014). Can Next-generation DNA Sequencing Solve the RH 
Complexity for Genotyping? Vox Sang, 107, suppl. 1, 57-248. 
 
The Rh blood group system is considered as the most polymorphic blood group system 
and contains many variants. These variants may cause severe complications to patients, 
due to alloimmunisation from mismatching products of blood transfusion. Next-
generation sequencing (NGS) is an intensely powerful technique capable of sequencing 
huge regions of the human genome. Here we sequenced the entire RHD and RHCE 
genes to genotype for the RhD and RhCE antigens, in order to provide a safer 
transfusion practice. DNA was extracted from random blood donors with known 
serology. By using long-range PCR (LR-PCR), four and three primer pairs were 
designed (giving PCR products in the range from 8 to 24 Kb) for RHD and RHCE, 
respectively. The sequencing libraries were then made by fragmenting the amplicons 
and ligating to adaptors using Ion XpressTM Plus Fragment Library Kit. Size selection 
was performed by SPRIselect magnetic beads. After that, the sequencing template was 
immobilised to beads, which possess a complementary strand to the adaptors, for clonal 
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amplification using emulsion PCR. Finally, the sequencing template was loaded onto a 
316 chip and sequenced on the Ion Torrent Personal Genome MachineTM Sequencer. 
Millions of reads were generated and the data were analysed with CLC Genomics 
Workbench (Version 6.5). Sanger sequencing will be utilised in order to validate any 
variants from the sequencing data. NGS using the  LR-PCR approach offers a crucial 
method assisting users to genotype many samples in a single run for detecting the Rh 
variants in depth. This will be extremely worthwhile to genotype the difficult alleles of 
Rh, especially hybrid genes, and will pave the way for the discovery of novel alleles. 
NGS for blood group alleles may represent a viable alternative to array and bead based 
platforms, and it is no more expensive and technically challenging on a per sample basis. 
 
Altayar, M. A., Halawani, A. J., Kiernan, M., Madgett, T. E. & Avent, N. D. (2015). 
Complete Gene Sequencing of ABO Blood Group by Next-generation Sequencing. Vox 
Sang, 109, suppl. 1, 1-379. 
 
The ABO blood group system is the most clinical significant in blood transfusion and 
transplantation medicine. Due to naturally occurring antibodies, mismatched transfusion 
of blood can cause rapid transfusion reactions. ABO is one of the most complex and 
polymorphic blood group genes, with an ever-increasing number of variant alleles. 
These variant alleles not only affect the specificity of the enzymes but also the activity 
of the enzymes, which might result in a weak phenotype. Therefore the determination of 
ABO alleles is important for the safety of blood transfusion and transplantation 
medicine. Although high-throughput platforms have revolution ised the approach 
towards blood group genotyping (BGG), they are based on pre-defined polymorphisms, 
which are not suitable for the discovery of new alleles. Next Generation Sequencing 
(NGS) circumvents this requirement and operates in discovery mode, which is critical 
for emerging alleles. NGS is capable of producing comprehensive, high-throughput, 
rapid and accurate data resulting in extensive genotyping. ABO genotyping has 
frequently only focused on exons 6 and 7, neglecting the rest of the gene. Following our 
successful NGS-genotyping of blood group genes Duffy (DARC) and Kidd (SLC14A1), 
here we have used the Ion Torrent Personal Genome MachineTM (PGMTM) sequencer 
to optimise and develop a reliable protocol for sequencing the entire ABO blood group 
gene including flanking regions. In this pilot study, four long-range polymerase chain 
reactions (LR-PCR) were used to target the entire ABO gene plus over 5 kb upstream, 
regulatory regions (Promoter and CBF/NF-Y),anddownstream in 16 randomly selected 
genomic DNA samples. DNA libraries were prepared by enzymatic fragmentation, 
ligation of barcoded adapters and size selection, before clonal amplification of templates 
was achieved using emulsion PCR and then the samples were loaded onto a 316 chip for 
sequencing. Millions of reads with great coverage depth (100–1800x) were generated, 
which were then aligned to the reference gene sequence (NG_006669.1). These data 
were analysed and visualised with multiple software packages, such as CLC Genomic 
Workbench version 6.5. The serological phenotype data matched that of ABO 
genotyping. Bioinformatics analysis revealed a number of polymorphisms including 
single nucleotide polymorphisms (SNPs) and insertion/deletions (indels) distributed 
throughout exons, introns and the regulatory regions at around 4 kb upstream. Examples 
of amino acid changes due to the SNPs found in exons are those causing the differences 
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between A and B alleles, previously described in exon 7 (Arg176Gly, Gly235-Ser, 
Leu266Met and Gly268Ala), whilst other SNPs found in exons 3, 4 and 5 have been 
found to be of higher frequency in our samples than previously reported, including 
Arg63His (13/16 samples) and Ser74Pro (14/16 samples) and found in all ABO 
phenotypes. In addition, in two samples (of A and O phenotype), we showed the 
Trp181stop mutation, previously described only for the rare ABO*O.06 (O6) allele. 
We suggest that NGS can provide a reliable approach to genotype ABO due to its 
powerful capabilities of comprehensive analysis and revealing novel alleles. NGS will 
supplant other genotyping platforms in the near future, becoming the potential 
methodology of choice for genotyping patients and donors for safe transfusion/ 
transplantation practice. 
 
Halawani, A. J., Altayar, M. A., Kiernan, M., Li, X., Madgett, T. E. & Avent, N. D. 
(2015). High Resolution Genotyping of the Rh Blood Group System by Next-generation 
Sequencing Vox Sang, 109, suppl. 1, 1-379. 
 
The RH blood group system is the most complicated blood group system due to 
encoding by two highly homologous genes, RHD and RHCE. Typing the antigens of 
this system by conventional serology is not very appropriate to distinguish between D 
positive, weak D and partial D. It is only possible to assign weak D and partial D alleles 
accurately using blood group genotyping (BGG). Here, 10 samples of the RH system 
were genotyped, 5 D positive and 5 weak D samples using a long-range PCR (LR-PCR) 
approach coupled with next generation sequencing (NGS). For every sample, both 
genes, RHD and RHCE, were amplified by LRPCR, with three amplicons for RHD and 
four amplicons for RHCE. Then the PCR products were fragmented ligated to barcoded 
adaptors and sequenced using NGS on an Ion Torrent PGMTM platform. We showed 
that LR-PCR for RHD and RHCE completely correlated with their corresponding 
genomic sequence. For the D positive samples, there were no obvious SNPs on the 
RHD exons. The 5 weak D samples have been identified as following; two weak D 
Type 1 (exon 6 809T>G Val270Gly), two weak D Type 2 (exon 9 1154G>C Gly385Ala) 
and one weak partial D 4.1 with [exon 1 48G>C (Trp16Cys), exon 4 602C>G 
(Thr201Arg), exon 5 667T>G (Phe223Val), exon 6 819G>A (silent)]. The LR-PCR 
method has confirmed that a novel heterozygous SNP, 208 C>T (Arg70Trp) in exon 2 is 
derived from the RHCE gene, although it had previously been identified by a Human 
Erythrocyte Antigen and Human Platelet Antigen panel as belonging to the RHD gene. 
More samples are currently being sequenced. Our approach, we believe, will facilitate 
the comprehensive genotyping of the antigens of the RH system, especially those with 
hybrid genes or insertions/deletions. Our method is able to demonstrate novel alleles by 































































A) Fragmented-purified library 
B) Fragmented-ligated purified library 
